[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f_SkUYkxnmqx9D5JvciQS16ZJyXPIPeTW85lBLc6dFjM":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":7,"truncated":8,"activeTrials":9,"phase3Count":10,"totalEnrollment":11,"activePrograms":12,"nonDrugCount":13,"topConditions":14,"upcomingReadouts":38,"phaseBuckets":88,"rows":95},"University of Washington",[4,6],"University of Washington, the Collaborative Health Studies Coordinating Center",1410,false,275,81,1448689,145,901,[15,18,21,24,27,30,32,35],{"name":16,"count":17},"Depression",51,{"name":19,"count":20},"HIV Infections",39,{"name":22,"count":23},"Cardiovascular Diseases",30,{"name":25,"count":26},"HIV",28,{"name":28,"count":29},"Heart Diseases",25,{"name":31,"count":29},"Chronic Pain",{"name":33,"count":34},"Multiple Sclerosis",23,{"name":36,"count":37},"Stage IV Breast Cancer",21,[39,44,49,53,58,63,68,73,78,83],{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT04692103","Serial FES PET\u002FCT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy","2021-10-01","F-18 16 Alpha-Fluoroestradiol",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT02157051","Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer","2022-11-25","CD105\u002FYb-1\u002FSOX2\u002FCDH3\u002FMDM2-polyepitope Plasmid DNA Vaccine",{"nctId":50,"briefTitle":51,"date":52,"intervention":48},"NCT05242965","A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer","2024-08-13",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT04528004","Mechanistic Studies of Nicotinamide Riboside in Human Heart Failure","2024-11-30","Nicotinamide riboside",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT02339922","Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma","2024-12-30","Ixazomib Citrate",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT05057858","The Women TDF-FTC Benchmark Study","2025-01-31","co-formulated 300 mg TDF\u002F 200mg FTC",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT01703949","Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma","2025-06-03","Brentuximab Vedotin",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT04341779","Simplifying Treatment and Monitoring for HIV (STREAM HIV)","2025-06-30","Point-of-care viral load testing and tenofovir adherence testing",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT02025023","Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study","2025-07","5-fluorouracil",{"nctId":84,"briefTitle":85,"date":86,"intervention":87},"NCT06552611","Non-invasive Electrical Spinal Cord Stimulation To Restore Upper Extremity Function in Multiple Sclerosis","2025-07-01","Transcutaneous electrical spinal cord stimulation + therapy",[89,90,91,92,93,94],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[96,282,315,459,488,513,542,560,583,612,630,654,682,700,748,775,793,820,848,871,889,907,936,965,1206,1298,1446,1567,1698,1775,1940,1974,2023,2131,2198,2369,2502,2577,2607,2646,2681,2721,2750,2781,2803,2847,2874,2983,3041,3078,3108,3186,3280,3338,3383,3442,3483,3509,3543,3575,3601,3639,3661,3690,3712,3741,3763,3785,3809,3836,3859,3877,3895,3913,3931,3949,3974,3992,4010,4035,4057,4081,4103,4128,4146,4164,4191,4209,4235,4254,4280,4298,4316,4334,4352,4370,4388,4406,4424,4442,4460,4484,4502,4520,4538,4556,4574,4592,4610,4628,4646,4677,4695,4713,4731,4749,4767,4785,4809,4844,4862,4931,4981,5024,5054,5093,5115,5134,5152,5199,5217,5240,5264,5288,5325,5360,5400,5422,5447,5472,5490,5508,5526,5548,5577,5600,5691,5745,5799,5842,5891,5928,5959,5992,6026,6059,6085,6108,6133,6159,6183,6201,6225,6243,6261,6279,6303,6327,6352,6375,6400,6423,6448,6466,6492,6510,6528,6553,6571,6593,6621,6639,6657,6686,6704,6729,6753,6778,6796,6822,6845,6869,6893,6911,6936,6954,6972,6995,7020,7038,7063,7081,7103,7126,7151,7178,7204,7222,7240,7266,7290,7314,7342,7360,7386,7409,7432,7455,7482,7500,7589,7639,7665,7709,7731,7768,7790,7818,7840,7858,7876,7894,7912,7930,7948,7973,7997,8015,8042,8060,8086,8104,8126,8150,8173,8199,8222,8248,8266,8291,8309,8335,8353,8380,8398,8427,8445,8463,8481,8499,8517,8535,8558,8582,8600,8626,8650,8673,8696,8722,8740,8758,8781,8799,8817,8835,8853,8871,8897,8925,8943,8965,8988,9006,9024,9047,9070,9088,9106,9124,9173,9206,9242,9285,9326,9355,9381,9407,9445,9479,9505,9531,9557,9593,9625,9651,9673,9698,9725,9747,9769,9803,9825,9860,9897,9919,9941,9963,9993,10015,10044,10069,10091,10109,10132,10156,10174,10195,10213,10236,10259,10277,10301,10319,10344,10362,10380,10398,10416,10440,10458,10476,10494,10512,10530,10553,10571,10589,10607,10632,10650,10668,10686,10712,10730,10748,10766,10789,10812,10830,10848,10866,10884,10902,10920,10938,10962,10980,10998,11016,11038,11056,11074,11092,11110,11128,11146,11170,11193,11211,11229,11255,11273,11291,11309,11333,11351,11369,11387,11411,11429,11452,11470,11496,11514,11532,11550,11572,11590,11608,11629,11655,11673,11691,11709,11727,11745,11763,11784,11802,11825,11843,11861,11883,11901,11924,11942,11966,11984,12005,12029,12047,12065,12089,12113,12131,12157,12179,12204,12233,12258,12276,12305,12331,12349,12374,12396,12419,12437,12455,12478,12496,12535,12576,12606,12631,12654,12677,12699,12717,12739,12757,12775,12797,12815,12838,12856,12880,12898,12916,12937,12955,12978,13000,13024,13042,13099,13117,13140,13158,13183,13201,13219,13243,13261,13283,13305,13323,13347,13370,13388,13465,13518,13568,13613,13674,13704,13745,13773,13815,13841,13870,13904,13930,13983,14020,14048,14086,14112,14141,14163,14189,14219,14246,14268,14290,14321,14348,14379,14403,14427,14449,14471,14497,14522,14547,14568,14592,14610,14628,14652,14674,14696,14720,14738,14763,14781,14803,14827,14850,14872,14895,14924,14949,14967,14989,15010,15036,15054,15078,15103,15126,15148,15170,15193,15211,15229,15247,15265,15288,15311,15337,15355,15373,15391,15409,15427,15448,15472,15490,15508,15526,15544,15566,15588,15606,15628,15649,15672,15698,15719,15744,15762,15785,15803,15821,15839,15857,15875],{"intervention":97,"totalTrials":98,"cells":99},"Dexamethasone",9,{"EARLY_PHASE1":100,"PHASE1":103,"PHASE2":126,"PHASE3":237,"PHASE4":239,"NA":265},{"trials":101,"activeCount":102},[],0,{"trials":104,"activeCount":102},[105],{"nctId":106,"briefTitle":107,"status":108,"phases":109,"primaryCompletion":110,"completion":111,"start":112,"enrollment":113,"conditions":114,"interventions":120},"NCT04156828","Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma","TERMINATED",[90],"2022-04-27","2023-06-08","2020-03-31",12,[115,116,117,118,119],"Grade 3b Follicular Lymphoma","Recurrent Diffuse Large B-Cell Lymphoma","Recurrent Follicular Lymphoma","Refractory Diffuse Large B-Cell Lymphoma","Non-Hodgkin's Lymphoma",[121,122,123,97,124,125],"Copanlisib","Gemcitabine","Carboplatin","Rituximab","Pegfilgrastim",{"trials":127,"activeCount":236,"soonestReadout":176},[128,171,185,209,220],{"nctId":129,"briefTitle":130,"status":131,"phases":132,"primaryCompletion":133,"start":134,"enrollment":135,"conditions":136,"interventions":166},"NCT01110135","Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma","COMPLETED",[91],"2013-11","2010-08",43,[137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165],"Adult Nasal Type Extranodal NK\u002FT-cell Lymphoma","Anaplastic Large Cell Lymphoma","Angioimmunoblastic T-cell Lymphoma","Cutaneous B-cell Non-Hodgkin Lymphoma","Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue","Intraocular Lymphoma","Nodal Marginal Zone B-cell Lymphoma","Peripheral T-cell Lymphoma","Recurrent Adult Burkitt Lymphoma","Recurrent Adult Diffuse Large Cell Lymphoma","Recurrent Adult Diffuse Mixed Cell Lymphoma","Recurrent Adult Diffuse Small Cleaved Cell Lymphoma","Recurrent Adult Grade III Lymphomatoid Granulomatosis","Recurrent Adult Hodgkin Lymphoma","Recurrent Adult Immunoblastic Large Cell Lymphoma","Recurrent Adult Lymphoblastic Lymphoma","Recurrent Adult T-cell Leukemia\u002FLymphoma","Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma","Recurrent Grade 1 Follicular Lymphoma","Recurrent Grade 2 Follicular Lymphoma","Recurrent Grade 3 Follicular Lymphoma","Recurrent Mantle Cell Lymphoma","Recurrent Marginal Zone Lymphoma","Recurrent Mycosis Fungoides\u002FSezary Syndrome","Recurrent Small Lymphocytic Lymphoma","Refractory Multiple Myeloma","Small Intestine Lymphoma","Splenic Marginal Zone Lymphoma","Waldenström Macroglobulinemia",[167,168,169,170],"bendamustine hydrochloride","dexamethasone","filgrastim","etoposide",{"nctId":172,"briefTitle":173,"status":174,"phases":175,"primaryCompletion":176,"completion":177,"start":178,"enrollment":23,"conditions":179,"interventions":181},"NCT04883242","Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma","ACTIVE_NOT_RECRUITING",[91],"2026-12-31","2031-12-31","2021-07-29",[180,162],"Recurrent Multiple Myeloma",[182,97,183,184],"Carfilzomib","Isatuximab","Pomalidomide",{"nctId":186,"briefTitle":187,"status":108,"phases":188,"primaryCompletion":189,"completion":190,"start":191,"enrollment":192,"conditions":193,"interventions":205},"NCT00895245","Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy",[91],"2010-09","2011-02","2009-02",6,[194,195,196,197,198,199,200,201,202,203,204],"Nausea and Vomiting","Stage III Squamous Cell Carcinoma of the Hypopharynx","Stage III Squamous Cell Carcinoma of the Larynx","Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage III Squamous Cell Carcinoma of the Nasopharynx","Stage III Squamous Cell Carcinoma of the Oropharynx","Stage IV Squamous Cell Carcinoma of the Hypopharynx","Stage IV Squamous Cell Carcinoma of the Larynx","Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IV Squamous Cell Carcinoma of the Nasopharynx","Stage IV Squamous Cell Carcinoma of the Oropharynx",[206,207,208,168],"fosaprepitant dimeglumine","cisplatin","palonosetron hydrochloride",{"nctId":210,"briefTitle":211,"status":108,"phases":212,"primaryCompletion":213,"completion":213,"start":214,"enrollment":98,"conditions":215,"interventions":218},"NCT03256045","Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma",[91],"2021-02-05","2018-02-08",[216,217],"Recurrent Plasma Cell Myeloma","Refractory Plasma Cell Myeloma",[182,97,219],"Panobinostat",{"nctId":221,"briefTitle":222,"status":108,"phases":223,"primaryCompletion":224,"completion":225,"start":226,"enrollment":227,"conditions":228,"interventions":232},"NCT00849251","Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma",[90,91],"2011-12","2015-06","2008-11",31,[162,229,230,231],"Stage I Multiple Myeloma","Stage II Multiple Myeloma","Stage III Multiple Myeloma",[233,234,235,168],"cyclophosphamide","pegylated liposomal doxorubicin hydrochloride","bortezomib",1,{"trials":238,"activeCount":102},[],{"trials":240,"activeCount":264,"soonestReadout":258},[241,253],{"nctId":242,"briefTitle":243,"status":244,"phases":245,"primaryCompletion":246,"completion":247,"start":248,"enrollment":249,"conditions":250,"interventions":252},"NCT07084441","Comparison of Outcomes of Management of Bowel Obstruction","RECRUITING",[93],"2030-06","2030-12","2026-02-03",550,[251],"Adhesive Small Bowel Obstruction",[97],{"nctId":254,"briefTitle":255,"status":256,"phases":257,"primaryCompletion":258,"completion":259,"start":260,"enrollment":261,"conditions":262,"interventions":263},"NCT06817551","Comparison of Outcomes of Management of Bowel Obstruction Pilot Study","ENROLLING_BY_INVITATION",[93],"2025-12","2026-03","2025-03-01",10,[251],[97],2,{"trials":266,"activeCount":102},[267],{"nctId":268,"briefTitle":269,"status":131,"phases":270,"primaryCompletion":271,"completion":271,"start":272,"enrollment":273,"conditions":274,"interventions":279},"NCT00343863","Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer",[94],"2010-12","2006-01",41,[275,194,276,277,278],"Male Breast Cancer","Stage I Breast Cancer","Stage II Breast Cancer","Stage IIIA Breast Cancer",[208,233,168,280,281],"doxorubicin hydrochloride","ondansetron hydrochloride",{"intervention":283,"totalTrials":264,"cells":284},"HPV vaccine",{"EARLY_PHASE1":285,"PHASE1":287,"PHASE2":289,"PHASE3":291,"PHASE4":293,"NA":313},{"trials":286,"activeCount":102},[],{"trials":288,"activeCount":102},[],{"trials":290,"activeCount":102},[],{"trials":292,"activeCount":102},[],{"trials":294,"activeCount":264,"soonestReadout":176},[295,305],{"nctId":296,"briefTitle":297,"status":174,"phases":298,"primaryCompletion":176,"completion":176,"start":299,"enrollment":300,"conditions":301,"interventions":304},"NCT05291871","Immunogenicity of Fractional Dose of the HPV Vaccines",[93],"2022-06-15",92,[302,303],"HPV Infection","HPV Vaccine",[283],{"nctId":306,"briefTitle":307,"status":174,"phases":308,"primaryCompletion":176,"completion":176,"start":309,"enrollment":310,"conditions":311,"interventions":312},"NCT04235257","Intradermal, Fractional Dose of HPV Vaccines:",[93],"2020-11-01",40,[302,303],[283],{"trials":314,"activeCount":102},[],{"intervention":316,"totalTrials":317,"cells":318},"letrozole",8,{"EARLY_PHASE1":319,"PHASE1":321,"PHASE2":323,"PHASE3":417,"PHASE4":419,"NA":434},{"trials":320,"activeCount":102},[],{"trials":322,"activeCount":102},[],{"trials":324,"activeCount":236,"soonestReadout":386},[325,343,366,382,406],{"nctId":326,"briefTitle":327,"status":131,"phases":328,"primaryCompletion":329,"completion":330,"start":331,"enrollment":332,"conditions":333,"interventions":339},"NCT01686828","T-IR- Study to Understand the Effects of Testosterone and Estrogen on the Body's Response to the Hormone Insulin",[90,91],"2015-05","2017-12","2013-06",53,[334,335,336,337,338],"Insulin Resistance","Type 2 Diabetes Mellitus","Obesity","Androgen Deficiency","Metabolic Disease",[340,341,342],"Acyline","Testosterone 1.62% gel","Letrozole",{"nctId":344,"briefTitle":345,"status":131,"phases":346,"primaryCompletion":347,"completion":348,"start":349,"enrollment":350,"conditions":351,"interventions":359},"NCT00194779","Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery",[91],"2010-06","2011-06","2003-10",50,[352,353,354,355,356,357,358,277,278],"Estrogen Receptor-negative Breast Cancer","Estrogen Receptor-positive Breast Cancer","HER2-positive Breast Cancer","Progesterone Receptor-negative Breast Cancer","Progesterone Receptor-positive Breast Cancer","Stage IA Breast Cancer","Stage IB Breast Cancer",[280,233,360,169,361,362,363,364,365,316],"paclitaxel","capecitabine","methotrexate","vinorelbine tartrate","trastuzumab","tamoxifen citrate",{"nctId":367,"briefTitle":368,"status":131,"phases":369,"primaryCompletion":370,"completion":370,"start":371,"enrollment":372,"conditions":373,"interventions":380},"NCT00416715","Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",[91],"2010-05","2006-10",100,[374,375,376,377,276,277,278,378,379],"Arthralgia","Musculoskeletal Complications","Pain","Recurrent Breast Cancer","Stage IIIB Breast Cancer","Stage IIIC Breast Cancer",[316,381],"calcium gluconate",{"nctId":383,"briefTitle":384,"status":244,"phases":385,"primaryCompletion":386,"completion":387,"start":388,"enrollment":389,"conditions":390,"interventions":397},"NCT06179303","Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer",[91],"2027-03-01","2028-06-01","2024-07-22",60,[391,392,393,394,395,396],"Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IV Breast Cancer AJCC v8","Locally Advanced Unresectable HER2-Negative Breast Carcinoma","Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma","Metastatic HER2-Negative Breast Carcinoma","Metastatic Hormone Receptor-Positive Breast Carcinoma",[398,399,400,401,402,403,342,404,405],"Abemaciclib","Anastrozole","Exemestane","Fluorine F 18 Fluoro Furanyl Norprogesterone","Fulvestrant","Gonadotropin-releasing Hormone Analog","Tamoxifen","Therapeutic Estradiol",{"nctId":407,"briefTitle":408,"status":108,"phases":409,"primaryCompletion":410,"completion":226,"start":411,"enrollment":236,"conditions":412,"interventions":414},"NCT00498901","Letrozole and Goserelin or Leuprolide in Treating Premenopausal Estrogen Receptor-Positive Patients With Stage IV Breast Cancer",[91],"2007-12","2007-02",[413],"Breast Cancer",[415,316,416],"goserelin","leuprolide acetate",{"trials":418,"activeCount":102},[],{"trials":420,"activeCount":236,"soonestReadout":425},[421],{"nctId":422,"briefTitle":423,"status":244,"phases":424,"primaryCompletion":425,"completion":425,"start":426,"enrollment":427,"conditions":428,"interventions":433},"NCT05183828","Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer",[93],"2026-06-30","2022-01-23",68,[429,430,391,431,432],"Anatomic Stage I Breast Cancer AJCC v8","Anatomic Stage II Breast Cancer AJCC v8","Breast Adenocarcinoma","Invasive Breast Carcinoma of No Special Type",[342],{"trials":435,"activeCount":102},[436,449],{"nctId":437,"briefTitle":438,"status":131,"phases":439,"primaryCompletion":440,"completion":441,"start":442,"enrollment":317,"conditions":443,"interventions":444},"NCT01153672","Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy",[94],"2012-07","2016-08-11","2010-11",[275,377,36],[445,446,316,447,448],"vorinostat","anastrozole","exemestane","gene expression analysis",{"nctId":450,"briefTitle":451,"status":131,"phases":452,"primaryCompletion":453,"completion":454,"start":455,"enrollment":456,"conditions":457,"interventions":458},"NCT01720602","Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy",[94],"2015-03","2020-01","2012-11",15,[275,377,36],[445,446,316,447],{"intervention":460,"totalTrials":236,"cells":461},"Cimetidine 200 MG",{"EARLY_PHASE1":462,"PHASE1":464,"PHASE2":466,"PHASE3":468,"PHASE4":470,"NA":486},{"trials":463,"activeCount":102},[],{"trials":465,"activeCount":102},[],{"trials":467,"activeCount":102},[],{"trials":469,"activeCount":102},[],{"trials":471,"activeCount":236,"soonestReadout":476},[472],{"nctId":473,"briefTitle":474,"status":244,"phases":475,"primaryCompletion":476,"completion":476,"start":477,"enrollment":350,"conditions":478,"interventions":485},"NCT06056583","Drug Excretion in Breast Milk",[93],"2028-09-30","2023-12-04",[479,480,481,482,483,484],"Postpartum","Lactation","Drugs in Breast Milk","Mammary Drug Transporters","BCRP","OCT1",[460],{"trials":487,"activeCount":102},[],{"intervention":489,"totalTrials":236,"cells":490},"Semaglutide Auto-Injector",{"EARLY_PHASE1":491,"PHASE1":493,"PHASE2":495,"PHASE3":497,"PHASE4":499,"NA":511},{"trials":492,"activeCount":102},[],{"trials":494,"activeCount":102},[],{"trials":496,"activeCount":102},[],{"trials":498,"activeCount":102},[],{"trials":500,"activeCount":236,"soonestReadout":505},[501],{"nctId":502,"briefTitle":503,"status":244,"phases":504,"primaryCompletion":505,"completion":176,"start":506,"enrollment":350,"conditions":507,"interventions":510},"NCT05780905","Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes",[93],"2026-03-31","2024-01-11",[508,509],"Diabetes Mellitus, Type 2","Stroke (CVA) or Transient Ischemic Attack",[489],{"trials":512,"activeCount":102},[],{"intervention":514,"totalTrials":236,"cells":515},"WHO-recommended periodic presumptive treatment",{"EARLY_PHASE1":516,"PHASE1":518,"PHASE2":520,"PHASE3":522,"PHASE4":524,"NA":540},{"trials":517,"activeCount":102},[],{"trials":519,"activeCount":102},[],{"trials":521,"activeCount":102},[],{"trials":523,"activeCount":102},[],{"trials":525,"activeCount":236,"soonestReadout":530},[526],{"nctId":527,"briefTitle":528,"status":244,"phases":529,"primaryCompletion":530,"completion":531,"start":532,"enrollment":533,"conditions":534,"interventions":538},"NCT06468462","Periodic Presumptive Treatment vs. doxyPEP for STI Control in Kenyan MSM",[93],"2028-10-31","2029-04-30","2025-10-29",2900,[535,536,537],"Gonorrhea Male","Chlamydia (Male)","Syphilis Male",[514,539],"Doxycycline post-exposure prophylaxis",{"trials":541,"activeCount":102},[],{"intervention":539,"totalTrials":236,"cells":543},{"EARLY_PHASE1":544,"PHASE1":546,"PHASE2":548,"PHASE3":550,"PHASE4":552,"NA":558},{"trials":545,"activeCount":102},[],{"trials":547,"activeCount":102},[],{"trials":549,"activeCount":102},[],{"trials":551,"activeCount":102},[],{"trials":553,"activeCount":236,"soonestReadout":530},[554],{"nctId":527,"briefTitle":528,"status":244,"phases":555,"primaryCompletion":530,"completion":531,"start":532,"enrollment":533,"conditions":556,"interventions":557},[93],[535,536,537],[514,539],{"trials":559,"activeCount":102},[],{"intervention":561,"totalTrials":236,"cells":562},"Shingrix",{"EARLY_PHASE1":563,"PHASE1":565,"PHASE2":567,"PHASE3":569,"PHASE4":571,"NA":581},{"trials":564,"activeCount":102},[],{"trials":566,"activeCount":102},[],{"trials":568,"activeCount":102},[],{"trials":570,"activeCount":102},[],{"trials":572,"activeCount":236,"soonestReadout":577},[573],{"nctId":574,"briefTitle":575,"status":174,"phases":576,"primaryCompletion":577,"completion":577,"start":110,"enrollment":350,"conditions":578,"interventions":580},"NCT04403139","VZV-specific Tissue Resident Memory T-cells After Shingrix Vaccination",[93],"2026-12",[579],"Varicella Zoster Virus Infection",[561],{"trials":582,"activeCount":102},[],{"intervention":584,"totalTrials":236,"cells":585},"Doxepin 6 mg",{"EARLY_PHASE1":586,"PHASE1":588,"PHASE2":590,"PHASE3":592,"PHASE4":594,"NA":610},{"trials":587,"activeCount":102},[],{"trials":589,"activeCount":102},[],{"trials":591,"activeCount":102},[],{"trials":593,"activeCount":102},[],{"trials":595,"activeCount":236,"soonestReadout":601},[596],{"nctId":597,"briefTitle":598,"status":599,"phases":600,"primaryCompletion":601,"completion":601,"start":602,"enrollment":603,"conditions":604,"interventions":608},"NCT07598734","Doxepin Alone or Combined With Ramelteon Versus Placebo for Improving Sleep Quality After Primary Total Knee Arthroplasty","NOT_YET_RECRUITING",[93],"2028-06","2026-06",129,[605,606,607],"Sleep Quality Post-TKA","Postoperative Knee Function","Quality of Life After Primary TKA",[584,609],"Ramelteon 8 mg",{"trials":611,"activeCount":102},[],{"intervention":609,"totalTrials":236,"cells":613},{"EARLY_PHASE1":614,"PHASE1":616,"PHASE2":618,"PHASE3":620,"PHASE4":622,"NA":628},{"trials":615,"activeCount":102},[],{"trials":617,"activeCount":102},[],{"trials":619,"activeCount":102},[],{"trials":621,"activeCount":102},[],{"trials":623,"activeCount":236,"soonestReadout":601},[624],{"nctId":597,"briefTitle":598,"status":599,"phases":625,"primaryCompletion":601,"completion":601,"start":602,"enrollment":603,"conditions":626,"interventions":627},[93],[605,606,607],[584,609],{"trials":629,"activeCount":102},[],{"intervention":631,"totalTrials":236,"cells":632},"Perflutren lipid",{"EARLY_PHASE1":633,"PHASE1":635,"PHASE2":637,"PHASE3":639,"PHASE4":641,"NA":652},{"trials":634,"activeCount":102},[],{"trials":636,"activeCount":102},[],{"trials":638,"activeCount":102},[],{"trials":640,"activeCount":102},[],{"trials":642,"activeCount":236,"soonestReadout":647},[643],{"nctId":644,"briefTitle":645,"status":244,"phases":646,"primaryCompletion":647,"completion":647,"start":648,"enrollment":350,"conditions":649,"interventions":651},"NCT06654804","Contrast-enhanced Ultrasound in the Treatment of Acute Spinal Cord Injury",[93],"2027-09-15","2023-09-28",[650],"Acute Spinal Cord Injury",[631],{"trials":653,"activeCount":102},[],{"intervention":655,"totalTrials":236,"cells":656},"IV Lidocaine",{"EARLY_PHASE1":657,"PHASE1":659,"PHASE2":661,"PHASE3":663,"PHASE4":665,"NA":680},{"trials":658,"activeCount":102},[],{"trials":660,"activeCount":102},[],{"trials":662,"activeCount":102},[],{"trials":664,"activeCount":102},[],{"trials":666,"activeCount":236,"soonestReadout":671},[667],{"nctId":668,"briefTitle":669,"status":599,"phases":670,"primaryCompletion":671,"completion":671,"start":672,"enrollment":673,"conditions":674,"interventions":678},"NCT06828601","Perioperative Lidocaine Infusions for the Management of Pain From Burn Injury",[93],"2026-01","2025-04",20,[675,676,677],"Pain Management","Burn Injury","Lidocaine",[655,679],"IV Saline",{"trials":681,"activeCount":102},[],{"intervention":679,"totalTrials":236,"cells":683},{"EARLY_PHASE1":684,"PHASE1":686,"PHASE2":688,"PHASE3":690,"PHASE4":692,"NA":698},{"trials":685,"activeCount":102},[],{"trials":687,"activeCount":102},[],{"trials":689,"activeCount":102},[],{"trials":691,"activeCount":102},[],{"trials":693,"activeCount":236,"soonestReadout":671},[694],{"nctId":668,"briefTitle":669,"status":599,"phases":695,"primaryCompletion":671,"completion":671,"start":672,"enrollment":673,"conditions":696,"interventions":697},[93],[675,676,677],[655,679],{"trials":699,"activeCount":102},[],{"intervention":701,"totalTrials":702,"cells":703},"Bupivacaine",3,{"EARLY_PHASE1":704,"PHASE1":706,"PHASE2":708,"PHASE3":710,"PHASE4":712,"NA":733},{"trials":705,"activeCount":102},[],{"trials":707,"activeCount":102},[],{"trials":709,"activeCount":102},[],{"trials":711,"activeCount":102},[],{"trials":713,"activeCount":236,"soonestReadout":727},[714,723],{"nctId":715,"briefTitle":716,"status":108,"phases":717,"primaryCompletion":718,"completion":718,"start":719,"enrollment":261,"conditions":720,"interventions":722},"NCT01550302","Superficial Cervical Plexus Block for Shoulder Pain After Lung Surgery",[93],"2014-05","2013-10",[721],"Shoulder Pain",[701],{"nctId":724,"briefTitle":725,"status":599,"phases":726,"primaryCompletion":727,"completion":728,"start":729,"enrollment":372,"conditions":730,"interventions":732},"NCT06474949","Local Anesthetic for Plateau Fractures",[93],"2026-08-01","2027-08-01","2024-08-01",[731],"Tibial Plateau Fractures",[701],{"trials":734,"activeCount":102},[735],{"nctId":736,"briefTitle":737,"status":131,"phases":738,"primaryCompletion":134,"completion":739,"start":740,"enrollment":741,"conditions":742,"interventions":744},"NCT01015807","Transversus Abdominis Plane (TAP) Block for Cesarean Section",[94],"2012-08","2009-11",90,[743],"Hyperalgesia, Secondary",[745,746,701,747],"Bupivacaine Placebo","Clonidine Placebo","Clonidine",{"intervention":749,"totalTrials":236,"cells":750},"Pentoxifylline",{"EARLY_PHASE1":751,"PHASE1":753,"PHASE2":755,"PHASE3":757,"PHASE4":771,"NA":773},{"trials":752,"activeCount":102},[],{"trials":754,"activeCount":102},[],{"trials":756,"activeCount":102},[],{"trials":758,"activeCount":236,"soonestReadout":763},[759],{"nctId":760,"briefTitle":761,"status":174,"phases":762,"primaryCompletion":763,"completion":425,"start":764,"enrollment":372,"conditions":765,"interventions":769},"NCT03040778","Pentoxifylline and Tocopherol (PENTO) in the Treatment of Medication-related Osteonecrosis of the Jaw (MRONJ)",[92],"2026-05","2018-04-01",[766,767,768],"Medication-related Osteonecrosis of the Jaw","Bisphosphonate-related Osteonecrosis of the Jaw","Avascular Necrosis",[749,770],"Tocopherol",{"trials":772,"activeCount":102},[],{"trials":774,"activeCount":102},[],{"intervention":770,"totalTrials":236,"cells":776},{"EARLY_PHASE1":777,"PHASE1":779,"PHASE2":781,"PHASE3":783,"PHASE4":789,"NA":791},{"trials":778,"activeCount":102},[],{"trials":780,"activeCount":102},[],{"trials":782,"activeCount":102},[],{"trials":784,"activeCount":236,"soonestReadout":763},[785],{"nctId":760,"briefTitle":761,"status":174,"phases":786,"primaryCompletion":763,"completion":425,"start":764,"enrollment":372,"conditions":787,"interventions":788},[92],[766,767,768],[749,770],{"trials":790,"activeCount":102},[],{"trials":792,"activeCount":102},[],{"intervention":794,"totalTrials":236,"cells":795},"Lactoferrin + Lysozyme",{"EARLY_PHASE1":796,"PHASE1":798,"PHASE2":800,"PHASE3":802,"PHASE4":816,"NA":818},{"trials":797,"activeCount":102},[],{"trials":799,"activeCount":102},[],{"trials":801,"activeCount":102},[],{"trials":803,"activeCount":236,"soonestReadout":808},[804],{"nctId":805,"briefTitle":806,"status":244,"phases":807,"primaryCompletion":808,"completion":577,"start":809,"enrollment":810,"conditions":811,"interventions":815},"NCT05519254","Lactoferrin and Lysozyme Supplementation for Long-term Diarrhea Sequelae",[92],"2026-07","2023-03-10",600,[812,813,814],"Diarrhea","Wasting","Malnutrition, Child",[794],{"trials":817,"activeCount":102},[],{"trials":819,"activeCount":102},[],{"intervention":821,"totalTrials":236,"cells":822},"Avelumab",{"EARLY_PHASE1":823,"PHASE1":825,"PHASE2":827,"PHASE3":829,"PHASE4":844,"NA":846},{"trials":824,"activeCount":102},[],{"trials":826,"activeCount":102},[],{"trials":828,"activeCount":102},[],{"trials":830,"activeCount":236,"soonestReadout":835},[831],{"nctId":832,"briefTitle":833,"status":174,"phases":834,"primaryCompletion":835,"completion":836,"start":837,"enrollment":838,"conditions":839,"interventions":843},"NCT03271372","Adjuvant Avelumab in Merkel Cell Cancer",[92],"2026-04-03","2029-02-18","2017-12-19",101,[840,841,842],"Stage III Merkel Cell Carcinoma AJCC v8","Stage IIIB Merkel Cell Carcinoma AJCC v8","Stage IIIA Merkel Cell Carcinoma AJCC v8",[821],{"trials":845,"activeCount":102},[],{"trials":847,"activeCount":102},[],{"intervention":82,"totalTrials":236,"cells":849},{"EARLY_PHASE1":850,"PHASE1":852,"PHASE2":854,"PHASE3":856,"PHASE4":867,"NA":869},{"trials":851,"activeCount":102},[],{"trials":853,"activeCount":102},[],{"trials":855,"activeCount":102},[],{"trials":857,"activeCount":236,"soonestReadout":81},[858],{"nctId":79,"briefTitle":80,"status":244,"phases":859,"primaryCompletion":81,"completion":808,"start":860,"enrollment":861,"conditions":862,"interventions":864},[92],"2013-12",120,[863],"Chalazion",[82,865,866],"Triamcinolone Acetonide","Triamcinolone Acetonide\u002F5-fluorouracil mixture",{"trials":868,"activeCount":102},[],{"trials":870,"activeCount":102},[],{"intervention":865,"totalTrials":236,"cells":872},{"EARLY_PHASE1":873,"PHASE1":875,"PHASE2":877,"PHASE3":879,"PHASE4":885,"NA":887},{"trials":874,"activeCount":102},[],{"trials":876,"activeCount":102},[],{"trials":878,"activeCount":102},[],{"trials":880,"activeCount":236,"soonestReadout":81},[881],{"nctId":79,"briefTitle":80,"status":244,"phases":882,"primaryCompletion":81,"completion":808,"start":860,"enrollment":861,"conditions":883,"interventions":884},[92],[863],[82,865,866],{"trials":886,"activeCount":102},[],{"trials":888,"activeCount":102},[],{"intervention":866,"totalTrials":236,"cells":890},{"EARLY_PHASE1":891,"PHASE1":893,"PHASE2":895,"PHASE3":897,"PHASE4":903,"NA":905},{"trials":892,"activeCount":102},[],{"trials":894,"activeCount":102},[],{"trials":896,"activeCount":102},[],{"trials":898,"activeCount":236,"soonestReadout":81},[899],{"nctId":79,"briefTitle":80,"status":244,"phases":900,"primaryCompletion":81,"completion":808,"start":860,"enrollment":861,"conditions":901,"interventions":902},[92],[863],[82,865,866],{"trials":904,"activeCount":102},[],{"trials":906,"activeCount":102},[],{"intervention":908,"totalTrials":236,"cells":909},"Bexsero",{"EARLY_PHASE1":910,"PHASE1":912,"PHASE2":914,"PHASE3":916,"PHASE4":932,"NA":934},{"trials":911,"activeCount":102},[],{"trials":913,"activeCount":102},[],{"trials":915,"activeCount":102},[],{"trials":917,"activeCount":236,"soonestReadout":922},[918],{"nctId":919,"briefTitle":920,"status":174,"phases":921,"primaryCompletion":922,"completion":923,"start":924,"enrollment":925,"conditions":926,"interventions":931},"NCT06446752","BIYELA - Bexsero Immunisation in Young Women in Africa",[92],"2026-10","2027-01","2024-08-14",1100,[927,928,929,930],"Gonorrhea","Gonorrhea of Pharynx","Gonorrhea of Anus","Gonorrhea of Cervix",[908],{"trials":933,"activeCount":102},[],{"trials":935,"activeCount":102},[],{"intervention":937,"totalTrials":236,"cells":938},"Xylitol Chewing gum",{"EARLY_PHASE1":939,"PHASE1":941,"PHASE2":943,"PHASE3":945,"PHASE4":961,"NA":963},{"trials":940,"activeCount":102},[],{"trials":942,"activeCount":102},[],{"trials":944,"activeCount":102},[],{"trials":946,"activeCount":236,"soonestReadout":951},[947],{"nctId":948,"briefTitle":949,"status":599,"phases":950,"primaryCompletion":951,"completion":951,"start":952,"enrollment":953,"conditions":954,"interventions":960},"NCT07424846","Xylitol and the Prevention of Periodontal Disease and Preterm Birth Trial",[91,92],"2030-09-30","2026-03-15",6000,[955,956,957,958,959],"Preterm Birth","Low Birthweight Neonate","Periodontitis","Gingivitis","Developmental Delay",[937],{"trials":962,"activeCount":102},[],{"trials":964,"activeCount":102},[],{"intervention":966,"totalTrials":456,"cells":967},"Prednisone",{"EARLY_PHASE1":968,"PHASE1":970,"PHASE2":1032,"PHASE3":1200,"PHASE4":1202,"NA":1204},{"trials":969,"activeCount":102},[],{"trials":971,"activeCount":236,"soonestReadout":976},[972,996,1016],{"nctId":973,"briefTitle":974,"status":244,"phases":975,"primaryCompletion":976,"completion":977,"start":978,"enrollment":979,"conditions":980,"interventions":990},"NCT04231877","Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma",[90],"2026-12-01","2031-12-01","2020-10-27",56,[981,982,983,984,985,986,987,988,989],"Aggressive Non-Hodgkin Lymphoma","ALK-Positive Large B-Cell Lymphoma","Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","High Grade B-Cell Lymphoma With MYC and BCL2 and\u002For BCL6 Rearrangements","High Grade B-Cell Lymphoma, Not Otherwise Specified","Primary Mediastinal Large B-Cell Lymphoma","T-Cell\u002FHistiocyte-Rich Large B-Cell Lymphoma","Gray-Zone Lymphoma",[991,124,966,992,993,994,995],"Polatuzumab Vedotin","Etoposide","Doxorubicin","Cyclophosphamide","Glofitamab",{"nctId":997,"briefTitle":998,"status":131,"phases":999,"primaryCompletion":1000,"completion":1000,"start":1001,"enrollment":23,"conditions":1002,"interventions":1012},"NCT02541565","Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma",[90],"2018-12-18","2015-11-24",[1003,115,1004,1005,1006,1007,1008,1009,1010,1011],"Composite Lymphoma","Stage I Diffuse Large B-Cell Lymphoma","Stage I Follicular Lymphoma","Stage II Diffuse Large B-Cell Lymphoma","Stage II Follicular Lymphoma","Stage III Diffuse Large B-Cell Lymphoma","Stage III Follicular Lymphoma","Stage IV Diffuse Large B-Cell Lymphoma","Stage IV Follicular Lymphoma",[994,1013,1014,966,124,1015],"Doxorubicin Hydrochloride","Pembrolizumab","Vincristine Sulfate",{"nctId":1017,"briefTitle":1018,"status":131,"phases":1019,"primaryCompletion":1020,"completion":1021,"start":1022,"enrollment":1023,"conditions":1024,"interventions":1029},"NCT03991884","Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia",[90],"2022-10-20","2023-06-28","2019-09-24",24,[1025,1026,1027,1028],"Recurrent B Acute Lymphoblastic Leukemia","Recurrent B Lymphoblastic Lymphoma","Refractory B Acute Lymphoblastic Leukemia","Refractory B Lymphoblastic Lymphoma",[992,993,1030,966,994,1031],"Vincristine","Inotuzumab Ozogamicin",{"trials":1033,"activeCount":192,"soonestReadout":1126},[1034,1048,1067,1080,1097,1107,1122,1132,1147,1164,1176,1189],{"nctId":1035,"briefTitle":1036,"status":131,"phases":1037,"primaryCompletion":1038,"completion":1039,"start":1040,"enrollment":1041,"conditions":1042,"interventions":1045},"NCT03023046","Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",[91],"2021-05-20","2022-05-01","2017-02-23",54,[1043,1044],"Acute Lymphoblastic Leukemia","Lymphoblastic Lymphoma",[994,1046,993,992,1047,966,124,1015],"Dasatinib","Imatinib Mesylate",{"nctId":1049,"briefTitle":1050,"status":108,"phases":1051,"primaryCompletion":1052,"completion":1053,"start":1054,"enrollment":261,"conditions":1055,"interventions":1064},"NCT03649841","Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer",[91],"2022-09-01","2023-02-01","2020-06-29",[1056,1057,1058,1059,1060,1061,1062,1063],"Castration-Sensitive Prostate Carcinoma","Metastatic Malignant Neoplasm in the Bone","Metastatic Prostate Carcinoma","Prostate Adenocarcinoma","Prostate Small Cell Neuroendocrine Carcinoma","Stage IV Prostate Cancer AJCC v8","Stage IVA Prostate Cancer AJCC v8","Stage IVB Prostate Cancer AJCC v8",[1065,1066,966],"Antiandrogen Therapy","Abiraterone Acetate",{"nctId":1068,"briefTitle":1069,"status":244,"phases":1070,"primaryCompletion":1071,"completion":1072,"start":1073,"enrollment":23,"conditions":1074,"interventions":1077},"NCT06738368","Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia",[91],"2028-01-31","2028-07-30","2026-05-08",[1075,1076],"B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative","T Acute Lymphoblastic Leukemia",[1078,994,993,992,1079,125,966,124,1030],"Asparaginase Erwinia chrysanthemi","Filgrastim",{"nctId":1081,"briefTitle":1082,"status":131,"phases":1083,"primaryCompletion":1084,"completion":1085,"start":1086,"enrollment":1087,"conditions":1088,"interventions":1093},"NCT02849990","A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy",[91],"2018-12-10","2020-12-10","2017-03-09",22,[1089,1090,1091,1092],"Stage III Prostate Adenocarcinoma AJCC v7","Stage III Prostate Cancer AJCC v7","Stage IV Prostate Adenocarcinoma AJCC v7","Stage IV Prostate Cancer AJCC v7",[1066,1094,1095,1096,966],"Apalutamide","Degarelix","Indomethacin",{"nctId":1098,"briefTitle":1099,"status":244,"phases":1100,"primaryCompletion":1101,"completion":1102,"start":1103,"enrollment":372,"conditions":1104,"interventions":1105},"NCT04175431","Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET\u002FCT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study",[91],"2028-07-01","2033-07-01","2020-09-30",[1059],[1066,966,1106],"Abiraterone",{"nctId":1108,"briefTitle":1109,"status":244,"phases":1110,"primaryCompletion":1111,"completion":1112,"start":1113,"enrollment":1114,"conditions":1115,"interventions":1118},"NCT05455697","Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma",[90,91],"2027-01-05","2027-07-06","2023-01-26",35,[1116,115,1117],"Diffuse Large B-Cell Lymphoma","High Grade B-Cell Lymphoma",[994,993,966,1119,1120,1121,1030,991],"Retifanlimab","Rituximab and Hyaluronidase Human","Tafasitamab",{"nctId":1123,"briefTitle":1124,"status":174,"phases":1125,"primaryCompletion":1126,"completion":1127,"start":1128,"enrollment":1129,"conditions":1130,"interventions":1131},"NCT05453500","Chemotherapy (DA-EPOCH+\u002F-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia",[91],"2026-04-28","2031-05-01","2023-03-27",32,[1075],[994,993,992,966,124,1121,1030],{"nctId":1133,"briefTitle":1134,"status":131,"phases":1135,"primaryCompletion":1136,"completion":1136,"start":1137,"enrollment":1023,"conditions":1138,"interventions":1143},"NCT01023061","Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate Cancer",[91],"2015-09","2010-03",[1139,1140,1141,1142],"Adenocarcinoma of the Prostate","Stage II Prostate Cancer","Stage III Prostate Cancer","Stage IV Prostate Cancer",[1144,1145,416,1146],"abiraterone acetate","prednisone","goserelin acetate",{"nctId":1148,"briefTitle":1149,"status":1150,"phases":1151,"primaryCompletion":1152,"completion":1153,"start":1154,"enrollment":102,"conditions":1155,"interventions":1162},"NCT02538926","Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","WITHDRAWN",[91],"2020-07-30","2021-07-30","2018-07-01",[1156,1157,1158,1026,1159,1028,1160,1076,1161],"B Acute Lymphoblastic Leukemia","B Lymphoblastic Lymphoma","Recurrent Adult Acute Lymphoblastic Leukemia","Recurrent T Lymphoblastic Leukemia\u002FLymphoma","Refractory T Lymphoblastic Lymphoma","T Lymphoblastic Lymphoma",[1163,994,1013,992,1047,966,124,1015],"Asparaginase",{"nctId":1165,"briefTitle":1166,"status":244,"phases":1167,"primaryCompletion":1168,"completion":1168,"start":1169,"enrollment":1170,"conditions":1171,"interventions":1174},"NCT07224100","Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia\u002FLymphoma",[91],"2028-07-31","2026-03-30",33,[1172,1173,1044],"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","B Lymphoblastic Leukemia\u002FLymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1",[994,993,992,1079,125,1175,966,124,1030],"Ponatinib",{"nctId":1177,"briefTitle":1178,"status":244,"phases":1179,"primaryCompletion":1180,"completion":1180,"start":1181,"enrollment":1182,"conditions":1183,"interventions":1187},"NCT07097363","Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma",[91],"2030-05-31","2025-12-07",18,[1184,1185,983,984,985,986,987,988,1186],"B-Cell Non-Hodgkin Lymphoma","Burkitt Lymphoma","Transformed B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma to Diffuse Large B-Ce",[994,993,1188,992,966,124],"Epcoritamab",{"nctId":1190,"briefTitle":1191,"status":131,"phases":1192,"primaryCompletion":1193,"completion":1193,"start":1194,"enrollment":1129,"conditions":1195,"interventions":1199},"NCT01503229","Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer",[91],"2020-03-12","2012-12",[1196,1058,1197,1198],"Hormone-Resistant Prostate Cancer","Recurrent Prostate Carcinoma","Stage IV Prostate Adenocarcinoma",[1066,966],{"trials":1201,"activeCount":102},[],{"trials":1203,"activeCount":102},[],{"trials":1205,"activeCount":102},[],{"intervention":993,"totalTrials":1207,"cells":1208},11,{"EARLY_PHASE1":1209,"PHASE1":1211,"PHASE2":1221,"PHASE3":1292,"PHASE4":1294,"NA":1296},{"trials":1210,"activeCount":102},[],{"trials":1212,"activeCount":236,"soonestReadout":976},[1213,1217],{"nctId":973,"briefTitle":974,"status":244,"phases":1214,"primaryCompletion":976,"completion":977,"start":978,"enrollment":979,"conditions":1215,"interventions":1216},[90],[981,982,983,984,985,986,987,988,989],[991,124,966,992,993,994,995],{"nctId":1017,"briefTitle":1018,"status":131,"phases":1218,"primaryCompletion":1020,"completion":1021,"start":1022,"enrollment":1023,"conditions":1219,"interventions":1220},[90],[1025,1026,1027,1028],[992,993,1030,966,994,1031],{"trials":1222,"activeCount":192,"soonestReadout":1126},[1223,1227,1231,1247,1264,1268,1280,1284,1288],{"nctId":1035,"briefTitle":1036,"status":131,"phases":1224,"primaryCompletion":1038,"completion":1039,"start":1040,"enrollment":1041,"conditions":1225,"interventions":1226},[91],[1043,1044],[994,1046,993,992,1047,966,124,1015],{"nctId":1068,"briefTitle":1069,"status":244,"phases":1228,"primaryCompletion":1071,"completion":1072,"start":1073,"enrollment":23,"conditions":1229,"interventions":1230},[91],[1075,1076],[1078,994,993,992,1079,125,966,124,1030],{"nctId":1232,"briefTitle":1233,"status":131,"phases":1234,"primaryCompletion":1235,"completion":1236,"start":1237,"enrollment":1238,"conditions":1239,"interventions":1243},"NCT04383743","Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer",[91],"2024-06-17","2025-03-04","2020-11-24",17,[1240,1241,1242],"Stage II Bladder Cancer AJCC v8","Stage IIIA Bladder Cancer AJCC v8","Muscle Invasive Bladder Carcinoma",[1244,993,1245,125,1014,1246],"Cisplatin","Methotrexate","Vinblastine Sulfate",{"nctId":1248,"briefTitle":1249,"status":244,"phases":1250,"primaryCompletion":1251,"completion":1252,"start":1253,"enrollment":1254,"conditions":1255,"interventions":1260},"NCT06745076","Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma",[91],"2032-01-03","2033-01-03","2025-03-06",125,[1256,1257,1258,1259],"Advanced Hodgkin Lymphoma","Classic Hodgkin Lymphoma","Lugano Classification Stage III Hodgkin Lymphoma AJCC v8","Lugano Classification Stage IV Hodgkin Lymphoma AJCC v8",[1261,993,1262,1263],"Dacarbazine","Nivolumab","Vinblastine",{"nctId":1108,"briefTitle":1109,"status":244,"phases":1265,"primaryCompletion":1111,"completion":1112,"start":1113,"enrollment":1114,"conditions":1266,"interventions":1267},[90,91],[1116,115,1117],[994,993,966,1119,1120,1121,1030,991],{"nctId":1269,"briefTitle":1270,"status":131,"phases":1271,"primaryCompletion":1272,"completion":1272,"start":1273,"enrollment":1274,"conditions":1275,"interventions":1277},"NCT00194753","Adjuvant Therapy for High-Risk Breast Cancer With Wkly Adriamycin & Oral Cytoxan With G-CSF for 12 Wks; Wkly Taxol x 12",[91],"2011-03","2001-12",80,[1276],"Breast Neoplasm",[1278,993,994,1279],"Paclitaxel","G-CSF",{"nctId":1123,"briefTitle":1124,"status":174,"phases":1281,"primaryCompletion":1126,"completion":1127,"start":1128,"enrollment":1129,"conditions":1282,"interventions":1283},[91],[1075],[994,993,992,966,124,1121,1030],{"nctId":1165,"briefTitle":1166,"status":244,"phases":1285,"primaryCompletion":1168,"completion":1168,"start":1169,"enrollment":1170,"conditions":1286,"interventions":1287},[91],[1172,1173,1044],[994,993,992,1079,125,1175,966,124,1030],{"nctId":1177,"briefTitle":1178,"status":244,"phases":1289,"primaryCompletion":1180,"completion":1180,"start":1181,"enrollment":1182,"conditions":1290,"interventions":1291},[91],[1184,1185,983,984,985,986,987,988,1186],[994,993,1188,992,966,124],{"trials":1293,"activeCount":102},[],{"trials":1295,"activeCount":102},[],{"trials":1297,"activeCount":102},[],{"intervention":992,"totalTrials":1299,"cells":1300},16,{"EARLY_PHASE1":1301,"PHASE1":1303,"PHASE2":1324,"PHASE3":1440,"PHASE4":1442,"NA":1444},{"trials":1302,"activeCount":102},[],{"trials":1304,"activeCount":236,"soonestReadout":976},[1305,1309,1320],{"nctId":973,"briefTitle":974,"status":244,"phases":1306,"primaryCompletion":976,"completion":977,"start":978,"enrollment":979,"conditions":1307,"interventions":1308},[90],[981,982,983,984,985,986,987,988,989],[991,124,966,992,993,994,995],{"nctId":1310,"briefTitle":1311,"status":108,"phases":1312,"primaryCompletion":453,"start":1313,"enrollment":192,"conditions":1314,"interventions":1319},"NCT01411098","Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery",[90],"2011-10",[1315,1316,1317,1318],"Recurrent Non-small Cell Lung Cancer","Stage IIB Non-small Cell Lung Cancer","Stage IIIA Non-small Cell Lung Cancer","Stage IIIB Non-small Cell Lung Cancer",[207,170],{"nctId":1017,"briefTitle":1018,"status":131,"phases":1321,"primaryCompletion":1020,"completion":1021,"start":1022,"enrollment":1023,"conditions":1322,"interventions":1323},[90],[1025,1026,1027,1028],[992,993,1030,966,994,1031],{"trials":1325,"activeCount":1439,"soonestReadout":1126},[1326,1330,1334,1342,1346,1359,1374,1387,1410,1423,1427,1431,1435],{"nctId":1035,"briefTitle":1036,"status":131,"phases":1327,"primaryCompletion":1038,"completion":1039,"start":1040,"enrollment":1041,"conditions":1328,"interventions":1329},[91],[1043,1044],[994,1046,993,992,1047,966,124,1015],{"nctId":129,"briefTitle":130,"status":131,"phases":1331,"primaryCompletion":133,"start":134,"enrollment":135,"conditions":1332,"interventions":1333},[91],[137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165],[167,168,169,170],{"nctId":1335,"briefTitle":1336,"status":131,"phases":1337,"primaryCompletion":225,"completion":225,"start":189,"enrollment":1338,"conditions":1339,"interventions":1340},"NCT01165112","Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma",[90,91],48,[146,150],[1341,123,124,992],"Bendamustine Hydrochloride",{"nctId":1068,"briefTitle":1069,"status":244,"phases":1343,"primaryCompletion":1071,"completion":1072,"start":1073,"enrollment":23,"conditions":1344,"interventions":1345},[91],[1075,1076],[1078,994,993,992,1079,125,966,124,1030],{"nctId":1347,"briefTitle":1348,"status":244,"phases":1349,"primaryCompletion":1350,"completion":1351,"start":1352,"enrollment":1353,"conditions":1354,"interventions":1357},"NCT06039371","Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study",[91],"2027-03-31","2027-12-31","2024-05-21",69,[1355,1356,1063],"Castration-Resistant Prostate Carcinoma","Metastatic Prostate Adenocarcinoma",[123,992,1358],"Testosterone Cypionate",{"nctId":1360,"briefTitle":1361,"status":108,"phases":1362,"primaryCompletion":1363,"completion":1363,"start":1364,"enrollment":236,"conditions":1365,"interventions":1371},"NCT04372927","ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy",[91],"2022-04-23","2021-12-10",[1366,1367,1368,1369,1370],"Locally Advanced Lung Non-Small Cell Carcinoma","Stage III Lung Cancer AJCC v8","Stage IIIA Lung Cancer AJCC v8","Stage IIIB Lung Cancer AJCC v8","Stage IIIC Lung Cancer AJCC v8",[1244,1372,992,1373],"Durvalumab","Pemetrexed",{"nctId":1375,"briefTitle":1376,"status":1150,"phases":1377,"primaryCompletion":1378,"completion":1379,"start":1380,"enrollment":102,"conditions":1381,"interventions":1386},"NCT05161533","Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial",[91],"2024-10-01","2024-12-31","2023-10-19",[1382,1383,1384,1385],"Extensive Stage Lung Small Cell Carcinoma","Stage IV Lung Cancer AJCC v8","Stage IVA Lung Cancer AJCC v8","Stage IVB Lung Cancer AJCC v8",[123,1244,1372,992],{"nctId":1388,"briefTitle":1389,"status":131,"phases":1390,"primaryCompletion":347,"start":410,"enrollment":1391,"conditions":1392,"interventions":1406},"NCT00601718","Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma",[90,91],29,[137,138,139,1393,140,141,143,1394,145,146,147,148,149,150,151,152,154,155,156,157,158,159,160,161,164,1395,1396,1397,1398,1399,1400,1401,1402,1403,1404,1405,165],"Contiguous Stage II Mantle Cell Lymphoma","Noncontiguous Stage II Mantle Cell Lymphoma","Stage I Cutaneous T-cell Non-Hodgkin Lymphoma","Stage I Mantle Cell Lymphoma","Stage I Mycosis Fungoides\u002FSezary Syndrome","Stage II Cutaneous T-cell Non-Hodgkin Lymphoma","Stage II Mycosis Fungoides\u002FSezary Syndrome","Stage III Cutaneous T-cell Non-Hodgkin Lymphoma","Stage III Mantle Cell Lymphoma","Stage III Mycosis Fungoides\u002FSezary Syndrome","Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma","Stage IV Mantle Cell Lymphoma","Stage IV Mycosis Fungoides\u002FSezary Syndrome",[445,1407,1408,1409,170,448],"rituximab","ifosfamide","carboplatin",{"nctId":1411,"briefTitle":1412,"status":131,"phases":1413,"primaryCompletion":1414,"completion":1415,"start":1416,"enrollment":1417,"conditions":1418,"interventions":1421},"NCT02227199","Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma",[90,91],"2020-03-30","2025-07-28","2014-10-10",45,[1419,1420],"Recurrent Hodgkin Lymphoma","Refractory Hodgkin Lymphoma",[72,123,992,1422],"Ifosfamide",{"nctId":1123,"briefTitle":1124,"status":174,"phases":1424,"primaryCompletion":1126,"completion":1127,"start":1128,"enrollment":1129,"conditions":1425,"interventions":1426},[91],[1075],[994,993,992,966,124,1121,1030],{"nctId":1148,"briefTitle":1149,"status":1150,"phases":1428,"primaryCompletion":1152,"completion":1153,"start":1154,"enrollment":102,"conditions":1429,"interventions":1430},[91],[1156,1157,1158,1026,1159,1028,1160,1076,1161],[1163,994,1013,992,1047,966,124,1015],{"nctId":1165,"briefTitle":1166,"status":244,"phases":1432,"primaryCompletion":1168,"completion":1168,"start":1169,"enrollment":1170,"conditions":1433,"interventions":1434},[91],[1172,1173,1044],[994,993,992,1079,125,1175,966,124,1030],{"nctId":1177,"briefTitle":1178,"status":244,"phases":1436,"primaryCompletion":1180,"completion":1180,"start":1181,"enrollment":1182,"conditions":1437,"interventions":1438},[91],[1184,1185,983,984,985,986,987,988,1186],[994,993,1188,992,966,124],5,{"trials":1441,"activeCount":102},[],{"trials":1443,"activeCount":102},[],{"trials":1445,"activeCount":102},[],{"intervention":124,"totalTrials":1299,"cells":1447},{"EARLY_PHASE1":1448,"PHASE1":1450,"PHASE2":1464,"PHASE3":1561,"PHASE4":1563,"NA":1565},{"trials":1449,"activeCount":102},[],{"trials":1451,"activeCount":236,"soonestReadout":976},[1452,1456,1460],{"nctId":973,"briefTitle":974,"status":244,"phases":1453,"primaryCompletion":976,"completion":977,"start":978,"enrollment":979,"conditions":1454,"interventions":1455},[90],[981,982,983,984,985,986,987,988,989],[991,124,966,992,993,994,995],{"nctId":106,"briefTitle":107,"status":108,"phases":1457,"primaryCompletion":110,"completion":111,"start":112,"enrollment":113,"conditions":1458,"interventions":1459},[90],[115,116,117,118,119],[121,122,123,97,124,125],{"nctId":997,"briefTitle":998,"status":131,"phases":1461,"primaryCompletion":1000,"completion":1000,"start":1001,"enrollment":23,"conditions":1462,"interventions":1463},[90],[1003,115,1004,1005,1006,1007,1008,1009,1010,1011],[994,1013,1014,966,124,1015],{"trials":1465,"activeCount":1439,"soonestReadout":61},[1466,1470,1485,1489,1493,1504,1516,1520,1533,1537,1541,1553,1557],{"nctId":1035,"briefTitle":1036,"status":131,"phases":1467,"primaryCompletion":1038,"completion":1039,"start":1040,"enrollment":1041,"conditions":1468,"interventions":1469},[91],[1043,1044],[994,1046,993,992,1047,966,124,1015],{"nctId":1471,"briefTitle":1472,"status":131,"phases":1473,"primaryCompletion":1474,"completion":1475,"start":1476,"enrollment":1477,"conditions":1478,"interventions":1483},"NCT00446251","Effects of Rituximab and Mycophenolate Mofetil (MMF) on Highly Sensitized Patients Awaiting Renal Transplant",[91],"2008-04","2008-12","2006-12",14,[1479,1480,1481,1482],"Kidney Failure, Chronic","Diabetic Nephropathies","Glomerulonephritis, IGA","Hypertension, Renal",[124,1484],"Mycophenolate mofetil",{"nctId":1335,"briefTitle":1336,"status":131,"phases":1486,"primaryCompletion":225,"completion":225,"start":189,"enrollment":1338,"conditions":1487,"interventions":1488},[90,91],[146,150],[1341,123,124,992],{"nctId":1068,"briefTitle":1069,"status":244,"phases":1490,"primaryCompletion":1071,"completion":1072,"start":1073,"enrollment":23,"conditions":1491,"interventions":1492},[91],[1075,1076],[1078,994,993,992,1079,125,966,124,1030],{"nctId":1494,"briefTitle":1495,"status":108,"phases":1496,"primaryCompletion":1497,"completion":1498,"start":1499,"enrollment":1182,"conditions":1500,"interventions":1502},"NCT03401853","Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma",[91],"2023-12-19","2024-09-19","2018-03-23",[116,117,118,1501],"Refractory Follicular Lymphoma",[1014,124,1503],"Obinutuzumab",{"nctId":1505,"briefTitle":1506,"status":108,"phases":1507,"primaryCompletion":1508,"completion":1508,"start":1509,"enrollment":236,"conditions":1510,"interventions":1514},"NCT04155840","Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",[91],"2021-03-16","2020-01-31",[1511,119,1512,1513],"Lymphoid Leukemia","Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma",[121,124,1515],"Bendamustine",{"nctId":1388,"briefTitle":1389,"status":131,"phases":1517,"primaryCompletion":347,"start":410,"enrollment":1391,"conditions":1518,"interventions":1519},[90,91],[137,138,139,1393,140,141,143,1394,145,146,147,148,149,150,151,152,154,155,156,157,158,159,160,161,164,1395,1396,1397,1398,1399,1400,1401,1402,1403,1404,1405,165],[445,1407,1408,1409,170,448],{"nctId":59,"briefTitle":60,"status":174,"phases":1521,"primaryCompletion":61,"completion":1522,"start":1523,"enrollment":1170,"conditions":1524,"interventions":1532},[91],"2031-01-06","2016-05-19",[1512,1525,1526,1527,1528,1529,1530,1513,1531],"Follicular Lymphoma","Lymphoplasmacytic Lymphoma","Mantle Cell Lymphoma","Marginal Zone Lymphoma","Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue","Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue","Waldenstrom Macroglobulinemia",[62,124],{"nctId":1123,"briefTitle":1124,"status":174,"phases":1534,"primaryCompletion":1126,"completion":1127,"start":1128,"enrollment":1129,"conditions":1535,"interventions":1536},[91],[1075],[994,993,992,966,124,1121,1030],{"nctId":1148,"briefTitle":1149,"status":1150,"phases":1538,"primaryCompletion":1152,"completion":1153,"start":1154,"enrollment":102,"conditions":1539,"interventions":1540},[91],[1156,1157,1158,1026,1159,1028,1160,1076,1161],[1163,994,1013,992,1047,966,124,1015],{"nctId":1542,"briefTitle":1543,"status":108,"phases":1544,"primaryCompletion":1545,"completion":1545,"start":1546,"enrollment":1547,"conditions":1548,"interventions":1552},"NCT03269552","Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma",[91],"2018-12-28","2017-12-18",4,[1528,159,1549,1550,1551,1531],"Recurrent Waldenstrom Macroglobulinemia","Refractory Marginal Zone Lymphoma","Refractory Waldenstrom Macroglobulinemia",[182,124],{"nctId":1165,"briefTitle":1166,"status":244,"phases":1554,"primaryCompletion":1168,"completion":1168,"start":1169,"enrollment":1170,"conditions":1555,"interventions":1556},[91],[1172,1173,1044],[994,993,992,1079,125,1175,966,124,1030],{"nctId":1177,"briefTitle":1178,"status":244,"phases":1558,"primaryCompletion":1180,"completion":1180,"start":1181,"enrollment":1182,"conditions":1559,"interventions":1560},[91],[1184,1185,983,984,985,986,987,988,1186],[994,993,1188,992,966,124],{"trials":1562,"activeCount":102},[],{"trials":1564,"activeCount":102},[],{"trials":1566,"activeCount":102},[],{"intervention":994,"totalTrials":673,"cells":1568},{"EARLY_PHASE1":1569,"PHASE1":1571,"PHASE2":1609,"PHASE3":1688,"PHASE4":1690,"NA":1692},{"trials":1570,"activeCount":102},[],{"trials":1572,"activeCount":236,"soonestReadout":976},[1573,1583,1587,1601,1605],{"nctId":1574,"briefTitle":1575,"status":1150,"phases":1576,"primaryCompletion":1577,"start":1578,"enrollment":102,"conditions":1579,"interventions":1580},"NCT01219907","Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast Cancer",[90],"2014-06","2012-06",[354,275,36],[1581,233,1582],"HER-2\u002Fneu peptide vaccine","ex vivo-expanded HER2-specific T cells",{"nctId":973,"briefTitle":974,"status":244,"phases":1584,"primaryCompletion":976,"completion":977,"start":978,"enrollment":979,"conditions":1585,"interventions":1586},[90],[981,982,983,984,985,986,987,988,989],[991,124,966,992,993,994,995],{"nctId":1588,"briefTitle":1589,"status":131,"phases":1590,"primaryCompletion":1591,"start":1592,"enrollment":317,"conditions":1593,"interventions":1599},"NCT00228358","Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2\u002FNeu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2\u002FNeu Vaccine",[90],"2011-05","2003-06",[354,377,1315,1594,1595,36,1596,1597,1598],"Recurrent Ovarian Epithelial Cancer","Recurrent Ovarian Germ Cell Tumor","Stage IV Non-small Cell Lung Cancer","Stage IV Ovarian Epithelial Cancer","Stage IV Ovarian Germ Cell Tumor",[1582,233,1600],"denileukin diftitox",{"nctId":997,"briefTitle":998,"status":131,"phases":1602,"primaryCompletion":1000,"completion":1000,"start":1001,"enrollment":23,"conditions":1603,"interventions":1604},[90],[1003,115,1004,1005,1006,1007,1008,1009,1010,1011],[994,1013,1014,966,124,1015],{"nctId":1017,"briefTitle":1018,"status":131,"phases":1606,"primaryCompletion":1020,"completion":1021,"start":1022,"enrollment":1023,"conditions":1607,"interventions":1608},[90],[1025,1026,1027,1028],[992,993,1030,966,994,1031],{"trials":1610,"activeCount":1439,"soonestReadout":1126},[1611,1615,1625,1629,1633,1637,1645,1655,1659,1663,1667,1671,1680,1684],{"nctId":1035,"briefTitle":1036,"status":131,"phases":1612,"primaryCompletion":1038,"completion":1039,"start":1040,"enrollment":1041,"conditions":1613,"interventions":1614},[91],[1043,1044],[994,1046,993,992,1047,966,124,1015],{"nctId":1616,"briefTitle":1617,"status":131,"phases":1618,"primaryCompletion":1619,"completion":1620,"start":1621,"enrollment":34,"conditions":1622,"interventions":1623},"NCT00791037","Vaccine Therapy in Treating Patients With Stage IV Breast Cancer",[90,91],"2013-07","2014-12","2008-10",[354,275,377,36],[1581,1582,233,1624],"sargramostim",{"nctId":1068,"briefTitle":1069,"status":244,"phases":1626,"primaryCompletion":1071,"completion":1072,"start":1073,"enrollment":23,"conditions":1627,"interventions":1628},[91],[1075,1076],[1078,994,993,992,1079,125,966,124,1030],{"nctId":344,"briefTitle":345,"status":131,"phases":1630,"primaryCompletion":347,"completion":348,"start":349,"enrollment":350,"conditions":1631,"interventions":1632},[91],[352,353,354,355,356,357,358,277,278],[280,233,360,169,361,362,363,364,365,316],{"nctId":1108,"briefTitle":1109,"status":244,"phases":1634,"primaryCompletion":1111,"completion":1112,"start":1113,"enrollment":1114,"conditions":1635,"interventions":1636},[90,91],[1116,115,1117],[994,993,966,1119,1120,1121,1030,991],{"nctId":1638,"briefTitle":1639,"status":131,"phases":1640,"primaryCompletion":190,"completion":1641,"start":1642,"enrollment":23,"conditions":1643,"interventions":1644},"NCT00331552","Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer",[90,91],"2012-02","2006-02",[354,275,377,36],[234,233,364],{"nctId":1646,"briefTitle":1647,"status":131,"phases":1648,"primaryCompletion":739,"completion":1649,"start":1650,"enrollment":427,"conditions":1651,"interventions":1653},"NCT00513695","Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer",[91],"2017-10-16","2007-06",[1652,275,277,278,378,379],"Inflammatory Breast Cancer",[1654,360,280,233,169],"sunitinib malate",{"nctId":1269,"briefTitle":1270,"status":131,"phases":1656,"primaryCompletion":1272,"completion":1272,"start":1273,"enrollment":1274,"conditions":1657,"interventions":1658},[91],[1276],[1278,993,994,1279],{"nctId":1123,"briefTitle":1124,"status":174,"phases":1660,"primaryCompletion":1126,"completion":1127,"start":1128,"enrollment":1129,"conditions":1661,"interventions":1662},[91],[1075],[994,993,992,966,124,1121,1030],{"nctId":221,"briefTitle":222,"status":108,"phases":1664,"primaryCompletion":224,"completion":225,"start":226,"enrollment":227,"conditions":1665,"interventions":1666},[90,91],[162,229,230,231],[233,234,235,168],{"nctId":1148,"briefTitle":1149,"status":1150,"phases":1668,"primaryCompletion":1152,"completion":1153,"start":1154,"enrollment":102,"conditions":1669,"interventions":1670},[91],[1156,1157,1158,1026,1159,1028,1160,1076,1161],[1163,994,1013,992,1047,966,124,1015],{"nctId":1672,"briefTitle":1673,"status":131,"phases":1674,"primaryCompletion":1675,"completion":440,"start":1676,"enrollment":389,"conditions":1677,"interventions":1678},"NCT00407888","Doxorubicin Hydrochloride, Cyclophosphamide, and Filgrastim Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation With or Without Trastuzumab in Treating Patients With Breast Cancer Previously Treated With Surgery",[91],"2009-05","2006-05",[353,354,357,358,277,278,378,379,36],[280,233,169,1679,364],"paclitaxel albumin-stabilized nanoparticle formulation",{"nctId":1165,"briefTitle":1166,"status":244,"phases":1681,"primaryCompletion":1168,"completion":1168,"start":1169,"enrollment":1170,"conditions":1682,"interventions":1683},[91],[1172,1173,1044],[994,993,992,1079,125,1175,966,124,1030],{"nctId":1177,"briefTitle":1178,"status":244,"phases":1685,"primaryCompletion":1180,"completion":1180,"start":1181,"enrollment":1182,"conditions":1686,"interventions":1687},[91],[1184,1185,983,984,985,986,987,988,1186],[994,993,1188,992,966,124],{"trials":1689,"activeCount":102},[],{"trials":1691,"activeCount":102},[],{"trials":1693,"activeCount":102},[1694],{"nctId":268,"briefTitle":269,"status":131,"phases":1695,"primaryCompletion":271,"completion":271,"start":272,"enrollment":273,"conditions":1696,"interventions":1697},[94],[275,194,276,277,278],[208,233,168,280,281],{"intervention":48,"totalTrials":1439,"cells":1699},{"EARLY_PHASE1":1700,"PHASE1":1702,"PHASE2":1713,"PHASE3":1769,"PHASE4":1771,"NA":1773},{"trials":1701,"activeCount":102},[],{"trials":1703,"activeCount":236,"soonestReadout":47},[1704],{"nctId":45,"briefTitle":46,"status":174,"phases":1705,"primaryCompletion":47,"completion":1706,"start":225,"enrollment":1707,"conditions":1708,"interventions":1712},[90],"2026-09-01",42,[1709,1710,278,378,379,36,1711],"HER2 Negative Breast Carcinoma","Recurrent Breast Carcinoma","Stage III Breast Cancer",[48],{"trials":1714,"activeCount":1547,"soonestReadout":52},[1715,1727,1739,1763],{"nctId":1716,"briefTitle":1717,"status":244,"phases":1718,"primaryCompletion":1168,"completion":1719,"start":1720,"enrollment":310,"conditions":1721,"interventions":1722},"NCT07112053","A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer",[91],"2028-12-31","2025-11-17",[392,395,396],[48,1723,1724,1725,43,1726,398],"Capecitabine","Cyclin-Dependent Kinase 4 Inhibitor","Cyclin-Dependent Kinase 6 Inhibitor","Hormone Therapy",{"nctId":1728,"briefTitle":1729,"status":244,"phases":1730,"primaryCompletion":1731,"completion":1732,"start":1733,"enrollment":673,"conditions":1734,"interventions":1736},"NCT07078604","A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer",[91],"2027-04-30","2028-06-30","2026-03-20",[392,1735],"Metastatic Triple-Negative Breast Carcinoma",[48,1737,1738],"Chemotherapy","Sargramostim",{"nctId":1740,"briefTitle":1741,"status":174,"phases":1742,"primaryCompletion":1743,"completion":1744,"start":1745,"enrollment":1170,"conditions":1746,"interventions":1762},"NCT05455658","STEMVAC in Patients With Early Stage Triple Negative Breast Cancer",[91],"2026-07-16","2028-07-16","2022-11-17",[1747,430,1748,1749,391,1750,1751,1752,1753,1754,1755,1756,1757,1758,1759,1760,1761],"Anatomic Stage IB Breast Cancer AJCC v8","Anatomic Stage IIA Breast Cancer AJCC v8","Anatomic Stage IIB Breast Cancer AJCC v8","Anatomic Stage IIIA Breast Cancer AJCC v8","Anatomic Stage IIIB Breast Cancer AJCC v8","Anatomic Stage IIIC Breast Cancer AJCC v8","Prognostic Stage IB Breast Cancer AJCC v8","Prognostic Stage II Breast Cancer AJCC v8","Prognostic Stage IIA Breast Cancer AJCC v8","Prognostic Stage IIB Breast Cancer AJCC v8","Prognostic Stage III Breast Cancer AJCC v8","Prognostic Stage IIIA Breast Cancer AJCC v8","Prognostic Stage IIIB Breast Cancer AJCC v8","Prognostic Stage IIIC Breast Cancer AJCC v8","Triple-Negative Breast Carcinoma",[48,1738],{"nctId":50,"briefTitle":51,"status":174,"phases":1764,"primaryCompletion":52,"completion":176,"start":1765,"enrollment":1439,"conditions":1766,"interventions":1768},[91],"2023-03-24",[1767,1383],"Lung Non-Small Cell Carcinoma",[48,1738],{"trials":1770,"activeCount":102},[],{"trials":1772,"activeCount":102},[],{"trials":1774,"activeCount":102},[],{"intervention":123,"totalTrials":1299,"cells":1776},{"EARLY_PHASE1":1777,"PHASE1":1779,"PHASE2":1795,"PHASE3":1934,"PHASE4":1936,"NA":1938},{"trials":1778,"activeCount":102},[],{"trials":1780,"activeCount":102},[1781,1785],{"nctId":106,"briefTitle":107,"status":108,"phases":1782,"primaryCompletion":110,"completion":111,"start":112,"enrollment":113,"conditions":1783,"interventions":1784},[90],[115,116,117,118,119],[121,122,123,97,124,125],{"nctId":1786,"briefTitle":1787,"status":131,"phases":1788,"completion":1789,"start":1790,"enrollment":1182,"conditions":1791,"interventions":1793},"NCT00238147","Combination Chemotherapy and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Esophageal Cancer",[90],"2008-08","2004-09",[1792],"Esophageal Cancer",[361,1409,1794],"docetaxel",{"trials":1796,"activeCount":1547,"soonestReadout":1801},[1797,1809,1822,1826,1845,1849,1859,1871,1879,1883,1887,1891,1900,1909],{"nctId":1798,"briefTitle":1799,"status":174,"phases":1800,"primaryCompletion":1801,"completion":1802,"start":1803,"enrollment":1087,"conditions":1804,"interventions":1808},"NCT04387227","Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",[91],"2025-09-12","2026-06-01","2021-03-18",[1805,1806,1807],"Recurrent Fallopian Tube Carcinoma","Recurrent Ovarian Carcinoma","Recurrent Primary Peritoneal Carcinoma",[123,1014],{"nctId":1810,"briefTitle":1811,"status":599,"phases":1812,"primaryCompletion":1813,"completion":476,"start":1814,"enrollment":1815,"conditions":1816,"interventions":1820},"NCT07495124","IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence",[91],"2027-09-29","2026-07-01",26,[1817,1818,1819],"Fallopian Tube Carcinoma","Ovarian Carcinoma","Primary Peritoneal Carcinoma",[1821,123],"pUMVC3-hIGFBP-2 Multi-epitope Plasmid DNA Vaccine",{"nctId":1335,"briefTitle":1336,"status":131,"phases":1823,"primaryCompletion":225,"completion":225,"start":189,"enrollment":1338,"conditions":1824,"interventions":1825},[90,91],[146,150],[1341,123,124,992],{"nctId":1827,"briefTitle":1828,"status":108,"phases":1829,"primaryCompletion":1830,"completion":1830,"start":1831,"enrollment":1182,"conditions":1832,"interventions":1841},"NCT03442556","Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency",[91],"2025-06-04","2018-08-24",[1833,1834,1835,1836,1355,1837,1838,1839,1840,1091],"ATM Gene Mutation","BRCA1 Gene Mutation","BRCA2 Gene Mutation","Castration Levels of Testosterone","Homologous Recombination Deficiency","Prostate Carcinoma Metastatic in the Bone","PSA Level Greater Than or Equal to Two","PSA Progression",[123,1842,1843,1844],"Docetaxel","Rucaparib Camsylate","Rucaparib",{"nctId":1347,"briefTitle":1348,"status":244,"phases":1846,"primaryCompletion":1350,"completion":1351,"start":1352,"enrollment":1353,"conditions":1847,"interventions":1848},[91],[1355,1356,1063],[123,992,1358],{"nctId":1850,"briefTitle":1851,"status":244,"phases":1852,"primaryCompletion":176,"completion":1351,"start":1853,"enrollment":29,"conditions":1854,"interventions":1855},"NCT04329065","Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer",[91],"2022-04-20",[429,430,391],[1856,1278,1857,1858,1842,123],"pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine","Trastuzumab","Pertuzumab",{"nctId":1860,"briefTitle":1861,"status":131,"phases":1862,"primaryCompletion":1863,"completion":1864,"start":1865,"enrollment":1866,"conditions":1867,"interventions":1869},"NCT00564733","FDG-Labeled PET Scan in Planning Chemotherapy in Treating Patients With Stage IIIB or IV Non-Small Cell Lung Cancer",[91],"2011-09","2012-03","2007-10",55,[1868,1318,1596],"Malignant Pleural Effusion",[1409,1794,1870,360],"gemcitabine hydrochloride",{"nctId":1872,"briefTitle":1873,"status":131,"phases":1874,"primaryCompletion":1875,"completion":1875,"start":1876,"enrollment":1477,"conditions":1877,"interventions":1878},"NCT02598895","Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1\u002F2 Pathway",[91],"2021-09-14","2016-01-26",[1836,1355,1058,1838,1840,1142],[123,1842],{"nctId":1375,"briefTitle":1376,"status":1150,"phases":1880,"primaryCompletion":1378,"completion":1379,"start":1380,"enrollment":102,"conditions":1881,"interventions":1882},[91],[1382,1383,1384,1385],[123,1244,1372,992],{"nctId":1388,"briefTitle":1389,"status":131,"phases":1884,"primaryCompletion":347,"start":410,"enrollment":1391,"conditions":1885,"interventions":1886},[90,91],[137,138,139,1393,140,141,143,1394,145,146,147,148,149,150,151,152,154,155,156,157,158,159,160,161,164,1395,1396,1397,1398,1399,1400,1401,1402,1403,1404,1405,165],[445,1407,1408,1409,170,448],{"nctId":1411,"briefTitle":1412,"status":131,"phases":1888,"primaryCompletion":1414,"completion":1415,"start":1416,"enrollment":1417,"conditions":1889,"interventions":1890},[90,91],[1419,1420],[72,123,992,1422],{"nctId":1892,"briefTitle":1893,"status":131,"phases":1894,"primaryCompletion":1895,"completion":1896,"start":1897,"enrollment":1391,"conditions":1898,"interventions":1899},"NCT03029598","Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",[90,91],"2021-04-20","2021-12-31","2017-03-14",[1805,1806,1807],[123,1014],{"nctId":1901,"briefTitle":1902,"status":108,"phases":1903,"primaryCompletion":1904,"completion":1904,"start":1905,"enrollment":26,"conditions":1906,"interventions":1907},"NCT02565901","Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer",[90,91],"2020-06-16","2016-02-29",[1355,1058,1092,1057],[123,1842,1908],"Sirolimus",{"nctId":1910,"briefTitle":1911,"status":108,"phases":1912,"primaryCompletion":1913,"completion":1914,"start":1915,"enrollment":1207,"conditions":1916,"interventions":1932},"NCT03029611","IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery",[91],"2018-10-17","2019-12-10","2017-04-03",[1917,1918,1919,1920,1921,1922,1923,1924,1925,1926,1927,1928,1929,1930,1931],"Stage III Fallopian Tube Cancer","Stage III Ovarian Cancer","Stage III Primary Peritoneal Cancer","Stage IIIA Fallopian Tube Cancer","Stage IIIA Ovarian Cancer","Stage IIIA Primary Peritoneal Cancer","Stage IIIB Fallopian Tube Cancer","Stage IIIB Ovarian Cancer","Stage IIIB Primary Peritoneal Cancer","Stage IIIC Fallopian Tube Cancer","Stage IIIC Ovarian Cancer","Stage IIIC Primary Peritoneal Cancer","Stage IV Fallopian Tube Cancer","Stage IV Ovarian Cancer","Stage IV Primary Peritoneal Cancer",[123,1278,1933],"pUMVC3-hIGFBP-2 Multi-Epitope Plasmid DNA Vaccine",{"trials":1935,"activeCount":102},[],{"trials":1937,"activeCount":102},[],{"trials":1939,"activeCount":102},[],{"intervention":1030,"totalTrials":1439,"cells":1941},{"EARLY_PHASE1":1942,"PHASE1":1944,"PHASE2":1950,"PHASE3":1968,"PHASE4":1970,"NA":1972},{"trials":1943,"activeCount":102},[],{"trials":1945,"activeCount":102},[1946],{"nctId":1017,"briefTitle":1018,"status":131,"phases":1947,"primaryCompletion":1020,"completion":1021,"start":1022,"enrollment":1023,"conditions":1948,"interventions":1949},[90],[1025,1026,1027,1028],[992,993,1030,966,994,1031],{"trials":1951,"activeCount":1547,"soonestReadout":1126},[1952,1956,1960,1964],{"nctId":1068,"briefTitle":1069,"status":244,"phases":1953,"primaryCompletion":1071,"completion":1072,"start":1073,"enrollment":23,"conditions":1954,"interventions":1955},[91],[1075,1076],[1078,994,993,992,1079,125,966,124,1030],{"nctId":1108,"briefTitle":1109,"status":244,"phases":1957,"primaryCompletion":1111,"completion":1112,"start":1113,"enrollment":1114,"conditions":1958,"interventions":1959},[90,91],[1116,115,1117],[994,993,966,1119,1120,1121,1030,991],{"nctId":1123,"briefTitle":1124,"status":174,"phases":1961,"primaryCompletion":1126,"completion":1127,"start":1128,"enrollment":1129,"conditions":1962,"interventions":1963},[91],[1075],[994,993,992,966,124,1121,1030],{"nctId":1165,"briefTitle":1166,"status":244,"phases":1965,"primaryCompletion":1168,"completion":1168,"start":1169,"enrollment":1170,"conditions":1966,"interventions":1967},[91],[1172,1173,1044],[994,993,992,1079,125,1175,966,124,1030],{"trials":1969,"activeCount":102},[],{"trials":1971,"activeCount":102},[],{"trials":1973,"activeCount":102},[],{"intervention":398,"totalTrials":1547,"cells":1975},{"EARLY_PHASE1":1976,"PHASE1":1978,"PHASE2":1990,"PHASE3":2017,"PHASE4":2019,"NA":2021},{"trials":1977,"activeCount":102},[],{"trials":1979,"activeCount":236,"soonestReadout":1984},[1980],{"nctId":1981,"briefTitle":1982,"status":244,"phases":1983,"primaryCompletion":1984,"completion":1985,"start":1986,"enrollment":1182,"conditions":1987,"interventions":1989},"NCT06025747","Evaluation of Abemaciclib and Radiation Therapy Before Surgery for the Treatment of High-Risk Adipocytic Retroperitoneal Sarcoma",[90],"2027-03-03","2029-03-03","2025-03-19",[1988],"Retroperitoneal Sarcoma",[398],{"trials":1991,"activeCount":702,"soonestReadout":2000},[1992,1996,2013],{"nctId":1716,"briefTitle":1717,"status":244,"phases":1993,"primaryCompletion":1168,"completion":1719,"start":1720,"enrollment":310,"conditions":1994,"interventions":1995},[91],[392,395,396],[48,1723,1724,1725,43,1726,398],{"nctId":1997,"briefTitle":1998,"status":174,"phases":1999,"primaryCompletion":2000,"completion":808,"start":2001,"enrollment":673,"conditions":2002,"interventions":2012},"NCT03891784","Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors",[91],"2025-11-01","2019-10-31",[2003,2004,2005,2006,2007,2008,2009,2010,2011],"Advanced Digestive System Neuroendocrine Neoplasm","Digestive System Neuroendocrine Tumor","Foregut Neuroendocrine Tumor","Hindgut Neuroendocrine Tumor","Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm","Metastatic Digestive System Neuroendocrine Neoplasm","Midgut Neuroendocrine Tumor","Pancreatic Neuroendocrine Tumor","Refractory Digestive System Neuroendocrine Neoplasm",[398],{"nctId":383,"briefTitle":384,"status":244,"phases":2014,"primaryCompletion":386,"completion":387,"start":388,"enrollment":389,"conditions":2015,"interventions":2016},[91],[391,392,393,394,395,396],[398,399,400,401,402,403,342,404,405],{"trials":2018,"activeCount":102},[],{"trials":2020,"activeCount":102},[],{"trials":2022,"activeCount":102},[],{"intervention":1624,"totalTrials":1207,"cells":2024},{"EARLY_PHASE1":2025,"PHASE1":2027,"PHASE2":2074,"PHASE3":2125,"PHASE4":2127,"NA":2129},{"trials":2026,"activeCount":102},[],{"trials":2028,"activeCount":102},[2029,2039,2052,2060],{"nctId":2030,"briefTitle":2031,"status":131,"phases":2032,"primaryCompletion":2033,"completion":2033,"start":2034,"conditions":2035,"interventions":2038},"NCT00005023","Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer",[90],"2001-01","1999-03",[413,2036,2037],"Lung Cancer","Ovarian Cancer",[1581,1624],{"nctId":2040,"briefTitle":2041,"status":131,"phases":2042,"primaryCompletion":1137,"completion":2043,"start":2044,"enrollment":2045,"conditions":2046,"interventions":2049},"NCT00436254","Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer",[90],"2025-04-01","2001-10",66,[354,2047,2048,278,378,379,36,1597,1598],"Stage III Ovarian Epithelial Cancer","Stage III Ovarian Germ Cell Tumor",[2050,1624,2051],"pNGVL3-hICD vaccine","protein expression analysis",{"nctId":2053,"briefTitle":2054,"status":131,"phases":2055,"primaryCompletion":2056,"completion":2056,"start":2057,"enrollment":389,"conditions":2058,"interventions":2059},"NCT00003002","HER-2\u002FNeu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer",[90],"2004-01","1996-04",[413,2036,2037],[1581,1624],{"nctId":2061,"briefTitle":2062,"status":131,"phases":2063,"primaryCompletion":2064,"completion":2065,"start":2066,"enrollment":1129,"conditions":2067,"interventions":2073},"NCT02780401","Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission",[90],"2020-10-08","2022-10-08","2016-09-02",[2068,2069,2070,358,277,2071,2072,1711,278,378,379],"HER2\u002FNeu Negative","No Evidence of Disease","One or More Positive Axillary Nodes","Stage IIA Breast Cancer","Stage IIB Breast Cancer",[1856,1738],{"trials":2075,"activeCount":702,"soonestReadout":52},[2076,2080,2084,2094,2098,2102,2110],{"nctId":1616,"briefTitle":1617,"status":131,"phases":2077,"primaryCompletion":1619,"completion":1620,"start":1621,"enrollment":34,"conditions":2078,"interventions":2079},[90,91],[354,275,377,36],[1581,1582,233,1624],{"nctId":1728,"briefTitle":1729,"status":244,"phases":2081,"primaryCompletion":1731,"completion":1732,"start":1733,"enrollment":673,"conditions":2082,"interventions":2083},[91],[392,1735],[48,1737,1738],{"nctId":2085,"briefTitle":2086,"status":131,"phases":2087,"primaryCompletion":225,"start":2088,"enrollment":2089,"conditions":2090,"interventions":2091},"NCT00343109","Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer",[91],"2004-03",38,[354,275,378,379,36],[2092,1624,2093],"HER-2\u002Fneu intracellular domain protein","synthetic tumor-associated peptide vaccine therapy",{"nctId":1740,"briefTitle":1741,"status":174,"phases":2095,"primaryCompletion":1743,"completion":1744,"start":1745,"enrollment":1170,"conditions":2096,"interventions":2097},[91],[1747,430,1748,1749,391,1750,1751,1752,1753,1754,1755,1756,1757,1758,1759,1760,1761],[48,1738],{"nctId":50,"briefTitle":51,"status":174,"phases":2099,"primaryCompletion":52,"completion":176,"start":1765,"enrollment":1439,"conditions":2100,"interventions":2101},[91],[1767,1383],[48,1738],{"nctId":2103,"briefTitle":2104,"status":131,"phases":2105,"primaryCompletion":133,"start":2106,"enrollment":350,"conditions":2107,"interventions":2108},"NCT01355393","Vaccine Therapy in Combination With Rintatolimod and\u002For Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer",[90,91],"2011-07",[354,275,377,277,278,378,379,36],[1581,1624,2109],"rintatolimod",{"nctId":2111,"briefTitle":2112,"status":131,"phases":2113,"primaryCompletion":2106,"start":1676,"enrollment":37,"conditions":2114,"interventions":2124},"NCT00466960","Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy",[91],[2115,2116,2117,2118,2119,2120,2121,2122,2123,1594,2047,1597],"Brenner Tumor","Fallopian Tube Cancer","Ovarian Clear Cell Cystadenocarcinoma","Ovarian Endometrioid Adenocarcinoma","Ovarian Mixed Epithelial Carcinoma","Ovarian Mucinous Cystadenocarcinoma","Ovarian Serous Cystadenocarcinoma","Ovarian Undifferentiated Adenocarcinoma","Peritoneal Cavity Cancer",[1624,1679],{"trials":2126,"activeCount":102},[],{"trials":2128,"activeCount":102},[],{"trials":2130,"activeCount":102},[],{"intervention":2132,"totalTrials":1439,"cells":2133},"Psilocybin",{"EARLY_PHASE1":2134,"PHASE1":2136,"PHASE2":2148,"PHASE3":2177,"PHASE4":2194,"NA":2196},{"trials":2135,"activeCount":102},[],{"trials":2137,"activeCount":102},[2138],{"nctId":2139,"briefTitle":2140,"status":131,"phases":2141,"primaryCompletion":2142,"completion":2142,"start":2143,"enrollment":456,"conditions":2144,"interventions":2147},"NCT06644170","A Second Psilocybin Group Therapy for the Treatment of Cancer-Related Anxiety in Partial Responders With Metastatic Cancer",[90],"2025-09-30","2024-11-19",[2145,2146],"Hematopoietic and Lymphatic System Neoplasm","Metastatic Malignant Solid Neoplasm",[2132],{"trials":2149,"activeCount":264,"soonestReadout":2154},[2150,2159,2168],{"nctId":2151,"briefTitle":2152,"status":244,"phases":2153,"primaryCompletion":2154,"completion":1351,"start":2155,"enrollment":1182,"conditions":2156,"interventions":2158},"NCT07336238","Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies",[91],"2027-07-01","2026-05-19",[2157,16,2145,2146],"Anxiety",[2132],{"nctId":2160,"briefTitle":2161,"status":599,"phases":2162,"primaryCompletion":2163,"completion":2164,"start":602,"enrollment":2165,"conditions":2166,"interventions":2167},"NCT07565909","Group Retreat Psilocybin Therapy for Healthcare Clinicians With Loss of Meaning in Their Work and Symptoms of Depression",[91],"2027-12","2028-07",72,[16,2157],[2132],{"nctId":2169,"briefTitle":2170,"status":131,"phases":2171,"primaryCompletion":2172,"completion":2173,"start":2174,"enrollment":1866,"conditions":2175,"interventions":2176},"NCT05847686","Psilocybin-Assisted Therapy for the Treatment of Cancer-Related Anxiety in Patients With Metastatic Cancer",[90,91],"2024-04-08","2024-10-17","2023-06-27",[2145,2146],[2132],{"trials":2178,"activeCount":102},[2179],{"nctId":2180,"briefTitle":2181,"status":131,"phases":2182,"primaryCompletion":2183,"completion":2184,"start":2185,"enrollment":23,"conditions":2186,"interventions":2192},"NCT05163496","Frontline Clinician Psilocybin Study",[92],"2023-12-30","2024-06-30","2022-03-03",[2187,2188,2189,16,2190,2191],"Burnout, Caregiver","Burnout, Professional","COVID-19","Post Traumatic Stress Disorder","Moral Injury",[2132,2193],"Active placebo",{"trials":2195,"activeCount":102},[],{"trials":2197,"activeCount":102},[],{"intervention":1014,"totalTrials":1299,"cells":2199},{"EARLY_PHASE1":2200,"PHASE1":2202,"PHASE2":2221,"PHASE3":2363,"PHASE4":2365,"NA":2367},{"trials":2201,"activeCount":102},[],{"trials":2203,"activeCount":102},[2204,2217],{"nctId":2205,"briefTitle":2206,"status":108,"phases":2207,"primaryCompletion":2208,"completion":2208,"start":2209,"enrollment":192,"conditions":2210,"interventions":2215},"NCT03260504","Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer",[90],"2022-07-26","2018-08-28",[2211,2212,2213,2214],"Advanced Clear Cell Renal Cell Carcinoma","Stage III Renal Cell Cancer","Stage IV Renal Cell Cancer","Metastatic Clear Cell Renal Cell Carcinoma",[2216,1014],"Aldesleukin",{"nctId":997,"briefTitle":998,"status":131,"phases":2218,"primaryCompletion":1000,"completion":1000,"start":1001,"enrollment":23,"conditions":2219,"interventions":2220},[90],[1003,115,1004,1005,1006,1007,1008,1009,1010,1011],[994,1013,1014,966,124,1015],{"trials":2222,"activeCount":264,"soonestReadout":1801},[2223,2227,2252,2256,2260,2269,2282,2293,2303,2319,2331,2335,2344,2354],{"nctId":1798,"briefTitle":1799,"status":174,"phases":2224,"primaryCompletion":1801,"completion":1802,"start":1803,"enrollment":1087,"conditions":2225,"interventions":2226},[91],[1805,1806,1807],[123,1014],{"nctId":2228,"briefTitle":2229,"status":131,"phases":2230,"primaryCompletion":2231,"completion":2232,"start":2233,"enrollment":350,"conditions":2234,"interventions":2250},"NCT02538510","Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and\u002For Cannot Be Removed by Surgery",[90,91],"2019-09-28","2023-09-15","2015-10-08",[2235,2236,2237,2238,2239,2240,2241,2242,2243,2244,2245,2246,2247,2248,2249],"Head and Neck Squamous Cell Carcinoma","Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma","Recurrent Nasopharynx Carcinoma","Recurrent Salivary Gland Carcinoma","Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary","Stage III Major Salivary Gland Carcinoma","Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma","Stage III Nasopharyngeal Carcinoma","Stage IV Nasopharyngeal Carcinoma","Stage IVA Major Salivary Gland Carcinoma","Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma","Stage IVB Major Salivary Gland Carcinoma","Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma","Stage IVC Major Salivary Gland Carcinoma","Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma",[1014,2251],"Vorinostat",{"nctId":1232,"briefTitle":1233,"status":131,"phases":2253,"primaryCompletion":1235,"completion":1236,"start":1237,"enrollment":1238,"conditions":2254,"interventions":2255},[91],[1240,1241,1242],[1244,993,1245,125,1014,1246],{"nctId":1494,"briefTitle":1495,"status":108,"phases":2257,"primaryCompletion":1497,"completion":1498,"start":1499,"enrollment":1182,"conditions":2258,"interventions":2259},[91],[116,117,118,1501],[1014,124,1503],{"nctId":2261,"briefTitle":2262,"status":108,"phases":2263,"primaryCompletion":1875,"completion":1875,"start":2264,"enrollment":192,"conditions":2265,"interventions":2267},"NCT03776864","Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma",[91],"2019-09-26",[2266],"Hodgkin's Lymphoma",[1014,2268],"Umbralisib",{"nctId":2270,"briefTitle":2271,"status":1150,"phases":2272,"primaryCompletion":2273,"completion":2274,"start":2275,"enrollment":102,"conditions":2276,"interventions":2281},"NCT03644589","Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer",[91],"2021-10-30","2022-10-30","2019-04-01",[2277,2068,2278,2279,1710,2280],"Estrogen Receptor Negative","Metastatic Breast Cancer","Progesterone Receptor Negative","Triple Negative Breast Cancer",[1014,1244],{"nctId":2283,"briefTitle":2284,"status":108,"phases":2285,"primaryCompletion":2286,"completion":2287,"start":2288,"enrollment":113,"conditions":2289,"interventions":2292},"NCT02767934","Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia",[91],"2019-07-31","2019-12-17","2017-01-13",[1156,2290,2291,1076],"Minimal Residual Disease","Recurrent Acute Lymphoblastic Leukemia",[1014],{"nctId":2294,"briefTitle":2295,"status":108,"phases":2296,"primaryCompletion":2297,"completion":2298,"start":2299,"enrollment":98,"conditions":2300,"interventions":2302},"NCT03498612","Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases",[91],"2021-06-09","2024-08-29","2018-07-09",[1525,2301,1528],"Indolent B-Cell Non-Hodgkin Lymphoma",[1014],{"nctId":2304,"briefTitle":2305,"status":108,"phases":2306,"primaryCompletion":2307,"completion":2308,"start":2309,"enrollment":37,"conditions":2310,"interventions":2316},"NCT03050060","Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer",[91],"2018-10-01","2020-07-12","2017-06-09",[2311,2312,2313,2314,2315],"Metastatic Kidney Carcinoma","Recurrent Lung Non-Small Cell Carcinoma","Stage IV Cutaneous Melanoma AJCC v6 and v7","Stage IV Renal Cell Cancer AJCC v7","Stage IV Lung Non-Small Cell Cancer AJCC v7",[2317,2318,1262,1014],"Atezolizumab","Nelfinavir Mesylate",{"nctId":2320,"briefTitle":2321,"status":108,"phases":2322,"primaryCompletion":2323,"completion":2324,"start":1895,"enrollment":264,"conditions":2325,"interventions":2329},"NCT04442581","Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer",[91],"2021-12-13","2022-03-08",[2326,2327,2328],"Advanced Hepatocellular Carcinoma","BCLC Stage B Hepatocellular Carcinoma","BCLC Stage C Hepatocellular Carcinoma",[2330,1014],"Cabozantinib S-malate",{"nctId":1892,"briefTitle":1893,"status":131,"phases":2332,"primaryCompletion":1895,"completion":1896,"start":1897,"enrollment":1391,"conditions":2333,"interventions":2334},[90,91],[1805,1806,1807],[123,1014],{"nctId":2336,"briefTitle":2337,"status":131,"phases":2338,"primaryCompletion":2339,"completion":2339,"start":2340,"enrollment":350,"conditions":2341,"interventions":2343},"NCT03331341","Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma",[90,91],"2023-12-21","2019-01-09",[2342],"Classical Hodgkin Lymphoma",[1261,1013,1014,1263],{"nctId":2345,"briefTitle":2346,"status":108,"phases":2347,"primaryCompletion":2348,"completion":2349,"start":2350,"enrollment":113,"conditions":2351,"interventions":2353},"NCT03486197","Neutron Radiation Therapy and Pembrolizumab in Treating Participants With Advanced Urothelial Carcinoma",[91],"2023-11-01","2024-05-01","2019-01-17",[2352],"Urothelial Carcinoma",[1014],{"nctId":2355,"briefTitle":2356,"status":244,"phases":2357,"primaryCompletion":2154,"completion":1101,"start":2358,"enrollment":23,"conditions":2359,"interventions":2361},"NCT05570825","SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer",[91],"2023-04-06",[2360,2312,1370,1383],"Metastatic Lung Non-Small Cell Carcinoma",[2362,1014],"CXCR1\u002F2 Inhibitor SX-682",{"trials":2364,"activeCount":102},[],{"trials":2366,"activeCount":102},[],{"trials":2368,"activeCount":102},[],{"intervention":169,"totalTrials":2370,"cells":2371},13,{"EARLY_PHASE1":2372,"PHASE1":2374,"PHASE2":2376,"PHASE3":2496,"PHASE4":2498,"NA":2500},{"trials":2373,"activeCount":102},[],{"trials":2375,"activeCount":102},[],{"trials":2377,"activeCount":264,"soonestReadout":1071},[2378,2382,2386,2405,2428,2432,2436,2445,2452,2472,2476,2480,2489],{"nctId":129,"briefTitle":130,"status":131,"phases":2379,"primaryCompletion":133,"start":134,"enrollment":135,"conditions":2380,"interventions":2381},[91],[137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165],[167,168,169,170],{"nctId":1068,"briefTitle":1069,"status":244,"phases":2383,"primaryCompletion":1071,"completion":1072,"start":1073,"enrollment":23,"conditions":2384,"interventions":2385},[91],[1075,1076],[1078,994,993,992,1079,125,966,124,1030],{"nctId":2387,"briefTitle":2388,"status":131,"phases":2389,"primaryCompletion":2390,"completion":2391,"start":2392,"enrollment":2393,"conditions":2394,"interventions":2400},"NCT02728050","Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome",[90,91],"2022-02-03","2023-04-04","2016-12-01",84,[2395,2396,2397,2398,2399],"Acute Biphenotypic Leukemia","Acute Myeloid Leukemia","de Novo Myelodysplastic Syndrome","Myelodysplastic Syndrome","Myeloproliferative Neoplasm",[2401,2402,1079,2403,2404],"Cladribine","Cytarabine","Mitoxantrone","Sorafenib",{"nctId":2406,"briefTitle":2407,"status":131,"phases":2408,"primaryCompletion":2409,"completion":2410,"start":2411,"enrollment":23,"conditions":2412,"interventions":2421},"NCT02756572","Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms",[91],"2020-03-01","2020-07-01","2016-09-22",[2413,2414,2415,2398,2416,2417,2418,2419,2420],"Blasts 10 Percent or More of Bone Marrow Nucleated Cells","Chronic Myelomonocytic Leukemia-2","High Grade Malignant Neoplasm","Myelodysplastic Syndrome With Excess Blasts-2","Myeloid Neoplasm","Previously Treated Myelodysplastic Syndrome","Recurrent Acute Myeloid Leukemia","Refractory Acute Myeloid Leukemia",[2401,2422,2402,1079,2423,2424,2425,2426,1908,2427],"Cyclosporine","Fludarabine Phosphate","Melphalan","Mitoxantrone Hydrochloride","Mycophenolate Mofetil","Melphalan Hydrochloride",{"nctId":344,"briefTitle":345,"status":131,"phases":2429,"primaryCompletion":347,"completion":348,"start":349,"enrollment":350,"conditions":2430,"interventions":2431},[91],[352,353,354,355,356,357,358,277,278],[280,233,360,169,361,362,363,364,365,316],{"nctId":1646,"briefTitle":1647,"status":131,"phases":2433,"primaryCompletion":739,"completion":1649,"start":1650,"enrollment":427,"conditions":2434,"interventions":2435},[91],[1652,275,277,278,378,379],[1654,360,280,233,169],{"nctId":2437,"briefTitle":2438,"status":108,"phases":2439,"primaryCompletion":1789,"completion":1789,"start":2440,"enrollment":2089,"conditions":2441,"interventions":2442},"NCT00041470","Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial",[90,91],"2001-03",[413],[1278,2443,2444,1079],"Vinorelbine","Herceptin",{"nctId":2446,"briefTitle":2447,"status":131,"phases":2448,"completion":1650,"start":2449,"enrollment":1338,"conditions":2450,"interventions":2451},"NCT00194740","Taxotere Plus Weekly Navelbine and G-CSF: A Study in Stage IV Breast Cancer",[91],"1997-11",[1276],[1842,2443,1079],{"nctId":2453,"briefTitle":2454,"status":131,"phases":2455,"primaryCompletion":331,"completion":2456,"start":134,"enrollment":350,"conditions":2457,"interventions":2469},"NCT01101880","Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and\u002For Advanced Myeloproliferative Neoplasm",[91],"2017-07",[2458,2459,2460,2461,2462,2463,2464,2465,2466,2467,2468],"Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities","Adult Acute Myeloid Leukemia With Del(5q)","Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)","Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)","Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)","Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)","Chronic Myelomonocytic Leukemia","de Novo Myelodysplastic Syndromes","Refractory Anemia With Excess Blasts","Untreated Adult Acute Myeloid Leukemia","Myeloproliferative Neoplasm With 10% Blasts or Higher",[169,2470,2471],"clofarabine","cytarabine",{"nctId":1672,"briefTitle":1673,"status":131,"phases":2473,"primaryCompletion":1675,"completion":440,"start":1676,"enrollment":389,"conditions":2474,"interventions":2475},[91],[353,354,357,358,277,278,378,379,36],[280,233,169,1679,364],{"nctId":1165,"briefTitle":1166,"status":244,"phases":2477,"primaryCompletion":1168,"completion":1168,"start":1169,"enrollment":1170,"conditions":2478,"interventions":2479},[91],[1172,1173,1044],[994,993,992,1079,125,1175,966,124,1030],{"nctId":2481,"briefTitle":2482,"status":131,"phases":2483,"primaryCompletion":1137,"completion":2484,"start":410,"enrollment":350,"conditions":2485,"interventions":2488},"NCT00602225","Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia",[90,91],"2015-04",[2396,2458,2460,2461,2462,2463,2486,2487],"Adult Acute Promyelocytic Leukemia (M3)","Recurrent Adult Acute Myeloid Leukemia",[2470,2471,169],{"nctId":2490,"briefTitle":2491,"status":108,"phases":2492,"primaryCompletion":190,"start":191,"enrollment":264,"conditions":2493,"interventions":2495},"NCT00863434","Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual Disease",[91],[2494,2458,2460,2461,2462,2463,2487],"Adult Acute Myeloid Leukemia in Remission",[2470,2471,169],{"trials":2497,"activeCount":102},[],{"trials":2499,"activeCount":102},[],{"trials":2501,"activeCount":102},[],{"intervention":1262,"totalTrials":192,"cells":2503},{"EARLY_PHASE1":2504,"PHASE1":2506,"PHASE2":2508,"PHASE3":2571,"PHASE4":2573,"NA":2575},{"trials":2505,"activeCount":102},[],{"trials":2507,"activeCount":102},[],{"trials":2509,"activeCount":264,"soonestReadout":71},[2510,2525,2529,2535,2551,2555],{"nctId":2511,"briefTitle":2512,"status":131,"phases":2513,"primaryCompletion":2514,"completion":2515,"start":2516,"enrollment":673,"conditions":2517,"interventions":2524},"NCT04205409","Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies",[91],"2024-09-20","2026-01-05","2020-06-05",[2518,116,117,155,156,157,2519,159,2520,216,2521,118,1501,1550,2522,217,158,2523],"Recurrent Chronic Lymphocytic Leukemia","Recurrent Grade 3a Follicular Lymphoma","Recurrent Non-Hodgkin Lymphoma","Refractory Chronic Lymphocytic Leukemia","Refractory Non-Hodgkin Lymphoma","Refractory Mantle Cell Lymphoma",[1262],{"nctId":1248,"briefTitle":1249,"status":244,"phases":2526,"primaryCompletion":1251,"completion":1252,"start":1253,"enrollment":1254,"conditions":2527,"interventions":2528},[91],[1256,1257,1258,1259],[1261,993,1262,1263],{"nctId":69,"briefTitle":70,"status":174,"phases":2530,"primaryCompletion":71,"completion":2531,"start":2532,"enrollment":26,"conditions":2533,"interventions":2534},[91],"2030-06-03","2013-03-20",[1419,2520,1420,2522],[72,1262],{"nctId":2536,"briefTitle":2537,"status":131,"phases":2538,"primaryCompletion":2539,"completion":2540,"start":2541,"enrollment":673,"conditions":2542,"interventions":2549},"NCT03749460","Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers",[90,91],"2022-11-05","2023-11-05","2019-01-15",[1057,2543,2544,2545,2546,2547,2548],"Metastatic Malignant Neoplasm in the Lung","Salivary Gland Carcinoma","Stage IV Major Salivary Gland Cancer AJCC v8","Stage IVA Major Salivary Gland Cancer AJCC v8","Stage IVB Major Salivary Gland Cancer AJCC v8","Stage IVC Major Salivary Gland Cancer AJCC v8",[1262,2550],"Ipilimumab",{"nctId":2304,"briefTitle":2305,"status":108,"phases":2552,"primaryCompletion":2307,"completion":2308,"start":2309,"enrollment":37,"conditions":2553,"interventions":2554},[91],[2311,2312,2313,2314,2315],[2317,2318,1262,1014],{"nctId":2556,"briefTitle":2557,"status":108,"phases":2558,"primaryCompletion":2559,"completion":2560,"start":2561,"enrollment":1439,"conditions":2562,"interventions":2569},"NCT02846792","Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer",[90,91],"2018-07-12","2018-08-16","2017-06-14",[2563,2564,2565,2566,2567,2568],"ALK Gene Translocation","EGFR Activating Mutation","Recurrent Non-Small Cell Lung Carcinoma","ROS1 Gene Translocation","Stage IIIB Non-Small Cell Lung Cancer AJCC v7","Stage IV Non-Small Cell Lung Cancer AJCC v7",[1262,2570],"Plinabulin",{"trials":2572,"activeCount":102},[],{"trials":2574,"activeCount":102},[],{"trials":2576,"activeCount":102},[],{"intervention":125,"totalTrials":1547,"cells":2578},{"EARLY_PHASE1":2579,"PHASE1":2581,"PHASE2":2587,"PHASE3":2601,"PHASE4":2603,"NA":2605},{"trials":2580,"activeCount":102},[],{"trials":2582,"activeCount":102},[2583],{"nctId":106,"briefTitle":107,"status":108,"phases":2584,"primaryCompletion":110,"completion":111,"start":112,"enrollment":113,"conditions":2585,"interventions":2586},[90],[115,116,117,118,119],[121,122,123,97,124,125],{"trials":2588,"activeCount":264,"soonestReadout":1071},[2589,2593,2597],{"nctId":1068,"briefTitle":1069,"status":244,"phases":2590,"primaryCompletion":1071,"completion":1072,"start":1073,"enrollment":23,"conditions":2591,"interventions":2592},[91],[1075,1076],[1078,994,993,992,1079,125,966,124,1030],{"nctId":1232,"briefTitle":1233,"status":131,"phases":2594,"primaryCompletion":1235,"completion":1236,"start":1237,"enrollment":1238,"conditions":2595,"interventions":2596},[91],[1240,1241,1242],[1244,993,1245,125,1014,1246],{"nctId":1165,"briefTitle":1166,"status":244,"phases":2598,"primaryCompletion":1168,"completion":1168,"start":1169,"enrollment":1170,"conditions":2599,"interventions":2600},[91],[1172,1173,1044],[994,993,992,1079,125,1175,966,124,1030],{"trials":2602,"activeCount":102},[],{"trials":2604,"activeCount":102},[],{"trials":2606,"activeCount":102},[],{"intervention":122,"totalTrials":702,"cells":2608},{"EARLY_PHASE1":2609,"PHASE1":2611,"PHASE2":2617,"PHASE3":2640,"PHASE4":2642,"NA":2644},{"trials":2610,"activeCount":102},[],{"trials":2612,"activeCount":102},[2613],{"nctId":106,"briefTitle":107,"status":108,"phases":2614,"primaryCompletion":110,"completion":111,"start":112,"enrollment":113,"conditions":2615,"interventions":2616},[90],[115,116,117,118,119],[121,122,123,97,124,125],{"trials":2618,"activeCount":264,"soonestReadout":2623},[2619,2629],{"nctId":2620,"briefTitle":2621,"status":599,"phases":2622,"primaryCompletion":2623,"completion":2624,"start":1802,"enrollment":1170,"conditions":2625,"interventions":2627},"NCT07332351","Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial",[91],"2027-01-01","2027-02-01",[2626,1240,1241],"Muscle Invasive Bladder Urothelial Carcinoma",[2628,1372,122,1244],"Nadofaragene Firadenovec",{"nctId":2630,"briefTitle":2631,"status":599,"phases":2632,"primaryCompletion":2633,"completion":2633,"start":1802,"enrollment":113,"conditions":2634,"interventions":2637},"NCT07579195","Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial",[90,91],"2029-12-31",[1242,2635,2636],"Stage III Bladder Cancer AJCC v8","Stage IV Bladder Cancer AJCC v8",[1244,122,2638,2639],"Fluorouracil","Mitomycin",{"trials":2641,"activeCount":102},[],{"trials":2643,"activeCount":102},[],{"trials":2645,"activeCount":102},[],{"intervention":991,"totalTrials":702,"cells":2647},{"EARLY_PHASE1":2648,"PHASE1":2650,"PHASE2":2656,"PHASE3":2675,"PHASE4":2677,"NA":2679},{"trials":2649,"activeCount":102},[],{"trials":2651,"activeCount":236,"soonestReadout":976},[2652],{"nctId":973,"briefTitle":974,"status":244,"phases":2653,"primaryCompletion":976,"completion":977,"start":978,"enrollment":979,"conditions":2654,"interventions":2655},[90],[981,982,983,984,985,986,987,988,989],[991,124,966,992,993,994,995],{"trials":2657,"activeCount":236,"soonestReadout":1111},[2658,2662],{"nctId":1108,"briefTitle":1109,"status":244,"phases":2659,"primaryCompletion":1111,"completion":1112,"start":1113,"enrollment":1114,"conditions":2660,"interventions":2661},[90,91],[1116,115,1117],[994,993,966,1119,1120,1121,1030,991],{"nctId":2663,"briefTitle":2664,"status":131,"phases":2665,"primaryCompletion":2666,"completion":2666,"start":2667,"enrollment":1707,"conditions":2668,"interventions":2673},"NCT05169658","Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma",[91],"2025-04-02","2022-03-23",[2669,2670,2671,2672,2301,1528,1529,1530],"Non-Hodgkin Lymphoma","Grade 1 Follicular Lymphoma","Grade 2 Follicular Lymphoma","Grade 3a Follicular Lymphoma",[2674,1503,991],"Mosunetuzumab",{"trials":2676,"activeCount":102},[],{"trials":2678,"activeCount":102},[],{"trials":2680,"activeCount":102},[],{"intervention":2674,"totalTrials":702,"cells":2682},{"EARLY_PHASE1":2683,"PHASE1":2685,"PHASE2":2687,"PHASE3":2715,"PHASE4":2717,"NA":2719},{"trials":2684,"activeCount":102},[],{"trials":2686,"activeCount":102},[],{"trials":2688,"activeCount":264,"soonestReadout":2693},[2689,2703,2711],{"nctId":2690,"briefTitle":2691,"status":244,"phases":2692,"primaryCompletion":2693,"completion":2694,"start":2298,"enrollment":673,"conditions":2695,"interventions":2702},"NCT06442475","Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma",[91],"2026-08-12","2027-02-12",[2696,2697,2698,2699,2700,2701,2670,2671,2672],"Ann Arbor Stage II Follicular Lymphoma","Ann Arbor Stage II Marginal Zone Lymphoma","Ann Arbor Stage III Follicular Lymphoma","Ann Arbor Stage III Marginal Zone Lymphoma","Ann Arbor Stage IV Follicular Lymphoma","Ann Arbor Stage IV Marginal Zone Lymphoma",[2674],{"nctId":2704,"briefTitle":2705,"status":244,"phases":2706,"primaryCompletion":2707,"completion":2707,"start":1720,"enrollment":1087,"conditions":2708,"interventions":2709},"NCT06948786","Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed\u002FRefractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial",[91],"2031-07-31",[2670,2671,2672,117,1501],[2710,2674],"Pirtobrutinib",{"nctId":2663,"briefTitle":2664,"status":131,"phases":2712,"primaryCompletion":2666,"completion":2666,"start":2667,"enrollment":1707,"conditions":2713,"interventions":2714},[91],[2669,2670,2671,2672,2301,1528,1529,1530],[2674,1503,991],{"trials":2716,"activeCount":102},[],{"trials":2718,"activeCount":102},[],{"trials":2720,"activeCount":102},[],{"intervention":403,"totalTrials":264,"cells":2722},{"EARLY_PHASE1":2723,"PHASE1":2725,"PHASE2":2727,"PHASE3":2744,"PHASE4":2746,"NA":2748},{"trials":2724,"activeCount":102},[],{"trials":2726,"activeCount":102},[],{"trials":2728,"activeCount":264,"soonestReadout":386},[2729,2740],{"nctId":2730,"briefTitle":2731,"status":599,"phases":2732,"primaryCompletion":2733,"completion":2733,"start":727,"enrollment":389,"conditions":2734,"interventions":2737},"NCT07466498","Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial",[91],"2029-06-01",[2735,2736,1063],"Castration-Sensitive Prostate Adenocarcinoma","Metastatic Castration-Sensitive Prostate Adenocarcinoma",[2738,2739,403],"Androgen Receptor Pathway Inhibitor","Transdermal Estrogen",{"nctId":383,"briefTitle":384,"status":244,"phases":2741,"primaryCompletion":386,"completion":387,"start":388,"enrollment":389,"conditions":2742,"interventions":2743},[91],[391,392,393,394,395,396],[398,399,400,401,402,403,342,404,405],{"trials":2745,"activeCount":102},[],{"trials":2747,"activeCount":102},[],{"trials":2749,"activeCount":102},[],{"intervention":1119,"totalTrials":264,"cells":2751},{"EARLY_PHASE1":2752,"PHASE1":2754,"PHASE2":2756,"PHASE3":2775,"PHASE4":2777,"NA":2779},{"trials":2753,"activeCount":102},[],{"trials":2755,"activeCount":102},[],{"trials":2757,"activeCount":264,"soonestReadout":1111},[2758,2762],{"nctId":1108,"briefTitle":1109,"status":244,"phases":2759,"primaryCompletion":1111,"completion":1112,"start":1113,"enrollment":1114,"conditions":2760,"interventions":2761},[90,91],[1116,115,1117],[994,993,966,1119,1120,1121,1030,991],{"nctId":2763,"briefTitle":2764,"status":174,"phases":2765,"primaryCompletion":2766,"completion":1731,"start":2767,"enrollment":113,"conditions":2768,"interventions":2772},"NCT06056895","Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma",[91],"2027-01-31","2023-11-08",[2769,2770,2771],"Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8","Clinical Stage IV Merkel Cell Carcinoma AJCC v8","Merkel Cell Carcinoma",[1119,2773,2774],"Tuparstobart","Verzistobart",{"trials":2776,"activeCount":102},[],{"trials":2778,"activeCount":102},[],{"trials":2780,"activeCount":102},[],{"intervention":1121,"totalTrials":264,"cells":2782},{"EARLY_PHASE1":2783,"PHASE1":2785,"PHASE2":2787,"PHASE3":2797,"PHASE4":2799,"NA":2801},{"trials":2784,"activeCount":102},[],{"trials":2786,"activeCount":102},[],{"trials":2788,"activeCount":264,"soonestReadout":1126},[2789,2793],{"nctId":1108,"briefTitle":1109,"status":244,"phases":2790,"primaryCompletion":1111,"completion":1112,"start":1113,"enrollment":1114,"conditions":2791,"interventions":2792},[90,91],[1116,115,1117],[994,993,966,1119,1120,1121,1030,991],{"nctId":1123,"briefTitle":1124,"status":174,"phases":2794,"primaryCompletion":1126,"completion":1127,"start":1128,"enrollment":1129,"conditions":2795,"interventions":2796},[91],[1075],[994,993,992,966,124,1121,1030],{"trials":2798,"activeCount":102},[],{"trials":2800,"activeCount":102},[],{"trials":2802,"activeCount":102},[],{"intervention":2804,"totalTrials":264,"cells":2805},"Pacritinib",{"EARLY_PHASE1":2806,"PHASE1":2808,"PHASE2":2810,"PHASE3":2841,"PHASE4":2843,"NA":2845},{"trials":2807,"activeCount":102},[],{"trials":2809,"activeCount":102},[],{"trials":2811,"activeCount":264,"soonestReadout":2829},[2812,2825],{"nctId":2813,"briefTitle":2814,"status":244,"phases":2815,"primaryCompletion":1719,"completion":1719,"start":2816,"enrollment":2817,"conditions":2818,"interventions":2821},"NCT07148947","Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms",[91],"2026-03-02",27,[2819,2820],"Accelerated Phase Myeloproliferative Neoplasm","Blast Phase Myeloproliferative Neoplasm",[2804,2822,2823,2824],"Decitabine","Decitabine and Cedazuridine","Azacitidine",{"nctId":2826,"briefTitle":2827,"status":244,"phases":2828,"primaryCompletion":2829,"completion":2829,"start":2830,"enrollment":29,"conditions":2831,"interventions":2838},"NCT04282187","Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated\u002FBlast Phase Myeloproliferative Neoplasms",[91],"2026-11-11","2020-03-24",[2396,2832,2398,2833,2399,2834,2835,2836,2837],"Essential Thrombocythemia","Myelodysplastic\u002FMyeloproliferative Neoplasm","Myeloproliferative Neoplasm, Not Otherwise Specified","Polycythemia Vera","Primary Myelofibrosis","Secondary Myelofibrosis",[2822,2839,2840,2804],"Ruxolitinib","Fedratinib",{"trials":2842,"activeCount":102},[],{"trials":2844,"activeCount":102},[],{"trials":2846,"activeCount":102},[],{"intervention":2362,"totalTrials":264,"cells":2848},{"EARLY_PHASE1":2849,"PHASE1":2851,"PHASE2":2853,"PHASE3":2868,"PHASE4":2870,"NA":2872},{"trials":2850,"activeCount":102},[],{"trials":2852,"activeCount":102},[],{"trials":2854,"activeCount":264,"soonestReadout":2154},[2855,2864],{"nctId":2856,"briefTitle":2857,"status":599,"phases":2858,"primaryCompletion":2859,"completion":2860,"start":1802,"enrollment":1129,"conditions":2861,"interventions":2863},"NCT07322341","SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer",[91],"2030-11-01","2031-11-01",[2862,2360,2312,1367,1383],"Advanced Lung Non-Small Cell Carcinoma",[2317,2362],{"nctId":2355,"briefTitle":2356,"status":244,"phases":2865,"primaryCompletion":2154,"completion":1101,"start":2358,"enrollment":23,"conditions":2866,"interventions":2867},[91],[2360,2312,1370,1383],[2362,1014],{"trials":2869,"activeCount":102},[],{"trials":2871,"activeCount":102},[],{"trials":2873,"activeCount":102},[],{"intervention":1244,"totalTrials":1477,"cells":2875},{"EARLY_PHASE1":2876,"PHASE1":2878,"PHASE2":2907,"PHASE3":2967,"PHASE4":2969,"NA":2971},{"trials":2877,"activeCount":102},[],{"trials":2879,"activeCount":102},[2880,2889,2903],{"nctId":2881,"briefTitle":2882,"status":131,"phases":2883,"primaryCompletion":2884,"completion":2884,"start":2885,"enrollment":113,"conditions":2886,"interventions":2887},"NCT02508246","WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck",[90],"2018-04-26","2015-07-22",[2235],[1244,1842,2888],"WEE1 Inhibitor AZD1775",{"nctId":2890,"briefTitle":2891,"status":131,"phases":2892,"primaryCompletion":2893,"completion":2894,"start":2895,"enrollment":350,"conditions":2896,"interventions":2901},"NCT01104259","Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and\u002For Metastatic Breast Cancer",[90],"2015-02","2017-04","2010-07",[352,2897,2898,2899,275,355,377,36,2900],"HER2-negative Breast Cancer","Hereditary Breast\u002FOvarian Cancer - BRCA1","Hereditary Breast\u002FOvarian Cancer - BRCA2","Triple-negative Breast Cancer",[2902,207,363],"veliparib",{"nctId":1310,"briefTitle":1311,"status":108,"phases":2904,"primaryCompletion":453,"start":1313,"enrollment":192,"conditions":2905,"interventions":2906},[90],[1315,1316,1317,1318],[207,170],{"trials":2908,"activeCount":264,"soonestReadout":2623},[2909,2917,2921,2925,2935,2939,2943,2947,2951,2955],{"nctId":2910,"briefTitle":2911,"status":131,"phases":2912,"primaryCompletion":1137,"completion":133,"start":2913,"enrollment":29,"conditions":2914,"interventions":2915},"NCT00227539","Positron Emission Tomography in Predicting Response in Patients Who Are Undergoing Treatment With Pemetrexed Disodium and Cisplatin With or Without Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer",[91],"2005-07",[2036],[207,2916],"pemetrexed disodium",{"nctId":1232,"briefTitle":1233,"status":131,"phases":2918,"primaryCompletion":1235,"completion":1236,"start":1237,"enrollment":1238,"conditions":2919,"interventions":2920},[91],[1240,1241,1242],[1244,993,1245,125,1014,1246],{"nctId":1360,"briefTitle":1361,"status":108,"phases":2922,"primaryCompletion":1363,"completion":1363,"start":1364,"enrollment":236,"conditions":2923,"interventions":2924},[91],[1366,1367,1368,1369,1370],[1244,1372,992,1373],{"nctId":2926,"briefTitle":2927,"status":131,"phases":2928,"primaryCompletion":2929,"start":2930,"enrollment":2931,"conditions":2932,"interventions":2933},"NCT00410826","Cisplatin and Radiation Therapy With or Without Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Head and Neck Cancer",[91],"2012-05","2006-06",204,[195,196,197,198,199,200,201,202,203,204],[2934,207],"erlotinib hydrochloride",{"nctId":186,"briefTitle":187,"status":108,"phases":2936,"primaryCompletion":189,"completion":190,"start":191,"enrollment":192,"conditions":2937,"interventions":2938},[91],[194,195,196,197,198,199,200,201,202,203,204],[206,207,208,168],{"nctId":1375,"briefTitle":1376,"status":1150,"phases":2940,"primaryCompletion":1378,"completion":1379,"start":1380,"enrollment":102,"conditions":2941,"interventions":2942},[91],[1382,1383,1384,1385],[123,1244,1372,992],{"nctId":2620,"briefTitle":2621,"status":599,"phases":2944,"primaryCompletion":2623,"completion":2624,"start":1802,"enrollment":1170,"conditions":2945,"interventions":2946},[91],[2626,1240,1241],[2628,1372,122,1244],{"nctId":2270,"briefTitle":2271,"status":1150,"phases":2948,"primaryCompletion":2273,"completion":2274,"start":2275,"enrollment":102,"conditions":2949,"interventions":2950},[91],[2277,2068,2278,2279,1710,2280],[1014,1244],{"nctId":2630,"briefTitle":2631,"status":599,"phases":2952,"primaryCompletion":2633,"completion":2633,"start":1802,"enrollment":113,"conditions":2953,"interventions":2954},[90,91],[1242,2635,2636],[1244,122,2638,2639],{"nctId":2956,"briefTitle":2957,"status":131,"phases":2958,"primaryCompletion":2959,"completion":2959,"start":719,"enrollment":37,"conditions":2960,"interventions":2965},"NCT01938573","Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer",[90,91],"2016-08-18",[2961,2962,2963,2964],"Recurrent Bladder Carcinoma","Stage II Bladder Cancer","Stage III Bladder Cancer","Stage IV Bladder Cancer",[1244,2966,1908],"Gemcitabine Hydrochloride",{"trials":2968,"activeCount":102},[],{"trials":2970,"activeCount":102},[],{"trials":2972,"activeCount":102},[2973],{"nctId":2974,"briefTitle":2975,"status":2976,"phases":2977,"conditions":2978,"interventions":2981},"NCT02985658","Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer","NO_LONGER_AVAILABLE",[],[2979,2980],"Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation","Triple-Negative Breast Cancer",[2982,1244,2443],"Veliparib",{"intervention":1737,"totalTrials":1547,"cells":2984},{"EARLY_PHASE1":2985,"PHASE1":2987,"PHASE2":2989,"PHASE3":2995,"PHASE4":2997,"NA":2999},{"trials":2986,"activeCount":102},[],{"trials":2988,"activeCount":102},[],{"trials":2990,"activeCount":236,"soonestReadout":1731},[2991],{"nctId":1728,"briefTitle":1729,"status":244,"phases":2992,"primaryCompletion":1731,"completion":1732,"start":1733,"enrollment":673,"conditions":2993,"interventions":2994},[91],[392,1735],[48,1737,1738],{"trials":2996,"activeCount":102},[],{"trials":2998,"activeCount":102},[],{"trials":3000,"activeCount":236,"soonestReadout":3005},[3001,3009,3019],{"nctId":3002,"briefTitle":3003,"status":244,"phases":3004,"primaryCompletion":3005,"completion":3005,"start":2264,"enrollment":1274,"conditions":3006,"interventions":3007},"NCT04151940","PET\u002FCT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer",[94],"2027-11-30",[2360,2312,1383],[1737,3008],"Immunotherapy",{"nctId":3010,"briefTitle":3011,"status":131,"phases":3012,"primaryCompletion":3013,"completion":3013,"start":3014,"enrollment":1238,"conditions":3015,"interventions":3018},"NCT01807091","Outpatient Induction Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome",[94],"2020-01-08","2013-05-21",[3016,3017],"Adult Acute Myeloid Leukemia","Adult Myelodysplastic Syndrome",[1737],{"nctId":3020,"briefTitle":3021,"status":131,"phases":3022,"primaryCompletion":3023,"completion":3024,"start":3025,"enrollment":1299,"conditions":3026,"interventions":3038},"NCT01872819","Treatment for Relapsed\u002FRefractory AML Based on a High Throughput Drug Sensitivity Assay",[94],"2014-11","2014-11-17","2013-08-02",[3027,3028,3029,3030,3031,3032,2458,2459,2460,2462,2463,3033,3034,3035,2464,3036,3037,2487,2466],"Adult Acute Megakaryoblastic Leukemia (M7)","Adult Acute Minimally Differentiated Myeloid Leukemia (M0)","Adult Acute Monoblastic Leukemia (M5a)","Adult Acute Monocytic Leukemia (M5b)","Adult Acute Myeloblastic Leukemia With Maturation (M2)","Adult Acute Myeloblastic Leukemia Without Maturation (M1)","Adult Acute Myelomonocytic Leukemia (M4)","Adult Erythroleukemia (M6a)","Adult Pure Erythroid Leukemia (M6b)","Myelodysplastic\u002FMyeloproliferative Neoplasm, Unclassifiable","Previously Treated Myelodysplastic Syndromes",[3039,3040],"chemotherapy","biological therapy",{"intervention":43,"totalTrials":702,"cells":3042},{"EARLY_PHASE1":3043,"PHASE1":3045,"PHASE2":3047,"PHASE3":3063,"PHASE4":3065,"NA":3067},{"trials":3044,"activeCount":102},[],{"trials":3046,"activeCount":102},[],{"trials":3048,"activeCount":264,"soonestReadout":42},[3049,3053],{"nctId":1716,"briefTitle":1717,"status":244,"phases":3050,"primaryCompletion":1168,"completion":1719,"start":1720,"enrollment":310,"conditions":3051,"interventions":3052},[91],[392,395,396],[48,1723,1724,1725,43,1726,398],{"nctId":40,"briefTitle":41,"status":174,"phases":3054,"primaryCompletion":42,"completion":3055,"start":3056,"enrollment":264,"conditions":3057,"interventions":3061},[91],"2041-04-30","2021-07-10",[3058,3059,3060],"Estrogen Receptor Positive","Primary or Recurrent Breast Carcinoma","Stage IV Breast Cancer AJCC v6 and v7",[43,3062],"Fludeoxyglucose F-18",{"trials":3064,"activeCount":102},[],{"trials":3066,"activeCount":102},[],{"trials":3068,"activeCount":102},[3069],{"nctId":3070,"briefTitle":3071,"status":108,"phases":3072,"primaryCompletion":3073,"completion":3074,"start":3075,"enrollment":1391,"conditions":3076,"interventions":3077},"NCT02149173","F-18 FES PET\u002FCT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy",[94],"2018-12-27","2021-01-13","2010-09-15",[3058,1710,3060],[43,3062],{"intervention":2822,"totalTrials":702,"cells":3079},{"EARLY_PHASE1":3080,"PHASE1":3082,"PHASE2":3084,"PHASE3":3094,"PHASE4":3096,"NA":3098},{"trials":3081,"activeCount":102},[],{"trials":3083,"activeCount":102},[],{"trials":3085,"activeCount":264,"soonestReadout":2829},[3086,3090],{"nctId":2813,"briefTitle":2814,"status":244,"phases":3087,"primaryCompletion":1719,"completion":1719,"start":2816,"enrollment":2817,"conditions":3088,"interventions":3089},[91],[2819,2820],[2804,2822,2823,2824],{"nctId":2826,"briefTitle":2827,"status":244,"phases":3091,"primaryCompletion":2829,"completion":2829,"start":2830,"enrollment":29,"conditions":3092,"interventions":3093},[91],[2396,2832,2398,2833,2399,2834,2835,2836,2837],[2822,2839,2840,2804],{"trials":3095,"activeCount":102},[],{"trials":3097,"activeCount":102},[],{"trials":3099,"activeCount":102},[3100],{"nctId":3101,"briefTitle":3102,"status":131,"phases":3103,"primaryCompletion":3104,"completion":3105,"start":1577,"enrollment":113,"conditions":3106,"interventions":3107},"NCT02121418","Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm",[94],"2017-02-08","2018-02-14",[2414,2398,2399,2467],[2402,2822],{"intervention":360,"totalTrials":1207,"cells":3109},{"EARLY_PHASE1":3110,"PHASE1":3112,"PHASE2":3125,"PHASE3":3180,"PHASE4":3182,"NA":3184},{"trials":3111,"activeCount":102},[],{"trials":3113,"activeCount":102},[3114],{"nctId":3115,"briefTitle":3116,"status":131,"phases":3117,"primaryCompletion":3118,"completion":3119,"start":3120,"enrollment":264,"conditions":3121,"interventions":3123},"NCT02881125","Paclitaxel and Nortriptyline Hydrochloride in Treating Patients With Relapsed Small Cell Carcinoma",[90],"2018-01-01","2019-11-30","2016-11-03",[3122],"Small Cell Carcinoma",[3124,1278],"Nortriptyline Hydrochloride",{"trials":3126,"activeCount":236,"soonestReadout":176},[3127,3135,3139,3148,3152,3160,3164,3168,3172,3176],{"nctId":3128,"briefTitle":3129,"status":108,"phases":3130,"primaryCompletion":2106,"completion":2106,"start":3131,"enrollment":26,"conditions":3132,"interventions":3133},"NCT00194792","Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer",[91],"2005-08",[353,2897,356,276,277,278],[447,3134,361,362,363,360],"triptorelin pamoate",{"nctId":1850,"briefTitle":1851,"status":244,"phases":3136,"primaryCompletion":176,"completion":1351,"start":1853,"enrollment":29,"conditions":3137,"interventions":3138},[91],[429,430,391],[1856,1278,1857,1858,1842,123],{"nctId":3140,"briefTitle":3141,"status":131,"phases":3142,"primaryCompletion":134,"completion":3143,"start":1642,"enrollment":3144,"conditions":3145,"interventions":3146},"NCT00408460","Imatinib Mesylate and Paclitaxel in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer",[91],"2012-10",34,[1868,1315,1318,1596],[3147,360],"imatinib mesylate",{"nctId":1860,"briefTitle":1861,"status":131,"phases":3149,"primaryCompletion":1863,"completion":1864,"start":1865,"enrollment":1866,"conditions":3150,"interventions":3151},[91],[1868,1318,1596],[1409,1794,1870,360],{"nctId":3153,"briefTitle":3154,"status":108,"phases":3155,"primaryCompletion":3156,"completion":1863,"start":3157,"enrollment":1439,"conditions":3158,"interventions":3159},"NCT00662311","Vorinostat, Paclitaxel, and Radiation Therapy in Treating Patients Unable to Tolerate Cisplatin With Stage III Non-Small Lung Cancer That Cannot Be Removed By Surgery",[90,91],"2010-01","2008-03",[1317,1318],[445,360],{"nctId":344,"briefTitle":345,"status":131,"phases":3161,"primaryCompletion":347,"completion":348,"start":349,"enrollment":350,"conditions":3162,"interventions":3163},[91],[352,353,354,355,356,357,358,277,278],[280,233,360,169,361,362,363,364,365,316],{"nctId":1646,"briefTitle":1647,"status":131,"phases":3165,"primaryCompletion":739,"completion":1649,"start":1650,"enrollment":427,"conditions":3166,"interventions":3167},[91],[1652,275,277,278,378,379],[1654,360,280,233,169],{"nctId":1269,"briefTitle":1270,"status":131,"phases":3169,"primaryCompletion":1272,"completion":1272,"start":1273,"enrollment":1274,"conditions":3170,"interventions":3171},[91],[1276],[1278,993,994,1279],{"nctId":2437,"briefTitle":2438,"status":108,"phases":3173,"primaryCompletion":1789,"completion":1789,"start":2440,"enrollment":2089,"conditions":3174,"interventions":3175},[90,91],[413],[1278,2443,2444,1079],{"nctId":1910,"briefTitle":1911,"status":108,"phases":3177,"primaryCompletion":1913,"completion":1914,"start":1915,"enrollment":1207,"conditions":3178,"interventions":3179},[91],[1917,1918,1919,1920,1921,1922,1923,1924,1925,1926,1927,1928,1929,1930,1931],[123,1278,1933],{"trials":3181,"activeCount":102},[],{"trials":3183,"activeCount":102},[],{"trials":3185,"activeCount":102},[],{"intervention":361,"totalTrials":98,"cells":3187},{"EARLY_PHASE1":3188,"PHASE1":3190,"PHASE2":3212,"PHASE3":3274,"PHASE4":3276,"NA":3278},{"trials":3189,"activeCount":102},[],{"trials":3191,"activeCount":102},[3192,3208],{"nctId":3193,"briefTitle":3194,"status":131,"phases":3195,"primaryCompletion":3196,"completion":3196,"start":3197,"enrollment":273,"conditions":3198,"interventions":3206},"NCT02451553","Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer",[90],"2022-04-16","2015-11-05",[3199,3200,3201,3202,3203,3204,3205],"Advanced Malignant Solid Neoplasm","Bile Duct Carcinoma","Recurrent Malignant Solid Neoplasm","Recurrent Pancreatic Carcinoma","Stage III Pancreatic Cancer AJCC v6 and v7","Stage IVA Pancreatic Cancer","Stage IVB Pancreatic Cancer",[3207,1723],"Afatinib Dimaleate",{"nctId":1786,"briefTitle":1787,"status":131,"phases":3209,"completion":1789,"start":1790,"enrollment":1182,"conditions":3210,"interventions":3211},[90],[1792],[361,1409,1794],{"trials":3213,"activeCount":236,"soonestReadout":1168},[3214,3218,3225,3239,3243,3247,3259],{"nctId":3128,"briefTitle":3129,"status":108,"phases":3215,"primaryCompletion":2106,"completion":2106,"start":3131,"enrollment":26,"conditions":3216,"interventions":3217},[91],[353,2897,356,276,277,278],[447,3134,361,362,363,360],{"nctId":3219,"briefTitle":3220,"status":131,"phases":3221,"primaryCompletion":1272,"completion":1272,"start":3222,"enrollment":310,"conditions":3223,"interventions":3224},"NCT00194727","Weekly Vinorelbine and Oral Capecitabine as Treatment for Stage IV Breast Cancer",[91],"2002-05",[1276],[2443,1723],{"nctId":3226,"briefTitle":3227,"status":131,"phases":3228,"primaryCompletion":3023,"completion":3229,"start":3230,"enrollment":1114,"conditions":3231,"interventions":3237},"NCT00609336","Perioperative Therapy for Resectable Pancreatic Cancer",[91],"2016-12","2008-01",[3232,3233,3234,3235,3236],"Adenocarcinoma of the Pancreas","Stage IA Pancreatic Cancer","Stage IB Pancreatic Cancer","Stage IIA Pancreatic Cancer","Stage IIB Pancreatic Cancer",[1870,1794,361,3238],"oxaliplatin",{"nctId":344,"briefTitle":345,"status":131,"phases":3240,"primaryCompletion":347,"completion":348,"start":349,"enrollment":350,"conditions":3241,"interventions":3242},[91],[352,353,354,355,356,357,358,277,278],[280,233,360,169,361,362,363,364,365,316],{"nctId":1716,"briefTitle":1717,"status":244,"phases":3244,"primaryCompletion":1168,"completion":1719,"start":1720,"enrollment":310,"conditions":3245,"interventions":3246},[91],[392,395,396],[48,1723,1724,1725,43,1726,398],{"nctId":3248,"briefTitle":3249,"status":108,"phases":3250,"primaryCompletion":3251,"completion":347,"start":3252,"enrollment":273,"conditions":3253,"interventions":3258},"NCT00787787","Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer",[91],"2010-04","2008-09",[3254,3255,3256,3257],"Adult Primary Hepatocellular Carcinoma","Advanced Adult Primary Liver Cancer","Localized Unresectable Adult Primary Liver Cancer","Recurrent Adult Primary Liver Cancer",[1654,361],{"nctId":3260,"briefTitle":3261,"status":108,"phases":3262,"primaryCompletion":3263,"completion":3263,"start":3264,"enrollment":2817,"conditions":3265,"interventions":3272},"NCT01729923","A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer",[91],"2016-09-06","2013-03",[3266,3267,3268,3269,3270,3271],"Recurrent Colon Carcinoma","Recurrent Rectal Carcinoma","Stage IVA Colon Cancer","Stage IVA Rectal Cancer","Stage IVB Colon Cancer","Stage IVB Rectal Cancer",[1723,3273],"Celecoxib",{"trials":3275,"activeCount":102},[],{"trials":3277,"activeCount":102},[],{"trials":3279,"activeCount":102},[],{"intervention":1372,"totalTrials":192,"cells":3281},{"EARLY_PHASE1":3282,"PHASE1":3284,"PHASE2":3286,"PHASE3":3332,"PHASE4":3334,"NA":3336},{"trials":3283,"activeCount":102},[],{"trials":3285,"activeCount":102},[],{"trials":3287,"activeCount":236,"soonestReadout":2623},[3288,3300,3304,3308,3312,3323],{"nctId":3289,"briefTitle":3290,"status":108,"phases":3291,"primaryCompletion":3292,"completion":3293,"start":3294,"enrollment":192,"conditions":3295,"interventions":3298},"NCT03522584","Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma",[90,91],"2021-12-16","2022-01-19","2018-05-17",[3296,3297],"Metastatic Head and Neck Squamous Cell Carcinoma","Recurrent Head and Neck Squamous Cell Carcinoma",[1372,3299],"Tremelimumab",{"nctId":1360,"briefTitle":1361,"status":108,"phases":3301,"primaryCompletion":1363,"completion":1363,"start":1364,"enrollment":236,"conditions":3302,"interventions":3303},[91],[1366,1367,1368,1369,1370],[1244,1372,992,1373],{"nctId":1375,"briefTitle":1376,"status":1150,"phases":3305,"primaryCompletion":1378,"completion":1379,"start":1380,"enrollment":102,"conditions":3306,"interventions":3307},[91],[1382,1383,1384,1385],[123,1244,1372,992],{"nctId":2620,"briefTitle":2621,"status":599,"phases":3309,"primaryCompletion":2623,"completion":2624,"start":1802,"enrollment":1170,"conditions":3310,"interventions":3311},[91],[2626,1240,1241],[2628,1372,122,1244],{"nctId":3313,"briefTitle":3314,"status":108,"phases":3315,"primaryCompletion":3316,"completion":3317,"start":3318,"enrollment":192,"conditions":3319,"interventions":3321},"NCT04336943","Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load",[91],"2024-06-20","2025-06-06","2021-04-13",[3320,1059],"Biochemically Recurrent Prostate Carcinoma",[1372,3322],"Olaparib",{"nctId":3324,"briefTitle":3325,"status":1150,"phases":3326,"primaryCompletion":3327,"completion":3327,"start":3328,"enrollment":102,"conditions":3329,"interventions":3331},"NCT02966587","Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer",[91],"2023-05-15","2018-05-15",[1836,1196,3330],"Microsatellite Instability",[1372],{"trials":3333,"activeCount":102},[],{"trials":3335,"activeCount":102},[],{"trials":3337,"activeCount":102},[],{"intervention":1066,"totalTrials":192,"cells":3339},{"EARLY_PHASE1":3340,"PHASE1":3342,"PHASE2":3344,"PHASE3":3377,"PHASE4":3379,"NA":3381},{"trials":3341,"activeCount":102},[],{"trials":3343,"activeCount":102},[],{"trials":3345,"activeCount":236,"soonestReadout":1101},[3346,3350,3354,3358,3369,3373],{"nctId":1049,"briefTitle":1050,"status":108,"phases":3347,"primaryCompletion":1052,"completion":1053,"start":1054,"enrollment":261,"conditions":3348,"interventions":3349},[91],[1056,1057,1058,1059,1060,1061,1062,1063],[1065,1066,966],{"nctId":1081,"briefTitle":1082,"status":131,"phases":3351,"primaryCompletion":1084,"completion":1085,"start":1086,"enrollment":1087,"conditions":3352,"interventions":3353},[91],[1089,1090,1091,1092],[1066,1094,1095,1096,966],{"nctId":1098,"briefTitle":1099,"status":244,"phases":3355,"primaryCompletion":1101,"completion":1102,"start":1103,"enrollment":372,"conditions":3356,"interventions":3357},[91],[1059],[1066,966,1106],{"nctId":3359,"briefTitle":3360,"status":108,"phases":3361,"primaryCompletion":3362,"completion":3362,"start":3363,"enrollment":702,"conditions":3364,"interventions":3366},"NCT03999515","Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer",[91],"2021-06-06","2020-04-27",[1355,3365,1058,1059,1061,1062,1063],"Double-Negative Prostate Carcinoma",[1066,3367,3368],"Enzalutamide","Erdafitinib",{"nctId":1133,"briefTitle":1134,"status":131,"phases":3370,"primaryCompletion":1136,"completion":1136,"start":1137,"enrollment":1023,"conditions":3371,"interventions":3372},[91],[1139,1140,1141,1142],[1144,1145,416,1146],{"nctId":1190,"briefTitle":1191,"status":131,"phases":3374,"primaryCompletion":1193,"completion":1193,"start":1194,"enrollment":1129,"conditions":3375,"interventions":3376},[91],[1196,1058,1197,1198],[1066,966],{"trials":3378,"activeCount":102},[],{"trials":3380,"activeCount":102},[],{"trials":3382,"activeCount":102},[],{"intervention":2401,"totalTrials":1439,"cells":3384},{"EARLY_PHASE1":3385,"PHASE1":3387,"PHASE2":3398,"PHASE3":3436,"PHASE4":3438,"NA":3440},{"trials":3386,"activeCount":102},[],{"trials":3388,"activeCount":102},[3389],{"nctId":3390,"briefTitle":3391,"status":108,"phases":3392,"primaryCompletion":3393,"completion":3393,"start":3394,"enrollment":2370,"conditions":3395,"interventions":3396},"NCT04196010","Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms",[90],"2021-10-13","2020-05-08",[2417,2419,2420],[2401,2402,3397,2403],"Recombinant Granulocyte Colony-Stimulating Factor",{"trials":3399,"activeCount":236,"soonestReadout":1351},[3400,3418,3428,3432],{"nctId":3401,"briefTitle":3402,"status":244,"phases":3403,"primaryCompletion":1351,"completion":1719,"start":3404,"enrollment":3405,"conditions":3406,"interventions":3416},"NCT04797767","Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms",[90,91],"2022-02-04",62,[2395,2396,3407,2417,3408,3409,3410,3411,3412,2420,3413,3414,3415],"Mixed Phenotype Acute Leukemia","Relapsed Acute Biphenotypic Leukemia","Relapsed Acute Myeloid Leukemia","Relapsed Mixed Phenotype Acute Leukemia","Relapsed Myeloid Neoplasm","Refractory Acute Biphenotypic Leukemia","Refractory Mixed Phenotype Acute Leukemia","Refractory Myeloid Neoplasm","Recurrent Myeloid Sarcoma",[2401,2402,2403,3397,3417],"Venetoclax",{"nctId":3419,"briefTitle":3420,"status":131,"phases":3421,"primaryCompletion":1085,"completion":3422,"start":3423,"enrollment":350,"conditions":3424,"interventions":3426},"NCT03012672","Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm",[91],"2021-02-26","2016-12-30",[3425,2396,2417],"Acute Leukemia of Ambiguous Lineage",[2401,2402,3427,2425],"Granulocyte Colony-Stimulating Factor",{"nctId":2387,"briefTitle":2388,"status":131,"phases":3429,"primaryCompletion":2390,"completion":2391,"start":2392,"enrollment":2393,"conditions":3430,"interventions":3431},[90,91],[2395,2396,2397,2398,2399],[2401,2402,1079,2403,2404],{"nctId":2406,"briefTitle":2407,"status":131,"phases":3433,"primaryCompletion":2409,"completion":2410,"start":2411,"enrollment":23,"conditions":3434,"interventions":3435},[91],[2413,2414,2415,2398,2416,2417,2418,2419,2420],[2401,2422,2402,1079,2423,2424,2425,2426,1908,2427],{"trials":3437,"activeCount":102},[],{"trials":3439,"activeCount":102},[],{"trials":3441,"activeCount":102},[],{"intervention":2317,"totalTrials":1547,"cells":3443},{"EARLY_PHASE1":3444,"PHASE1":3446,"PHASE2":3448,"PHASE3":3477,"PHASE4":3479,"NA":3481},{"trials":3445,"activeCount":102},[],{"trials":3447,"activeCount":102},[],{"trials":3449,"activeCount":236,"soonestReadout":2859},[3450,3458,3469,3473],{"nctId":3451,"briefTitle":3452,"status":1150,"phases":3453,"primaryCompletion":1168,"completion":1168,"start":3454,"enrollment":102,"conditions":3455,"interventions":3456},"NCT05935774","OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer",[91],"2023-12-01",[2360,2312,1383],[2317,3457],"Trabedersen",{"nctId":3459,"briefTitle":3460,"status":108,"phases":3461,"primaryCompletion":3462,"completion":3463,"start":3464,"enrollment":702,"conditions":3465,"interventions":3467},"NCT05191797","Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer",[90,91],"2023-08-03","2024-04-05","2022-04-11",[1382,3466],"Limited Stage Lung Small Cell Carcinoma",[3468,2317],"Bomedemstat",{"nctId":2856,"briefTitle":2857,"status":599,"phases":3470,"primaryCompletion":2859,"completion":2860,"start":1802,"enrollment":1129,"conditions":3471,"interventions":3472},[91],[2862,2360,2312,1367,1383],[2317,2362],{"nctId":2304,"briefTitle":2305,"status":108,"phases":3474,"primaryCompletion":2307,"completion":2308,"start":2309,"enrollment":37,"conditions":3475,"interventions":3476},[91],[2311,2312,2313,2314,2315],[2317,2318,1262,1014],{"trials":3478,"activeCount":102},[],{"trials":3480,"activeCount":102},[],{"trials":3482,"activeCount":102},[],{"intervention":2403,"totalTrials":702,"cells":3484},{"EARLY_PHASE1":3485,"PHASE1":3487,"PHASE2":3493,"PHASE3":3503,"PHASE4":3505,"NA":3507},{"trials":3486,"activeCount":102},[],{"trials":3488,"activeCount":102},[3489],{"nctId":3390,"briefTitle":3391,"status":108,"phases":3490,"primaryCompletion":3393,"completion":3393,"start":3394,"enrollment":2370,"conditions":3491,"interventions":3492},[90],[2417,2419,2420],[2401,2402,3397,2403],{"trials":3494,"activeCount":236,"soonestReadout":1351},[3495,3499],{"nctId":3401,"briefTitle":3402,"status":244,"phases":3496,"primaryCompletion":1351,"completion":1719,"start":3404,"enrollment":3405,"conditions":3497,"interventions":3498},[90,91],[2395,2396,3407,2417,3408,3409,3410,3411,3412,2420,3413,3414,3415],[2401,2402,2403,3397,3417],{"nctId":2387,"briefTitle":2388,"status":131,"phases":3500,"primaryCompletion":2390,"completion":2391,"start":2392,"enrollment":2393,"conditions":3501,"interventions":3502},[90,91],[2395,2396,2397,2398,2399],[2401,2402,1079,2403,2404],{"trials":3504,"activeCount":102},[],{"trials":3506,"activeCount":102},[],{"trials":3508,"activeCount":102},[],{"intervention":72,"totalTrials":702,"cells":3510},{"EARLY_PHASE1":3511,"PHASE1":3513,"PHASE2":3515,"PHASE3":3537,"PHASE4":3539,"NA":3541},{"trials":3512,"activeCount":102},[],{"trials":3514,"activeCount":102},[],{"trials":3516,"activeCount":236,"soonestReadout":71},[3517,3529,3533],{"nctId":3518,"briefTitle":3519,"status":1150,"phases":3520,"primaryCompletion":3521,"completion":3521,"start":3522,"enrollment":102,"conditions":3523,"interventions":3527},"NCT02729961","Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma",[90,91],"2023-07-01","2018-01-03",[3524,3525,3526],"Anaplastic Large Cell Lymphoma, ALK-Positive","CD30-Positive Neoplastic Cells Present","Systemic Anaplastic Large Cell Lymphoma",[72,3528],"Ceritinib",{"nctId":69,"briefTitle":70,"status":174,"phases":3530,"primaryCompletion":71,"completion":2531,"start":2532,"enrollment":26,"conditions":3531,"interventions":3532},[91],[1419,2520,1420,2522],[72,1262],{"nctId":1411,"briefTitle":1412,"status":131,"phases":3534,"primaryCompletion":1414,"completion":1415,"start":1416,"enrollment":1417,"conditions":3535,"interventions":3536},[90,91],[1419,1420],[72,123,992,1422],{"trials":3538,"activeCount":102},[],{"trials":3540,"activeCount":102},[],{"trials":3542,"activeCount":102},[],{"intervention":1821,"totalTrials":702,"cells":3544},{"EARLY_PHASE1":3545,"PHASE1":3547,"PHASE2":3559,"PHASE3":3569,"PHASE4":3571,"NA":3573},{"trials":3546,"activeCount":102},[],{"trials":3548,"activeCount":102},[3549],{"nctId":3550,"briefTitle":3551,"status":131,"phases":3552,"primaryCompletion":3553,"completion":3554,"start":3555,"enrollment":29,"conditions":3556,"interventions":3557},"NCT01322802","Vaccine Therapy in Treating Patients With Stage III-IV or Recurrent Ovarian Cancer",[90],"2015-01-09","2020-12-01","2012-03-06",[2047,2048,1597,1598],[3558],"pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine",{"trials":3560,"activeCount":236,"soonestReadout":1813},[3561,3565],{"nctId":1810,"briefTitle":1811,"status":599,"phases":3562,"primaryCompletion":1813,"completion":476,"start":1814,"enrollment":1815,"conditions":3563,"interventions":3564},[91],[1817,1818,1819],[1821,123],{"nctId":1910,"briefTitle":1911,"status":108,"phases":3566,"primaryCompletion":1913,"completion":1914,"start":1915,"enrollment":1207,"conditions":3567,"interventions":3568},[91],[1917,1918,1919,1920,1921,1922,1923,1924,1925,1926,1927,1928,1929,1930,1931],[123,1278,1933],{"trials":3570,"activeCount":102},[],{"trials":3572,"activeCount":102},[],{"trials":3574,"activeCount":102},[],{"intervention":182,"totalTrials":702,"cells":3576},{"EARLY_PHASE1":3577,"PHASE1":3579,"PHASE2":3581,"PHASE3":3595,"PHASE4":3597,"NA":3599},{"trials":3578,"activeCount":102},[],{"trials":3580,"activeCount":102},[],{"trials":3582,"activeCount":236,"soonestReadout":176},[3583,3587,3591],{"nctId":172,"briefTitle":173,"status":174,"phases":3584,"primaryCompletion":176,"completion":177,"start":178,"enrollment":23,"conditions":3585,"interventions":3586},[91],[180,162],[182,97,183,184],{"nctId":210,"briefTitle":211,"status":108,"phases":3588,"primaryCompletion":213,"completion":213,"start":214,"enrollment":98,"conditions":3589,"interventions":3590},[91],[216,217],[182,97,219],{"nctId":1542,"briefTitle":1543,"status":108,"phases":3592,"primaryCompletion":1545,"completion":1545,"start":1546,"enrollment":1547,"conditions":3593,"interventions":3594},[91],[1528,159,1549,1550,1551,1531],[182,124],{"trials":3596,"activeCount":102},[],{"trials":3598,"activeCount":102},[],{"trials":3600,"activeCount":102},[],{"intervention":1094,"totalTrials":702,"cells":3602},{"EARLY_PHASE1":3603,"PHASE1":3605,"PHASE2":3607,"PHASE3":3633,"PHASE4":3635,"NA":3637},{"trials":3604,"activeCount":102},[],{"trials":3606,"activeCount":102},[],{"trials":3608,"activeCount":236,"soonestReadout":3617},[3609,3613,3624],{"nctId":1081,"briefTitle":1082,"status":131,"phases":3610,"primaryCompletion":1084,"completion":1085,"start":1086,"enrollment":1087,"conditions":3611,"interventions":3612},[91],[1089,1090,1091,1092],[1066,1094,1095,1096,966],{"nctId":3614,"briefTitle":3615,"status":174,"phases":3616,"primaryCompletion":3617,"completion":3618,"start":3619,"enrollment":317,"conditions":3620,"interventions":3622},"NCT05960578","Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study",[91],"2025-07-29","2027-04-14","2024-05-23",[3621,1059,1061],"Metastatic Castration-Resistant Prostate Carcinoma",[1094,3623],"Golimumab",{"nctId":3625,"briefTitle":3626,"status":108,"phases":3627,"primaryCompletion":3628,"completion":3629,"start":3630,"enrollment":1023,"conditions":3631,"interventions":3632},"NCT02721979","Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance",[91],"2020-02-12","2021-11-30","2017-11-02",[1059],[1094],{"trials":3634,"activeCount":102},[],{"trials":3636,"activeCount":102},[],{"trials":3638,"activeCount":102},[],{"intervention":3397,"totalTrials":264,"cells":3640},{"EARLY_PHASE1":3641,"PHASE1":3643,"PHASE2":3649,"PHASE3":3655,"PHASE4":3657,"NA":3659},{"trials":3642,"activeCount":102},[],{"trials":3644,"activeCount":102},[3645],{"nctId":3390,"briefTitle":3391,"status":108,"phases":3646,"primaryCompletion":3393,"completion":3393,"start":3394,"enrollment":2370,"conditions":3647,"interventions":3648},[90],[2417,2419,2420],[2401,2402,3397,2403],{"trials":3650,"activeCount":236,"soonestReadout":1351},[3651],{"nctId":3401,"briefTitle":3402,"status":244,"phases":3652,"primaryCompletion":1351,"completion":1719,"start":3404,"enrollment":3405,"conditions":3653,"interventions":3654},[90,91],[2395,2396,3407,2417,3408,3409,3410,3411,3412,2420,3413,3414,3415],[2401,2402,2403,3397,3417],{"trials":3656,"activeCount":102},[],{"trials":3658,"activeCount":102},[],{"trials":3660,"activeCount":102},[],{"intervention":1358,"totalTrials":264,"cells":3662},{"EARLY_PHASE1":3663,"PHASE1":3665,"PHASE2":3667,"PHASE3":3684,"PHASE4":3686,"NA":3688},{"trials":3664,"activeCount":102},[],{"trials":3666,"activeCount":102},[],{"trials":3668,"activeCount":236,"soonestReadout":1350},[3669,3673],{"nctId":1347,"briefTitle":1348,"status":244,"phases":3670,"primaryCompletion":1350,"completion":1351,"start":1352,"enrollment":1353,"conditions":3671,"interventions":3672},[91],[1355,1356,1063],[123,992,1358],{"nctId":3674,"briefTitle":3675,"status":131,"phases":3676,"primaryCompletion":3677,"completion":3678,"start":3679,"enrollment":3680,"conditions":3681,"interventions":3682},"NCT03516812","Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer",[91],"2021-03-05","2024-04-12","2018-08-29",36,[1355,1059],[3322,3683,1358],"Testosterone Enanthate",{"trials":3685,"activeCount":102},[],{"trials":3687,"activeCount":102},[],{"trials":3689,"activeCount":102},[],{"intervention":1856,"totalTrials":264,"cells":3691},{"EARLY_PHASE1":3692,"PHASE1":3694,"PHASE2":3700,"PHASE3":3706,"PHASE4":3708,"NA":3710},{"trials":3693,"activeCount":102},[],{"trials":3695,"activeCount":102},[3696],{"nctId":2061,"briefTitle":2062,"status":131,"phases":3697,"primaryCompletion":2064,"completion":2065,"start":2066,"enrollment":1129,"conditions":3698,"interventions":3699},[90],[2068,2069,2070,358,277,2071,2072,1711,278,378,379],[1856,1738],{"trials":3701,"activeCount":236,"soonestReadout":176},[3702],{"nctId":1850,"briefTitle":1851,"status":244,"phases":3703,"primaryCompletion":176,"completion":1351,"start":1853,"enrollment":29,"conditions":3704,"interventions":3705},[91],[429,430,391],[1856,1278,1857,1858,1842,123],{"trials":3707,"activeCount":102},[],{"trials":3709,"activeCount":102},[],{"trials":3711,"activeCount":102},[],{"intervention":1858,"totalTrials":264,"cells":3713},{"EARLY_PHASE1":3714,"PHASE1":3716,"PHASE2":3718,"PHASE3":3735,"PHASE4":3737,"NA":3739},{"trials":3715,"activeCount":102},[],{"trials":3717,"activeCount":102},[],{"trials":3719,"activeCount":236,"soonestReadout":176},[3720,3724],{"nctId":1850,"briefTitle":1851,"status":244,"phases":3721,"primaryCompletion":176,"completion":1351,"start":1853,"enrollment":29,"conditions":3722,"interventions":3723},[91],[429,430,391],[1856,1278,1857,1858,1842,123],{"nctId":3725,"briefTitle":3726,"status":131,"phases":3727,"primaryCompletion":2001,"completion":3728,"start":3729,"enrollment":227,"conditions":3730,"interventions":3732},"NCT01922921","Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy",[90,91],"2021-09-01","2014-02-05",[3731,1710,36],"HER2\u002FNeu Positive",[3733,1858,3734,1857],"HER-2\u002Fneu Intracellular Domain Protein","Polysaccharide-K",{"trials":3736,"activeCount":102},[],{"trials":3738,"activeCount":102},[],{"trials":3740,"activeCount":102},[],{"intervention":1261,"totalTrials":264,"cells":3742},{"EARLY_PHASE1":3743,"PHASE1":3745,"PHASE2":3747,"PHASE3":3757,"PHASE4":3759,"NA":3761},{"trials":3744,"activeCount":102},[],{"trials":3746,"activeCount":102},[],{"trials":3748,"activeCount":236,"soonestReadout":1251},[3749,3753],{"nctId":1248,"briefTitle":1249,"status":244,"phases":3750,"primaryCompletion":1251,"completion":1252,"start":1253,"enrollment":1254,"conditions":3751,"interventions":3752},[91],[1256,1257,1258,1259],[1261,993,1262,1263],{"nctId":2336,"briefTitle":2337,"status":131,"phases":3754,"primaryCompletion":2339,"completion":2339,"start":2340,"enrollment":350,"conditions":3755,"interventions":3756},[90,91],[2342],[1261,1013,1014,1263],{"trials":3758,"activeCount":102},[],{"trials":3760,"activeCount":102},[],{"trials":3762,"activeCount":102},[],{"intervention":1263,"totalTrials":264,"cells":3764},{"EARLY_PHASE1":3765,"PHASE1":3767,"PHASE2":3769,"PHASE3":3779,"PHASE4":3781,"NA":3783},{"trials":3766,"activeCount":102},[],{"trials":3768,"activeCount":102},[],{"trials":3770,"activeCount":236,"soonestReadout":1251},[3771,3775],{"nctId":1248,"briefTitle":1249,"status":244,"phases":3772,"primaryCompletion":1251,"completion":1252,"start":1253,"enrollment":1254,"conditions":3773,"interventions":3774},[91],[1256,1257,1258,1259],[1261,993,1262,1263],{"nctId":2336,"briefTitle":2337,"status":131,"phases":3776,"primaryCompletion":2339,"completion":2339,"start":2340,"enrollment":350,"conditions":3777,"interventions":3778},[90,91],[2342],[1261,1013,1014,1263],{"trials":3780,"activeCount":102},[],{"trials":3782,"activeCount":102},[],{"trials":3784,"activeCount":102},[],{"intervention":3786,"totalTrials":236,"cells":3787},"Disulfiram 250 mg",{"EARLY_PHASE1":3788,"PHASE1":3790,"PHASE2":3792,"PHASE3":3803,"PHASE4":3805,"NA":3807},{"trials":3789,"activeCount":102},[],{"trials":3791,"activeCount":102},[],{"trials":3793,"activeCount":236,"soonestReadout":2624},[3794],{"nctId":3795,"briefTitle":3796,"status":244,"phases":3797,"primaryCompletion":2624,"completion":3798,"start":3799,"enrollment":23,"conditions":3800,"interventions":3802},"NCT05626920","Disulfiram for Treatment of Retinal Degeneration",[90,91],"2027-05-01","2026-05-03",[3801],"Inherited Retinal Dystrophy Primarily Involving Sensory Retina",[3786],{"trials":3804,"activeCount":102},[],{"trials":3806,"activeCount":102},[],{"trials":3808,"activeCount":102},[],{"intervention":3810,"totalTrials":236,"cells":3811},"Gallium Ga 68 Gozetotide",{"EARLY_PHASE1":3812,"PHASE1":3814,"PHASE2":3816,"PHASE3":3830,"PHASE4":3832,"NA":3834},{"trials":3813,"activeCount":102},[],{"trials":3815,"activeCount":102},[],{"trials":3817,"activeCount":236,"soonestReadout":3822},[3818],{"nctId":3819,"briefTitle":3820,"status":174,"phases":3821,"primaryCompletion":3822,"completion":3823,"start":3824,"enrollment":3825,"conditions":3826,"interventions":3829},"NCT04777071","An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer",[91],"2025-07-15","2030-07-15","2021-05-17",141,[3320,3621,1059,3827,3828,1063],"Stage IIC Prostate Cancer AJCC v8","Stage III Prostate Cancer AJCC v8",[3810],{"trials":3831,"activeCount":102},[],{"trials":3833,"activeCount":102},[],{"trials":3835,"activeCount":102},[],{"intervention":3837,"totalTrials":236,"cells":3838},"emicizumab",{"EARLY_PHASE1":3839,"PHASE1":3841,"PHASE2":3843,"PHASE3":3853,"PHASE4":3855,"NA":3857},{"trials":3840,"activeCount":102},[],{"trials":3842,"activeCount":102},[],{"trials":3844,"activeCount":236,"soonestReadout":808},[3845],{"nctId":3846,"briefTitle":3847,"status":174,"phases":3848,"primaryCompletion":808,"completion":577,"start":3849,"enrollment":17,"conditions":3850,"interventions":3852},"NCT05345197","Emicizumab in Patients With Acquired Hemophilia A",[91],"2022-08-31",[3851],"Acquired Hemophilia A",[3837],{"trials":3854,"activeCount":102},[],{"trials":3856,"activeCount":102},[],{"trials":3858,"activeCount":102},[],{"intervention":2738,"totalTrials":236,"cells":3860},{"EARLY_PHASE1":3861,"PHASE1":3863,"PHASE2":3865,"PHASE3":3871,"PHASE4":3873,"NA":3875},{"trials":3862,"activeCount":102},[],{"trials":3864,"activeCount":102},[],{"trials":3866,"activeCount":236,"soonestReadout":2733},[3867],{"nctId":2730,"briefTitle":2731,"status":599,"phases":3868,"primaryCompletion":2733,"completion":2733,"start":727,"enrollment":389,"conditions":3869,"interventions":3870},[91],[2735,2736,1063],[2738,2739,403],{"trials":3872,"activeCount":102},[],{"trials":3874,"activeCount":102},[],{"trials":3876,"activeCount":102},[],{"intervention":2739,"totalTrials":236,"cells":3878},{"EARLY_PHASE1":3879,"PHASE1":3881,"PHASE2":3883,"PHASE3":3889,"PHASE4":3891,"NA":3893},{"trials":3880,"activeCount":102},[],{"trials":3882,"activeCount":102},[],{"trials":3884,"activeCount":236,"soonestReadout":2733},[3885],{"nctId":2730,"briefTitle":2731,"status":599,"phases":3886,"primaryCompletion":2733,"completion":2733,"start":727,"enrollment":389,"conditions":3887,"interventions":3888},[91],[2735,2736,1063],[2738,2739,403],{"trials":3890,"activeCount":102},[],{"trials":3892,"activeCount":102},[],{"trials":3894,"activeCount":102},[],{"intervention":3417,"totalTrials":236,"cells":3896},{"EARLY_PHASE1":3897,"PHASE1":3899,"PHASE2":3901,"PHASE3":3907,"PHASE4":3909,"NA":3911},{"trials":3898,"activeCount":102},[],{"trials":3900,"activeCount":102},[],{"trials":3902,"activeCount":236,"soonestReadout":1351},[3903],{"nctId":3401,"briefTitle":3402,"status":244,"phases":3904,"primaryCompletion":1351,"completion":1719,"start":3404,"enrollment":3405,"conditions":3905,"interventions":3906},[90,91],[2395,2396,3407,2417,3408,3409,3410,3411,3412,2420,3413,3414,3415],[2401,2402,2403,3397,3417],{"trials":3908,"activeCount":102},[],{"trials":3910,"activeCount":102},[],{"trials":3912,"activeCount":102},[],{"intervention":183,"totalTrials":236,"cells":3914},{"EARLY_PHASE1":3915,"PHASE1":3917,"PHASE2":3919,"PHASE3":3925,"PHASE4":3927,"NA":3929},{"trials":3916,"activeCount":102},[],{"trials":3918,"activeCount":102},[],{"trials":3920,"activeCount":236,"soonestReadout":176},[3921],{"nctId":172,"briefTitle":173,"status":174,"phases":3922,"primaryCompletion":176,"completion":177,"start":178,"enrollment":23,"conditions":3923,"interventions":3924},[91],[180,162],[182,97,183,184],{"trials":3926,"activeCount":102},[],{"trials":3928,"activeCount":102},[],{"trials":3930,"activeCount":102},[],{"intervention":184,"totalTrials":236,"cells":3932},{"EARLY_PHASE1":3933,"PHASE1":3935,"PHASE2":3937,"PHASE3":3943,"PHASE4":3945,"NA":3947},{"trials":3934,"activeCount":102},[],{"trials":3936,"activeCount":102},[],{"trials":3938,"activeCount":236,"soonestReadout":176},[3939],{"nctId":172,"briefTitle":173,"status":174,"phases":3940,"primaryCompletion":176,"completion":177,"start":178,"enrollment":23,"conditions":3941,"interventions":3942},[91],[180,162],[182,97,183,184],{"trials":3944,"activeCount":102},[],{"trials":3946,"activeCount":102},[],{"trials":3948,"activeCount":102},[],{"intervention":3950,"totalTrials":236,"cells":3951},"Immune Checkpoint Inhibitor",{"EARLY_PHASE1":3952,"PHASE1":3954,"PHASE2":3956,"PHASE3":3968,"PHASE4":3970,"NA":3972},{"trials":3953,"activeCount":102},[],{"trials":3955,"activeCount":102},[],{"trials":3957,"activeCount":236,"soonestReadout":1351},[3958],{"nctId":3959,"briefTitle":3960,"status":244,"phases":3961,"primaryCompletion":1351,"completion":3962,"start":3963,"enrollment":1087,"conditions":3964,"interventions":3966},"NCT06502691","[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer",[90,91],"2030-12-31","2026-02-26",[392,3965],"Metastatic Breast Carcinoma",[3950,3967],"Poly (ADP-Ribose) Polymerase Inhibitor",{"trials":3969,"activeCount":102},[],{"trials":3971,"activeCount":102},[],{"trials":3973,"activeCount":102},[],{"intervention":3967,"totalTrials":236,"cells":3975},{"EARLY_PHASE1":3976,"PHASE1":3978,"PHASE2":3980,"PHASE3":3986,"PHASE4":3988,"NA":3990},{"trials":3977,"activeCount":102},[],{"trials":3979,"activeCount":102},[],{"trials":3981,"activeCount":236,"soonestReadout":1351},[3982],{"nctId":3959,"briefTitle":3960,"status":244,"phases":3983,"primaryCompletion":1351,"completion":3962,"start":3963,"enrollment":1087,"conditions":3984,"interventions":3985},[90,91],[392,3965],[3950,3967],{"trials":3987,"activeCount":102},[],{"trials":3989,"activeCount":102},[],{"trials":3991,"activeCount":102},[],{"intervention":1078,"totalTrials":236,"cells":3993},{"EARLY_PHASE1":3994,"PHASE1":3996,"PHASE2":3998,"PHASE3":4004,"PHASE4":4006,"NA":4008},{"trials":3995,"activeCount":102},[],{"trials":3997,"activeCount":102},[],{"trials":3999,"activeCount":236,"soonestReadout":1071},[4000],{"nctId":1068,"briefTitle":1069,"status":244,"phases":4001,"primaryCompletion":1071,"completion":1072,"start":1073,"enrollment":23,"conditions":4002,"interventions":4003},[91],[1075,1076],[1078,994,993,992,1079,125,966,124,1030],{"trials":4005,"activeCount":102},[],{"trials":4007,"activeCount":102},[],{"trials":4009,"activeCount":102},[],{"intervention":4011,"totalTrials":236,"cells":4012},"Tinidazole",{"EARLY_PHASE1":4013,"PHASE1":4015,"PHASE2":4017,"PHASE3":4029,"PHASE4":4031,"NA":4033},{"trials":4014,"activeCount":102},[],{"trials":4016,"activeCount":102},[],{"trials":4018,"activeCount":236,"soonestReadout":727},[4019],{"nctId":4020,"briefTitle":4021,"status":244,"phases":4022,"primaryCompletion":727,"completion":4023,"start":4024,"enrollment":310,"conditions":4025,"interventions":4028},"NCT07088419","\"Sexual Health Assessment of TinidaZole Against M. Genitalium (SHAZAM)\"",[91],"2026-08-31","2025-07-23",[4026,4027],"Mycoplasma Genitalium","Non-gonococcal Urethritis (NGU)",[4011],{"trials":4030,"activeCount":102},[],{"trials":4032,"activeCount":102},[],{"trials":4034,"activeCount":102},[],{"intervention":4036,"totalTrials":236,"cells":4037},"Gemtuzumab Ozogamicin",{"EARLY_PHASE1":4038,"PHASE1":4040,"PHASE2":4042,"PHASE3":4051,"PHASE4":4053,"NA":4055},{"trials":4039,"activeCount":102},[],{"trials":4041,"activeCount":102},[],{"trials":4043,"activeCount":236,"soonestReadout":176},[4044],{"nctId":4045,"briefTitle":4046,"status":244,"phases":4047,"primaryCompletion":176,"completion":176,"start":4048,"enrollment":3680,"conditions":4049,"interventions":4050},"NCT03737955","Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia",[91],"2018-11-30",[2396],[4036],{"trials":4052,"activeCount":102},[],{"trials":4054,"activeCount":102},[],{"trials":4056,"activeCount":102},[],{"intervention":4058,"totalTrials":236,"cells":4059},"Semaglutide",{"EARLY_PHASE1":4060,"PHASE1":4062,"PHASE2":4064,"PHASE3":4075,"PHASE4":4077,"NA":4079},{"trials":4061,"activeCount":102},[],{"trials":4063,"activeCount":102},[],{"trials":4065,"activeCount":236,"soonestReadout":4070},[4066],{"nctId":4067,"briefTitle":4068,"status":244,"phases":4069,"primaryCompletion":4070,"completion":2163,"start":3463,"enrollment":389,"conditions":4071,"interventions":4074},"NCT05822609","Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes",[91],"2027-06",[4072,4073],"Diabetic Kidney Disease","Type 1 Diabetes",[4058],{"trials":4076,"activeCount":102},[],{"trials":4078,"activeCount":102},[],{"trials":4080,"activeCount":102},[],{"intervention":4082,"totalTrials":236,"cells":4083},"Lutetium Lu 177 Vipivotide Tetraxetan",{"EARLY_PHASE1":4084,"PHASE1":4086,"PHASE2":4088,"PHASE3":4097,"PHASE4":4099,"NA":4101},{"trials":4085,"activeCount":102},[],{"trials":4087,"activeCount":102},[],{"trials":4089,"activeCount":236,"soonestReadout":1351},[4090],{"nctId":4091,"briefTitle":4092,"status":244,"phases":4093,"primaryCompletion":1351,"completion":1351,"start":4094,"enrollment":17,"conditions":4095,"interventions":4096},"NCT06526299","Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease",[91],"2025-04-29",[3621,1063],[4082],{"trials":4098,"activeCount":102},[],{"trials":4100,"activeCount":102},[],{"trials":4102,"activeCount":102},[],{"intervention":4104,"totalTrials":236,"cells":4105},"Oral calcitriol with cinacalcet rescue",{"EARLY_PHASE1":4106,"PHASE1":4108,"PHASE2":4110,"PHASE3":4122,"PHASE4":4124,"NA":4126},{"trials":4107,"activeCount":102},[],{"trials":4109,"activeCount":102},[],{"trials":4111,"activeCount":236,"soonestReadout":4116},[4112],{"nctId":4113,"briefTitle":4114,"status":174,"phases":4115,"primaryCompletion":4116,"completion":4116,"start":4117,"enrollment":741,"conditions":4118,"interventions":4120},"NCT06288451","DePTH: De-emphasize PTH",[91],"2027-02-28","2024-03-11",[1479,4119],"Chronic Kidney Disease-Mineral and Bone Disorder",[4104,4121],"IV activated vitamin D",{"trials":4123,"activeCount":102},[],{"trials":4125,"activeCount":102},[],{"trials":4127,"activeCount":102},[],{"intervention":4121,"totalTrials":236,"cells":4129},{"EARLY_PHASE1":4130,"PHASE1":4132,"PHASE2":4134,"PHASE3":4140,"PHASE4":4142,"NA":4144},{"trials":4131,"activeCount":102},[],{"trials":4133,"activeCount":102},[],{"trials":4135,"activeCount":236,"soonestReadout":4116},[4136],{"nctId":4113,"briefTitle":4114,"status":174,"phases":4137,"primaryCompletion":4116,"completion":4116,"start":4117,"enrollment":741,"conditions":4138,"interventions":4139},[91],[1479,4119],[4104,4121],{"trials":4141,"activeCount":102},[],{"trials":4143,"activeCount":102},[],{"trials":4145,"activeCount":102},[],{"intervention":1106,"totalTrials":236,"cells":4147},{"EARLY_PHASE1":4148,"PHASE1":4150,"PHASE2":4152,"PHASE3":4158,"PHASE4":4160,"NA":4162},{"trials":4149,"activeCount":102},[],{"trials":4151,"activeCount":102},[],{"trials":4153,"activeCount":236,"soonestReadout":1101},[4154],{"nctId":1098,"briefTitle":1099,"status":244,"phases":4155,"primaryCompletion":1101,"completion":1102,"start":1103,"enrollment":372,"conditions":4156,"interventions":4157},[91],[1059],[1066,966,1106],{"trials":4159,"activeCount":102},[],{"trials":4161,"activeCount":102},[],{"trials":4163,"activeCount":102},[],{"intervention":4165,"totalTrials":236,"cells":4166},"Acalabrutinib",{"EARLY_PHASE1":4167,"PHASE1":4169,"PHASE2":4171,"PHASE3":4185,"PHASE4":4187,"NA":4189},{"trials":4168,"activeCount":102},[],{"trials":4170,"activeCount":102},[],{"trials":4172,"activeCount":236,"soonestReadout":4177},[4173],{"nctId":4174,"briefTitle":4175,"status":174,"phases":4176,"primaryCompletion":4177,"completion":4178,"start":4179,"enrollment":34,"conditions":4180,"interventions":4183},"NCT04257578","Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma",[90,91],"2025-08-07","2031-03-01","2020-12-02",[1184,983,1117,4181,4182,2670,2671,2672],"Primary Mediastinal (Thymic) Large B-Cell Lymphoma","Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma",[4165,4184],"Axicabtagene Ciloleucel",{"trials":4186,"activeCount":102},[],{"trials":4188,"activeCount":102},[],{"trials":4190,"activeCount":102},[],{"intervention":4184,"totalTrials":236,"cells":4192},{"EARLY_PHASE1":4193,"PHASE1":4195,"PHASE2":4197,"PHASE3":4203,"PHASE4":4205,"NA":4207},{"trials":4194,"activeCount":102},[],{"trials":4196,"activeCount":102},[],{"trials":4198,"activeCount":236,"soonestReadout":4177},[4199],{"nctId":4174,"briefTitle":4175,"status":174,"phases":4200,"primaryCompletion":4177,"completion":4178,"start":4179,"enrollment":34,"conditions":4201,"interventions":4202},[90,91],[1184,983,1117,4181,4182,2670,2671,2672],[4165,4184],{"trials":4204,"activeCount":102},[],{"trials":4206,"activeCount":102},[],{"trials":4208,"activeCount":102},[],{"intervention":4210,"totalTrials":236,"cells":4211},"Loncastuximab Tesirine",{"EARLY_PHASE1":4212,"PHASE1":4214,"PHASE2":4216,"PHASE3":4229,"PHASE4":4231,"NA":4233},{"trials":4213,"activeCount":102},[],{"trials":4215,"activeCount":102},[],{"trials":4217,"activeCount":236,"soonestReadout":4222},[4218],{"nctId":4219,"briefTitle":4220,"status":244,"phases":4221,"primaryCompletion":4222,"completion":4223,"start":4224,"enrollment":673,"conditions":4225,"interventions":4228},"NCT05453396","Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies",[91],"2027-12-15","2028-07-06","2023-08-07",[4226,116,117,158,4227,118,1501,2523],"Recurrent B-Cell Non-Hodgkin Lymphoma","Refractory B-Cell Non-Hodgkin Lymphoma",[4210],{"trials":4230,"activeCount":102},[],{"trials":4232,"activeCount":102},[],{"trials":4234,"activeCount":102},[],{"intervention":67,"totalTrials":236,"cells":4236},{"EARLY_PHASE1":4237,"PHASE1":4239,"PHASE2":4241,"PHASE3":4248,"PHASE4":4250,"NA":4252},{"trials":4238,"activeCount":102},[],{"trials":4240,"activeCount":102},[],{"trials":4242,"activeCount":236,"soonestReadout":66},[4243],{"nctId":64,"briefTitle":65,"status":174,"phases":4244,"primaryCompletion":66,"completion":66,"start":4245,"enrollment":2165,"conditions":4246,"interventions":4247},[91],"2022-04-25",[19],[67],{"trials":4249,"activeCount":102},[],{"trials":4251,"activeCount":102},[],{"trials":4253,"activeCount":102},[],{"intervention":4255,"totalTrials":236,"cells":4256},"Valsartan 40 mg",{"EARLY_PHASE1":4257,"PHASE1":4259,"PHASE2":4261,"PHASE3":4274,"PHASE4":4276,"NA":4278},{"trials":4258,"activeCount":102},[],{"trials":4260,"activeCount":102},[],{"trials":4262,"activeCount":236,"soonestReadout":2154},[4263],{"nctId":4264,"briefTitle":4265,"status":244,"phases":4266,"primaryCompletion":2154,"completion":2154,"start":4267,"enrollment":389,"conditions":4268,"interventions":4273},"NCT06053580","Repurposing Valsartan May Protect Against Pulmonary Hypertension",[91],"2024-02-28",[4269,4270,4271,4272],"Pulmonary Arterial Hypertension","Right Heart Failure","Right Ventricular Dysfunction","Pulmonary Vascular Disorder",[4255],{"trials":4275,"activeCount":102},[],{"trials":4277,"activeCount":102},[],{"trials":4279,"activeCount":102},[],{"intervention":1724,"totalTrials":236,"cells":4281},{"EARLY_PHASE1":4282,"PHASE1":4284,"PHASE2":4286,"PHASE3":4292,"PHASE4":4294,"NA":4296},{"trials":4283,"activeCount":102},[],{"trials":4285,"activeCount":102},[],{"trials":4287,"activeCount":236,"soonestReadout":1168},[4288],{"nctId":1716,"briefTitle":1717,"status":244,"phases":4289,"primaryCompletion":1168,"completion":1719,"start":1720,"enrollment":310,"conditions":4290,"interventions":4291},[91],[392,395,396],[48,1723,1724,1725,43,1726,398],{"trials":4293,"activeCount":102},[],{"trials":4295,"activeCount":102},[],{"trials":4297,"activeCount":102},[],{"intervention":1725,"totalTrials":236,"cells":4299},{"EARLY_PHASE1":4300,"PHASE1":4302,"PHASE2":4304,"PHASE3":4310,"PHASE4":4312,"NA":4314},{"trials":4301,"activeCount":102},[],{"trials":4303,"activeCount":102},[],{"trials":4305,"activeCount":236,"soonestReadout":1168},[4306],{"nctId":1716,"briefTitle":1717,"status":244,"phases":4307,"primaryCompletion":1168,"completion":1719,"start":1720,"enrollment":310,"conditions":4308,"interventions":4309},[91],[392,395,396],[48,1723,1724,1725,43,1726,398],{"trials":4311,"activeCount":102},[],{"trials":4313,"activeCount":102},[],{"trials":4315,"activeCount":102},[],{"intervention":1726,"totalTrials":236,"cells":4317},{"EARLY_PHASE1":4318,"PHASE1":4320,"PHASE2":4322,"PHASE3":4328,"PHASE4":4330,"NA":4332},{"trials":4319,"activeCount":102},[],{"trials":4321,"activeCount":102},[],{"trials":4323,"activeCount":236,"soonestReadout":1168},[4324],{"nctId":1716,"briefTitle":1717,"status":244,"phases":4325,"primaryCompletion":1168,"completion":1719,"start":1720,"enrollment":310,"conditions":4326,"interventions":4327},[91],[392,395,396],[48,1723,1724,1725,43,1726,398],{"trials":4329,"activeCount":102},[],{"trials":4331,"activeCount":102},[],{"trials":4333,"activeCount":102},[],{"intervention":2628,"totalTrials":236,"cells":4335},{"EARLY_PHASE1":4336,"PHASE1":4338,"PHASE2":4340,"PHASE3":4346,"PHASE4":4348,"NA":4350},{"trials":4337,"activeCount":102},[],{"trials":4339,"activeCount":102},[],{"trials":4341,"activeCount":236,"soonestReadout":2623},[4342],{"nctId":2620,"briefTitle":2621,"status":599,"phases":4343,"primaryCompletion":2623,"completion":2624,"start":1802,"enrollment":1170,"conditions":4344,"interventions":4345},[91],[2626,1240,1241],[2628,1372,122,1244],{"trials":4347,"activeCount":102},[],{"trials":4349,"activeCount":102},[],{"trials":4351,"activeCount":102},[],{"intervention":1120,"totalTrials":236,"cells":4353},{"EARLY_PHASE1":4354,"PHASE1":4356,"PHASE2":4358,"PHASE3":4364,"PHASE4":4366,"NA":4368},{"trials":4355,"activeCount":102},[],{"trials":4357,"activeCount":102},[],{"trials":4359,"activeCount":236,"soonestReadout":1111},[4360],{"nctId":1108,"briefTitle":1109,"status":244,"phases":4361,"primaryCompletion":1111,"completion":1112,"start":1113,"enrollment":1114,"conditions":4362,"interventions":4363},[90,91],[1116,115,1117],[994,993,966,1119,1120,1121,1030,991],{"trials":4365,"activeCount":102},[],{"trials":4367,"activeCount":102},[],{"trials":4369,"activeCount":102},[],{"intervention":2823,"totalTrials":236,"cells":4371},{"EARLY_PHASE1":4372,"PHASE1":4374,"PHASE2":4376,"PHASE3":4382,"PHASE4":4384,"NA":4386},{"trials":4373,"activeCount":102},[],{"trials":4375,"activeCount":102},[],{"trials":4377,"activeCount":236,"soonestReadout":1719},[4378],{"nctId":2813,"briefTitle":2814,"status":244,"phases":4379,"primaryCompletion":1719,"completion":1719,"start":2816,"enrollment":2817,"conditions":4380,"interventions":4381},[91],[2819,2820],[2804,2822,2823,2824],{"trials":4383,"activeCount":102},[],{"trials":4385,"activeCount":102},[],{"trials":4387,"activeCount":102},[],{"intervention":2824,"totalTrials":236,"cells":4389},{"EARLY_PHASE1":4390,"PHASE1":4392,"PHASE2":4394,"PHASE3":4400,"PHASE4":4402,"NA":4404},{"trials":4391,"activeCount":102},[],{"trials":4393,"activeCount":102},[],{"trials":4395,"activeCount":236,"soonestReadout":1719},[4396],{"nctId":2813,"briefTitle":2814,"status":244,"phases":4397,"primaryCompletion":1719,"completion":1719,"start":2816,"enrollment":2817,"conditions":4398,"interventions":4399},[91],[2819,2820],[2804,2822,2823,2824],{"trials":4401,"activeCount":102},[],{"trials":4403,"activeCount":102},[],{"trials":4405,"activeCount":102},[],{"intervention":2638,"totalTrials":236,"cells":4407},{"EARLY_PHASE1":4408,"PHASE1":4410,"PHASE2":4412,"PHASE3":4418,"PHASE4":4420,"NA":4422},{"trials":4409,"activeCount":102},[],{"trials":4411,"activeCount":102},[],{"trials":4413,"activeCount":236,"soonestReadout":2633},[4414],{"nctId":2630,"briefTitle":2631,"status":599,"phases":4415,"primaryCompletion":2633,"completion":2633,"start":1802,"enrollment":113,"conditions":4416,"interventions":4417},[90,91],[1242,2635,2636],[1244,122,2638,2639],{"trials":4419,"activeCount":102},[],{"trials":4421,"activeCount":102},[],{"trials":4423,"activeCount":102},[],{"intervention":2639,"totalTrials":236,"cells":4425},{"EARLY_PHASE1":4426,"PHASE1":4428,"PHASE2":4430,"PHASE3":4436,"PHASE4":4438,"NA":4440},{"trials":4427,"activeCount":102},[],{"trials":4429,"activeCount":102},[],{"trials":4431,"activeCount":236,"soonestReadout":2633},[4432],{"nctId":2630,"briefTitle":2631,"status":599,"phases":4433,"primaryCompletion":2633,"completion":2633,"start":1802,"enrollment":113,"conditions":4434,"interventions":4435},[90,91],[1242,2635,2636],[1244,122,2638,2639],{"trials":4437,"activeCount":102},[],{"trials":4439,"activeCount":102},[],{"trials":4441,"activeCount":102},[],{"intervention":62,"totalTrials":236,"cells":4443},{"EARLY_PHASE1":4444,"PHASE1":4446,"PHASE2":4448,"PHASE3":4454,"PHASE4":4456,"NA":4458},{"trials":4445,"activeCount":102},[],{"trials":4447,"activeCount":102},[],{"trials":4449,"activeCount":236,"soonestReadout":61},[4450],{"nctId":59,"briefTitle":60,"status":174,"phases":4451,"primaryCompletion":61,"completion":1522,"start":1523,"enrollment":1170,"conditions":4452,"interventions":4453},[91],[1512,1525,1526,1527,1528,1529,1530,1513,1531],[62,124],{"trials":4455,"activeCount":102},[],{"trials":4457,"activeCount":102},[],{"trials":4459,"activeCount":102},[],{"intervention":4461,"totalTrials":236,"cells":4462},"Povidone-iodine solution",{"EARLY_PHASE1":4463,"PHASE1":4465,"PHASE2":4467,"PHASE3":4478,"PHASE4":4480,"NA":4482},{"trials":4464,"activeCount":102},[],{"trials":4466,"activeCount":102},[],{"trials":4468,"activeCount":236,"soonestReadout":1350},[4469],{"nctId":4470,"briefTitle":4471,"status":244,"phases":4472,"primaryCompletion":1350,"completion":1350,"start":4473,"enrollment":1274,"conditions":4474,"interventions":4477},"NCT06616207","Topical 10% Povidone-Iodine in Preventing White Spots",[91],"2024-09-13",[4475,4476],"White Spot Lesions","Gingival Inflammation and Bleeding",[4461],{"trials":4479,"activeCount":102},[],{"trials":4481,"activeCount":102},[],{"trials":4483,"activeCount":102},[],{"intervention":2839,"totalTrials":236,"cells":4485},{"EARLY_PHASE1":4486,"PHASE1":4488,"PHASE2":4490,"PHASE3":4496,"PHASE4":4498,"NA":4500},{"trials":4487,"activeCount":102},[],{"trials":4489,"activeCount":102},[],{"trials":4491,"activeCount":236,"soonestReadout":2829},[4492],{"nctId":2826,"briefTitle":2827,"status":244,"phases":4493,"primaryCompletion":2829,"completion":2829,"start":2830,"enrollment":29,"conditions":4494,"interventions":4495},[91],[2396,2832,2398,2833,2399,2834,2835,2836,2837],[2822,2839,2840,2804],{"trials":4497,"activeCount":102},[],{"trials":4499,"activeCount":102},[],{"trials":4501,"activeCount":102},[],{"intervention":2840,"totalTrials":236,"cells":4503},{"EARLY_PHASE1":4504,"PHASE1":4506,"PHASE2":4508,"PHASE3":4514,"PHASE4":4516,"NA":4518},{"trials":4505,"activeCount":102},[],{"trials":4507,"activeCount":102},[],{"trials":4509,"activeCount":236,"soonestReadout":2829},[4510],{"nctId":2826,"briefTitle":2827,"status":244,"phases":4511,"primaryCompletion":2829,"completion":2829,"start":2830,"enrollment":29,"conditions":4512,"interventions":4513},[91],[2396,2832,2398,2833,2399,2834,2835,2836,2837],[2822,2839,2840,2804],{"trials":4515,"activeCount":102},[],{"trials":4517,"activeCount":102},[],{"trials":4519,"activeCount":102},[],{"intervention":2710,"totalTrials":236,"cells":4521},{"EARLY_PHASE1":4522,"PHASE1":4524,"PHASE2":4526,"PHASE3":4532,"PHASE4":4534,"NA":4536},{"trials":4523,"activeCount":102},[],{"trials":4525,"activeCount":102},[],{"trials":4527,"activeCount":236,"soonestReadout":2707},[4528],{"nctId":2704,"briefTitle":2705,"status":244,"phases":4529,"primaryCompletion":2707,"completion":2707,"start":1720,"enrollment":1087,"conditions":4530,"interventions":4531},[91],[2670,2671,2672,117,1501],[2710,2674],{"trials":4533,"activeCount":102},[],{"trials":4535,"activeCount":102},[],{"trials":4537,"activeCount":102},[],{"intervention":401,"totalTrials":236,"cells":4539},{"EARLY_PHASE1":4540,"PHASE1":4542,"PHASE2":4544,"PHASE3":4550,"PHASE4":4552,"NA":4554},{"trials":4541,"activeCount":102},[],{"trials":4543,"activeCount":102},[],{"trials":4545,"activeCount":236,"soonestReadout":386},[4546],{"nctId":383,"briefTitle":384,"status":244,"phases":4547,"primaryCompletion":386,"completion":387,"start":388,"enrollment":389,"conditions":4548,"interventions":4549},[91],[391,392,393,394,395,396],[398,399,400,401,402,403,342,404,405],{"trials":4551,"activeCount":102},[],{"trials":4553,"activeCount":102},[],{"trials":4555,"activeCount":102},[],{"intervention":402,"totalTrials":236,"cells":4557},{"EARLY_PHASE1":4558,"PHASE1":4560,"PHASE2":4562,"PHASE3":4568,"PHASE4":4570,"NA":4572},{"trials":4559,"activeCount":102},[],{"trials":4561,"activeCount":102},[],{"trials":4563,"activeCount":236,"soonestReadout":386},[4564],{"nctId":383,"briefTitle":384,"status":244,"phases":4565,"primaryCompletion":386,"completion":387,"start":388,"enrollment":389,"conditions":4566,"interventions":4567},[91],[391,392,393,394,395,396],[398,399,400,401,402,403,342,404,405],{"trials":4569,"activeCount":102},[],{"trials":4571,"activeCount":102},[],{"trials":4573,"activeCount":102},[],{"intervention":404,"totalTrials":236,"cells":4575},{"EARLY_PHASE1":4576,"PHASE1":4578,"PHASE2":4580,"PHASE3":4586,"PHASE4":4588,"NA":4590},{"trials":4577,"activeCount":102},[],{"trials":4579,"activeCount":102},[],{"trials":4581,"activeCount":236,"soonestReadout":386},[4582],{"nctId":383,"briefTitle":384,"status":244,"phases":4583,"primaryCompletion":386,"completion":387,"start":388,"enrollment":389,"conditions":4584,"interventions":4585},[91],[391,392,393,394,395,396],[398,399,400,401,402,403,342,404,405],{"trials":4587,"activeCount":102},[],{"trials":4589,"activeCount":102},[],{"trials":4591,"activeCount":102},[],{"intervention":405,"totalTrials":236,"cells":4593},{"EARLY_PHASE1":4594,"PHASE1":4596,"PHASE2":4598,"PHASE3":4604,"PHASE4":4606,"NA":4608},{"trials":4595,"activeCount":102},[],{"trials":4597,"activeCount":102},[],{"trials":4599,"activeCount":236,"soonestReadout":386},[4600],{"nctId":383,"briefTitle":384,"status":244,"phases":4601,"primaryCompletion":386,"completion":387,"start":388,"enrollment":389,"conditions":4602,"interventions":4603},[91],[391,392,393,394,395,396],[398,399,400,401,402,403,342,404,405],{"trials":4605,"activeCount":102},[],{"trials":4607,"activeCount":102},[],{"trials":4609,"activeCount":102},[],{"intervention":2773,"totalTrials":236,"cells":4611},{"EARLY_PHASE1":4612,"PHASE1":4614,"PHASE2":4616,"PHASE3":4622,"PHASE4":4624,"NA":4626},{"trials":4613,"activeCount":102},[],{"trials":4615,"activeCount":102},[],{"trials":4617,"activeCount":236,"soonestReadout":2766},[4618],{"nctId":2763,"briefTitle":2764,"status":174,"phases":4619,"primaryCompletion":2766,"completion":1731,"start":2767,"enrollment":113,"conditions":4620,"interventions":4621},[91],[2769,2770,2771],[1119,2773,2774],{"trials":4623,"activeCount":102},[],{"trials":4625,"activeCount":102},[],{"trials":4627,"activeCount":102},[],{"intervention":2774,"totalTrials":236,"cells":4629},{"EARLY_PHASE1":4630,"PHASE1":4632,"PHASE2":4634,"PHASE3":4640,"PHASE4":4642,"NA":4644},{"trials":4631,"activeCount":102},[],{"trials":4633,"activeCount":102},[],{"trials":4635,"activeCount":236,"soonestReadout":2766},[4636],{"nctId":2763,"briefTitle":2764,"status":174,"phases":4637,"primaryCompletion":2766,"completion":1731,"start":2767,"enrollment":113,"conditions":4638,"interventions":4639},[91],[2769,2770,2771],[1119,2773,2774],{"trials":4641,"activeCount":102},[],{"trials":4643,"activeCount":102},[],{"trials":4645,"activeCount":102},[],{"intervention":4647,"totalTrials":236,"cells":4648},"Darbepoetin Alfa",{"EARLY_PHASE1":4649,"PHASE1":4651,"PHASE2":4653,"PHASE3":4671,"PHASE4":4673,"NA":4675},{"trials":4650,"activeCount":102},[],{"trials":4652,"activeCount":102},[],{"trials":4654,"activeCount":236,"soonestReadout":4659},[4655],{"nctId":4656,"briefTitle":4657,"status":244,"phases":4658,"primaryCompletion":4659,"completion":4660,"start":4661,"enrollment":861,"conditions":4662,"interventions":4667},"NCT05340465","Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants",[91],"2027-01-30","2027-06-30","2022-11-27",[4663,4664,4665,4666],"Prematurity","Iron-deficiency","Iron Deficiency Anemia","Iron Malabsorption",[4647,4668,4669,4670],"Low Molecular Weight Iron Dextran","Ferumoxytol","Oral iron supplements",{"trials":4672,"activeCount":102},[],{"trials":4674,"activeCount":102},[],{"trials":4676,"activeCount":102},[],{"intervention":4668,"totalTrials":236,"cells":4678},{"EARLY_PHASE1":4679,"PHASE1":4681,"PHASE2":4683,"PHASE3":4689,"PHASE4":4691,"NA":4693},{"trials":4680,"activeCount":102},[],{"trials":4682,"activeCount":102},[],{"trials":4684,"activeCount":236,"soonestReadout":4659},[4685],{"nctId":4656,"briefTitle":4657,"status":244,"phases":4686,"primaryCompletion":4659,"completion":4660,"start":4661,"enrollment":861,"conditions":4687,"interventions":4688},[91],[4663,4664,4665,4666],[4647,4668,4669,4670],{"trials":4690,"activeCount":102},[],{"trials":4692,"activeCount":102},[],{"trials":4694,"activeCount":102},[],{"intervention":4669,"totalTrials":236,"cells":4696},{"EARLY_PHASE1":4697,"PHASE1":4699,"PHASE2":4701,"PHASE3":4707,"PHASE4":4709,"NA":4711},{"trials":4698,"activeCount":102},[],{"trials":4700,"activeCount":102},[],{"trials":4702,"activeCount":236,"soonestReadout":4659},[4703],{"nctId":4656,"briefTitle":4657,"status":244,"phases":4704,"primaryCompletion":4659,"completion":4660,"start":4661,"enrollment":861,"conditions":4705,"interventions":4706},[91],[4663,4664,4665,4666],[4647,4668,4669,4670],{"trials":4708,"activeCount":102},[],{"trials":4710,"activeCount":102},[],{"trials":4712,"activeCount":102},[],{"intervention":4670,"totalTrials":236,"cells":4714},{"EARLY_PHASE1":4715,"PHASE1":4717,"PHASE2":4719,"PHASE3":4725,"PHASE4":4727,"NA":4729},{"trials":4716,"activeCount":102},[],{"trials":4718,"activeCount":102},[],{"trials":4720,"activeCount":236,"soonestReadout":4659},[4721],{"nctId":4656,"briefTitle":4657,"status":244,"phases":4722,"primaryCompletion":4659,"completion":4660,"start":4661,"enrollment":861,"conditions":4723,"interventions":4724},[91],[4663,4664,4665,4666],[4647,4668,4669,4670],{"trials":4726,"activeCount":102},[],{"trials":4728,"activeCount":102},[],{"trials":4730,"activeCount":102},[],{"intervention":1175,"totalTrials":236,"cells":4732},{"EARLY_PHASE1":4733,"PHASE1":4735,"PHASE2":4737,"PHASE3":4743,"PHASE4":4745,"NA":4747},{"trials":4734,"activeCount":102},[],{"trials":4736,"activeCount":102},[],{"trials":4738,"activeCount":236,"soonestReadout":1168},[4739],{"nctId":1165,"briefTitle":1166,"status":244,"phases":4740,"primaryCompletion":1168,"completion":1168,"start":1169,"enrollment":1170,"conditions":4741,"interventions":4742},[91],[1172,1173,1044],[994,993,992,1079,125,1175,966,124,1030],{"trials":4744,"activeCount":102},[],{"trials":4746,"activeCount":102},[],{"trials":4748,"activeCount":102},[],{"intervention":3623,"totalTrials":236,"cells":4750},{"EARLY_PHASE1":4751,"PHASE1":4753,"PHASE2":4755,"PHASE3":4761,"PHASE4":4763,"NA":4765},{"trials":4752,"activeCount":102},[],{"trials":4754,"activeCount":102},[],{"trials":4756,"activeCount":236,"soonestReadout":3617},[4757],{"nctId":3614,"briefTitle":3615,"status":174,"phases":4758,"primaryCompletion":3617,"completion":3618,"start":3619,"enrollment":317,"conditions":4759,"interventions":4760},[91],[3621,1059,1061],[1094,3623],{"trials":4762,"activeCount":102},[],{"trials":4764,"activeCount":102},[],{"trials":4766,"activeCount":102},[],{"intervention":1188,"totalTrials":236,"cells":4768},{"EARLY_PHASE1":4769,"PHASE1":4771,"PHASE2":4773,"PHASE3":4779,"PHASE4":4781,"NA":4783},{"trials":4770,"activeCount":102},[],{"trials":4772,"activeCount":102},[],{"trials":4774,"activeCount":236,"soonestReadout":1180},[4775],{"nctId":1177,"briefTitle":1178,"status":244,"phases":4776,"primaryCompletion":1180,"completion":1180,"start":1181,"enrollment":1182,"conditions":4777,"interventions":4778},[91],[1184,1185,983,984,985,986,987,988,1186],[994,993,1188,992,966,124],{"trials":4780,"activeCount":102},[],{"trials":4782,"activeCount":102},[],{"trials":4784,"activeCount":102},[],{"intervention":4786,"totalTrials":236,"cells":4787},"Doxycycline 200mg daily for 14 days",{"EARLY_PHASE1":4788,"PHASE1":4790,"PHASE2":4792,"PHASE3":4803,"PHASE4":4805,"NA":4807},{"trials":4789,"activeCount":102},[],{"trials":4791,"activeCount":102},[],{"trials":4793,"activeCount":236,"soonestReadout":4798},[4794],{"nctId":4795,"briefTitle":4796,"status":244,"phases":4797,"primaryCompletion":4798,"completion":4798,"start":4799,"enrollment":456,"conditions":4800,"interventions":4802},"NCT06683638","Daily Doxycycline for Early Syphillis",[91],"2026-06-26","2025-03-03",[4801],"Syphilis",[4786],{"trials":4804,"activeCount":102},[],{"trials":4806,"activeCount":102},[],{"trials":4808,"activeCount":102},[],{"intervention":4810,"totalTrials":236,"cells":4811},"Odronextamab",{"EARLY_PHASE1":4812,"PHASE1":4814,"PHASE2":4816,"PHASE3":4838,"PHASE4":4840,"NA":4842},{"trials":4813,"activeCount":102},[],{"trials":4815,"activeCount":102},[],{"trials":4817,"activeCount":236,"soonestReadout":4822},[4818],{"nctId":4819,"briefTitle":4820,"status":244,"phases":4821,"primaryCompletion":4822,"completion":4823,"start":4824,"enrollment":2817,"conditions":4825,"interventions":4836},"NCT06784726","Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T",[91],"2028-04-10","2033-04-11","2025-09-04",[116,4826,4827,4828,4829,4830,118,4831,4832,4833,4834,4835],"Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","Recurrent Grade 3b Follicular Lymphoma","Recurrent High Grade B-Cell Lymphoma","Recurrent Primary Mediastinal Large B-Cell Lymphoma","Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma","Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","Refractory Grade 3b Follicular Lymphoma","Refractory High Grade B-Cell Lymphoma","Refractory Primary Mediastinal Large B-Cell Lymphoma","Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma",[4810,4837],"Chimeric Antigen Receptor T-Cell Therapy",{"trials":4839,"activeCount":102},[],{"trials":4841,"activeCount":102},[],{"trials":4843,"activeCount":102},[],{"intervention":4837,"totalTrials":236,"cells":4845},{"EARLY_PHASE1":4846,"PHASE1":4848,"PHASE2":4850,"PHASE3":4856,"PHASE4":4858,"NA":4860},{"trials":4847,"activeCount":102},[],{"trials":4849,"activeCount":102},[],{"trials":4851,"activeCount":236,"soonestReadout":4822},[4852],{"nctId":4819,"briefTitle":4820,"status":244,"phases":4853,"primaryCompletion":4822,"completion":4823,"start":4824,"enrollment":2817,"conditions":4854,"interventions":4855},[91],[116,4826,4827,4828,4829,4830,118,4831,4832,4833,4834,4835],[4810,4837],{"trials":4857,"activeCount":102},[],{"trials":4859,"activeCount":102},[],{"trials":4861,"activeCount":102},[],{"intervention":1842,"totalTrials":1207,"cells":4863},{"EARLY_PHASE1":4864,"PHASE1":4866,"PHASE2":4876,"PHASE3":4916,"PHASE4":4918,"NA":4920},{"trials":4865,"activeCount":102},[],{"trials":4867,"activeCount":102},[4868,4872],{"nctId":2881,"briefTitle":2882,"status":131,"phases":4869,"primaryCompletion":2884,"completion":2884,"start":2885,"enrollment":113,"conditions":4870,"interventions":4871},[90],[2235],[1244,1842,2888],{"nctId":1786,"briefTitle":1787,"status":131,"phases":4873,"completion":1789,"start":1790,"enrollment":1182,"conditions":4874,"interventions":4875},[90],[1792],[361,1409,1794],{"trials":4877,"activeCount":236,"soonestReadout":176},[4878,4882,4886,4890,4894,4898,4902,4912],{"nctId":1827,"briefTitle":1828,"status":108,"phases":4879,"primaryCompletion":1830,"completion":1830,"start":1831,"enrollment":1182,"conditions":4880,"interventions":4881},[91],[1833,1834,1835,1836,1355,1837,1838,1839,1840,1091],[123,1842,1843,1844],{"nctId":1850,"briefTitle":1851,"status":244,"phases":4883,"primaryCompletion":176,"completion":1351,"start":1853,"enrollment":29,"conditions":4884,"interventions":4885},[91],[429,430,391],[1856,1278,1857,1858,1842,123],{"nctId":1860,"briefTitle":1861,"status":131,"phases":4887,"primaryCompletion":1863,"completion":1864,"start":1865,"enrollment":1866,"conditions":4888,"interventions":4889},[91],[1868,1318,1596],[1409,1794,1870,360],{"nctId":3226,"briefTitle":3227,"status":131,"phases":4891,"primaryCompletion":3023,"completion":3229,"start":3230,"enrollment":1114,"conditions":4892,"interventions":4893},[91],[3232,3233,3234,3235,3236],[1870,1794,361,3238],{"nctId":1872,"briefTitle":1873,"status":131,"phases":4895,"primaryCompletion":1875,"completion":1875,"start":1876,"enrollment":1477,"conditions":4896,"interventions":4897},[91],[1836,1355,1058,1838,1840,1142],[123,1842],{"nctId":2446,"briefTitle":2447,"status":131,"phases":4899,"completion":1650,"start":2449,"enrollment":1338,"conditions":4900,"interventions":4901},[91],[1276],[1842,2443,1079],{"nctId":4903,"briefTitle":4904,"status":131,"phases":4905,"completion":4906,"start":4907,"enrollment":23,"conditions":4908,"interventions":4910},"NCT00283829","Immunotherapy After Chemotherapy for Patients With Hormone Refractory Metastatic Prostate Cancer",[90,91],"2006-07","2002-09",[4909],"Prostate Cancer",[1794,4911],"IL2",{"nctId":1901,"briefTitle":1902,"status":108,"phases":4913,"primaryCompletion":1904,"completion":1904,"start":1905,"enrollment":26,"conditions":4914,"interventions":4915},[90,91],[1355,1058,1092,1057],[123,1842,1908],{"trials":4917,"activeCount":102},[],{"trials":4919,"activeCount":102},[],{"trials":4921,"activeCount":102},[4922],{"nctId":4923,"briefTitle":4924,"status":131,"phases":4925,"primaryCompletion":370,"start":4926,"enrollment":1207,"conditions":4927,"interventions":4929},"NCT00392938","Carbon-11 Acetate and Fludeoxyglucose F 18 PET Scan of the Bone in Patients With Metastatic Prostate Cancer That Has Spread to the Bone",[],"2005-12",[4928,4909],"Metastatic Cancer",[4930,1794],"antiandrogen therapy",{"intervention":2402,"totalTrials":98,"cells":4932},{"EARLY_PHASE1":4933,"PHASE1":4935,"PHASE2":4941,"PHASE3":4971,"PHASE4":4973,"NA":4975},{"trials":4934,"activeCount":102},[],{"trials":4936,"activeCount":102},[4937],{"nctId":3390,"briefTitle":3391,"status":108,"phases":4938,"primaryCompletion":3393,"completion":3393,"start":3394,"enrollment":2370,"conditions":4939,"interventions":4940},[90],[2417,2419,2420],[2401,2402,3397,2403],{"trials":4942,"activeCount":236,"soonestReadout":1351},[4943,4947,4951,4955,4959,4963,4967],{"nctId":3401,"briefTitle":3402,"status":244,"phases":4944,"primaryCompletion":1351,"completion":1719,"start":3404,"enrollment":3405,"conditions":4945,"interventions":4946},[90,91],[2395,2396,3407,2417,3408,3409,3410,3411,3412,2420,3413,3414,3415],[2401,2402,2403,3397,3417],{"nctId":3419,"briefTitle":3420,"status":131,"phases":4948,"primaryCompletion":1085,"completion":3422,"start":3423,"enrollment":350,"conditions":4949,"interventions":4950},[91],[3425,2396,2417],[2401,2402,3427,2425],{"nctId":2387,"briefTitle":2388,"status":131,"phases":4952,"primaryCompletion":2390,"completion":2391,"start":2392,"enrollment":2393,"conditions":4953,"interventions":4954},[90,91],[2395,2396,2397,2398,2399],[2401,2402,1079,2403,2404],{"nctId":2406,"briefTitle":2407,"status":131,"phases":4956,"primaryCompletion":2409,"completion":2410,"start":2411,"enrollment":23,"conditions":4957,"interventions":4958},[91],[2413,2414,2415,2398,2416,2417,2418,2419,2420],[2401,2422,2402,1079,2423,2424,2425,2426,1908,2427],{"nctId":2453,"briefTitle":2454,"status":131,"phases":4960,"primaryCompletion":331,"completion":2456,"start":134,"enrollment":350,"conditions":4961,"interventions":4962},[91],[2458,2459,2460,2461,2462,2463,2464,2465,2466,2467,2468],[169,2470,2471],{"nctId":2481,"briefTitle":2482,"status":131,"phases":4964,"primaryCompletion":1137,"completion":2484,"start":410,"enrollment":350,"conditions":4965,"interventions":4966},[90,91],[2396,2458,2460,2461,2462,2463,2486,2487],[2470,2471,169],{"nctId":2490,"briefTitle":2491,"status":108,"phases":4968,"primaryCompletion":190,"start":191,"enrollment":264,"conditions":4969,"interventions":4970},[91],[2494,2458,2460,2461,2462,2463,2487],[2470,2471,169],{"trials":4972,"activeCount":102},[],{"trials":4974,"activeCount":102},[],{"trials":4976,"activeCount":102},[4977],{"nctId":3101,"briefTitle":3102,"status":131,"phases":4978,"primaryCompletion":3104,"completion":3105,"start":1577,"enrollment":113,"conditions":4979,"interventions":4980},[94],[2414,2398,2399,2467],[2402,2822],{"intervention":1857,"totalTrials":192,"cells":4982},{"EARLY_PHASE1":4983,"PHASE1":4985,"PHASE2":4987,"PHASE3":5009,"PHASE4":5011,"NA":5013},{"trials":4984,"activeCount":102},[],{"trials":4986,"activeCount":102},[],{"trials":4988,"activeCount":236,"soonestReadout":176},[4989,4993,4997,5001,5005],{"nctId":1850,"briefTitle":1851,"status":244,"phases":4990,"primaryCompletion":176,"completion":1351,"start":1853,"enrollment":29,"conditions":4991,"interventions":4992},[91],[429,430,391],[1856,1278,1857,1858,1842,123],{"nctId":344,"briefTitle":345,"status":131,"phases":4994,"primaryCompletion":347,"completion":348,"start":349,"enrollment":350,"conditions":4995,"interventions":4996},[91],[352,353,354,355,356,357,358,277,278],[280,233,360,169,361,362,363,364,365,316],{"nctId":3725,"briefTitle":3726,"status":131,"phases":4998,"primaryCompletion":2001,"completion":3728,"start":3729,"enrollment":227,"conditions":4999,"interventions":5000},[90,91],[3731,1710,36],[3733,1858,3734,1857],{"nctId":1638,"briefTitle":1639,"status":131,"phases":5002,"primaryCompletion":190,"completion":1641,"start":1642,"enrollment":23,"conditions":5003,"interventions":5004},[90,91],[354,275,377,36],[234,233,364],{"nctId":1672,"briefTitle":1673,"status":131,"phases":5006,"primaryCompletion":1675,"completion":440,"start":1676,"enrollment":389,"conditions":5007,"interventions":5008},[91],[353,354,357,358,277,278,378,379,36],[280,233,169,1679,364],{"trials":5010,"activeCount":102},[],{"trials":5012,"activeCount":102},[],{"trials":5014,"activeCount":102},[5015],{"nctId":5016,"briefTitle":5017,"status":108,"phases":5018,"primaryCompletion":5019,"completion":5020,"start":5021,"enrollment":2370,"conditions":5022,"interventions":5023},"NCT03738553","Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy",[],"2020-09","2026-03-01","2013-08",[354],[1857],{"intervention":447,"totalTrials":1547,"cells":5025},{"EARLY_PHASE1":5026,"PHASE1":5028,"PHASE2":5030,"PHASE3":5040,"PHASE4":5042,"NA":5044},{"trials":5027,"activeCount":102},[],{"trials":5029,"activeCount":102},[],{"trials":5031,"activeCount":236,"soonestReadout":386},[5032,5036],{"nctId":3128,"briefTitle":3129,"status":108,"phases":5033,"primaryCompletion":2106,"completion":2106,"start":3131,"enrollment":26,"conditions":5034,"interventions":5035},[91],[353,2897,356,276,277,278],[447,3134,361,362,363,360],{"nctId":383,"briefTitle":384,"status":244,"phases":5037,"primaryCompletion":386,"completion":387,"start":388,"enrollment":389,"conditions":5038,"interventions":5039},[91],[391,392,393,394,395,396],[398,399,400,401,402,403,342,404,405],{"trials":5041,"activeCount":102},[],{"trials":5043,"activeCount":102},[],{"trials":5045,"activeCount":102},[5046,5050],{"nctId":437,"briefTitle":438,"status":131,"phases":5047,"primaryCompletion":440,"completion":441,"start":442,"enrollment":317,"conditions":5048,"interventions":5049},[94],[275,377,36],[445,446,316,447,448],{"nctId":450,"briefTitle":451,"status":131,"phases":5051,"primaryCompletion":453,"completion":454,"start":455,"enrollment":456,"conditions":5052,"interventions":5053},[94],[275,377,36],[445,446,316,447],{"intervention":446,"totalTrials":1547,"cells":5055},{"EARLY_PHASE1":5056,"PHASE1":5058,"PHASE2":5060,"PHASE3":5079,"PHASE4":5081,"NA":5083},{"trials":5057,"activeCount":102},[],{"trials":5059,"activeCount":102},[],{"trials":5061,"activeCount":236,"soonestReadout":386},[5062,5075],{"nctId":5063,"briefTitle":5064,"status":131,"phases":5065,"primaryCompletion":1864,"completion":1864,"start":5066,"enrollment":5067,"conditions":5068,"interventions":5070},"NCT01215292","ITT4 Intratesticular Hormonal Milieu in Man (ITT4)",[90,91],"2011-01",46,[5069],"Healthy Males",[340,5071,5072,5073,5074,399],"Testosterone gel","ketoconazole 400","Ketoconazole 800","Dutasteride",{"nctId":383,"briefTitle":384,"status":244,"phases":5076,"primaryCompletion":386,"completion":387,"start":388,"enrollment":389,"conditions":5077,"interventions":5078},[91],[391,392,393,394,395,396],[398,399,400,401,402,403,342,404,405],{"trials":5080,"activeCount":102},[],{"trials":5082,"activeCount":102},[],{"trials":5084,"activeCount":102},[5085,5089],{"nctId":437,"briefTitle":438,"status":131,"phases":5086,"primaryCompletion":440,"completion":441,"start":442,"enrollment":317,"conditions":5087,"interventions":5088},[94],[275,377,36],[445,446,316,447,448],{"nctId":450,"briefTitle":451,"status":131,"phases":5090,"primaryCompletion":453,"completion":454,"start":455,"enrollment":456,"conditions":5091,"interventions":5092},[94],[275,377,36],[445,446,316,447],{"intervention":3062,"totalTrials":264,"cells":5094},{"EARLY_PHASE1":5095,"PHASE1":5097,"PHASE2":5099,"PHASE3":5105,"PHASE4":5107,"NA":5109},{"trials":5096,"activeCount":102},[],{"trials":5098,"activeCount":102},[],{"trials":5100,"activeCount":236,"soonestReadout":42},[5101],{"nctId":40,"briefTitle":41,"status":174,"phases":5102,"primaryCompletion":42,"completion":3055,"start":3056,"enrollment":264,"conditions":5103,"interventions":5104},[91],[3058,3059,3060],[43,3062],{"trials":5106,"activeCount":102},[],{"trials":5108,"activeCount":102},[],{"trials":5110,"activeCount":102},[5111],{"nctId":3070,"briefTitle":3071,"status":108,"phases":5112,"primaryCompletion":3073,"completion":3074,"start":3075,"enrollment":1391,"conditions":5113,"interventions":5114},[94],[3058,1710,3060],[43,3062],{"intervention":87,"totalTrials":236,"cells":5116},{"EARLY_PHASE1":5117,"PHASE1":5119,"PHASE2":5126,"PHASE3":5128,"PHASE4":5130,"NA":5132},{"trials":5118,"activeCount":102},[],{"trials":5120,"activeCount":236,"soonestReadout":86},[5121],{"nctId":84,"briefTitle":85,"status":244,"phases":5122,"primaryCompletion":86,"completion":86,"start":5123,"enrollment":1547,"conditions":5124,"interventions":5125},[90],"2024-08-08",[33],[87],{"trials":5127,"activeCount":102},[],{"trials":5129,"activeCount":102},[],{"trials":5131,"activeCount":102},[],{"trials":5133,"activeCount":102},[],{"intervention":995,"totalTrials":236,"cells":5135},{"EARLY_PHASE1":5136,"PHASE1":5138,"PHASE2":5144,"PHASE3":5146,"PHASE4":5148,"NA":5150},{"trials":5137,"activeCount":102},[],{"trials":5139,"activeCount":236,"soonestReadout":976},[5140],{"nctId":973,"briefTitle":974,"status":244,"phases":5141,"primaryCompletion":976,"completion":977,"start":978,"enrollment":979,"conditions":5142,"interventions":5143},[90],[981,982,983,984,985,986,987,988,989],[991,124,966,992,993,994,995],{"trials":5145,"activeCount":102},[],{"trials":5147,"activeCount":102},[],{"trials":5149,"activeCount":102},[],{"trials":5151,"activeCount":102},[],{"intervention":5153,"totalTrials":236,"cells":5154},"Dostarlimab",{"EARLY_PHASE1":5155,"PHASE1":5157,"PHASE2":5191,"PHASE3":5193,"PHASE4":5195,"NA":5197},{"trials":5156,"activeCount":102},[],{"trials":5158,"activeCount":236,"soonestReadout":5163},[5159],{"nctId":5160,"briefTitle":5161,"status":174,"phases":5162,"primaryCompletion":5163,"completion":5164,"start":5165,"enrollment":1182,"conditions":5166,"interventions":5189},"NCT04673448","Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer",[90],"2025-12-31","2026-09-30","2021-10-18",[391,392,5167,5168,5169,3965,5170,2146,5171,5172,5173,1757,5174,5175,5176,5177,5178,5179,5180,5181,5182,5183,5184,5185,5186,5187,5188],"BRCA-Associated Malignant Neoplasm","BRCA Hereditary Ovarian Carcinoma","Metastatic BRCA Hereditary Breast Carcinoma","Metastatic Fallopian Tube Carcinoma","Metastatic Ovarian Carcinoma","Metastatic Pancreatic Carcinoma","Metastatic Primary Peritoneal Carcinoma","Prognostic Stage IV Breast Cancer AJCC v8","Stage III Fallopian Tube Cancer AJCC v8","Stage III Ovarian Cancer AJCC v8","Stage III Pancreatic Cancer AJCC v8","Stage III Primary Peritoneal Cancer AJCC v8","Stage IV Fallopian Tube Cancer AJCC v8","Stage IV Ovarian Cancer AJCC v8","Stage IV Pancreatic Cancer AJCC v8","Stage IV Primary Peritoneal Cancer AJCC v8","Unresectable Breast Carcinoma","Unresectable Fallopian Tube Carcinoma","Unresectable Malignant Solid Neoplasm","Unresectable Ovarian Carcinoma","Unresectable Pancreatic Carcinoma","Unresectable Primary Peritoneal Carcinoma",[5153,5190],"Niraparib",{"trials":5192,"activeCount":102},[],{"trials":5194,"activeCount":102},[],{"trials":5196,"activeCount":102},[],{"trials":5198,"activeCount":102},[],{"intervention":5190,"totalTrials":236,"cells":5200},{"EARLY_PHASE1":5201,"PHASE1":5203,"PHASE2":5209,"PHASE3":5211,"PHASE4":5213,"NA":5215},{"trials":5202,"activeCount":102},[],{"trials":5204,"activeCount":236,"soonestReadout":5163},[5205],{"nctId":5160,"briefTitle":5161,"status":174,"phases":5206,"primaryCompletion":5163,"completion":5164,"start":5165,"enrollment":1182,"conditions":5207,"interventions":5208},[90],[391,392,5167,5168,5169,3965,5170,2146,5171,5172,5173,1757,5174,5175,5176,5177,5178,5179,5180,5181,5182,5183,5184,5185,5186,5187,5188],[5153,5190],{"trials":5210,"activeCount":102},[],{"trials":5212,"activeCount":102},[],{"trials":5214,"activeCount":102},[],{"trials":5216,"activeCount":102},[],{"intervention":57,"totalTrials":236,"cells":5218},{"EARLY_PHASE1":5219,"PHASE1":5230,"PHASE2":5232,"PHASE3":5234,"PHASE4":5236,"NA":5238},{"trials":5220,"activeCount":236,"soonestReadout":56},[5221],{"nctId":54,"briefTitle":55,"status":174,"phases":5222,"primaryCompletion":56,"completion":5223,"start":5224,"enrollment":1129,"conditions":5225,"interventions":5229},[89],"2025-07-31","2020-09-26",[5226,5227,5228],"Heart Failure, Systolic","Heart Failure NYHA Class IV","Metabolic Disturbance",[57],{"trials":5231,"activeCount":102},[],{"trials":5233,"activeCount":102},[],{"trials":5235,"activeCount":102},[],{"trials":5237,"activeCount":102},[],{"trials":5239,"activeCount":102},[],{"intervention":5241,"totalTrials":236,"cells":5242},"Bladder chemodenervation",{"EARLY_PHASE1":5243,"PHASE1":5254,"PHASE2":5256,"PHASE3":5258,"PHASE4":5260,"NA":5262},{"trials":5244,"activeCount":236,"soonestReadout":5249},[5245],{"nctId":5246,"briefTitle":5247,"status":256,"phases":5248,"primaryCompletion":5249,"completion":476,"start":5250,"enrollment":261,"conditions":5251,"interventions":5253},"NCT06793683","Early BOTOX After Spinal Cord Injury",[89],"2028-04-30","2024-07-27",[5252],"Spinal Cord Injuries",[5241],{"trials":5255,"activeCount":102},[],{"trials":5257,"activeCount":102},[],{"trials":5259,"activeCount":102},[],{"trials":5261,"activeCount":102},[],{"trials":5263,"activeCount":102},[],{"intervention":5265,"totalTrials":236,"cells":5266},"midomafetamine (MDMA)-Assisted Therapy",{"EARLY_PHASE1":5267,"PHASE1":5278,"PHASE2":5280,"PHASE3":5282,"PHASE4":5284,"NA":5286},{"trials":5268,"activeCount":236,"soonestReadout":5273},[5269],{"nctId":5270,"briefTitle":5271,"status":174,"phases":5272,"primaryCompletion":5273,"completion":2766,"start":5274,"enrollment":113,"conditions":5275,"interventions":5277},"NCT06565494","MDMA-Assisted Therapy for Pathological Narcissism",[89],"2026-08-15","2024-08-27",[5276],"Narcissism",[5265],{"trials":5279,"activeCount":102},[],{"trials":5281,"activeCount":102},[],{"trials":5283,"activeCount":102},[],{"trials":5285,"activeCount":102},[],{"trials":5287,"activeCount":102},[],{"intervention":5289,"totalTrials":264,"cells":5290},"Tranexamic acid",{"EARLY_PHASE1":5291,"PHASE1":5293,"PHASE2":5295,"PHASE3":5297,"PHASE4":5311,"NA":5313},{"trials":5292,"activeCount":102},[],{"trials":5294,"activeCount":102},[],{"trials":5296,"activeCount":102},[],{"trials":5298,"activeCount":102},[5299],{"nctId":5300,"briefTitle":5301,"status":131,"phases":5302,"primaryCompletion":5303,"completion":5304,"start":5305,"enrollment":5306,"conditions":5307,"interventions":5309},"NCT02578901","American Trial Using Tranexamic Acid in Thrombocytopenia",[92],"2020-03","2020-06-11","2016-06",330,[5308],"Thrombocytopenia",[5310],"Tranexamic Acid",{"trials":5312,"activeCount":102},[],{"trials":5314,"activeCount":236,"soonestReadout":577},[5315],{"nctId":5316,"briefTitle":5317,"status":244,"phases":5318,"primaryCompletion":577,"completion":577,"start":5319,"enrollment":5320,"conditions":5321,"interventions":5323},"NCT04146376","Von Willebrand Factor in Pregnancy (VIP) Study",[],"2019-10-12",110,[5322],"Von Willebrand Diseases",[5324,5289],"VWF replacement therapy with Wilate",{"intervention":5326,"totalTrials":264,"cells":5327},"Chlorhexidine Gluconate",{"EARLY_PHASE1":5328,"PHASE1":5330,"PHASE2":5332,"PHASE3":5334,"PHASE4":5336,"NA":5349},{"trials":5329,"activeCount":102},[],{"trials":5331,"activeCount":102},[],{"trials":5333,"activeCount":102},[],{"trials":5335,"activeCount":102},[],{"trials":5337,"activeCount":102},[5338],{"nctId":5339,"briefTitle":5340,"status":131,"phases":5341,"primaryCompletion":5342,"completion":5343,"start":5344,"enrollment":350,"conditions":5345,"interventions":5347},"NCT04021524","BPO vs Hibiclens Soap for Surgical Preparation",[93],"2019-05-31","2021-04-16","2018-09-10",[5346],"Propionibacterium Acnes",[5348,5326],"Benzoyl Peroxide 10% Bar",{"trials":5350,"activeCount":236,"soonestReadout":176},[5351],{"nctId":5352,"briefTitle":5353,"status":244,"phases":5354,"primaryCompletion":176,"completion":1351,"start":5355,"enrollment":310,"conditions":5356,"interventions":5359},"NCT06464770","Optimizing Infection Prophylaxis Prior to Shoulder Surgery",[94],"2024-08-31",[5357,5358],"Arthroplasty Shoulder","Periprosthetic Joint Infection",[5326],{"intervention":5361,"totalTrials":264,"cells":5362},"Atorvastatin",{"EARLY_PHASE1":5363,"PHASE1":5365,"PHASE2":5367,"PHASE3":5369,"PHASE4":5371,"NA":5388},{"trials":5364,"activeCount":102},[],{"trials":5366,"activeCount":102},[],{"trials":5368,"activeCount":102},[],{"trials":5370,"activeCount":102},[],{"trials":5372,"activeCount":102},[5373],{"nctId":5374,"briefTitle":5375,"status":131,"phases":5376,"primaryCompletion":5377,"completion":5378,"start":5379,"enrollment":5380,"conditions":5381,"interventions":5385},"NCT00715273","Evaluate Carotid Artery Plaque Composition by Magnetic Resonance Imaging in People Receiving Cholesterol Medication",[93],"2018-12-12","2019-03-01","2001-05-01",217,[5382,5383,5384],"Coronary Artery Disease","Carotid Artery Diseases","Atherosclerosis",[5361,5386,5387],"Niacin","Colesevelam",{"trials":5389,"activeCount":236,"soonestReadout":5394},[5390],{"nctId":5391,"briefTitle":5392,"status":174,"phases":5393,"primaryCompletion":5394,"completion":5394,"start":5395,"enrollment":372,"conditions":5396,"interventions":5399},"NCT04575857","Role of Statins In Slowing Rheumatic Heart Disease (RHD) Progression",[],"2040-02","2022-02-08",[5397,5398],"Rheumatic Heart Disease","Valvular Disease",[5361],{"intervention":77,"totalTrials":236,"cells":5401},{"EARLY_PHASE1":5402,"PHASE1":5404,"PHASE2":5406,"PHASE3":5408,"PHASE4":5410,"NA":5412},{"trials":5403,"activeCount":102},[],{"trials":5405,"activeCount":102},[],{"trials":5407,"activeCount":102},[],{"trials":5409,"activeCount":102},[],{"trials":5411,"activeCount":102},[],{"trials":5413,"activeCount":236,"soonestReadout":76},[5414],{"nctId":74,"briefTitle":75,"status":174,"phases":5415,"primaryCompletion":76,"completion":176,"start":5416,"enrollment":5417,"conditions":5418,"interventions":5421},[94],"2021-02-04",539,[5419,5420],"HIV\u002FAIDS","HIV-1-infection",[77],{"intervention":5423,"totalTrials":236,"cells":5424},"Anti-hypertensive medications",{"EARLY_PHASE1":5425,"PHASE1":5427,"PHASE2":5429,"PHASE3":5431,"PHASE4":5433,"NA":5435},{"trials":5426,"activeCount":102},[],{"trials":5428,"activeCount":102},[],{"trials":5430,"activeCount":102},[],{"trials":5432,"activeCount":102},[],{"trials":5434,"activeCount":102},[],{"trials":5436,"activeCount":236,"soonestReadout":5441},[5437],{"nctId":5438,"briefTitle":5439,"status":174,"phases":5440,"primaryCompletion":5441,"completion":5441,"start":5442,"enrollment":5443,"conditions":5444,"interventions":5446},"NCT05159999","The Home Blood Pressure (BP) Trial",[94],"2026-04-30","2022-02-02",200,[5445],"End Stage Renal Disease on Dialysis",[5423],{"intervention":5448,"totalTrials":236,"cells":5449},"doxy-PEP",{"EARLY_PHASE1":5450,"PHASE1":5452,"PHASE2":5454,"PHASE3":5456,"PHASE4":5458,"NA":5460},{"trials":5451,"activeCount":102},[],{"trials":5453,"activeCount":102},[],{"trials":5455,"activeCount":102},[],{"trials":5457,"activeCount":102},[],{"trials":5459,"activeCount":102},[],{"trials":5461,"activeCount":236,"soonestReadout":5466},[5462],{"nctId":5463,"briefTitle":5464,"status":599,"phases":5465,"primaryCompletion":5466,"completion":246,"start":763,"enrollment":5467,"conditions":5468,"interventions":5470},"NCT07361926","Sexual Health Access at Retail Pharmacies: Advancing Pharmacy-based Delivery of Primary STI and HIV Prevention for Cisgender Women",[94],"2029-06",720,[5469,19],"Sexually Transmitted Infections (Not HIV or Hepatitis)",[5448,5471],"HIV PEP\u002FPrEP",{"intervention":5471,"totalTrials":236,"cells":5473},{"EARLY_PHASE1":5474,"PHASE1":5476,"PHASE2":5478,"PHASE3":5480,"PHASE4":5482,"NA":5484},{"trials":5475,"activeCount":102},[],{"trials":5477,"activeCount":102},[],{"trials":5479,"activeCount":102},[],{"trials":5481,"activeCount":102},[],{"trials":5483,"activeCount":102},[],{"trials":5485,"activeCount":236,"soonestReadout":5466},[5486],{"nctId":5463,"briefTitle":5464,"status":599,"phases":5487,"primaryCompletion":5466,"completion":246,"start":763,"enrollment":5467,"conditions":5488,"interventions":5489},[94],[5469,19],[5448,5471],{"intervention":5324,"totalTrials":236,"cells":5491},{"EARLY_PHASE1":5492,"PHASE1":5494,"PHASE2":5496,"PHASE3":5498,"PHASE4":5500,"NA":5502},{"trials":5493,"activeCount":102},[],{"trials":5495,"activeCount":102},[],{"trials":5497,"activeCount":102},[],{"trials":5499,"activeCount":102},[],{"trials":5501,"activeCount":102},[],{"trials":5503,"activeCount":236,"soonestReadout":577},[5504],{"nctId":5316,"briefTitle":5317,"status":244,"phases":5505,"primaryCompletion":577,"completion":577,"start":5319,"enrollment":5320,"conditions":5506,"interventions":5507},[],[5322],[5324,5289],{"intervention":3008,"totalTrials":236,"cells":5509},{"EARLY_PHASE1":5510,"PHASE1":5512,"PHASE2":5514,"PHASE3":5516,"PHASE4":5518,"NA":5520},{"trials":5511,"activeCount":102},[],{"trials":5513,"activeCount":102},[],{"trials":5515,"activeCount":102},[],{"trials":5517,"activeCount":102},[],{"trials":5519,"activeCount":102},[],{"trials":5521,"activeCount":236,"soonestReadout":3005},[5522],{"nctId":3002,"briefTitle":3003,"status":244,"phases":5523,"primaryCompletion":3005,"completion":3005,"start":2264,"enrollment":1274,"conditions":5524,"interventions":5525},[94],[2360,2312,1383],[1737,3008],{"intervention":5527,"totalTrials":236,"cells":5528},"Radium Ra 223 Dichloride",{"EARLY_PHASE1":5529,"PHASE1":5531,"PHASE2":5533,"PHASE3":5535,"PHASE4":5537,"NA":5539},{"trials":5530,"activeCount":102},[],{"trials":5532,"activeCount":102},[],{"trials":5534,"activeCount":102},[],{"trials":5536,"activeCount":102},[],{"trials":5538,"activeCount":102},[],{"trials":5540,"activeCount":236,"soonestReadout":727},[5541],{"nctId":5542,"briefTitle":5543,"status":244,"phases":5544,"primaryCompletion":727,"completion":5545,"start":5343,"enrollment":1338,"conditions":5546,"interventions":5547},"NCT04489719","Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer",[],"2029-08-01",[1355,1057,1058,1063],[5527],{"intervention":5549,"totalTrials":236,"cells":5550},"Targeted Long-read sequencing",{"EARLY_PHASE1":5551,"PHASE1":5553,"PHASE2":5555,"PHASE3":5557,"PHASE4":5559,"NA":5561},{"trials":5552,"activeCount":102},[],{"trials":5554,"activeCount":102},[],{"trials":5556,"activeCount":102},[],{"trials":5558,"activeCount":102},[],{"trials":5560,"activeCount":102},[],{"trials":5562,"activeCount":236,"soonestReadout":5567},[5563],{"nctId":5564,"briefTitle":5565,"status":244,"phases":5566,"primaryCompletion":5567,"completion":5568,"start":5569,"enrollment":372,"conditions":5570,"interventions":5576},"NCT06725173","Detailed Phenotypic and Genotype Study to Correlate RB1 Mutations Relating to Primary Ocular Tumors and Secondary Extra-ocular Metastasis.",[],"2030-01-01","2031-01-01","2026-03-16",[5571,5572,5573,5574,5575],"Retinoblastoma Bilateral","Retinoblastoma Unilateral","Retinoblastoma, Extraocular","Retinoblastoma, Recurrent","Retinoblastoma",[5549],{"intervention":5578,"totalTrials":236,"cells":5579},"Ciprofloxacin 500 mg",{"EARLY_PHASE1":5580,"PHASE1":5582,"PHASE2":5584,"PHASE3":5586,"PHASE4":5588,"NA":5590},{"trials":5581,"activeCount":102},[],{"trials":5583,"activeCount":102},[],{"trials":5585,"activeCount":102},[],{"trials":5587,"activeCount":102},[],{"trials":5589,"activeCount":102},[],{"trials":5591,"activeCount":236,"soonestReadout":5163},[5592],{"nctId":5593,"briefTitle":5594,"status":244,"phases":5595,"primaryCompletion":5163,"completion":176,"start":2185,"enrollment":5596,"conditions":5597,"interventions":5599},"NCT05286931","SpeeDx Ciprofloxacin gyrA Assay for N. Gonorrhoeae Gonococcal Infection",[94],1800,[5598],"Neisseria Gonorrhoeae Infection",[5578],{"intervention":5071,"totalTrials":98,"cells":5601},{"EARLY_PHASE1":5602,"PHASE1":5604,"PHASE2":5627,"PHASE3":5658,"PHASE4":5679,"NA":5689},{"trials":5603,"activeCount":102},[],{"trials":5605,"activeCount":102},[5606,5616],{"nctId":5607,"briefTitle":5608,"status":131,"phases":5609,"primaryCompletion":5610,"completion":5610,"start":5611,"enrollment":2370,"conditions":5612,"interventions":5615},"NCT00161486","The Effects of Testosterone on Prostate Tissue (ACYP-1)",[90],"2004-11","2004-07",[5613,5614],"Hypogonadism","Contraception",[5071,340],{"nctId":5617,"briefTitle":5618,"status":131,"phases":5619,"primaryCompletion":5620,"completion":5620,"start":5621,"enrollment":5622,"conditions":5623,"interventions":5624},"NCT00229593","NES Gel-1, To Evaluate Nestorone Gel in Combination With Testosterone Gel",[90],"2007-01","2005-09",140,[5614],[5625,5626],"Nestorone gel","Testosterone Gel",{"trials":5628,"activeCount":102},[5629,5637,5646,5654],{"nctId":5630,"briefTitle":5631,"status":131,"phases":5632,"primaryCompletion":2913,"completion":2913,"start":5633,"enrollment":34,"conditions":5634,"interventions":5635},"NCT00156650","Manipulation of the Intratesticular Hormonal Milieu With Exogenous Testosterone (HOP 5) Testicular Aspiration Addendum",[90,91],"2004-12",[5614],[340,5626,5636],"Depo-Medroxyprogesterone",{"nctId":5638,"briefTitle":5639,"status":131,"phases":5640,"primaryCompletion":189,"completion":442,"start":5641,"enrollment":5642,"conditions":5643,"interventions":5644},"NCT00839319","HOP-3 Manipulation of the Intratesticular Hormonal Milieu With Exogenous Testosterone",[90,91],"2009-03",59,[5069],[340,5645,5645,5645,5071],"hCG",{"nctId":5647,"briefTitle":5648,"status":131,"phases":5649,"primaryCompletion":5650,"completion":5650,"start":5651,"enrollment":135,"conditions":5652,"interventions":5653},"NCT00161447","Male Hormonal Contraceptive Development-ACY-5",[90,91],"2006-04","2004-05",[5614],[340,5626,5636],{"nctId":5063,"briefTitle":5064,"status":131,"phases":5655,"primaryCompletion":1864,"completion":1864,"start":5066,"enrollment":5067,"conditions":5656,"interventions":5657},[90,91],[5069],[340,5071,5072,5073,5074,399],{"trials":5659,"activeCount":102},[5660,5669],{"nctId":5661,"briefTitle":5662,"status":131,"phases":5663,"primaryCompletion":5664,"completion":1864,"start":5665,"enrollment":1129,"conditions":5666,"interventions":5668},"NCT00490555","PROS-1-Male Hormonal Contraceptive Regimens on Prostate Tissue",[91,92],"2012-01","2009-01",[5667],"Healthy",[5071,5074,5636],{"nctId":5670,"briefTitle":5671,"status":131,"phases":5672,"primaryCompletion":2106,"completion":2929,"start":5673,"enrollment":1087,"conditions":5674,"interventions":5677},"NCT00539305","Hormone and Information Processing Study",[92],"2009-07",[5675,5676],"Mild Cognitive Impairment","Alzheimer's Disease",[5678],"testosterone gel",{"trials":5680,"activeCount":102},[5681],{"nctId":5682,"briefTitle":5683,"status":131,"phases":5684,"primaryCompletion":3251,"completion":271,"start":5685,"enrollment":332,"conditions":5686,"interventions":5688},"NCT00194675","TRADE-Testosterone Replacement and Dutasteride Effectiveness",[93],"2005-03",[5613,5687],"Benign Prostatic Hyperplasia",[5074,5071],{"trials":5690,"activeCount":102},[],{"intervention":5074,"totalTrials":192,"cells":5692},{"EARLY_PHASE1":5693,"PHASE1":5695,"PHASE2":5697,"PHASE3":5731,"PHASE4":5737,"NA":5743},{"trials":5694,"activeCount":102},[],{"trials":5696,"activeCount":102},[],{"trials":5698,"activeCount":102},[5699,5703,5715,5723],{"nctId":5063,"briefTitle":5064,"status":131,"phases":5700,"primaryCompletion":1864,"completion":1864,"start":5066,"enrollment":5067,"conditions":5701,"interventions":5702},[90,91],[5069],[340,5071,5072,5073,5074,399],{"nctId":5704,"briefTitle":5705,"status":1150,"phases":5706,"primaryCompletion":5707,"completion":577,"start":5708,"enrollment":102,"conditions":5709,"interventions":5711},"NCT02147964","ITT-5 Mechanisms of Spermatogenesis in Man",[91],"2021-12","2019-06",[5710],"Gonadotropin Deficiency",[5712,340,5074,5713,5714],"Testosterone 1% Gel","Ketoconazole","HCG",{"nctId":5716,"briefTitle":5717,"status":131,"phases":5718,"primaryCompletion":5719,"completion":5719,"start":5720,"enrollment":673,"conditions":5721,"interventions":5722},"NCT00399165","Oral Androgens in Man-4: (Short Title: Oral T-4)",[90,91],"2007-05","2006-11",[5614],[3683,3683,5074,5074],{"nctId":5724,"briefTitle":5725,"status":131,"phases":5726,"primaryCompletion":4906,"completion":4906,"start":5685,"enrollment":1182,"conditions":5727,"interventions":5728},"NCT00161421","Oral Androgens in Man-3 (ORAL T-3) Pharmacokinetics of Oral Testosterone",[91],[5614,5613],[5729,5730,5074],"Oral Testosterone","Leuprolide",{"trials":5732,"activeCount":102},[5733],{"nctId":5661,"briefTitle":5662,"status":131,"phases":5734,"primaryCompletion":5664,"completion":1864,"start":5665,"enrollment":1129,"conditions":5735,"interventions":5736},[91,92],[5667],[5071,5074,5636],{"trials":5738,"activeCount":102},[5739],{"nctId":5682,"briefTitle":5683,"status":131,"phases":5740,"primaryCompletion":3251,"completion":271,"start":5685,"enrollment":332,"conditions":5741,"interventions":5742},[93],[5613,5687],[5074,5071],{"trials":5744,"activeCount":102},[],{"intervention":5746,"totalTrials":1547,"cells":5747},"Doxycycline",{"EARLY_PHASE1":5748,"PHASE1":5750,"PHASE2":5752,"PHASE3":5764,"PHASE4":5776,"NA":5797},{"trials":5749,"activeCount":102},[],{"trials":5751,"activeCount":102},[],{"trials":5753,"activeCount":102},[5754],{"nctId":5755,"briefTitle":5756,"status":108,"phases":5757,"primaryCompletion":5758,"completion":5758,"start":5759,"enrollment":113,"conditions":5760,"interventions":5762},"NCT05111002","Lefamulin for M. Genitalium Treatment Failures",[90,91],"2023-11-30","2022-04-22",[5761],"Mycoplasma Genitalium Infection",[5763,5746],"Lefamulin",{"trials":5765,"activeCount":102},[5766],{"nctId":5767,"briefTitle":5768,"status":131,"phases":5769,"primaryCompletion":5770,"completion":5770,"start":5620,"enrollment":5771,"conditions":5772,"interventions":5774},"NCT00358462","Mycoplasma Genitalium Antibiotic Susceptibility and Treatment (MEGA)",[92],"2011-11",606,[5773],"Urethritis",[5775,5746],"Azithromycin",{"trials":5777,"activeCount":102},[5778,5786],{"nctId":5779,"briefTitle":5780,"status":131,"phases":5781,"primaryCompletion":5782,"completion":5782,"start":52,"enrollment":389,"conditions":5783,"interventions":5785},"NCT06582966","Weekly Doxycycline DOT for STI Prevention Among Cisgender Women Taking HIV PrEP in Kisumu, Kenya",[93],"2025-05-27",[5784],"STI",[5746],{"nctId":5787,"briefTitle":5788,"status":131,"phases":5789,"primaryCompletion":2274,"completion":2274,"start":5790,"enrollment":5791,"conditions":5792,"interventions":5796},"NCT04050540","Doxycycline PEP for Prevention of Sexually Transmitted Infections Among Kenyan Women Using HIV PrEP",[93],"2020-02-05",449,[19,5419,5793,5794,5795],"Neisseria Gonorrheae Infection","Chlamydia Trachomatis Infection","Syphilis Infection",[5746],{"trials":5798,"activeCount":102},[],{"intervention":5800,"totalTrials":702,"cells":5801},"niacin",{"EARLY_PHASE1":5802,"PHASE1":5804,"PHASE2":5806,"PHASE3":5808,"PHASE4":5834,"NA":5840},{"trials":5803,"activeCount":102},[],{"trials":5805,"activeCount":102},[],{"trials":5807,"activeCount":102},[],{"trials":5809,"activeCount":102},[5810,5822],{"nctId":5811,"briefTitle":5812,"status":131,"phases":5813,"completion":5814,"start":5815,"conditions":5816,"interventions":5819},"NCT00000553","HDL-Atherosclerosis Treatment Study (HATS)",[92],"2001-02","1994-09",[22,5817,28,5818],"Coronary Disease","Myocardial Ischemia",[5820,5800,5821],"simvastatin","antioxidants",{"nctId":5823,"briefTitle":5824,"status":131,"phases":5825,"primaryCompletion":5826,"completion":5826,"start":5827,"enrollment":5828,"conditions":5829,"interventions":5831},"NCT00000512","Familial Atherosclerosis Treatment Study",[92],"1989-08","1984-01",146,[22,5830,5817,28,5818],"Coronary Arteriosclerosis",[5832,5833,5800],"lovastatin","colestipol",{"trials":5835,"activeCount":102},[5836],{"nctId":5374,"briefTitle":5375,"status":131,"phases":5837,"primaryCompletion":5377,"completion":5378,"start":5379,"enrollment":5380,"conditions":5838,"interventions":5839},[93],[5382,5383,5384],[5361,5386,5387],{"trials":5841,"activeCount":102},[],{"intervention":5775,"totalTrials":702,"cells":5843},{"EARLY_PHASE1":5844,"PHASE1":5846,"PHASE2":5848,"PHASE3":5850,"PHASE4":5871,"NA":5889},{"trials":5845,"activeCount":102},[],{"trials":5847,"activeCount":102},[],{"trials":5849,"activeCount":102},[],{"trials":5851,"activeCount":102},[5852,5856],{"nctId":5767,"briefTitle":5768,"status":131,"phases":5853,"primaryCompletion":5770,"completion":5770,"start":5620,"enrollment":5771,"conditions":5854,"interventions":5855},[92],[5773],[5775,5746],{"nctId":5857,"briefTitle":5858,"status":108,"phases":5859,"primaryCompletion":5860,"completion":5861,"start":5862,"enrollment":5863,"conditions":5864,"interventions":5866},"NCT04354428","Treatment for COVID-19 in High-Risk Adult Outpatients",[91,92],"2020-11-03","2020-11-30","2020-04-16",289,[2189,5865],"SARS-CoV-2",[5867,5868,5775,5869,5870],"Ascorbic Acid","Hydroxychloroquine Sulfate","Folic Acid","Lopinavir 200 MG \u002F Ritonavir 50 MG [Kaletra]",{"trials":5872,"activeCount":102},[5873],{"nctId":5874,"briefTitle":5875,"status":5876,"phases":5877,"primaryCompletion":5878,"completion":5879,"start":5880,"enrollment":5881,"conditions":5882,"interventions":5888},"NCT02414399","Azithromycin to Prevent Post-discharge Morbidity and Mortality in Kenyan Children","UNKNOWN",[93],"2020-05-04","2025-12-28","2016-06-28",1400,[5883,812,5884,5885,5886,5887],"Pneumonia","Malaria","Co-infection","Death","Malnutrition",[5775],{"trials":5890,"activeCount":102},[],{"intervention":5892,"totalTrials":264,"cells":5893},"Insulin Glargine",{"EARLY_PHASE1":5894,"PHASE1":5896,"PHASE2":5898,"PHASE3":5900,"PHASE4":5902,"NA":5926},{"trials":5895,"activeCount":102},[],{"trials":5897,"activeCount":102},[],{"trials":5899,"activeCount":102},[],{"trials":5901,"activeCount":102},[],{"trials":5903,"activeCount":102},[5904,5914],{"nctId":5905,"briefTitle":5906,"status":131,"phases":5907,"primaryCompletion":5908,"completion":5909,"start":5910,"enrollment":5642,"conditions":5911,"interventions":5912},"NCT04623086","Comparison of Glargine to Degludec Insulin Transition With or Without a Bridging Glargine Dose",[93],"2022-09-07","2023-12-31","2020-02-14",[4073],[5913,5892],"Insulin Degludec",{"nctId":5915,"briefTitle":5916,"status":131,"phases":5917,"primaryCompletion":5918,"completion":5918,"start":739,"enrollment":5919,"conditions":5920,"interventions":5922},"NCT01524705","FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)",[93],"2014-07",102,[5921],"Type 2 Diabetes",[5892,5923,5924,5925],"Metformin","Prandial insulin","Exenatide",{"trials":5927,"activeCount":102},[],{"intervention":5929,"totalTrials":264,"cells":5930},"Valganciclovir",{"EARLY_PHASE1":5931,"PHASE1":5933,"PHASE2":5935,"PHASE3":5946,"PHASE4":5948,"NA":5957},{"trials":5932,"activeCount":102},[],{"trials":5934,"activeCount":102},[],{"trials":5936,"activeCount":102},[5937],{"nctId":5938,"briefTitle":5939,"status":131,"phases":5940,"primaryCompletion":5685,"completion":5685,"start":5941,"enrollment":1129,"conditions":5942,"interventions":5944},"NCT00194467","Suppression of Oral HHV8 Shedding With Valganciclovir",[91],"2002-12",[5943],"Human Herpesvirus 8",[5945],"valganciclovir",{"trials":5947,"activeCount":102},[],{"trials":5949,"activeCount":102},[5950],{"nctId":5951,"briefTitle":5952,"status":1150,"phases":5953,"primaryCompletion":1675,"completion":1675,"start":1475,"enrollment":102,"conditions":5954,"interventions":5956},"NCT00361933","Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's Disease",[93],[5955],"Giant Lymph Node Hyperplasia",[5929],{"trials":5958,"activeCount":102},[],{"intervention":5960,"totalTrials":264,"cells":5961},"NuvaRing",{"EARLY_PHASE1":5962,"PHASE1":5964,"PHASE2":5966,"PHASE3":5968,"PHASE4":5970,"NA":5990},{"trials":5963,"activeCount":102},[],{"trials":5965,"activeCount":102},[],{"trials":5967,"activeCount":102},[],{"trials":5969,"activeCount":102},[],{"trials":5971,"activeCount":102},[5972,5982],{"nctId":5973,"briefTitle":5974,"status":131,"phases":5975,"primaryCompletion":5976,"completion":5977,"start":5978,"enrollment":861,"conditions":5979,"interventions":5981},"NCT02445989","Effects of Contraceptive Ring on Vaginal Microbiota, HIV Shedding and Local Immunity",[93],"2018-11","2018-12","2016-05",[5980,25],"Bacterial Vaginosis",[5960],{"nctId":5983,"briefTitle":5984,"status":131,"phases":5985,"primaryCompletion":5986,"completion":5986,"start":5987,"enrollment":10,"conditions":5988,"interventions":5989},"NCT02432404","Effects of a Vaginal Contraceptive Ring on Vaginal Microbiota and Local Immunity",[93],"2021-11","2016-03",[5980],[5960],{"trials":5991,"activeCount":102},[],{"intervention":5993,"totalTrials":264,"cells":5994},"Naproxen",{"EARLY_PHASE1":5995,"PHASE1":5997,"PHASE2":5999,"PHASE3":6001,"PHASE4":6003,"NA":6024},{"trials":5996,"activeCount":102},[],{"trials":5998,"activeCount":102},[],{"trials":6000,"activeCount":102},[],{"trials":6002,"activeCount":102},[],{"trials":6004,"activeCount":102},[6005,6015],{"nctId":6006,"briefTitle":6007,"status":5876,"phases":6008,"primaryCompletion":6009,"completion":6010,"start":6011,"enrollment":23,"conditions":6012,"interventions":6014},"NCT04449471","Naproxen Pharmacogenetic Study (Project 1, Aim 2)",[93],"2021-07-31","2022-07-31","2016-01-12",[6013],"Pharmacogenetics",[5993],{"nctId":6016,"briefTitle":6017,"status":131,"phases":6018,"primaryCompletion":6019,"completion":6019,"start":6020,"enrollment":3144,"conditions":6021,"interventions":6023},"NCT02519231","Copper IUD Treatment Observation Study",[93],"2017-11","2016-02",[6022],"Menorrhagia",[5993],{"trials":6025,"activeCount":102},[],{"intervention":6027,"totalTrials":264,"cells":6028},"Ketamine",{"EARLY_PHASE1":6029,"PHASE1":6031,"PHASE2":6033,"PHASE3":6035,"PHASE4":6043,"NA":6057},{"trials":6030,"activeCount":102},[],{"trials":6032,"activeCount":102},[],{"trials":6034,"activeCount":102},[],{"trials":6036,"activeCount":102},[6037],{"nctId":6038,"briefTitle":6039,"status":5876,"phases":6040,"primaryCompletion":225,"completion":225,"start":3023,"enrollment":1129,"conditions":6041,"interventions":6042},"NCT02303847","Ultra-low Dose Oral Ketamine for Chronic Pain in the Primary Care Setting",[92],[31],[6027],{"trials":6044,"activeCount":102},[6045],{"nctId":6046,"briefTitle":6047,"status":131,"phases":6048,"primaryCompletion":6049,"completion":6049,"start":6050,"enrollment":5320,"conditions":6051,"interventions":6055},"NCT04871425","Ketamine Versus Fentanyl for Surgical Abortions",[93],"2021-10-14","2021-04-27",[6052,6053,6054],"Abortion in First Trimester","Pain, Procedural","Opioid Use",[6027,6056],"Fentanyl",{"trials":6058,"activeCount":102},[],{"intervention":6060,"totalTrials":236,"cells":6061},"Baloxavir Marboxil",{"EARLY_PHASE1":6062,"PHASE1":6064,"PHASE2":6066,"PHASE3":6068,"PHASE4":6070,"NA":6083},{"trials":6063,"activeCount":102},[],{"trials":6065,"activeCount":102},[],{"trials":6067,"activeCount":102},[],{"trials":6069,"activeCount":102},[],{"trials":6071,"activeCount":102},[6072],{"nctId":6073,"briefTitle":6074,"status":131,"phases":6075,"primaryCompletion":6076,"completion":6076,"start":6077,"enrollment":6078,"conditions":6079,"interventions":6082},"NCT04141930","Pilot of Cohort of Households for Influenza Monitoring and Evaluation in Seattle",[93],"2020-04-01","2019-11-01",481,[6080,6081],"Influenza","Respiratory Viral Infection",[6060],{"trials":6084,"activeCount":102},[],{"intervention":6086,"totalTrials":236,"cells":6087},"Viagra",{"EARLY_PHASE1":6088,"PHASE1":6090,"PHASE2":6092,"PHASE3":6094,"PHASE4":6096,"NA":6106},{"trials":6089,"activeCount":102},[],{"trials":6091,"activeCount":102},[],{"trials":6093,"activeCount":102},[],{"trials":6095,"activeCount":102},[],{"trials":6097,"activeCount":102},[6098],{"nctId":6099,"briefTitle":6100,"status":108,"phases":6101,"completion":6102,"start":5611,"enrollment":23,"conditions":6103,"interventions":6105},"NCT00194597","Trial of Viagra' in Men With Chronic Pelvic Pain Syndrome Type III",[93],"2007-07",[6104],"Prostatitis",[6086],{"trials":6107,"activeCount":102},[],{"intervention":6109,"totalTrials":236,"cells":6110},"Belladonna and Opium",{"EARLY_PHASE1":6111,"PHASE1":6113,"PHASE2":6115,"PHASE3":6117,"PHASE4":6119,"NA":6131},{"trials":6112,"activeCount":102},[],{"trials":6114,"activeCount":102},[],{"trials":6116,"activeCount":102},[],{"trials":6118,"activeCount":102},[],{"trials":6120,"activeCount":102},[6121],{"nctId":6122,"briefTitle":6123,"status":131,"phases":6124,"primaryCompletion":6125,"completion":6126,"start":5021,"enrollment":6127,"conditions":6128,"interventions":6130},"NCT03332056","The Use of Belladonna and Opium Suppository in the Treatment of Postoperative Stent Pain",[93],"2014-10","2015-10",71,[6129],"Nephrolithiasis",[6109],{"trials":6132,"activeCount":102},[],{"intervention":6134,"totalTrials":236,"cells":6135},"Local anesthetic",{"EARLY_PHASE1":6136,"PHASE1":6138,"PHASE2":6140,"PHASE3":6142,"PHASE4":6144,"NA":6157},{"trials":6137,"activeCount":102},[],{"trials":6139,"activeCount":102},[],{"trials":6141,"activeCount":102},[],{"trials":6143,"activeCount":102},[],{"trials":6145,"activeCount":102},[6146],{"nctId":6147,"briefTitle":6148,"status":131,"phases":6149,"primaryCompletion":6150,"completion":6150,"start":6151,"enrollment":1114,"conditions":6152,"interventions":6156},"NCT05338671","Effect of Post-Operative Anesthetics on Post-Operative Pain in Patients Receiving Endodontic Treatment",[93],"2024-06-01","2021-09-29",[6153,6154,6155],"Endodontic Disease","Post Operative Pain","Symptomatic Irreversible Pulpitis",[6134],{"trials":6158,"activeCount":102},[],{"intervention":6160,"totalTrials":236,"cells":6161},"IV acetaminophen",{"EARLY_PHASE1":6162,"PHASE1":6164,"PHASE2":6166,"PHASE3":6168,"PHASE4":6170,"NA":6181},{"trials":6163,"activeCount":102},[],{"trials":6165,"activeCount":102},[],{"trials":6167,"activeCount":102},[],{"trials":6169,"activeCount":102},[],{"trials":6171,"activeCount":102},[6172],{"nctId":6173,"briefTitle":6174,"status":131,"phases":6175,"primaryCompletion":860,"completion":6176,"start":440,"enrollment":427,"conditions":6177,"interventions":6180},"NCT01544062","IV Acetaminophen as an Adjunct Analgesic in Cardiac Surgery",[93],"2014-08",[6178,6179],"Acute Pain","Hyperalgesia",[6160],{"trials":6182,"activeCount":102},[],{"intervention":5913,"totalTrials":236,"cells":6184},{"EARLY_PHASE1":6185,"PHASE1":6187,"PHASE2":6189,"PHASE3":6191,"PHASE4":6193,"NA":6199},{"trials":6186,"activeCount":102},[],{"trials":6188,"activeCount":102},[],{"trials":6190,"activeCount":102},[],{"trials":6192,"activeCount":102},[],{"trials":6194,"activeCount":102},[6195],{"nctId":5905,"briefTitle":5906,"status":131,"phases":6196,"primaryCompletion":5908,"completion":5909,"start":5910,"enrollment":5642,"conditions":6197,"interventions":6198},[93],[4073],[5913,5892],{"trials":6200,"activeCount":102},[],{"intervention":6202,"totalTrials":236,"cells":6203},"FTC-TDF PrEP",{"EARLY_PHASE1":6204,"PHASE1":6206,"PHASE2":6208,"PHASE3":6210,"PHASE4":6212,"NA":6223},{"trials":6205,"activeCount":102},[],{"trials":6207,"activeCount":102},[],{"trials":6209,"activeCount":102},[],{"trials":6211,"activeCount":102},[],{"trials":6213,"activeCount":102},[6214],{"nctId":6215,"briefTitle":6216,"status":131,"phases":6217,"primaryCompletion":5305,"completion":5305,"start":455,"enrollment":6218,"conditions":6219,"interventions":6221},"NCT02775929","Partners Demonstration Project of PrEP and ART",[93],1013,[6220],"HIV Infection",[6202,6222],"ART",{"trials":6224,"activeCount":102},[],{"intervention":5923,"totalTrials":236,"cells":6226},{"EARLY_PHASE1":6227,"PHASE1":6229,"PHASE2":6231,"PHASE3":6233,"PHASE4":6235,"NA":6241},{"trials":6228,"activeCount":102},[],{"trials":6230,"activeCount":102},[],{"trials":6232,"activeCount":102},[],{"trials":6234,"activeCount":102},[],{"trials":6236,"activeCount":102},[6237],{"nctId":5915,"briefTitle":5916,"status":131,"phases":6238,"primaryCompletion":5918,"completion":5918,"start":739,"enrollment":5919,"conditions":6239,"interventions":6240},[93],[5921],[5892,5923,5924,5925],{"trials":6242,"activeCount":102},[],{"intervention":5924,"totalTrials":236,"cells":6244},{"EARLY_PHASE1":6245,"PHASE1":6247,"PHASE2":6249,"PHASE3":6251,"PHASE4":6253,"NA":6259},{"trials":6246,"activeCount":102},[],{"trials":6248,"activeCount":102},[],{"trials":6250,"activeCount":102},[],{"trials":6252,"activeCount":102},[],{"trials":6254,"activeCount":102},[6255],{"nctId":5915,"briefTitle":5916,"status":131,"phases":6256,"primaryCompletion":5918,"completion":5918,"start":739,"enrollment":5919,"conditions":6257,"interventions":6258},[93],[5921],[5892,5923,5924,5925],{"trials":6260,"activeCount":102},[],{"intervention":5925,"totalTrials":236,"cells":6262},{"EARLY_PHASE1":6263,"PHASE1":6265,"PHASE2":6267,"PHASE3":6269,"PHASE4":6271,"NA":6277},{"trials":6264,"activeCount":102},[],{"trials":6266,"activeCount":102},[],{"trials":6268,"activeCount":102},[],{"trials":6270,"activeCount":102},[],{"trials":6272,"activeCount":102},[6273],{"nctId":5915,"briefTitle":5916,"status":131,"phases":6274,"primaryCompletion":5918,"completion":5918,"start":739,"enrollment":5919,"conditions":6275,"interventions":6276},[93],[5921],[5892,5923,5924,5925],{"trials":6278,"activeCount":102},[],{"intervention":6280,"totalTrials":236,"cells":6281},"Slo-Niacin, atorvastatin",{"EARLY_PHASE1":6282,"PHASE1":6284,"PHASE2":6286,"PHASE3":6288,"PHASE4":6290,"NA":6301},{"trials":6283,"activeCount":102},[],{"trials":6285,"activeCount":102},[],{"trials":6287,"activeCount":102},[],{"trials":6289,"activeCount":102},[],{"trials":6291,"activeCount":102},[6292],{"nctId":6293,"briefTitle":6294,"status":131,"phases":6295,"primaryCompletion":272,"completion":272,"start":6296,"enrollment":6297,"conditions":6298,"interventions":6300},"NCT00194402","SLIM: Combined Effects of Slo-Niacin and Atorvastatin on Lipoproteins and Inflammatory Markers in Hyperlipidemia",[93],"2003-08",64,[6299],"Dyslipidemia",[6280],{"trials":6302,"activeCount":102},[],{"intervention":6304,"totalTrials":236,"cells":6305},"Carbidopa Levodopa",{"EARLY_PHASE1":6306,"PHASE1":6308,"PHASE2":6310,"PHASE3":6312,"PHASE4":6314,"NA":6325},{"trials":6307,"activeCount":102},[],{"trials":6309,"activeCount":102},[],{"trials":6311,"activeCount":102},[],{"trials":6313,"activeCount":102},[],{"trials":6315,"activeCount":102},[6316],{"nctId":6317,"briefTitle":6318,"status":1150,"phases":6319,"primaryCompletion":6320,"completion":6320,"start":6321,"enrollment":102,"conditions":6322,"interventions":6324},"NCT04742348","Research on Translational Outcomes of Alcohol (Project RETRO)",[93],"2023-08","2023-02",[6323],"Alcohol Drinking",[6304],{"trials":6326,"activeCount":102},[],{"intervention":6328,"totalTrials":236,"cells":6329},"Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine",{"EARLY_PHASE1":6330,"PHASE1":6332,"PHASE2":6334,"PHASE3":6336,"PHASE4":6338,"NA":6350},{"trials":6331,"activeCount":102},[],{"trials":6333,"activeCount":102},[],{"trials":6335,"activeCount":102},[],{"trials":6337,"activeCount":102},[],{"trials":6339,"activeCount":102},[6340],{"nctId":6341,"briefTitle":6342,"status":131,"phases":6343,"primaryCompletion":6344,"completion":6344,"start":6345,"enrollment":6346,"conditions":6347,"interventions":6349},"NCT05435209","Effectiveness of the Q-HPV Vaccine 9-years Post Vaccination Among HIV Positive Adolescents",[93],"2023-10-31","2022-05-25",158,[302,6348],"HPV Vaccination",[6328],{"trials":6351,"activeCount":102},[],{"intervention":6353,"totalTrials":236,"cells":6354},"Protocol for Management of Muscle Relaxation With Rocuronium Using Objective Monitoring and Reversal With Neostigmine or Sugammadex",{"EARLY_PHASE1":6355,"PHASE1":6357,"PHASE2":6359,"PHASE3":6361,"PHASE4":6363,"NA":6373},{"trials":6356,"activeCount":102},[],{"trials":6358,"activeCount":102},[],{"trials":6360,"activeCount":102},[],{"trials":6362,"activeCount":102},[],{"trials":6364,"activeCount":102},[6365],{"nctId":6366,"briefTitle":6367,"status":131,"phases":6368,"primaryCompletion":1509,"completion":112,"start":6369,"enrollment":5443,"conditions":6370,"interventions":6372},"NCT03958201","Best Management of Muscle Relaxation- Objective Monitoring",[93],"2019-05-28",[6371],"Residual Paralysis, Post Anesthesia",[6353],{"trials":6374,"activeCount":102},[],{"intervention":6376,"totalTrials":236,"cells":6377},"OOPEN+BBCC",{"EARLY_PHASE1":6378,"PHASE1":6380,"PHASE2":6382,"PHASE3":6384,"PHASE4":6386,"NA":6398},{"trials":6379,"activeCount":102},[],{"trials":6381,"activeCount":102},[],{"trials":6383,"activeCount":102},[],{"trials":6385,"activeCount":102},[],{"trials":6387,"activeCount":102},[6388],{"nctId":6389,"briefTitle":6390,"status":131,"phases":6391,"primaryCompletion":6392,"completion":6392,"start":6393,"enrollment":6394,"conditions":6395,"interventions":6397},"NCT01788306","Project OOPEN: Opioid Overdose Prevention, Education and Intervention",[93],"2018-10","2013-01",256,[6396],"Opioid Overdose",[6376],{"trials":6399,"activeCount":102},[],{"intervention":6401,"totalTrials":236,"cells":6402},"Botulinum Toxin A",{"EARLY_PHASE1":6403,"PHASE1":6405,"PHASE2":6407,"PHASE3":6409,"PHASE4":6411,"NA":6421},{"trials":6404,"activeCount":102},[],{"trials":6406,"activeCount":102},[],{"trials":6408,"activeCount":102},[],{"trials":6410,"activeCount":102},[],{"trials":6412,"activeCount":102},[6413],{"nctId":6414,"briefTitle":6415,"status":108,"phases":6416,"completion":6417,"start":6296,"enrollment":23,"conditions":6418,"interventions":6420},"NCT00194623","Botox as a Treatment for Chronic Male Pelvic Pain Syndrome",[93],"2007-08",[6419],"Chronic Male Pelvic Pain Syndrome",[6401],{"trials":6422,"activeCount":102},[],{"intervention":6424,"totalTrials":236,"cells":6425},"Calcium Sulfate",{"EARLY_PHASE1":6426,"PHASE1":6428,"PHASE2":6430,"PHASE3":6432,"PHASE4":6434,"NA":6446},{"trials":6427,"activeCount":102},[],{"trials":6429,"activeCount":102},[],{"trials":6431,"activeCount":102},[],{"trials":6433,"activeCount":102},[],{"trials":6435,"activeCount":102},[6436],{"nctId":6437,"briefTitle":6438,"status":108,"phases":6439,"primaryCompletion":6440,"completion":6440,"start":6441,"enrollment":236,"conditions":6442,"interventions":6444},"NCT03042546","Calcium Sulfate Spacer in Open Tibia Fractures",[93],"2018-05-29","2017-02-01",[6443],"Open tíbia Fracture With Sub-segmental Bone Loss",[6424,6445],"PMMA",{"trials":6447,"activeCount":102},[],{"intervention":6445,"totalTrials":236,"cells":6449},{"EARLY_PHASE1":6450,"PHASE1":6452,"PHASE2":6454,"PHASE3":6456,"PHASE4":6458,"NA":6464},{"trials":6451,"activeCount":102},[],{"trials":6453,"activeCount":102},[],{"trials":6455,"activeCount":102},[],{"trials":6457,"activeCount":102},[],{"trials":6459,"activeCount":102},[6460],{"nctId":6437,"briefTitle":6438,"status":108,"phases":6461,"primaryCompletion":6440,"completion":6440,"start":6441,"enrollment":236,"conditions":6462,"interventions":6463},[93],[6443],[6424,6445],{"trials":6465,"activeCount":102},[],{"intervention":6467,"totalTrials":236,"cells":6468},"Standard blood components",{"EARLY_PHASE1":6469,"PHASE1":6471,"PHASE2":6473,"PHASE3":6475,"PHASE4":6477,"NA":6490},{"trials":6470,"activeCount":102},[],{"trials":6472,"activeCount":102},[],{"trials":6474,"activeCount":102},[],{"trials":6476,"activeCount":102},[],{"trials":6478,"activeCount":102},[6479],{"nctId":6480,"briefTitle":6481,"status":131,"phases":6482,"primaryCompletion":134,"completion":6483,"start":4906,"enrollment":6484,"conditions":6485,"interventions":6487},"NCT00810810","Immunomodulation Following Transfusion",[93],"2011-08",287,[6486],"Blood Component Transfusion",[6467,6488,6489],"Leukoreduced blood components","Leukoreduced and irradiated",{"trials":6491,"activeCount":102},[],{"intervention":6488,"totalTrials":236,"cells":6493},{"EARLY_PHASE1":6494,"PHASE1":6496,"PHASE2":6498,"PHASE3":6500,"PHASE4":6502,"NA":6508},{"trials":6495,"activeCount":102},[],{"trials":6497,"activeCount":102},[],{"trials":6499,"activeCount":102},[],{"trials":6501,"activeCount":102},[],{"trials":6503,"activeCount":102},[6504],{"nctId":6480,"briefTitle":6481,"status":131,"phases":6505,"primaryCompletion":134,"completion":6483,"start":4906,"enrollment":6484,"conditions":6506,"interventions":6507},[93],[6486],[6467,6488,6489],{"trials":6509,"activeCount":102},[],{"intervention":6489,"totalTrials":236,"cells":6511},{"EARLY_PHASE1":6512,"PHASE1":6514,"PHASE2":6516,"PHASE3":6518,"PHASE4":6520,"NA":6526},{"trials":6513,"activeCount":102},[],{"trials":6515,"activeCount":102},[],{"trials":6517,"activeCount":102},[],{"trials":6519,"activeCount":102},[],{"trials":6521,"activeCount":102},[6522],{"nctId":6480,"briefTitle":6481,"status":131,"phases":6523,"primaryCompletion":134,"completion":6483,"start":4906,"enrollment":6484,"conditions":6524,"interventions":6525},[93],[6486],[6467,6488,6489],{"trials":6527,"activeCount":102},[],{"intervention":6529,"totalTrials":236,"cells":6530},"Selective serotonin reuptake inhibitor",{"EARLY_PHASE1":6531,"PHASE1":6533,"PHASE2":6535,"PHASE3":6537,"PHASE4":6539,"NA":6551},{"trials":6532,"activeCount":102},[],{"trials":6534,"activeCount":102},[],{"trials":6536,"activeCount":102},[],{"trials":6538,"activeCount":102},[],{"trials":6540,"activeCount":102},[6541],{"nctId":6542,"briefTitle":6543,"status":131,"phases":6544,"primaryCompletion":729,"completion":729,"start":6545,"enrollment":6546,"conditions":6547,"interventions":6549},"NCT04597190","Sequenced Treatment Effectiveness for Posttraumatic Stress",[93],"2020-06-01",700,[6548],"PTSD",[6529,6550],"Serotonin-norepinephrine reuptake inhibitor",{"trials":6552,"activeCount":102},[],{"intervention":6550,"totalTrials":236,"cells":6554},{"EARLY_PHASE1":6555,"PHASE1":6557,"PHASE2":6559,"PHASE3":6561,"PHASE4":6563,"NA":6569},{"trials":6556,"activeCount":102},[],{"trials":6558,"activeCount":102},[],{"trials":6560,"activeCount":102},[],{"trials":6562,"activeCount":102},[],{"trials":6564,"activeCount":102},[6565],{"nctId":6542,"briefTitle":6543,"status":131,"phases":6566,"primaryCompletion":729,"completion":729,"start":6545,"enrollment":6546,"conditions":6567,"interventions":6568},[93],[6548],[6529,6550],{"trials":6570,"activeCount":102},[],{"intervention":6572,"totalTrials":236,"cells":6573},"Miglustat",{"EARLY_PHASE1":6574,"PHASE1":6576,"PHASE2":6578,"PHASE3":6580,"PHASE4":6582,"NA":6591},{"trials":6575,"activeCount":102},[],{"trials":6577,"activeCount":102},[],{"trials":6579,"activeCount":102},[],{"trials":6581,"activeCount":102},[],{"trials":6583,"activeCount":102},[6584],{"nctId":6585,"briefTitle":6586,"status":131,"phases":6587,"primaryCompletion":272,"completion":272,"start":6588,"enrollment":317,"conditions":6589,"interventions":6590},"NCT00194649","Glycosphingolipid Inhibition and Spermatogenesis in Man: A Pilot Study (MIG 2)",[93],"2005-06",[5614],[6572],{"trials":6592,"activeCount":102},[],{"intervention":6594,"totalTrials":236,"cells":6595},"FTC\u002FTDF and DMPA",{"EARLY_PHASE1":6596,"PHASE1":6598,"PHASE2":6600,"PHASE3":6602,"PHASE4":6604,"NA":6619},{"trials":6597,"activeCount":102},[],{"trials":6599,"activeCount":102},[],{"trials":6601,"activeCount":102},[],{"trials":6603,"activeCount":102},[],{"trials":6605,"activeCount":102},[6606],{"nctId":6607,"briefTitle":6608,"status":131,"phases":6609,"primaryCompletion":2339,"completion":2339,"start":3328,"enrollment":6610,"conditions":6611,"interventions":6616},"NCT03464266","The Kampala Women's Bone Study",[93],500,[6612,6613,6614,6615],"Bone Demineralization","Hypoestrogenism","Subclinical Kidney Injury","Bone Microarchitecture",[6594,6617,6618],"FTC\u002FTDF","DMPA",{"trials":6620,"activeCount":102},[],{"intervention":6617,"totalTrials":236,"cells":6622},{"EARLY_PHASE1":6623,"PHASE1":6625,"PHASE2":6627,"PHASE3":6629,"PHASE4":6631,"NA":6637},{"trials":6624,"activeCount":102},[],{"trials":6626,"activeCount":102},[],{"trials":6628,"activeCount":102},[],{"trials":6630,"activeCount":102},[],{"trials":6632,"activeCount":102},[6633],{"nctId":6607,"briefTitle":6608,"status":131,"phases":6634,"primaryCompletion":2339,"completion":2339,"start":3328,"enrollment":6610,"conditions":6635,"interventions":6636},[93],[6612,6613,6614,6615],[6594,6617,6618],{"trials":6638,"activeCount":102},[],{"intervention":6618,"totalTrials":236,"cells":6640},{"EARLY_PHASE1":6641,"PHASE1":6643,"PHASE2":6645,"PHASE3":6647,"PHASE4":6649,"NA":6655},{"trials":6642,"activeCount":102},[],{"trials":6644,"activeCount":102},[],{"trials":6646,"activeCount":102},[],{"trials":6648,"activeCount":102},[],{"trials":6650,"activeCount":102},[6651],{"nctId":6607,"briefTitle":6608,"status":131,"phases":6652,"primaryCompletion":2339,"completion":2339,"start":3328,"enrollment":6610,"conditions":6653,"interventions":6654},[93],[6612,6613,6614,6615],[6594,6617,6618],{"trials":6656,"activeCount":102},[],{"intervention":6658,"totalTrials":236,"cells":6659},"Meperidine",{"EARLY_PHASE1":6660,"PHASE1":6662,"PHASE2":6664,"PHASE3":6666,"PHASE4":6668,"NA":6684},{"trials":6661,"activeCount":102},[],{"trials":6663,"activeCount":102},[],{"trials":6665,"activeCount":102},[],{"trials":6667,"activeCount":102},[],{"trials":6669,"activeCount":102},[6670],{"nctId":6671,"briefTitle":6672,"status":131,"phases":6673,"primaryCompletion":6674,"completion":6675,"start":6676,"enrollment":6677,"conditions":6678,"interventions":6683},"NCT04068948","Comparing Pediatric Dental Oral Sedation Outcomes With and Without Meperidine in Children Aged 3-7 Years",[93],"2022-12-31","2023-01-31","2019-06-25",37,[6679,6680,6658,6681,6682],"Dental Caries in Children","Pediatric Dental Sedation","Hydroxyzine","Midazolam",[6658,6681,6682],{"trials":6685,"activeCount":102},[],{"intervention":6681,"totalTrials":236,"cells":6687},{"EARLY_PHASE1":6688,"PHASE1":6690,"PHASE2":6692,"PHASE3":6694,"PHASE4":6696,"NA":6702},{"trials":6689,"activeCount":102},[],{"trials":6691,"activeCount":102},[],{"trials":6693,"activeCount":102},[],{"trials":6695,"activeCount":102},[],{"trials":6697,"activeCount":102},[6698],{"nctId":6671,"briefTitle":6672,"status":131,"phases":6699,"primaryCompletion":6674,"completion":6675,"start":6676,"enrollment":6677,"conditions":6700,"interventions":6701},[93],[6679,6680,6658,6681,6682],[6658,6681,6682],{"trials":6703,"activeCount":102},[],{"intervention":6705,"totalTrials":236,"cells":6706},"dapagliflozin",{"EARLY_PHASE1":6707,"PHASE1":6709,"PHASE2":6711,"PHASE3":6713,"PHASE4":6715,"NA":6727},{"trials":6708,"activeCount":102},[],{"trials":6710,"activeCount":102},[],{"trials":6712,"activeCount":102},[],{"trials":6714,"activeCount":102},[],{"trials":6716,"activeCount":102},[6717],{"nctId":6718,"briefTitle":6719,"status":131,"phases":6720,"primaryCompletion":6721,"completion":6721,"start":6722,"enrollment":3405,"conditions":6723,"interventions":6726},"NCT03782259","Effects of SGLT-2 Inhibition on Myocardial Fibrosis and Inflammation as Assessed by Cardiac MRI in Patients With DM2",[93],"2022-11-16","2019-02-26",[335,6724,6725],"Myocardial Fibrosis","Myocardial Inflammation",[6705],{"trials":6728,"activeCount":102},[],{"intervention":6730,"totalTrials":236,"cells":6731},"Point-of-care molecular testing and treatment of influenza",{"EARLY_PHASE1":6732,"PHASE1":6734,"PHASE2":6736,"PHASE3":6738,"PHASE4":6740,"NA":6751},{"trials":6733,"activeCount":102},[],{"trials":6735,"activeCount":102},[],{"trials":6737,"activeCount":102},[],{"trials":6739,"activeCount":102},[],{"trials":6741,"activeCount":102},[6742],{"nctId":6743,"briefTitle":6744,"status":108,"phases":6745,"primaryCompletion":6746,"completion":6746,"start":6747,"enrollment":6748,"conditions":6749,"interventions":6750},"NCT04141917","Test-and-treat for Influenza in Homeless Shelters",[93],"2021-03-31","2019-11-15",1618,[6080,6081],[6730],{"trials":6752,"activeCount":102},[],{"intervention":6754,"totalTrials":236,"cells":6755},"Protocol for rocuronium neuromuscular block",{"EARLY_PHASE1":6756,"PHASE1":6758,"PHASE2":6760,"PHASE3":6762,"PHASE4":6764,"NA":6776},{"trials":6757,"activeCount":102},[],{"trials":6759,"activeCount":102},[],{"trials":6761,"activeCount":102},[],{"trials":6763,"activeCount":102},[],{"trials":6765,"activeCount":102},[6766],{"nctId":6767,"briefTitle":6768,"status":131,"phases":6769,"primaryCompletion":6770,"completion":6770,"start":6771,"enrollment":6772,"conditions":6773,"interventions":6775},"NCT03543826","Best Practice Using Rocuronium and Reversal With Neostigmine or Sugammadex",[93],"2018-11-26","2018-05-21",201,[6774],"Muscle Weakness",[6754],{"trials":6777,"activeCount":102},[],{"intervention":5348,"totalTrials":236,"cells":6779},{"EARLY_PHASE1":6780,"PHASE1":6782,"PHASE2":6784,"PHASE3":6786,"PHASE4":6788,"NA":6794},{"trials":6781,"activeCount":102},[],{"trials":6783,"activeCount":102},[],{"trials":6785,"activeCount":102},[],{"trials":6787,"activeCount":102},[],{"trials":6789,"activeCount":102},[6790],{"nctId":5339,"briefTitle":5340,"status":131,"phases":6791,"primaryCompletion":5342,"completion":5343,"start":5344,"enrollment":350,"conditions":6792,"interventions":6793},[93],[5346],[5348,5326],{"trials":6795,"activeCount":102},[],{"intervention":6797,"totalTrials":236,"cells":6798},"Sugammadex administration",{"EARLY_PHASE1":6799,"PHASE1":6801,"PHASE2":6803,"PHASE3":6805,"PHASE4":6807,"NA":6820},{"trials":6800,"activeCount":102},[],{"trials":6802,"activeCount":102},[],{"trials":6804,"activeCount":102},[],{"trials":6806,"activeCount":102},[],{"trials":6808,"activeCount":102},[6809],{"nctId":6810,"briefTitle":6811,"status":131,"phases":6812,"primaryCompletion":6813,"completion":6813,"start":6814,"enrollment":372,"conditions":6815,"interventions":6819},"NCT05246397","Sugammadex Titration in Cardiac Surgery Patients",[93],"2022-11-10","2022-02-01",[5382,6816,6817,6818],"Valvular Heart Disease","Aorta Disease","Heart Failure",[6797],{"trials":6821,"activeCount":102},[],{"intervention":6823,"totalTrials":236,"cells":6824},"Zoster Vaccine Live",{"EARLY_PHASE1":6825,"PHASE1":6827,"PHASE2":6829,"PHASE3":6831,"PHASE4":6833,"NA":6843},{"trials":6826,"activeCount":102},[],{"trials":6828,"activeCount":102},[],{"trials":6830,"activeCount":102},[],{"trials":6832,"activeCount":102},[],{"trials":6834,"activeCount":102},[6835],{"nctId":6836,"briefTitle":6837,"status":131,"phases":6838,"primaryCompletion":6839,"completion":6839,"start":6020,"enrollment":261,"conditions":6840,"interventions":6842},"NCT02624375","Immune Response to Shingles Vaccination",[93],"2019-11",[6841],"Shingles",[6823],{"trials":6844,"activeCount":102},[],{"intervention":6846,"totalTrials":236,"cells":6847},"Abatacept",{"EARLY_PHASE1":6848,"PHASE1":6850,"PHASE2":6852,"PHASE3":6854,"PHASE4":6856,"NA":6867},{"trials":6849,"activeCount":102},[],{"trials":6851,"activeCount":102},[],{"trials":6853,"activeCount":102},[],{"trials":6855,"activeCount":102},[],{"trials":6857,"activeCount":102},[6858],{"nctId":6859,"briefTitle":6860,"status":131,"phases":6861,"primaryCompletion":6862,"completion":6862,"start":6863,"enrollment":29,"conditions":6864,"interventions":6866},"NCT03882008","A Study to Evaluate Biomarkers to Predict Efficacy of Abatacept in Rheumatoid Arthritis",[93],"2023-06-30","2019-05-23",[6865],"Rheumatoid Arthritis",[6846],{"trials":6868,"activeCount":102},[],{"intervention":6870,"totalTrials":236,"cells":6871},"TDF",{"EARLY_PHASE1":6872,"PHASE1":6874,"PHASE2":6876,"PHASE3":6878,"PHASE4":6880,"NA":6891},{"trials":6873,"activeCount":102},[],{"trials":6875,"activeCount":102},[],{"trials":6877,"activeCount":102},[],{"trials":6879,"activeCount":102},[],{"trials":6881,"activeCount":102},[6882],{"nctId":6883,"briefTitle":6884,"status":131,"phases":6885,"primaryCompletion":225,"completion":225,"start":1641,"enrollment":6886,"conditions":6887,"interventions":6889},"NCT01448616","Effect of Tenofovir on Genital Herpes Simplex Virus (HSV) Shedding",[93],73,[6888],"Herpes Simplex Type II",[6870,6890],"Vaginal TFV Gel",{"trials":6892,"activeCount":102},[],{"intervention":6890,"totalTrials":236,"cells":6894},{"EARLY_PHASE1":6895,"PHASE1":6897,"PHASE2":6899,"PHASE3":6901,"PHASE4":6903,"NA":6909},{"trials":6896,"activeCount":102},[],{"trials":6898,"activeCount":102},[],{"trials":6900,"activeCount":102},[],{"trials":6902,"activeCount":102},[],{"trials":6904,"activeCount":102},[6905],{"nctId":6883,"briefTitle":6884,"status":131,"phases":6906,"primaryCompletion":225,"completion":225,"start":1641,"enrollment":6886,"conditions":6907,"interventions":6908},[93],[6888],[6870,6890],{"trials":6910,"activeCount":102},[],{"intervention":6912,"totalTrials":236,"cells":6913},"Rocuronium",{"EARLY_PHASE1":6914,"PHASE1":6916,"PHASE2":6918,"PHASE3":6920,"PHASE4":6922,"NA":6934},{"trials":6915,"activeCount":102},[],{"trials":6917,"activeCount":102},[],{"trials":6919,"activeCount":102},[],{"trials":6921,"activeCount":102},[],{"trials":6923,"activeCount":102},[6924],{"nctId":6925,"briefTitle":6926,"status":131,"phases":6927,"primaryCompletion":3023,"completion":2893,"start":6176,"enrollment":6928,"conditions":6929,"interventions":6931},"NCT02237443","Mask Ventilation Before and After Neuromuscular Blockade",[93],210,[6930],"Anesthesia",[6912,6932,6933],"Vecuronium Bromide","Succinylcholine",{"trials":6935,"activeCount":102},[],{"intervention":6932,"totalTrials":236,"cells":6937},{"EARLY_PHASE1":6938,"PHASE1":6940,"PHASE2":6942,"PHASE3":6944,"PHASE4":6946,"NA":6952},{"trials":6939,"activeCount":102},[],{"trials":6941,"activeCount":102},[],{"trials":6943,"activeCount":102},[],{"trials":6945,"activeCount":102},[],{"trials":6947,"activeCount":102},[6948],{"nctId":6925,"briefTitle":6926,"status":131,"phases":6949,"primaryCompletion":3023,"completion":2893,"start":6176,"enrollment":6928,"conditions":6950,"interventions":6951},[93],[6930],[6912,6932,6933],{"trials":6953,"activeCount":102},[],{"intervention":6933,"totalTrials":236,"cells":6955},{"EARLY_PHASE1":6956,"PHASE1":6958,"PHASE2":6960,"PHASE3":6962,"PHASE4":6964,"NA":6970},{"trials":6957,"activeCount":102},[],{"trials":6959,"activeCount":102},[],{"trials":6961,"activeCount":102},[],{"trials":6963,"activeCount":102},[],{"trials":6965,"activeCount":102},[6966],{"nctId":6925,"briefTitle":6926,"status":131,"phases":6967,"primaryCompletion":3023,"completion":2893,"start":6176,"enrollment":6928,"conditions":6968,"interventions":6969},[93],[6930],[6912,6932,6933],{"trials":6971,"activeCount":102},[],{"intervention":6973,"totalTrials":236,"cells":6974},"Asacol",{"EARLY_PHASE1":6975,"PHASE1":6977,"PHASE2":6979,"PHASE3":6981,"PHASE4":6983,"NA":6993},{"trials":6976,"activeCount":102},[],{"trials":6978,"activeCount":102},[],{"trials":6980,"activeCount":102},[],{"trials":6982,"activeCount":102},[],{"trials":6984,"activeCount":102},[6985],{"nctId":6986,"briefTitle":6987,"status":131,"phases":6988,"primaryCompletion":6417,"completion":6417,"start":1592,"enrollment":6989,"conditions":6990,"interventions":6992},"NCT00194818","Asacol Dosing Study for Active Ulcerative Colitis",[93],7,[6991],"Ulcerative Colitis",[6973],{"trials":6994,"activeCount":102},[],{"intervention":6996,"totalTrials":236,"cells":6997},"Hepsera",{"EARLY_PHASE1":6998,"PHASE1":7000,"PHASE2":7002,"PHASE3":7004,"PHASE4":7006,"NA":7018},{"trials":6999,"activeCount":102},[],{"trials":7001,"activeCount":102},[],{"trials":7003,"activeCount":102},[],{"trials":7005,"activeCount":102},[],{"trials":7007,"activeCount":102},[7008],{"nctId":7009,"briefTitle":7010,"status":131,"phases":7011,"completion":6417,"start":7012,"enrollment":7013,"conditions":7014,"interventions":7016},"NCT00230477","Hepsera Versus Hepsera Plus Lamivudine for Treatment of Chronic Hepatitis B in Patients With Normal ALT",[93],"2003-04",19,[7015],"Hepatitis B",[6996,7017],"Hepsera and lamivudine",{"trials":7019,"activeCount":102},[],{"intervention":7017,"totalTrials":236,"cells":7021},{"EARLY_PHASE1":7022,"PHASE1":7024,"PHASE2":7026,"PHASE3":7028,"PHASE4":7030,"NA":7036},{"trials":7023,"activeCount":102},[],{"trials":7025,"activeCount":102},[],{"trials":7027,"activeCount":102},[],{"trials":7029,"activeCount":102},[],{"trials":7031,"activeCount":102},[7032],{"nctId":7009,"briefTitle":7010,"status":131,"phases":7033,"completion":6417,"start":7012,"enrollment":7013,"conditions":7034,"interventions":7035},[93],[7015],[6996,7017],{"trials":7037,"activeCount":102},[],{"intervention":7039,"totalTrials":236,"cells":7040},"Isotretinoin",{"EARLY_PHASE1":7041,"PHASE1":7043,"PHASE2":7045,"PHASE3":7047,"PHASE4":7049,"NA":7061},{"trials":7042,"activeCount":102},[],{"trials":7044,"activeCount":102},[],{"trials":7046,"activeCount":102},[],{"trials":7048,"activeCount":102},[],{"trials":7050,"activeCount":102},[7051],{"nctId":7052,"briefTitle":7053,"status":131,"phases":7054,"primaryCompletion":7055,"completion":7055,"start":7056,"enrollment":1170,"conditions":7057,"interventions":7059},"NCT03076021","Effects of Isotretinoin on CYP2D6 Activity",[93],"2023-11-27","2016-07-26",[7058],"CYP2D6 Polymorphism",[7039,7060],"dextromethorphan",{"trials":7062,"activeCount":102},[],{"intervention":7060,"totalTrials":236,"cells":7064},{"EARLY_PHASE1":7065,"PHASE1":7067,"PHASE2":7069,"PHASE3":7071,"PHASE4":7073,"NA":7079},{"trials":7066,"activeCount":102},[],{"trials":7068,"activeCount":102},[],{"trials":7070,"activeCount":102},[],{"trials":7072,"activeCount":102},[],{"trials":7074,"activeCount":102},[7075],{"nctId":7052,"briefTitle":7053,"status":131,"phases":7076,"primaryCompletion":7055,"completion":7055,"start":7056,"enrollment":1170,"conditions":7077,"interventions":7078},[93],[7058],[7039,7060],{"trials":7080,"activeCount":102},[],{"intervention":7082,"totalTrials":236,"cells":7083},"Memantine",{"EARLY_PHASE1":7084,"PHASE1":7086,"PHASE2":7088,"PHASE3":7090,"PHASE4":7092,"NA":7101},{"trials":7085,"activeCount":102},[],{"trials":7087,"activeCount":102},[],{"trials":7089,"activeCount":102},[],{"trials":7091,"activeCount":102},[],{"trials":7093,"activeCount":102},[7094],{"nctId":7095,"briefTitle":7096,"status":5876,"phases":7097,"primaryCompletion":348,"completion":1863,"start":3156,"enrollment":861,"conditions":7098,"interventions":7100},"NCT01041313","Memantine for Post-Operative Pain Control",[93],[7099],"Pain, Post-operative",[7082],{"trials":7102,"activeCount":102},[],{"intervention":7104,"totalTrials":236,"cells":7105},"escitalopram",{"EARLY_PHASE1":7106,"PHASE1":7108,"PHASE2":7110,"PHASE3":7112,"PHASE4":7114,"NA":7124},{"trials":7107,"activeCount":102},[],{"trials":7109,"activeCount":102},[],{"trials":7111,"activeCount":102},[],{"trials":7113,"activeCount":102},[],{"trials":7115,"activeCount":102},[7116],{"nctId":7117,"briefTitle":7118,"status":108,"phases":7119,"primaryCompletion":134,"completion":1194,"start":5665,"enrollment":702,"conditions":7120,"interventions":7123},"NCT00754793","Sinusitis and Facial Pain Disorders Anti-Depression Trial",[93],[7121,7122,16],"Chronic Sinusitis","Facial Pain Disorder",[7104],{"trials":7125,"activeCount":102},[],{"intervention":7127,"totalTrials":236,"cells":7128},"venlafaxine XR",{"EARLY_PHASE1":7129,"PHASE1":7131,"PHASE2":7133,"PHASE3":7135,"PHASE4":7137,"NA":7149},{"trials":7130,"activeCount":102},[],{"trials":7132,"activeCount":102},[],{"trials":7134,"activeCount":102},[],{"trials":7136,"activeCount":102},[],{"trials":7138,"activeCount":102},[7139],{"nctId":7140,"briefTitle":7141,"status":131,"phases":7142,"primaryCompletion":7143,"completion":7143,"start":6102,"enrollment":7144,"conditions":7145,"interventions":7148},"NCT00592384","Project to Improve Symptoms and Mood in People With Spinal Cord Injury",[93],"2012-09",133,[7146,7147,5252],"Major Depressive Disorder","Dysthymia",[7127],{"trials":7150,"activeCount":102},[],{"intervention":7152,"totalTrials":236,"cells":7153},"Psychotropic medication optimization",{"EARLY_PHASE1":7154,"PHASE1":7156,"PHASE2":7158,"PHASE3":7160,"PHASE4":7162,"NA":7176},{"trials":7155,"activeCount":102},[],{"trials":7157,"activeCount":102},[],{"trials":7159,"activeCount":102},[],{"trials":7161,"activeCount":102},[],{"trials":7163,"activeCount":102},[7164],{"nctId":7165,"briefTitle":7166,"status":131,"phases":7167,"primaryCompletion":7168,"completion":7168,"start":2930,"enrollment":7169,"conditions":7170,"interventions":7175},"NCT00347269","Primary Care Intervention Strategy for Anxiety Disorders",[93],"2009-10",1004,[7171,7172,7173,7174],"Post-traumatic Stress Disorder","Generalized Anxiety Disorder","Panic Disorder","Social Anxiety Disorder",[7152],{"trials":7177,"activeCount":102},[],{"intervention":7179,"totalTrials":236,"cells":7180},"Epidural steroid",{"EARLY_PHASE1":7181,"PHASE1":7183,"PHASE2":7185,"PHASE3":7187,"PHASE4":7189,"NA":7202},{"trials":7182,"activeCount":102},[],{"trials":7184,"activeCount":102},[],{"trials":7186,"activeCount":102},[],{"trials":7188,"activeCount":102},[],{"trials":7190,"activeCount":102},[7191],{"nctId":7192,"briefTitle":7193,"status":131,"phases":7194,"primaryCompletion":5021,"completion":1136,"start":7195,"enrollment":7196,"conditions":7197,"interventions":7200},"NCT01238536","Lumbar Epidural Steroid Injections for Spinal Stenosis Multicenter Randomized, Controlled Trial (LESS Trial)",[93],"2011-04",400,[7198,7199],"Spinal Stenosis","Low Back Pain",[7179,7201],"Epidural local anesthetic",{"trials":7203,"activeCount":102},[],{"intervention":7201,"totalTrials":236,"cells":7205},{"EARLY_PHASE1":7206,"PHASE1":7208,"PHASE2":7210,"PHASE3":7212,"PHASE4":7214,"NA":7220},{"trials":7207,"activeCount":102},[],{"trials":7209,"activeCount":102},[],{"trials":7211,"activeCount":102},[],{"trials":7213,"activeCount":102},[],{"trials":7215,"activeCount":102},[7216],{"nctId":7192,"briefTitle":7193,"status":131,"phases":7217,"primaryCompletion":5021,"completion":1136,"start":7195,"enrollment":7196,"conditions":7218,"interventions":7219},[93],[7198,7199],[7179,7201],{"trials":7221,"activeCount":102},[],{"intervention":6056,"totalTrials":236,"cells":7223},{"EARLY_PHASE1":7224,"PHASE1":7226,"PHASE2":7228,"PHASE3":7230,"PHASE4":7232,"NA":7238},{"trials":7225,"activeCount":102},[],{"trials":7227,"activeCount":102},[],{"trials":7229,"activeCount":102},[],{"trials":7231,"activeCount":102},[],{"trials":7233,"activeCount":102},[7234],{"nctId":6046,"briefTitle":6047,"status":131,"phases":7235,"primaryCompletion":6049,"completion":6049,"start":6050,"enrollment":5320,"conditions":7236,"interventions":7237},[93],[6052,6053,6054],[6027,6056],{"trials":7239,"activeCount":102},[],{"intervention":7241,"totalTrials":236,"cells":7242},"Daily oral PrEP",{"EARLY_PHASE1":7243,"PHASE1":7245,"PHASE2":7247,"PHASE3":7249,"PHASE4":7251,"NA":7264},{"trials":7244,"activeCount":102},[],{"trials":7246,"activeCount":102},[],{"trials":7248,"activeCount":102},[],{"trials":7250,"activeCount":102},[],{"trials":7252,"activeCount":102},[7253],{"nctId":7254,"briefTitle":7255,"status":131,"phases":7256,"primaryCompletion":7257,"completion":7257,"start":7258,"enrollment":7259,"conditions":7260,"interventions":7263},"NCT04664998","Alignment of PrEP Use With HIV Risk in Young Women and Men",[93],"2023-12-10","2018-05-01",212,[7261,7262,19],"Pre-Exposure Prophylaxis","Sexually Transmitted Diseases, Bacterial",[7241,7241],{"trials":7265,"activeCount":102},[],{"intervention":7267,"totalTrials":236,"cells":7268},"Stribild (Elvitegravir\u002FCobicistat\u002FEmtricitabine\u002FTenofovir DF) 1 tablet daily X 48 weeks",{"EARLY_PHASE1":7269,"PHASE1":7271,"PHASE2":7273,"PHASE3":7275,"PHASE4":7277,"NA":7288},{"trials":7270,"activeCount":102},[],{"trials":7272,"activeCount":102},[],{"trials":7274,"activeCount":102},[],{"trials":7276,"activeCount":102},[],{"trials":7278,"activeCount":102},[7279],{"nctId":7280,"briefTitle":7281,"status":131,"phases":7282,"primaryCompletion":7283,"completion":7283,"start":7284,"enrollment":23,"conditions":7285,"interventions":7287},"NCT02180438","An Open Label Trial of Stribild for Antiretroviral (ARV)-naïve HIV-2 Infected Adults in Dakar, Senegal",[93],"2017-01","2014-09",[7286],"HIV-2 Infection",[7267],{"trials":7289,"activeCount":102},[],{"intervention":7291,"totalTrials":236,"cells":7292},"Botox",{"EARLY_PHASE1":7293,"PHASE1":7295,"PHASE2":7297,"PHASE3":7299,"PHASE4":7301,"NA":7312},{"trials":7294,"activeCount":102},[],{"trials":7296,"activeCount":102},[],{"trials":7298,"activeCount":102},[],{"trials":7300,"activeCount":102},[],{"trials":7302,"activeCount":102},[7303],{"nctId":7304,"briefTitle":7305,"status":131,"phases":7306,"primaryCompletion":7307,"completion":189,"start":5651,"enrollment":673,"conditions":7308,"interventions":7311},"NCT00194610","Botox as a Treatment for Interstitial Cystitis in Women",[93],"2009-06",[7309,7310],"Painful Bladder Syndrome","Interstitial Cystitis",[7291],{"trials":7313,"activeCount":102},[],{"intervention":7315,"totalTrials":236,"cells":7316},"glucose, insulin, and potassium",{"EARLY_PHASE1":7317,"PHASE1":7319,"PHASE2":7321,"PHASE3":7323,"PHASE4":7325,"NA":7340},{"trials":7318,"activeCount":102},[],{"trials":7320,"activeCount":102},[],{"trials":7322,"activeCount":102},[],{"trials":7324,"activeCount":102},[],{"trials":7326,"activeCount":102},[7327],{"nctId":7328,"briefTitle":7329,"status":131,"phases":7330,"primaryCompletion":7331,"completion":7332,"start":7333,"enrollment":7334,"conditions":7335,"interventions":7338},"NCT06624956","Prevention and Treatment of Common Hyperglycemia in Surgery Pilot",[93],"2025-09-28","2026-01-01","2024-09-04",106,[7336,7337],"Surgery","Non Diabetic Hyperglycemia",[7315,7339],"Crystalloid",{"trials":7341,"activeCount":102},[],{"intervention":7339,"totalTrials":236,"cells":7343},{"EARLY_PHASE1":7344,"PHASE1":7346,"PHASE2":7348,"PHASE3":7350,"PHASE4":7352,"NA":7358},{"trials":7345,"activeCount":102},[],{"trials":7347,"activeCount":102},[],{"trials":7349,"activeCount":102},[],{"trials":7351,"activeCount":102},[],{"trials":7353,"activeCount":102},[7354],{"nctId":7328,"briefTitle":7329,"status":131,"phases":7355,"primaryCompletion":7331,"completion":7332,"start":7333,"enrollment":7334,"conditions":7356,"interventions":7357},[93],[7336,7337],[7315,7339],{"trials":7359,"activeCount":102},[],{"intervention":7361,"totalTrials":236,"cells":7362},"Dronabinol",{"EARLY_PHASE1":7363,"PHASE1":7365,"PHASE2":7367,"PHASE3":7369,"PHASE4":7371,"NA":7384},{"trials":7364,"activeCount":102},[],{"trials":7366,"activeCount":102},[],{"trials":7368,"activeCount":102},[],{"trials":7370,"activeCount":102},[],{"trials":7372,"activeCount":102},[7373],{"nctId":7374,"briefTitle":7375,"status":131,"phases":7376,"primaryCompletion":7377,"completion":7378,"start":7379,"enrollment":1477,"conditions":7380,"interventions":7383},"NCT04374773","Effects of Pregnancy-associated Hormones on THC Metabolism in Women",[93],"2026-02-14","2026-02-28","2020-10-19",[7381,7382],"Pregnancy Related","Cannabis Use",[7361],{"trials":7385,"activeCount":102},[],{"intervention":7387,"totalTrials":236,"cells":7388},"3-drug anti-HIV therapy",{"EARLY_PHASE1":7389,"PHASE1":7391,"PHASE2":7393,"PHASE3":7395,"PHASE4":7397,"NA":7407},{"trials":7390,"activeCount":102},[],{"trials":7392,"activeCount":102},[],{"trials":7394,"activeCount":102},[],{"trials":7396,"activeCount":102},[],{"trials":7398,"activeCount":102},[7399],{"nctId":7400,"briefTitle":7401,"status":108,"phases":7402,"primaryCompletion":1641,"completion":719,"start":191,"enrollment":261,"conditions":7403,"interventions":7405},"NCT00781287","Raltegravir (Isentress\u002FMK-0518) and HIV-1 Infected CD4 Cells During Acute\u002FEarly HIV-1",[93],[7404],"Human Immunodeficiency Virus",[7387,7406],"Raltegravir",{"trials":7408,"activeCount":102},[],{"intervention":7410,"totalTrials":236,"cells":7411},"Perflutren Lipid Microsphere",{"EARLY_PHASE1":7412,"PHASE1":7414,"PHASE2":7416,"PHASE3":7418,"PHASE4":7420,"NA":7430},{"trials":7413,"activeCount":102},[],{"trials":7415,"activeCount":102},[],{"trials":7417,"activeCount":102},[],{"trials":7419,"activeCount":102},[],{"trials":7421,"activeCount":102},[7422],{"nctId":7423,"briefTitle":7424,"status":131,"phases":7425,"primaryCompletion":7426,"completion":7426,"start":7427,"enrollment":2817,"conditions":7428,"interventions":7429},"NCT04056988","tSCI Contrast Enhanced Ultrasound Study",[93],"2023-11-20","2018-07-31",[650],[7410],{"trials":7431,"activeCount":102},[],{"intervention":7433,"totalTrials":236,"cells":7434},"valdecoxib",{"EARLY_PHASE1":7435,"PHASE1":7437,"PHASE2":7439,"PHASE3":7441,"PHASE4":7443,"NA":7453},{"trials":7436,"activeCount":102},[],{"trials":7438,"activeCount":102},[],{"trials":7440,"activeCount":102},[],{"trials":7442,"activeCount":102},[],{"trials":7444,"activeCount":102},[7445],{"nctId":7446,"briefTitle":7447,"status":131,"phases":7448,"completion":272,"start":7449,"enrollment":23,"conditions":7450,"interventions":7452},"NCT00122096","Perioperative Inflammation and Cyclooxygenase 2 (COX-2)",[93],"2002-11",[7451,376],"Neurosurgery",[7433],{"trials":7454,"activeCount":102},[],{"intervention":7456,"totalTrials":236,"cells":7457},"Midazolam Injectable Solution",{"EARLY_PHASE1":7458,"PHASE1":7460,"PHASE2":7462,"PHASE3":7464,"PHASE4":7466,"NA":7480},{"trials":7459,"activeCount":102},[],{"trials":7461,"activeCount":102},[],{"trials":7463,"activeCount":102},[],{"trials":7465,"activeCount":102},[],{"trials":7467,"activeCount":102},[7468],{"nctId":7469,"briefTitle":7470,"status":131,"phases":7471,"primaryCompletion":7472,"completion":7472,"start":7473,"enrollment":1087,"conditions":7474,"interventions":7476},"NCT05469204","Effect of Estrogen Treatment on Drug Metabolism and Transport",[93],"2025-07-30","2022-11-01",[7475],"Transgender Persons",[7477,7478,7479,7456],"Midazolam oral solution","Digoxin Oral","Acetaminophen Oral",{"trials":7481,"activeCount":102},[],{"intervention":5387,"totalTrials":236,"cells":7483},{"EARLY_PHASE1":7484,"PHASE1":7486,"PHASE2":7488,"PHASE3":7490,"PHASE4":7492,"NA":7498},{"trials":7485,"activeCount":102},[],{"trials":7487,"activeCount":102},[],{"trials":7489,"activeCount":102},[],{"trials":7491,"activeCount":102},[],{"trials":7493,"activeCount":102},[7494],{"nctId":5374,"briefTitle":5375,"status":131,"phases":7495,"primaryCompletion":5377,"completion":5378,"start":5379,"enrollment":5380,"conditions":7496,"interventions":7497},[93],[5382,5383,5384],[5361,5386,5387],{"trials":7499,"activeCount":102},[],{"intervention":340,"totalTrials":2370,"cells":7501},{"EARLY_PHASE1":7502,"PHASE1":7504,"PHASE2":7531,"PHASE3":7572,"PHASE4":7585,"NA":7587},{"trials":7503,"activeCount":102},[],{"trials":7505,"activeCount":102},[7506,7510,7518,7524],{"nctId":5607,"briefTitle":5608,"status":131,"phases":7507,"primaryCompletion":5610,"completion":5610,"start":5611,"enrollment":2370,"conditions":7508,"interventions":7509},[90],[5613,5614],[5071,340],{"nctId":7511,"briefTitle":7512,"status":131,"phases":7513,"primaryCompletion":1675,"completion":7307,"start":1621,"enrollment":1299,"conditions":7514,"interventions":7515},"NCT00663793","ORAL T-6: Oral Androgens in Man-6",[90],[5614,5613],[340,7516,7517],"Testosterone","Finasteride",{"nctId":7519,"briefTitle":7520,"status":131,"phases":7521,"primaryCompletion":6417,"completion":6417,"start":1650,"enrollment":98,"conditions":7522,"interventions":7523},"NCT00471185","ACY-6 Oral Administration of Acyline",[90],[5614],[340],{"nctId":7525,"briefTitle":7526,"status":131,"phases":7527,"primaryCompletion":7528,"completion":1578,"start":2895,"enrollment":1477,"conditions":7529,"interventions":7530},"NCT01167829","ORAL T-8 Oral Testosterone for Male Hormonal Contraception",[90],"2010-10",[5667],[5729,340],{"trials":7532,"activeCount":102},[7533,7537,7541,7545,7549,7553,7561,7565],{"nctId":5630,"briefTitle":5631,"status":131,"phases":7534,"primaryCompletion":2913,"completion":2913,"start":5633,"enrollment":34,"conditions":7535,"interventions":7536},[90,91],[5614],[340,5626,5636],{"nctId":5638,"briefTitle":5639,"status":131,"phases":7538,"primaryCompletion":189,"completion":442,"start":5641,"enrollment":5642,"conditions":7539,"interventions":7540},[90,91],[5069],[340,5645,5645,5645,5071],{"nctId":5647,"briefTitle":5648,"status":131,"phases":7542,"primaryCompletion":5650,"completion":5650,"start":5651,"enrollment":135,"conditions":7543,"interventions":7544},[90,91],[5614],[340,5626,5636],{"nctId":5063,"briefTitle":5064,"status":131,"phases":7546,"primaryCompletion":1864,"completion":1864,"start":5066,"enrollment":5067,"conditions":7547,"interventions":7548},[90,91],[5069],[340,5071,5072,5073,5074,399],{"nctId":326,"briefTitle":327,"status":131,"phases":7550,"primaryCompletion":329,"completion":330,"start":331,"enrollment":332,"conditions":7551,"interventions":7552},[90,91],[334,335,336,337,338],[340,341,342],{"nctId":7554,"briefTitle":7555,"status":131,"phases":7556,"primaryCompletion":370,"completion":370,"start":1475,"enrollment":227,"conditions":7557,"interventions":7558},"NCT00729859","CEP-1 Hormonal Regulation of Circulating Endothelial Progenitor Cells and HDL-C in Men",[91],[5667],[340,7559,7560],"Acyline + Testosterone gel","Acyline + testosterone gel + anastrozole",{"nctId":5704,"briefTitle":5705,"status":1150,"phases":7562,"primaryCompletion":5707,"completion":577,"start":5708,"enrollment":102,"conditions":7563,"interventions":7564},[91],[5710],[5712,340,5074,5713,5714],{"nctId":7566,"briefTitle":7567,"status":131,"phases":7568,"primaryCompletion":7569,"completion":7569,"start":3230,"enrollment":1547,"conditions":7570,"interventions":7571},"NCT00603187","ACY-7 Oral Administration of Acyline",[90,91],"2008-02",[5667],[340],{"trials":7573,"activeCount":102},[7574],{"nctId":7575,"briefTitle":7576,"status":131,"phases":7577,"primaryCompletion":1577,"completion":1620,"start":1313,"enrollment":3405,"conditions":7578,"interventions":7579},"NCT01327495","PROS-2 Dose Response Effects of Exogenous Testosterone on the Prostate",[91,92],[5667],[7580,7581,7582,7583,7584,340],"Testosterone 1% gel 1.25 g","Testosterone 1% gel 2.5 g","Testosterone 1% gel 5.0 g","testosterone 1% gel 10 g","testosterone 1% gel 15 g",{"trials":7586,"activeCount":102},[],{"trials":7588,"activeCount":102},[],{"intervention":7590,"totalTrials":702,"cells":7591},"Mexiletine",{"EARLY_PHASE1":7592,"PHASE1":7594,"PHASE2":7596,"PHASE3":7614,"PHASE4":7635,"NA":7637},{"trials":7593,"activeCount":102},[],{"trials":7595,"activeCount":102},[],{"trials":7597,"activeCount":102},[7598,7607],{"nctId":7599,"briefTitle":7600,"status":131,"phases":7601,"primaryCompletion":7602,"completion":7602,"start":7603,"enrollment":673,"conditions":7604,"interventions":7606},"NCT02781454","Mexiletine in Sporadic Amyotrophic Lateral Sclerosis",[91],"2018-09-30","2016-10",[7605],"Sporadic Amyotrophic Lateral Sclerosis",[7590],{"nctId":7608,"briefTitle":7609,"status":131,"phases":7610,"primaryCompletion":6176,"completion":6176,"start":1619,"enrollment":7611,"conditions":7612,"interventions":7613},"NCT01849770","Mexiletine in Sporadic Amyotrophic Lateral Sclerosis (SALS)",[91],75,[7605],[7590],{"trials":7615,"activeCount":102},[7616],{"nctId":7617,"briefTitle":7618,"status":131,"phases":7619,"primaryCompletion":7620,"start":7621,"conditions":7622,"interventions":7627},"NCT00000464","Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE)",[92],"1992-12","1987-04",[7623,22,7624,28,7625,7626],"Arrhythmia","Heart Arrest","Myocardial Infarction","Ventricular Fibrillation",[7628,7629,7630,7631,7632,7633,7634],"amiodarone","imipramine","mexiletine","procainamide","propafenone","quinidine","sotalol",{"trials":7636,"activeCount":102},[],{"trials":7638,"activeCount":102},[],{"intervention":5636,"totalTrials":702,"cells":7640},{"EARLY_PHASE1":7641,"PHASE1":7643,"PHASE2":7645,"PHASE3":7655,"PHASE4":7661,"NA":7663},{"trials":7642,"activeCount":102},[],{"trials":7644,"activeCount":102},[],{"trials":7646,"activeCount":102},[7647,7651],{"nctId":5630,"briefTitle":5631,"status":131,"phases":7648,"primaryCompletion":2913,"completion":2913,"start":5633,"enrollment":34,"conditions":7649,"interventions":7650},[90,91],[5614],[340,5626,5636],{"nctId":5647,"briefTitle":5648,"status":131,"phases":7652,"primaryCompletion":5650,"completion":5650,"start":5651,"enrollment":135,"conditions":7653,"interventions":7654},[90,91],[5614],[340,5626,5636],{"trials":7656,"activeCount":102},[7657],{"nctId":5661,"briefTitle":5662,"status":131,"phases":7658,"primaryCompletion":5664,"completion":1864,"start":5665,"enrollment":1129,"conditions":7659,"interventions":7660},[91,92],[5667],[5071,5074,5636],{"trials":7662,"activeCount":102},[],{"trials":7664,"activeCount":102},[],{"intervention":677,"totalTrials":702,"cells":7666},{"EARLY_PHASE1":7667,"PHASE1":7669,"PHASE2":7671,"PHASE3":7693,"PHASE4":7705,"NA":7707},{"trials":7668,"activeCount":102},[],{"trials":7670,"activeCount":102},[],{"trials":7672,"activeCount":102},[7673,7683],{"nctId":7674,"briefTitle":7675,"status":131,"phases":7676,"primaryCompletion":7677,"completion":1039,"start":7678,"enrollment":98,"conditions":7679,"interventions":7681},"NCT04216017","Glenohumeral Cortisone Injection",[91],"2022-04-01","2020-01-01",[7680],"Humeral Fractures",[7682,677],"kenalog",{"nctId":7684,"briefTitle":7685,"status":131,"phases":7686,"primaryCompletion":7687,"completion":7687,"start":7688,"enrollment":7689,"conditions":7690,"interventions":7691},"NCT06661902","Buffered Lidocaine for Reducing Pain in Patients Undergoing Prostate Biopsy, BURN Trial",[90,91],"2026-01-27","2025-01-09",350,[4909],[7692,677],"Buffered Lidocaine",{"trials":7694,"activeCount":102},[7695],{"nctId":7696,"briefTitle":7697,"status":131,"phases":7698,"primaryCompletion":7699,"completion":7700,"start":2929,"enrollment":7701,"conditions":7702,"interventions":7704},"NCT01401647","Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia",[92],"2015-12","2016-01",3024,[7703],"Cardiac Arrest",[7628,677],{"trials":7706,"activeCount":102},[],{"trials":7708,"activeCount":102},[],{"intervention":7628,"totalTrials":264,"cells":7710},{"EARLY_PHASE1":7711,"PHASE1":7713,"PHASE2":7715,"PHASE3":7717,"PHASE4":7727,"NA":7729},{"trials":7712,"activeCount":102},[],{"trials":7714,"activeCount":102},[],{"trials":7716,"activeCount":102},[],{"trials":7718,"activeCount":102},[7719,7723],{"nctId":7617,"briefTitle":7618,"status":131,"phases":7720,"primaryCompletion":7620,"start":7621,"conditions":7721,"interventions":7722},[92],[7623,22,7624,28,7625,7626],[7628,7629,7630,7631,7632,7633,7634],{"nctId":7696,"briefTitle":7697,"status":131,"phases":7724,"primaryCompletion":7699,"completion":7700,"start":2929,"enrollment":7701,"conditions":7725,"interventions":7726},[92],[7703],[7628,677],{"trials":7728,"activeCount":102},[],{"trials":7730,"activeCount":102},[],{"intervention":7732,"totalTrials":264,"cells":7733},"7.5% Hypertonic Saline",{"EARLY_PHASE1":7734,"PHASE1":7736,"PHASE2":7738,"PHASE3":7740,"PHASE4":7764,"NA":7766},{"trials":7735,"activeCount":102},[],{"trials":7737,"activeCount":102},[],{"trials":7739,"activeCount":102},[],{"trials":7741,"activeCount":102},[7742,7752],{"nctId":7743,"briefTitle":7744,"status":108,"phases":7745,"primaryCompletion":1675,"completion":3156,"start":1676,"enrollment":7746,"conditions":7747,"interventions":7749},"NCT00316004","Hypertonic Resuscitation Following Severe Traumatic Brain Injury (TBI)",[92],1331,[7748],"Brain Injuries, Traumatic",[7750,7732,7751],"7.5% Hypertonic Saline in 6% Dextran-70","0.9% Normal Saline",{"nctId":7753,"briefTitle":7754,"status":108,"phases":7755,"primaryCompletion":7756,"completion":7756,"start":1676,"enrollment":7757,"conditions":7758,"interventions":7760},"NCT00316017","Hypertonic Resuscitation Following Traumatic Injury",[92],"2009-08",895,[7759],"Shock, Traumatic",[7761,7762,7763],"7.5% hypertonic saline\u002F6% Dextran-70","7.5% hypertonic saline","0.9% normal saline",{"trials":7765,"activeCount":102},[],{"trials":7767,"activeCount":102},[],{"intervention":7751,"totalTrials":264,"cells":7769},{"EARLY_PHASE1":7770,"PHASE1":7772,"PHASE2":7774,"PHASE3":7776,"PHASE4":7786,"NA":7788},{"trials":7771,"activeCount":102},[],{"trials":7773,"activeCount":102},[],{"trials":7775,"activeCount":102},[],{"trials":7777,"activeCount":102},[7778,7782],{"nctId":7743,"briefTitle":7744,"status":108,"phases":7779,"primaryCompletion":1675,"completion":3156,"start":1676,"enrollment":7746,"conditions":7780,"interventions":7781},[92],[7748],[7750,7732,7751],{"nctId":7753,"briefTitle":7754,"status":108,"phases":7783,"primaryCompletion":7756,"completion":7756,"start":1676,"enrollment":7757,"conditions":7784,"interventions":7785},[92],[7759],[7761,7762,7763],{"trials":7787,"activeCount":102},[],{"trials":7789,"activeCount":102},[],{"intervention":5868,"totalTrials":264,"cells":7791},{"EARLY_PHASE1":7792,"PHASE1":7794,"PHASE2":7796,"PHASE3":7798,"PHASE4":7814,"NA":7816},{"trials":7793,"activeCount":102},[],{"trials":7795,"activeCount":102},[],{"trials":7797,"activeCount":102},[],{"trials":7799,"activeCount":102},[7800,7810],{"nctId":7801,"briefTitle":7802,"status":131,"phases":7803,"primaryCompletion":7804,"completion":2064,"start":112,"enrollment":7805,"conditions":7806,"interventions":7809},"NCT04328961","Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)",[91,92],"2020-09-24",943,[2189,7807,7808,5865],"Corona Virus Infection","SARS (Severe Acute Respiratory Syndrome)",[5868,5867],{"nctId":5857,"briefTitle":5858,"status":108,"phases":7811,"primaryCompletion":5860,"completion":5861,"start":5862,"enrollment":5863,"conditions":7812,"interventions":7813},[91,92],[2189,5865],[5867,5868,5775,5869,5870],{"trials":7815,"activeCount":102},[],{"trials":7817,"activeCount":102},[],{"intervention":5867,"totalTrials":264,"cells":7819},{"EARLY_PHASE1":7820,"PHASE1":7822,"PHASE2":7824,"PHASE3":7826,"PHASE4":7836,"NA":7838},{"trials":7821,"activeCount":102},[],{"trials":7823,"activeCount":102},[],{"trials":7825,"activeCount":102},[],{"trials":7827,"activeCount":102},[7828,7832],{"nctId":7801,"briefTitle":7802,"status":131,"phases":7829,"primaryCompletion":7804,"completion":2064,"start":112,"enrollment":7805,"conditions":7830,"interventions":7831},[91,92],[2189,7807,7808,5865],[5868,5867],{"nctId":5857,"briefTitle":5858,"status":108,"phases":7833,"primaryCompletion":5860,"completion":5861,"start":5862,"enrollment":5863,"conditions":7834,"interventions":7835},[91,92],[2189,5865],[5867,5868,5775,5869,5870],{"trials":7837,"activeCount":102},[],{"trials":7839,"activeCount":102},[],{"intervention":7629,"totalTrials":236,"cells":7841},{"EARLY_PHASE1":7842,"PHASE1":7844,"PHASE2":7846,"PHASE3":7848,"PHASE4":7854,"NA":7856},{"trials":7843,"activeCount":102},[],{"trials":7845,"activeCount":102},[],{"trials":7847,"activeCount":102},[],{"trials":7849,"activeCount":102},[7850],{"nctId":7617,"briefTitle":7618,"status":131,"phases":7851,"primaryCompletion":7620,"start":7621,"conditions":7852,"interventions":7853},[92],[7623,22,7624,28,7625,7626],[7628,7629,7630,7631,7632,7633,7634],{"trials":7855,"activeCount":102},[],{"trials":7857,"activeCount":102},[],{"intervention":7631,"totalTrials":236,"cells":7859},{"EARLY_PHASE1":7860,"PHASE1":7862,"PHASE2":7864,"PHASE3":7866,"PHASE4":7872,"NA":7874},{"trials":7861,"activeCount":102},[],{"trials":7863,"activeCount":102},[],{"trials":7865,"activeCount":102},[],{"trials":7867,"activeCount":102},[7868],{"nctId":7617,"briefTitle":7618,"status":131,"phases":7869,"primaryCompletion":7620,"start":7621,"conditions":7870,"interventions":7871},[92],[7623,22,7624,28,7625,7626],[7628,7629,7630,7631,7632,7633,7634],{"trials":7873,"activeCount":102},[],{"trials":7875,"activeCount":102},[],{"intervention":7632,"totalTrials":236,"cells":7877},{"EARLY_PHASE1":7878,"PHASE1":7880,"PHASE2":7882,"PHASE3":7884,"PHASE4":7890,"NA":7892},{"trials":7879,"activeCount":102},[],{"trials":7881,"activeCount":102},[],{"trials":7883,"activeCount":102},[],{"trials":7885,"activeCount":102},[7886],{"nctId":7617,"briefTitle":7618,"status":131,"phases":7887,"primaryCompletion":7620,"start":7621,"conditions":7888,"interventions":7889},[92],[7623,22,7624,28,7625,7626],[7628,7629,7630,7631,7632,7633,7634],{"trials":7891,"activeCount":102},[],{"trials":7893,"activeCount":102},[],{"intervention":7633,"totalTrials":236,"cells":7895},{"EARLY_PHASE1":7896,"PHASE1":7898,"PHASE2":7900,"PHASE3":7902,"PHASE4":7908,"NA":7910},{"trials":7897,"activeCount":102},[],{"trials":7899,"activeCount":102},[],{"trials":7901,"activeCount":102},[],{"trials":7903,"activeCount":102},[7904],{"nctId":7617,"briefTitle":7618,"status":131,"phases":7905,"primaryCompletion":7620,"start":7621,"conditions":7906,"interventions":7907},[92],[7623,22,7624,28,7625,7626],[7628,7629,7630,7631,7632,7633,7634],{"trials":7909,"activeCount":102},[],{"trials":7911,"activeCount":102},[],{"intervention":7634,"totalTrials":236,"cells":7913},{"EARLY_PHASE1":7914,"PHASE1":7916,"PHASE2":7918,"PHASE3":7920,"PHASE4":7926,"NA":7928},{"trials":7915,"activeCount":102},[],{"trials":7917,"activeCount":102},[],{"trials":7919,"activeCount":102},[],{"trials":7921,"activeCount":102},[7922],{"nctId":7617,"briefTitle":7618,"status":131,"phases":7923,"primaryCompletion":7620,"start":7621,"conditions":7924,"interventions":7925},[92],[7623,22,7624,28,7625,7626],[7628,7629,7630,7631,7632,7633,7634],{"trials":7927,"activeCount":102},[],{"trials":7929,"activeCount":102},[],{"intervention":2193,"totalTrials":236,"cells":7931},{"EARLY_PHASE1":7932,"PHASE1":7934,"PHASE2":7936,"PHASE3":7938,"PHASE4":7944,"NA":7946},{"trials":7933,"activeCount":102},[],{"trials":7935,"activeCount":102},[],{"trials":7937,"activeCount":102},[],{"trials":7939,"activeCount":102},[7940],{"nctId":2180,"briefTitle":2181,"status":131,"phases":7941,"primaryCompletion":2183,"completion":2184,"start":2185,"enrollment":23,"conditions":7942,"interventions":7943},[92],[2187,2188,2189,16,2190,2191],[2132,2193],{"trials":7945,"activeCount":102},[],{"trials":7947,"activeCount":102},[],{"intervention":7949,"totalTrials":236,"cells":7950},"Gabapentin",{"EARLY_PHASE1":7951,"PHASE1":7953,"PHASE2":7955,"PHASE3":7957,"PHASE4":7969,"NA":7971},{"trials":7952,"activeCount":102},[],{"trials":7954,"activeCount":102},[],{"trials":7956,"activeCount":102},[],{"trials":7958,"activeCount":102},[7959],{"nctId":7960,"briefTitle":7961,"status":131,"phases":7962,"primaryCompletion":7963,"completion":7964,"start":7965,"enrollment":29,"conditions":7966,"interventions":7968},"NCT02355886","Gabapentin in Reducing the Need for Pain Medication in Patients With Bladder Cancer Undergoing Radical Cystectomy",[91,92],"2018-02-28","2019-02-28","2015-04-22",[7967],"Bladder Carcinoma",[7949],{"trials":7970,"activeCount":102},[],{"trials":7972,"activeCount":102},[],{"intervention":7974,"totalTrials":236,"cells":7975},"gentamicin 360mg IM",{"EARLY_PHASE1":7976,"PHASE1":7978,"PHASE2":7980,"PHASE3":7982,"PHASE4":7993,"NA":7995},{"trials":7977,"activeCount":102},[],{"trials":7979,"activeCount":102},[],{"trials":7981,"activeCount":102},[],{"trials":7983,"activeCount":102},[7984],{"nctId":7985,"briefTitle":7986,"status":108,"phases":7987,"primaryCompletion":7988,"completion":7988,"start":7989,"enrollment":2370,"conditions":7990,"interventions":7992},"NCT03632109","Gent for Pharyngeal Gonorrhea (GC)",[91,92],"2019-03-12","2018-09-17",[7991],"Pharyngeal Gonococcal Infection",[7974],{"trials":7994,"activeCount":102},[],{"trials":7996,"activeCount":102},[],{"intervention":5821,"totalTrials":236,"cells":7998},{"EARLY_PHASE1":7999,"PHASE1":8001,"PHASE2":8003,"PHASE3":8005,"PHASE4":8011,"NA":8013},{"trials":8000,"activeCount":102},[],{"trials":8002,"activeCount":102},[],{"trials":8004,"activeCount":102},[],{"trials":8006,"activeCount":102},[8007],{"nctId":5811,"briefTitle":5812,"status":131,"phases":8008,"completion":5814,"start":5815,"conditions":8009,"interventions":8010},[92],[22,5817,28,5818],[5820,5800,5821],{"trials":8012,"activeCount":102},[],{"trials":8014,"activeCount":102},[],{"intervention":8016,"totalTrials":236,"cells":8017},"Active Treatment Group 7% Hypertonic Saline",{"EARLY_PHASE1":8018,"PHASE1":8020,"PHASE2":8022,"PHASE3":8024,"PHASE4":8038,"NA":8040},{"trials":8019,"activeCount":102},[],{"trials":8021,"activeCount":102},[],{"trials":8023,"activeCount":102},[],{"trials":8025,"activeCount":102},[8026],{"nctId":8027,"briefTitle":8028,"status":131,"phases":8029,"primaryCompletion":8030,"completion":8031,"start":8032,"enrollment":8033,"conditions":8034,"interventions":8036},"NCT02950883","Saline Hypertonic in Preschoolers + CT",[91,92],"2020-12-15","2021-06-25","2015-03-24",116,[8035],"Cystic Fibrosis",[8016,8037],"Control Group 0.9% Isotonic Saline",{"trials":8039,"activeCount":102},[],{"trials":8041,"activeCount":102},[],{"intervention":8037,"totalTrials":236,"cells":8043},{"EARLY_PHASE1":8044,"PHASE1":8046,"PHASE2":8048,"PHASE3":8050,"PHASE4":8056,"NA":8058},{"trials":8045,"activeCount":102},[],{"trials":8047,"activeCount":102},[],{"trials":8049,"activeCount":102},[],{"trials":8051,"activeCount":102},[8052],{"nctId":8027,"briefTitle":8028,"status":131,"phases":8053,"primaryCompletion":8030,"completion":8031,"start":8032,"enrollment":8033,"conditions":8054,"interventions":8055},[91,92],[8035],[8016,8037],{"trials":8057,"activeCount":102},[],{"trials":8059,"activeCount":102},[],{"intervention":8061,"totalTrials":236,"cells":8062},"Fluconazole",{"EARLY_PHASE1":8063,"PHASE1":8065,"PHASE2":8067,"PHASE3":8069,"PHASE4":8082,"NA":8084},{"trials":8064,"activeCount":102},[],{"trials":8066,"activeCount":102},[],{"trials":8068,"activeCount":102},[],{"trials":8070,"activeCount":102},[8071],{"nctId":8072,"briefTitle":8073,"status":131,"phases":8074,"primaryCompletion":1476,"completion":1476,"start":8075,"enrollment":7196,"conditions":8076,"interventions":8080},"NCT00170430","Reducing Vaginal Infections in Women",[92],"2003-05",[8077,8078,8079],"Bacterial Diseases","Other Mycoses","Sexually Transmitted Infection",[8061,8081],"Metronizadole",{"trials":8083,"activeCount":102},[],{"trials":8085,"activeCount":102},[],{"intervention":8081,"totalTrials":236,"cells":8087},{"EARLY_PHASE1":8088,"PHASE1":8090,"PHASE2":8092,"PHASE3":8094,"PHASE4":8100,"NA":8102},{"trials":8089,"activeCount":102},[],{"trials":8091,"activeCount":102},[],{"trials":8093,"activeCount":102},[],{"trials":8095,"activeCount":102},[8096],{"nctId":8072,"briefTitle":8073,"status":131,"phases":8097,"primaryCompletion":1476,"completion":1476,"start":8075,"enrollment":7196,"conditions":8098,"interventions":8099},[92],[8077,8078,8079],[8061,8081],{"trials":8101,"activeCount":102},[],{"trials":8103,"activeCount":102},[],{"intervention":8105,"totalTrials":236,"cells":8106},"co-formulated 25mg TAF\u002F 200mg FTC",{"EARLY_PHASE1":8107,"PHASE1":8109,"PHASE2":8111,"PHASE3":8113,"PHASE4":8122,"NA":8124},{"trials":8108,"activeCount":102},[],{"trials":8110,"activeCount":102},[],{"trials":8112,"activeCount":102},[],{"trials":8114,"activeCount":102},[8115],{"nctId":8116,"briefTitle":8117,"status":131,"phases":8118,"primaryCompletion":1497,"completion":1497,"start":8119,"enrollment":1041,"conditions":8120,"interventions":8121},"NCT05140954","The Women TAF-FTC Benchmark Study",[91,92],"2023-03-28",[19],[8105],{"trials":8123,"activeCount":102},[],{"trials":8125,"activeCount":102},[],{"intervention":8127,"totalTrials":236,"cells":8128},"Epo",{"EARLY_PHASE1":8129,"PHASE1":8131,"PHASE2":8133,"PHASE3":8135,"PHASE4":8146,"NA":8148},{"trials":8130,"activeCount":102},[],{"trials":8132,"activeCount":102},[],{"trials":8134,"activeCount":102},[],{"trials":8136,"activeCount":102},[8137],{"nctId":8138,"briefTitle":8139,"status":131,"phases":8140,"primaryCompletion":7964,"completion":8141,"start":860,"enrollment":8142,"conditions":8143,"interventions":8145},"NCT01378273","Preterm Erythropoietin Neuroprotection Trial (PENUT Trial)",[92],"2020-02-28",941,[8144],"Extreme Prematurity",[8127],{"trials":8147,"activeCount":102},[],{"trials":8149,"activeCount":102},[],{"intervention":8151,"totalTrials":236,"cells":8152},"Fluoride varnish",{"EARLY_PHASE1":8153,"PHASE1":8155,"PHASE2":8157,"PHASE3":8159,"PHASE4":8169,"NA":8171},{"trials":8154,"activeCount":102},[],{"trials":8156,"activeCount":102},[],{"trials":8158,"activeCount":102},[],{"trials":8160,"activeCount":102},[8161],{"nctId":8162,"briefTitle":8163,"status":131,"phases":8164,"primaryCompletion":2913,"completion":3131,"start":8165,"enrollment":6610,"conditions":8166,"interventions":8168},"NCT00067353","Yakima Head Start Fluoride Varnish Study",[92],"2003-11",[8167],"Dental Caries",[8151],{"trials":8170,"activeCount":102},[],{"trials":8172,"activeCount":102},[],{"intervention":8174,"totalTrials":236,"cells":8175},"magnesium sulfate",{"EARLY_PHASE1":8176,"PHASE1":8178,"PHASE2":8180,"PHASE3":8182,"PHASE4":8195,"NA":8197},{"trials":8177,"activeCount":102},[],{"trials":8179,"activeCount":102},[],{"trials":8181,"activeCount":102},[],{"trials":8183,"activeCount":102},[8184],{"nctId":8185,"briefTitle":8186,"status":131,"phases":8187,"primaryCompletion":8188,"completion":8188,"start":8189,"conditions":8190,"interventions":8194},"NCT00004730","Magnesium Sulfate For Brain Injury",[92],"2005-05","1998-08",[8191,8192,8193],"Brain Injuries","Head Injury","Brain Concussion",[8174],{"trials":8196,"activeCount":102},[],{"trials":8198,"activeCount":102},[],{"intervention":8200,"totalTrials":236,"cells":8201},"FTC\u002FTDF PrEP",{"EARLY_PHASE1":8202,"PHASE1":8204,"PHASE2":8206,"PHASE3":8208,"PHASE4":8218,"NA":8220},{"trials":8203,"activeCount":102},[],{"trials":8205,"activeCount":102},[],{"trials":8207,"activeCount":102},[],{"trials":8209,"activeCount":102},[8210],{"nctId":8211,"briefTitle":8212,"status":131,"phases":8213,"primaryCompletion":329,"completion":7699,"start":8214,"enrollment":350,"conditions":8215,"interventions":8217},"NCT02776748","PrEP in Breastfeeding Study",[91,92],"2015-01",[8216],"HIV Pre-exposure Prophylaxis During Breastfeeding",[8200],{"trials":8219,"activeCount":102},[],{"trials":8221,"activeCount":102},[],{"intervention":8223,"totalTrials":236,"cells":8224},"sodium nitrite 45 mg",{"EARLY_PHASE1":8225,"PHASE1":8227,"PHASE2":8229,"PHASE3":8231,"PHASE4":8244,"NA":8246},{"trials":8226,"activeCount":102},[],{"trials":8228,"activeCount":102},[],{"trials":8230,"activeCount":102},[],{"trials":8232,"activeCount":102},[8233],{"nctId":8234,"briefTitle":8235,"status":131,"phases":8236,"primaryCompletion":8237,"completion":8238,"start":214,"enrollment":8239,"conditions":8240,"interventions":8242},"NCT03452917","Clinical Trial of Sodium Nitrite for Out of Hospital Cardiac Arrest",[91,92],"2019-12-31","2020-04-30",1502,[8241],"Out-Of-Hospital Cardiac Arrest",[8223,8243],"sodium nitrite 60 mg",{"trials":8245,"activeCount":102},[],{"trials":8247,"activeCount":102},[],{"intervention":8243,"totalTrials":236,"cells":8249},{"EARLY_PHASE1":8250,"PHASE1":8252,"PHASE2":8254,"PHASE3":8256,"PHASE4":8262,"NA":8264},{"trials":8251,"activeCount":102},[],{"trials":8253,"activeCount":102},[],{"trials":8255,"activeCount":102},[],{"trials":8257,"activeCount":102},[8258],{"nctId":8234,"briefTitle":8235,"status":131,"phases":8259,"primaryCompletion":8237,"completion":8238,"start":214,"enrollment":8239,"conditions":8260,"interventions":8261},[91,92],[8241],[8223,8243],{"trials":8263,"activeCount":102},[],{"trials":8265,"activeCount":102},[],{"intervention":8267,"totalTrials":236,"cells":8268},"Tenofovir Disoproxil Fumarate",{"EARLY_PHASE1":8269,"PHASE1":8271,"PHASE2":8273,"PHASE3":8275,"PHASE4":8287,"NA":8289},{"trials":8270,"activeCount":102},[],{"trials":8272,"activeCount":102},[],{"trials":8274,"activeCount":102},[],{"trials":8276,"activeCount":102},[8277],{"nctId":8278,"briefTitle":8279,"status":131,"phases":8280,"primaryCompletion":719,"completion":719,"start":8281,"enrollment":8282,"conditions":8283,"interventions":8285},"NCT00557245","Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples",[92],"2008-05",4758,[8284,19],"HIV-1 Infections",[8267,8286],"Emtricitabine\u002FTenofovir Disoproxil Fumarate",{"trials":8288,"activeCount":102},[],{"trials":8290,"activeCount":102},[],{"intervention":8286,"totalTrials":236,"cells":8292},{"EARLY_PHASE1":8293,"PHASE1":8295,"PHASE2":8297,"PHASE3":8299,"PHASE4":8305,"NA":8307},{"trials":8294,"activeCount":102},[],{"trials":8296,"activeCount":102},[],{"trials":8298,"activeCount":102},[],{"trials":8300,"activeCount":102},[8301],{"nctId":8278,"briefTitle":8279,"status":131,"phases":8302,"primaryCompletion":719,"completion":719,"start":8281,"enrollment":8282,"conditions":8303,"interventions":8304},[92],[8284,19],[8267,8286],{"trials":8306,"activeCount":102},[],{"trials":8308,"activeCount":102},[],{"intervention":8310,"totalTrials":236,"cells":8311},"trimethoprim-sulfamethoxazole",{"EARLY_PHASE1":8312,"PHASE1":8314,"PHASE2":8316,"PHASE3":8318,"PHASE4":8331,"NA":8333},{"trials":8313,"activeCount":102},[],{"trials":8315,"activeCount":102},[],{"trials":8317,"activeCount":102},[],{"trials":8319,"activeCount":102},[8320],{"nctId":8321,"briefTitle":8322,"status":131,"phases":8323,"primaryCompletion":8324,"completion":8324,"start":8325,"enrollment":264,"conditions":8326,"interventions":8329},"NCT00324922","Vancomycin Or Trimethoprim\u002FSulfamethoxazole for Methicillin-resistant Staphylococcus Aureus Osteomyelitis",[92],"2007-05-01","2006-05-01",[8327,8328],"Osteomyelitis","Methicillin-resistant Staphylococcus Aureus",[8310,8330],"vancomycin",{"trials":8332,"activeCount":102},[],{"trials":8334,"activeCount":102},[],{"intervention":8330,"totalTrials":236,"cells":8336},{"EARLY_PHASE1":8337,"PHASE1":8339,"PHASE2":8341,"PHASE3":8343,"PHASE4":8349,"NA":8351},{"trials":8338,"activeCount":102},[],{"trials":8340,"activeCount":102},[],{"trials":8342,"activeCount":102},[],{"trials":8344,"activeCount":102},[8345],{"nctId":8321,"briefTitle":8322,"status":131,"phases":8346,"primaryCompletion":8324,"completion":8324,"start":8325,"enrollment":264,"conditions":8347,"interventions":8348},[92],[8327,8328],[8310,8330],{"trials":8350,"activeCount":102},[],{"trials":8352,"activeCount":102},[],{"intervention":8354,"totalTrials":236,"cells":8355},"Oral Rehydration Solution",{"EARLY_PHASE1":8356,"PHASE1":8358,"PHASE2":8360,"PHASE3":8362,"PHASE4":8376,"NA":8378},{"trials":8357,"activeCount":102},[],{"trials":8359,"activeCount":102},[],{"trials":8361,"activeCount":102},[],{"trials":8363,"activeCount":102},[8364],{"nctId":8365,"briefTitle":8366,"status":131,"phases":8367,"primaryCompletion":8368,"completion":8369,"start":8370,"enrollment":23,"conditions":8371,"interventions":8374},"NCT04732624","Enteral Resuscitation Nepal (Pilot Study)",[92],"2022-05-31","2022-06-04","2021-09-30",[8372,8373],"Burn Body Region Unspecified","Burn Shock",[8354,8375],"Lactated Ringer",{"trials":8377,"activeCount":102},[],{"trials":8379,"activeCount":102},[],{"intervention":8375,"totalTrials":236,"cells":8381},{"EARLY_PHASE1":8382,"PHASE1":8384,"PHASE2":8386,"PHASE3":8388,"PHASE4":8394,"NA":8396},{"trials":8383,"activeCount":102},[],{"trials":8385,"activeCount":102},[],{"trials":8387,"activeCount":102},[],{"trials":8389,"activeCount":102},[8390],{"nctId":8365,"briefTitle":8366,"status":131,"phases":8391,"primaryCompletion":8368,"completion":8369,"start":8370,"enrollment":23,"conditions":8392,"interventions":8393},[92],[8372,8373],[8354,8375],{"trials":8395,"activeCount":102},[],{"trials":8397,"activeCount":102},[],{"intervention":8399,"totalTrials":236,"cells":8400},"AZT\u002F3TC\u002FNVP",{"EARLY_PHASE1":8401,"PHASE1":8403,"PHASE2":8405,"PHASE3":8407,"PHASE4":8423,"NA":8425},{"trials":8402,"activeCount":102},[],{"trials":8404,"activeCount":102},[],{"trials":8406,"activeCount":102},[],{"trials":8408,"activeCount":102},[8409],{"nctId":8410,"briefTitle":8411,"status":108,"phases":8412,"primaryCompletion":1675,"completion":8413,"start":8414,"enrollment":3144,"conditions":8415,"interventions":8416},"NCT00427297","Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, Kenya",[92],"2009-12","2007-09",[19],[8399,8417,8418,8419,8420,8421,8422],"d4T\u002F3TC\u002FNVP","AZT\u002F3TC\u002FABC","d4T\u002F3TC\u002FABC","ddI\u002FABC\u002FLPV\u002Fr","ABC\u002F ddI or TDF \u002F NVP or EFV","ABC\u002F3TC\u002FNVP",{"trials":8424,"activeCount":102},[],{"trials":8426,"activeCount":102},[],{"intervention":8417,"totalTrials":236,"cells":8428},{"EARLY_PHASE1":8429,"PHASE1":8431,"PHASE2":8433,"PHASE3":8435,"PHASE4":8441,"NA":8443},{"trials":8430,"activeCount":102},[],{"trials":8432,"activeCount":102},[],{"trials":8434,"activeCount":102},[],{"trials":8436,"activeCount":102},[8437],{"nctId":8410,"briefTitle":8411,"status":108,"phases":8438,"primaryCompletion":1675,"completion":8413,"start":8414,"enrollment":3144,"conditions":8439,"interventions":8440},[92],[19],[8399,8417,8418,8419,8420,8421,8422],{"trials":8442,"activeCount":102},[],{"trials":8444,"activeCount":102},[],{"intervention":8418,"totalTrials":236,"cells":8446},{"EARLY_PHASE1":8447,"PHASE1":8449,"PHASE2":8451,"PHASE3":8453,"PHASE4":8459,"NA":8461},{"trials":8448,"activeCount":102},[],{"trials":8450,"activeCount":102},[],{"trials":8452,"activeCount":102},[],{"trials":8454,"activeCount":102},[8455],{"nctId":8410,"briefTitle":8411,"status":108,"phases":8456,"primaryCompletion":1675,"completion":8413,"start":8414,"enrollment":3144,"conditions":8457,"interventions":8458},[92],[19],[8399,8417,8418,8419,8420,8421,8422],{"trials":8460,"activeCount":102},[],{"trials":8462,"activeCount":102},[],{"intervention":8419,"totalTrials":236,"cells":8464},{"EARLY_PHASE1":8465,"PHASE1":8467,"PHASE2":8469,"PHASE3":8471,"PHASE4":8477,"NA":8479},{"trials":8466,"activeCount":102},[],{"trials":8468,"activeCount":102},[],{"trials":8470,"activeCount":102},[],{"trials":8472,"activeCount":102},[8473],{"nctId":8410,"briefTitle":8411,"status":108,"phases":8474,"primaryCompletion":1675,"completion":8413,"start":8414,"enrollment":3144,"conditions":8475,"interventions":8476},[92],[19],[8399,8417,8418,8419,8420,8421,8422],{"trials":8478,"activeCount":102},[],{"trials":8480,"activeCount":102},[],{"intervention":8420,"totalTrials":236,"cells":8482},{"EARLY_PHASE1":8483,"PHASE1":8485,"PHASE2":8487,"PHASE3":8489,"PHASE4":8495,"NA":8497},{"trials":8484,"activeCount":102},[],{"trials":8486,"activeCount":102},[],{"trials":8488,"activeCount":102},[],{"trials":8490,"activeCount":102},[8491],{"nctId":8410,"briefTitle":8411,"status":108,"phases":8492,"primaryCompletion":1675,"completion":8413,"start":8414,"enrollment":3144,"conditions":8493,"interventions":8494},[92],[19],[8399,8417,8418,8419,8420,8421,8422],{"trials":8496,"activeCount":102},[],{"trials":8498,"activeCount":102},[],{"intervention":8421,"totalTrials":236,"cells":8500},{"EARLY_PHASE1":8501,"PHASE1":8503,"PHASE2":8505,"PHASE3":8507,"PHASE4":8513,"NA":8515},{"trials":8502,"activeCount":102},[],{"trials":8504,"activeCount":102},[],{"trials":8506,"activeCount":102},[],{"trials":8508,"activeCount":102},[8509],{"nctId":8410,"briefTitle":8411,"status":108,"phases":8510,"primaryCompletion":1675,"completion":8413,"start":8414,"enrollment":3144,"conditions":8511,"interventions":8512},[92],[19],[8399,8417,8418,8419,8420,8421,8422],{"trials":8514,"activeCount":102},[],{"trials":8516,"activeCount":102},[],{"intervention":8422,"totalTrials":236,"cells":8518},{"EARLY_PHASE1":8519,"PHASE1":8521,"PHASE2":8523,"PHASE3":8525,"PHASE4":8531,"NA":8533},{"trials":8520,"activeCount":102},[],{"trials":8522,"activeCount":102},[],{"trials":8524,"activeCount":102},[],{"trials":8526,"activeCount":102},[8527],{"nctId":8410,"briefTitle":8411,"status":108,"phases":8528,"primaryCompletion":1675,"completion":8413,"start":8414,"enrollment":3144,"conditions":8529,"interventions":8530},[92],[19],[8399,8417,8418,8419,8420,8421,8422],{"trials":8532,"activeCount":102},[],{"trials":8534,"activeCount":102},[],{"intervention":8536,"totalTrials":236,"cells":8537},"Lactobacillus crispatus CTV-05",{"EARLY_PHASE1":8538,"PHASE1":8540,"PHASE2":8542,"PHASE3":8544,"PHASE4":8554,"NA":8556},{"trials":8539,"activeCount":102},[],{"trials":8541,"activeCount":102},[],{"trials":8543,"activeCount":102},[],{"trials":8545,"activeCount":102},[8546],{"nctId":8547,"briefTitle":8548,"status":131,"phases":8549,"primaryCompletion":8550,"completion":8550,"start":1136,"enrollment":2817,"conditions":8551,"interventions":8553},"NCT03151967","Lactobacillus Probiotic for Prevention of UTI",[91,92],"2017-04-05",[8552],"Urinary Tract Infections (UTI's)",[8536],{"trials":8555,"activeCount":102},[],{"trials":8557,"activeCount":102},[],{"intervention":8559,"totalTrials":236,"cells":8560},"Rapid infusion of cold normal saline",{"EARLY_PHASE1":8561,"PHASE1":8563,"PHASE2":8565,"PHASE3":8567,"PHASE4":8578,"NA":8580},{"trials":8562,"activeCount":102},[],{"trials":8564,"activeCount":102},[],{"trials":8566,"activeCount":102},[],{"trials":8568,"activeCount":102},[8569],{"nctId":8570,"briefTitle":8571,"status":131,"phases":8572,"primaryCompletion":8573,"completion":5021,"start":410,"enrollment":8574,"conditions":8575,"interventions":8577},"NCT00391469","Induction of Mild Hypothermia Following Out-of-hospital Cardiac Arrest",[91,92],"2013-05",1359,[8576],"Out-of-hospital Cardiac Arrest",[8559],{"trials":8579,"activeCount":102},[],{"trials":8581,"activeCount":102},[],{"intervention":7750,"totalTrials":236,"cells":8583},{"EARLY_PHASE1":8584,"PHASE1":8586,"PHASE2":8588,"PHASE3":8590,"PHASE4":8596,"NA":8598},{"trials":8585,"activeCount":102},[],{"trials":8587,"activeCount":102},[],{"trials":8589,"activeCount":102},[],{"trials":8591,"activeCount":102},[8592],{"nctId":7743,"briefTitle":7744,"status":108,"phases":8593,"primaryCompletion":1675,"completion":3156,"start":1676,"enrollment":7746,"conditions":8594,"interventions":8595},[92],[7748],[7750,7732,7751],{"trials":8597,"activeCount":102},[],{"trials":8599,"activeCount":102},[],{"intervention":8601,"totalTrials":236,"cells":8602},"Antidepressant Drug Therapy",{"EARLY_PHASE1":8603,"PHASE1":8605,"PHASE2":8607,"PHASE3":8609,"PHASE4":8622,"NA":8624},{"trials":8604,"activeCount":102},[],{"trials":8606,"activeCount":102},[],{"trials":8608,"activeCount":102},[],{"trials":8610,"activeCount":102},[8611],{"nctId":8612,"briefTitle":8613,"status":131,"phases":8614,"primaryCompletion":8615,"completion":8616,"start":8617,"enrollment":8618,"conditions":8619,"interventions":8621},"NCT02358343","A Trial of Sertraline vs. CBT for End-stage Renal Disease Patients With Depression {ASCEND}",[92],"2017-11-15","2017-12-15","2015-03-23",184,[16,8620],"End Stage Renal Disease",[8601],{"trials":8623,"activeCount":102},[],{"trials":8625,"activeCount":102},[],{"intervention":8627,"totalTrials":236,"cells":8628},"Generic acyclovir",{"EARLY_PHASE1":8629,"PHASE1":8631,"PHASE2":8633,"PHASE3":8635,"PHASE4":8646,"NA":8648},{"trials":8630,"activeCount":102},[],{"trials":8632,"activeCount":102},[],{"trials":8634,"activeCount":102},[],{"trials":8636,"activeCount":102},[8637],{"nctId":8638,"briefTitle":8639,"status":131,"phases":8640,"primaryCompletion":740,"completion":1137,"start":5610,"enrollment":8641,"conditions":8642,"interventions":8645},"NCT00194519","Herpes Simplex Virus Type 2 (HSV-2) Suppression to Prevent HIV Transmission",[92],3408,[6220,8643,8644],"Herpes Simplex, Genital","Sexually Transmitted Diseases",[8627],{"trials":8647,"activeCount":102},[],{"trials":8649,"activeCount":102},[],{"intervention":8651,"totalTrials":236,"cells":8652},"HemeRX epinephrine pellets",{"EARLY_PHASE1":8653,"PHASE1":8655,"PHASE2":8657,"PHASE3":8659,"PHASE4":8669,"NA":8671},{"trials":8654,"activeCount":102},[],{"trials":8656,"activeCount":102},[],{"trials":8658,"activeCount":102},[],{"trials":8660,"activeCount":102},[8661],{"nctId":8662,"briefTitle":8663,"status":131,"phases":8664,"primaryCompletion":3119,"completion":3119,"start":8665,"enrollment":2370,"conditions":8666,"interventions":8668},"NCT04688346","Cardiovascular Effects of Racemic Epinephrine Pellets",[91,92],"2019-06-10",[8667],"Epinephrine Causing Adverse Effects in Therapeutic Use",[8651],{"trials":8670,"activeCount":102},[],{"trials":8672,"activeCount":102},[],{"intervention":8674,"totalTrials":236,"cells":8675},"streptokinase",{"EARLY_PHASE1":8676,"PHASE1":8678,"PHASE2":8680,"PHASE3":8682,"PHASE4":8692,"NA":8694},{"trials":8677,"activeCount":102},[],{"trials":8679,"activeCount":102},[],{"trials":8681,"activeCount":102},[],{"trials":8683,"activeCount":102},[8684],{"nctId":8685,"briefTitle":8686,"status":131,"phases":8687,"completion":8688,"start":8689,"conditions":8690,"interventions":8691},"NCT00000507","Intravenous Streptokinase in Acute Myocardial Infarction",[92],"1994-10","1983-08",[22,5817,28,7625,5818],[8674],{"trials":8693,"activeCount":102},[],{"trials":8695,"activeCount":102},[],{"intervention":8697,"totalTrials":236,"cells":8698},"Ibuprofen 400 mg",{"EARLY_PHASE1":8699,"PHASE1":8701,"PHASE2":8703,"PHASE3":8705,"PHASE4":8718,"NA":8720},{"trials":8700,"activeCount":102},[],{"trials":8702,"activeCount":102},[],{"trials":8704,"activeCount":102},[],{"trials":8706,"activeCount":102},[8707],{"nctId":8708,"briefTitle":8709,"status":131,"phases":8710,"primaryCompletion":8711,"completion":8711,"start":8712,"enrollment":1707,"conditions":8713,"interventions":8715},"NCT03055507","Effect of Post-operative Ibuprofen After Surgery for Chronic Rhinosinusitis",[91,92],"2017-12-31","2017-04-01",[8714],"Chronic Rhinosinusitis (Diagnosis)",[8697,8716,8717],"Acetaminophen 650 mg","OxyCODONE 5 Mg Oral",{"trials":8719,"activeCount":102},[],{"trials":8721,"activeCount":102},[],{"intervention":8716,"totalTrials":236,"cells":8723},{"EARLY_PHASE1":8724,"PHASE1":8726,"PHASE2":8728,"PHASE3":8730,"PHASE4":8736,"NA":8738},{"trials":8725,"activeCount":102},[],{"trials":8727,"activeCount":102},[],{"trials":8729,"activeCount":102},[],{"trials":8731,"activeCount":102},[8732],{"nctId":8708,"briefTitle":8709,"status":131,"phases":8733,"primaryCompletion":8711,"completion":8711,"start":8712,"enrollment":1707,"conditions":8734,"interventions":8735},[91,92],[8714],[8697,8716,8717],{"trials":8737,"activeCount":102},[],{"trials":8739,"activeCount":102},[],{"intervention":8717,"totalTrials":236,"cells":8741},{"EARLY_PHASE1":8742,"PHASE1":8744,"PHASE2":8746,"PHASE3":8748,"PHASE4":8754,"NA":8756},{"trials":8743,"activeCount":102},[],{"trials":8745,"activeCount":102},[],{"trials":8747,"activeCount":102},[],{"trials":8749,"activeCount":102},[8750],{"nctId":8708,"briefTitle":8709,"status":131,"phases":8751,"primaryCompletion":8711,"completion":8711,"start":8712,"enrollment":1707,"conditions":8752,"interventions":8753},[91,92],[8714],[8697,8716,8717],{"trials":8755,"activeCount":102},[],{"trials":8757,"activeCount":102},[],{"intervention":8759,"totalTrials":236,"cells":8760},"OnabotulinumtoxinA",{"EARLY_PHASE1":8761,"PHASE1":8763,"PHASE2":8765,"PHASE3":8767,"PHASE4":8777,"NA":8779},{"trials":8762,"activeCount":102},[],{"trials":8764,"activeCount":102},[],{"trials":8766,"activeCount":102},[],{"trials":8768,"activeCount":102},[8769],{"nctId":8770,"briefTitle":8771,"status":108,"phases":8772,"primaryCompletion":8773,"completion":8773,"start":718,"enrollment":2370,"conditions":8774,"interventions":8776},"NCT02160535","Treatment of Chronic Post-Traumatic Headache With OnabotulinumtoxinA",[92],"2016-08",[8775],"Chronic Post Traumatic Headache",[8759],{"trials":8778,"activeCount":102},[],{"trials":8780,"activeCount":102},[],{"intervention":7580,"totalTrials":236,"cells":8782},{"EARLY_PHASE1":8783,"PHASE1":8785,"PHASE2":8787,"PHASE3":8789,"PHASE4":8795,"NA":8797},{"trials":8784,"activeCount":102},[],{"trials":8786,"activeCount":102},[],{"trials":8788,"activeCount":102},[],{"trials":8790,"activeCount":102},[8791],{"nctId":7575,"briefTitle":7576,"status":131,"phases":8792,"primaryCompletion":1577,"completion":1620,"start":1313,"enrollment":3405,"conditions":8793,"interventions":8794},[91,92],[5667],[7580,7581,7582,7583,7584,340],{"trials":8796,"activeCount":102},[],{"trials":8798,"activeCount":102},[],{"intervention":7581,"totalTrials":236,"cells":8800},{"EARLY_PHASE1":8801,"PHASE1":8803,"PHASE2":8805,"PHASE3":8807,"PHASE4":8813,"NA":8815},{"trials":8802,"activeCount":102},[],{"trials":8804,"activeCount":102},[],{"trials":8806,"activeCount":102},[],{"trials":8808,"activeCount":102},[8809],{"nctId":7575,"briefTitle":7576,"status":131,"phases":8810,"primaryCompletion":1577,"completion":1620,"start":1313,"enrollment":3405,"conditions":8811,"interventions":8812},[91,92],[5667],[7580,7581,7582,7583,7584,340],{"trials":8814,"activeCount":102},[],{"trials":8816,"activeCount":102},[],{"intervention":7582,"totalTrials":236,"cells":8818},{"EARLY_PHASE1":8819,"PHASE1":8821,"PHASE2":8823,"PHASE3":8825,"PHASE4":8831,"NA":8833},{"trials":8820,"activeCount":102},[],{"trials":8822,"activeCount":102},[],{"trials":8824,"activeCount":102},[],{"trials":8826,"activeCount":102},[8827],{"nctId":7575,"briefTitle":7576,"status":131,"phases":8828,"primaryCompletion":1577,"completion":1620,"start":1313,"enrollment":3405,"conditions":8829,"interventions":8830},[91,92],[5667],[7580,7581,7582,7583,7584,340],{"trials":8832,"activeCount":102},[],{"trials":8834,"activeCount":102},[],{"intervention":7583,"totalTrials":236,"cells":8836},{"EARLY_PHASE1":8837,"PHASE1":8839,"PHASE2":8841,"PHASE3":8843,"PHASE4":8849,"NA":8851},{"trials":8838,"activeCount":102},[],{"trials":8840,"activeCount":102},[],{"trials":8842,"activeCount":102},[],{"trials":8844,"activeCount":102},[8845],{"nctId":7575,"briefTitle":7576,"status":131,"phases":8846,"primaryCompletion":1577,"completion":1620,"start":1313,"enrollment":3405,"conditions":8847,"interventions":8848},[91,92],[5667],[7580,7581,7582,7583,7584,340],{"trials":8850,"activeCount":102},[],{"trials":8852,"activeCount":102},[],{"intervention":7584,"totalTrials":236,"cells":8854},{"EARLY_PHASE1":8855,"PHASE1":8857,"PHASE2":8859,"PHASE3":8861,"PHASE4":8867,"NA":8869},{"trials":8856,"activeCount":102},[],{"trials":8858,"activeCount":102},[],{"trials":8860,"activeCount":102},[],{"trials":8862,"activeCount":102},[8863],{"nctId":7575,"briefTitle":7576,"status":131,"phases":8864,"primaryCompletion":1577,"completion":1620,"start":1313,"enrollment":3405,"conditions":8865,"interventions":8866},[91,92],[5667],[7580,7581,7582,7583,7584,340],{"trials":8868,"activeCount":102},[],{"trials":8870,"activeCount":102},[],{"intervention":8872,"totalTrials":236,"cells":8873},"Chlorhexidine rinse",{"EARLY_PHASE1":8874,"PHASE1":8876,"PHASE2":8878,"PHASE3":8880,"PHASE4":8893,"NA":8895},{"trials":8875,"activeCount":102},[],{"trials":8877,"activeCount":102},[],{"trials":8879,"activeCount":102},[],{"trials":8881,"activeCount":102},[8882],{"nctId":8883,"briefTitle":8884,"status":131,"phases":8885,"primaryCompletion":8281,"completion":1621,"start":8886,"enrollment":8887,"conditions":8888,"interventions":8892},"NCT00004640","\"Clinical Trials to Enhance Elders' Oral Health\" (\"TEETH\")",[92],"1998-05",1101,[8889,8890,8891],"Tooth Loss","Periodontal Disease","Tooth Decay",[8872],{"trials":8894,"activeCount":102},[],{"trials":8896,"activeCount":102},[],{"intervention":8898,"totalTrials":236,"cells":8899},"Ibuprofen suspension 5mg\u002F100ml",{"EARLY_PHASE1":8900,"PHASE1":8902,"PHASE2":8904,"PHASE3":8906,"PHASE4":8921,"NA":8923},{"trials":8901,"activeCount":102},[],{"trials":8903,"activeCount":102},[],{"trials":8905,"activeCount":102},[],{"trials":8907,"activeCount":102},[8908],{"nctId":8909,"briefTitle":8910,"status":131,"phases":8911,"primaryCompletion":8912,"completion":8913,"start":8914,"enrollment":34,"conditions":8915,"interventions":8919},"NCT03509675","Use of Topical NSAID to Reduce Pain in Oral Lichen Planus and Oral Lichenoid Lesions.",[91,92],"2019-01-30","2019-04-29","2018-04-29",[8916,8917,8918],"Oral Lichen Planus","Oral Lichenoid Mucositis","Oral Lichenoid Reaction",[8898,8920],"Placebos",{"trials":8922,"activeCount":102},[],{"trials":8924,"activeCount":102},[],{"intervention":8920,"totalTrials":236,"cells":8926},{"EARLY_PHASE1":8927,"PHASE1":8929,"PHASE2":8931,"PHASE3":8933,"PHASE4":8939,"NA":8941},{"trials":8928,"activeCount":102},[],{"trials":8930,"activeCount":102},[],{"trials":8932,"activeCount":102},[],{"trials":8934,"activeCount":102},[8935],{"nctId":8909,"briefTitle":8910,"status":131,"phases":8936,"primaryCompletion":8912,"completion":8913,"start":8914,"enrollment":34,"conditions":8937,"interventions":8938},[91,92],[8916,8917,8918],[8898,8920],{"trials":8940,"activeCount":102},[],{"trials":8942,"activeCount":102},[],{"intervention":8944,"totalTrials":236,"cells":8945},"Chlorhexidine mouth rinse",{"EARLY_PHASE1":8946,"PHASE1":8948,"PHASE2":8950,"PHASE3":8952,"PHASE4":8961,"NA":8963},{"trials":8947,"activeCount":102},[],{"trials":8949,"activeCount":102},[],{"trials":8951,"activeCount":102},[],{"trials":8953,"activeCount":102},[8954],{"nctId":8955,"briefTitle":8956,"status":108,"phases":8957,"primaryCompletion":4906,"completion":4906,"start":7012,"enrollment":8958,"conditions":8959,"interventions":8960},"NCT00067340","Caries Transmission Prevention in Alaska Native Infants",[92],250,[8167],[8944],{"trials":8962,"activeCount":102},[],{"trials":8964,"activeCount":102},[],{"intervention":8966,"totalTrials":236,"cells":8967},"Tramadol",{"EARLY_PHASE1":8968,"PHASE1":8970,"PHASE2":8972,"PHASE3":8974,"PHASE4":8984,"NA":8986},{"trials":8969,"activeCount":102},[],{"trials":8971,"activeCount":102},[],{"trials":8973,"activeCount":102},[],{"trials":8975,"activeCount":102},[8976],{"nctId":8977,"briefTitle":8978,"status":131,"phases":8979,"primaryCompletion":7427,"completion":7427,"start":2929,"enrollment":8980,"conditions":8981,"interventions":8983},"NCT01598753","Combined Behavioral and Analgesic Trial for Fibromyalgia",[92],134,[8982],"Fibromyalgia",[8966],{"trials":8985,"activeCount":102},[],{"trials":8987,"activeCount":102},[],{"intervention":5832,"totalTrials":236,"cells":8989},{"EARLY_PHASE1":8990,"PHASE1":8992,"PHASE2":8994,"PHASE3":8996,"PHASE4":9002,"NA":9004},{"trials":8991,"activeCount":102},[],{"trials":8993,"activeCount":102},[],{"trials":8995,"activeCount":102},[],{"trials":8997,"activeCount":102},[8998],{"nctId":5823,"briefTitle":5824,"status":131,"phases":8999,"primaryCompletion":5826,"completion":5826,"start":5827,"enrollment":5828,"conditions":9000,"interventions":9001},[92],[22,5830,5817,28,5818],[5832,5833,5800],{"trials":9003,"activeCount":102},[],{"trials":9005,"activeCount":102},[],{"intervention":5833,"totalTrials":236,"cells":9007},{"EARLY_PHASE1":9008,"PHASE1":9010,"PHASE2":9012,"PHASE3":9014,"PHASE4":9020,"NA":9022},{"trials":9009,"activeCount":102},[],{"trials":9011,"activeCount":102},[],{"trials":9013,"activeCount":102},[],{"trials":9015,"activeCount":102},[9016],{"nctId":5823,"briefTitle":5824,"status":131,"phases":9017,"primaryCompletion":5826,"completion":5826,"start":5827,"enrollment":5828,"conditions":9018,"interventions":9019},[92],[22,5830,5817,28,5818],[5832,5833,5800],{"trials":9021,"activeCount":102},[],{"trials":9023,"activeCount":102},[],{"intervention":9025,"totalTrials":236,"cells":9026},"tissue plasminogen activator",{"EARLY_PHASE1":9027,"PHASE1":9029,"PHASE2":9031,"PHASE3":9033,"PHASE4":9043,"NA":9045},{"trials":9028,"activeCount":102},[],{"trials":9030,"activeCount":102},[],{"trials":9032,"activeCount":102},[],{"trials":9034,"activeCount":102},[9035],{"nctId":9036,"briefTitle":9037,"status":131,"phases":9038,"completion":9039,"start":9040,"conditions":9041,"interventions":9042},"NCT00000468","Myocardial Infarction Triage and Intervention Project (MITI)",[92],"1992-03","1988-04",[22,5817,28,7625,5818],[9025],{"trials":9044,"activeCount":102},[],{"trials":9046,"activeCount":102},[],{"intervention":9048,"totalTrials":236,"cells":9049},"Aztreonam",{"EARLY_PHASE1":9050,"PHASE1":9052,"PHASE2":9054,"PHASE3":9056,"PHASE4":9066,"NA":9068},{"trials":9051,"activeCount":102},[],{"trials":9053,"activeCount":102},[],{"trials":9055,"activeCount":102},[],{"trials":9057,"activeCount":102},[9058],{"nctId":9059,"briefTitle":9060,"status":131,"phases":9061,"primaryCompletion":9062,"completion":9062,"start":9063,"enrollment":1129,"conditions":9064,"interventions":9065},"NCT03867734","Aztreonam for Pharyngeal Gonorrhea",[91,92],"2019-09-30","2019-04-05",[928,927],[9048],{"trials":9067,"activeCount":102},[],{"trials":9069,"activeCount":102},[],{"intervention":5869,"totalTrials":236,"cells":9071},{"EARLY_PHASE1":9072,"PHASE1":9074,"PHASE2":9076,"PHASE3":9078,"PHASE4":9084,"NA":9086},{"trials":9073,"activeCount":102},[],{"trials":9075,"activeCount":102},[],{"trials":9077,"activeCount":102},[],{"trials":9079,"activeCount":102},[9080],{"nctId":5857,"briefTitle":5858,"status":108,"phases":9081,"primaryCompletion":5860,"completion":5861,"start":5862,"enrollment":5863,"conditions":9082,"interventions":9083},[91,92],[2189,5865],[5867,5868,5775,5869,5870],{"trials":9085,"activeCount":102},[],{"trials":9087,"activeCount":102},[],{"intervention":5870,"totalTrials":236,"cells":9089},{"EARLY_PHASE1":9090,"PHASE1":9092,"PHASE2":9094,"PHASE3":9096,"PHASE4":9102,"NA":9104},{"trials":9091,"activeCount":102},[],{"trials":9093,"activeCount":102},[],{"trials":9095,"activeCount":102},[],{"trials":9097,"activeCount":102},[9098],{"nctId":5857,"briefTitle":5858,"status":108,"phases":9099,"primaryCompletion":5860,"completion":5861,"start":5862,"enrollment":5863,"conditions":9100,"interventions":9101},[91,92],[2189,5865],[5867,5868,5775,5869,5870],{"trials":9103,"activeCount":102},[],{"trials":9105,"activeCount":102},[],{"intervention":7761,"totalTrials":236,"cells":9107},{"EARLY_PHASE1":9108,"PHASE1":9110,"PHASE2":9112,"PHASE3":9114,"PHASE4":9120,"NA":9122},{"trials":9109,"activeCount":102},[],{"trials":9111,"activeCount":102},[],{"trials":9113,"activeCount":102},[],{"trials":9115,"activeCount":102},[9116],{"nctId":7753,"briefTitle":7754,"status":108,"phases":9117,"primaryCompletion":7756,"completion":7756,"start":1676,"enrollment":7757,"conditions":9118,"interventions":9119},[92],[7759],[7761,7762,7763],{"trials":9121,"activeCount":102},[],{"trials":9123,"activeCount":102},[],{"intervention":1581,"totalTrials":6989,"cells":9125},{"EARLY_PHASE1":9126,"PHASE1":9128,"PHASE2":9142,"PHASE3":9167,"PHASE4":9169,"NA":9171},{"trials":9127,"activeCount":102},[],{"trials":9129,"activeCount":102},[9130,9134,9138],{"nctId":2030,"briefTitle":2031,"status":131,"phases":9131,"primaryCompletion":2033,"completion":2033,"start":2034,"conditions":9132,"interventions":9133},[90],[413,2036,2037],[1581,1624],{"nctId":2053,"briefTitle":2054,"status":131,"phases":9135,"primaryCompletion":2056,"completion":2056,"start":2057,"enrollment":389,"conditions":9136,"interventions":9137},[90],[413,2036,2037],[1581,1624],{"nctId":1574,"briefTitle":1575,"status":1150,"phases":9139,"primaryCompletion":1577,"start":1578,"enrollment":102,"conditions":9140,"interventions":9141},[90],[354,275,36],[1581,233,1582],{"trials":9143,"activeCount":102},[9144,9148,9157,9163],{"nctId":1616,"briefTitle":1617,"status":131,"phases":9145,"primaryCompletion":1619,"completion":1620,"start":1621,"enrollment":34,"conditions":9146,"interventions":9147},[90,91],[354,275,377,36],[1581,1582,233,1624],{"nctId":9149,"briefTitle":9150,"status":131,"phases":9151,"primaryCompletion":6746,"completion":9152,"start":5978,"enrollment":1087,"conditions":9153,"interventions":9155},"NCT00194714","Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab",[90,91],"2023-05-22",[3731,9154,36,1930],"HLA-A2 Positive Cells Present",[9156],"HER-2\u002Fneu Peptide Vaccine",{"nctId":9158,"briefTitle":9159,"status":108,"phases":9160,"primaryCompletion":331,"start":1194,"enrollment":702,"conditions":9161,"interventions":9162},"NCT01729884","Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer",[91],[354,275,377,36],[1581],{"nctId":2103,"briefTitle":2104,"status":131,"phases":9164,"primaryCompletion":133,"start":2106,"enrollment":350,"conditions":9165,"interventions":9166},[90,91],[354,275,377,277,278,378,379,36],[1581,1624,2109],{"trials":9168,"activeCount":102},[],{"trials":9170,"activeCount":102},[],{"trials":9172,"activeCount":102},[],{"intervention":1047,"totalTrials":1547,"cells":9174},{"EARLY_PHASE1":9175,"PHASE1":9177,"PHASE2":9179,"PHASE3":9200,"PHASE4":9202,"NA":9204},{"trials":9176,"activeCount":102},[],{"trials":9178,"activeCount":102},[],{"trials":9180,"activeCount":102},[9181,9185,9189,9196],{"nctId":1035,"briefTitle":1036,"status":131,"phases":9182,"primaryCompletion":1038,"completion":1039,"start":1040,"enrollment":1041,"conditions":9183,"interventions":9184},[91],[1043,1044],[994,1046,993,992,1047,966,124,1015],{"nctId":3140,"briefTitle":3141,"status":131,"phases":9186,"primaryCompletion":134,"completion":3143,"start":1642,"enrollment":3144,"conditions":9187,"interventions":9188},[91],[1868,1315,1318,1596],[3147,360],{"nctId":9190,"briefTitle":9191,"status":131,"phases":9192,"primaryCompletion":1865,"completion":5673,"start":5720,"enrollment":350,"conditions":9193,"interventions":9194},"NCT00425646","Imatinib Mesylate and Bevacizumab After First-Line Chemotherapy and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer",[91],[2036],[9195,3147],"bevacizumab",{"nctId":1148,"briefTitle":1149,"status":1150,"phases":9197,"primaryCompletion":1152,"completion":1153,"start":1154,"enrollment":102,"conditions":9198,"interventions":9199},[91],[1156,1157,1158,1026,1159,1028,1160,1076,1161],[1163,994,1013,992,1047,966,124,1015],{"trials":9201,"activeCount":102},[],{"trials":9203,"activeCount":102},[],{"trials":9205,"activeCount":102},[],{"intervention":362,"totalTrials":1547,"cells":9207},{"EARLY_PHASE1":9208,"PHASE1":9210,"PHASE2":9212,"PHASE3":9236,"PHASE4":9238,"NA":9240},{"trials":9209,"activeCount":102},[],{"trials":9211,"activeCount":102},[],{"trials":9213,"activeCount":102},[9214,9218,9222,9226],{"nctId":3128,"briefTitle":3129,"status":108,"phases":9215,"primaryCompletion":2106,"completion":2106,"start":3131,"enrollment":26,"conditions":9216,"interventions":9217},[91],[353,2897,356,276,277,278],[447,3134,361,362,363,360],{"nctId":1232,"briefTitle":1233,"status":131,"phases":9219,"primaryCompletion":1235,"completion":1236,"start":1237,"enrollment":1238,"conditions":9220,"interventions":9221},[91],[1240,1241,1242],[1244,993,1245,125,1014,1246],{"nctId":344,"briefTitle":345,"status":131,"phases":9223,"primaryCompletion":347,"completion":348,"start":349,"enrollment":350,"conditions":9224,"interventions":9225},[91],[352,353,354,355,356,357,358,277,278],[280,233,360,169,361,362,363,364,365,316],{"nctId":9227,"briefTitle":9228,"status":131,"phases":9229,"primaryCompletion":331,"completion":6125,"start":7195,"enrollment":702,"conditions":9230,"interventions":9234},"NCT00992602","Liposomal Cytarabine and High-Dose Methotrexate in Treating Patients With Central Nervous System Metastases From Breast Cancer",[91],[9231,9232,377,36,9233],"Central Nervous System Metastases","Leptomeningeal Metastases","Tumors Metastatic to Brain",[362,9235],"liposomal cytarabine",{"trials":9237,"activeCount":102},[],{"trials":9239,"activeCount":102},[],{"trials":9241,"activeCount":102},[],{"intervention":3322,"totalTrials":1547,"cells":9243},{"EARLY_PHASE1":9244,"PHASE1":9246,"PHASE2":9248,"PHASE3":9279,"PHASE4":9281,"NA":9283},{"trials":9245,"activeCount":102},[],{"trials":9247,"activeCount":102},[],{"trials":9249,"activeCount":102},[9250,9258,9262,9266],{"nctId":9251,"briefTitle":9252,"status":108,"phases":9253,"primaryCompletion":9254,"completion":9254,"start":9255,"enrollment":264,"conditions":9256,"interventions":9257},"NCT04951492","Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma",[91],"2023-10-15","2022-11-09",[1355,1059],[3322],{"nctId":3313,"briefTitle":3314,"status":108,"phases":9259,"primaryCompletion":3316,"completion":3317,"start":3318,"enrollment":192,"conditions":9260,"interventions":9261},[91],[3320,1059],[1372,3322],{"nctId":3674,"briefTitle":3675,"status":131,"phases":9263,"primaryCompletion":3677,"completion":3678,"start":3679,"enrollment":3680,"conditions":9264,"interventions":9265},[91],[1355,1059],[3322,3683,1358],{"nctId":9267,"briefTitle":9268,"status":108,"phases":9269,"primaryCompletion":5342,"completion":9270,"start":9271,"enrollment":264,"conditions":9272,"interventions":9278},"NCT03570476","Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer",[91],"2019-07-03","2018-09-11",[9273,9274,9275,9276,9277,3827],"Prostate Adenocarcinoma Without Neuroendocrine Differentiation","Stage I Prostate Cancer AJCC v8","Stage II Prostate Cancer AJCC v8","Stage IIA Prostate Cancer AJCC v8","Stage IIB Prostate Cancer AJCC v8",[3322],{"trials":9280,"activeCount":102},[],{"trials":9282,"activeCount":102},[],{"trials":9284,"activeCount":102},[],{"intervention":1679,"totalTrials":1547,"cells":9286},{"EARLY_PHASE1":9287,"PHASE1":9289,"PHASE2":9291,"PHASE3":9320,"PHASE4":9322,"NA":9324},{"trials":9288,"activeCount":102},[],{"trials":9290,"activeCount":102},[],{"trials":9292,"activeCount":102},[9293,9302,9312,9316],{"nctId":9294,"briefTitle":9295,"status":131,"phases":9296,"primaryCompletion":9297,"completion":9298,"start":9299,"enrollment":5642,"conditions":9300,"interventions":9301},"NCT00733408","Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer",[91],"2017-07-05","2017-09-28","2008-04-23",[352,2897,355,377,36,2900],[1679,9195,2934],{"nctId":9303,"briefTitle":9304,"status":131,"phases":9305,"primaryCompletion":9306,"completion":8913,"start":9307,"enrollment":1815,"conditions":9308,"interventions":9310},"NCT01620190","Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer",[91],"2017-10-24","2012-12-02",[2565,9309],"Stage IV Non-Small Cell Lung Cancer",[9311],"Paclitaxel Albumin-Stabilized Nanoparticle Formulation",{"nctId":1672,"briefTitle":1673,"status":131,"phases":9313,"primaryCompletion":1675,"completion":440,"start":1676,"enrollment":389,"conditions":9314,"interventions":9315},[91],[353,354,357,358,277,278,378,379,36],[280,233,169,1679,364],{"nctId":2111,"briefTitle":2112,"status":131,"phases":9317,"primaryCompletion":2106,"start":1676,"enrollment":37,"conditions":9318,"interventions":9319},[91],[2115,2116,2117,2118,2119,2120,2121,2122,2123,1594,2047,1597],[1624,1679],{"trials":9321,"activeCount":102},[],{"trials":9323,"activeCount":102},[],{"trials":9325,"activeCount":102},[],{"intervention":9327,"totalTrials":702,"cells":9328},"mycophenolate mofetil",{"EARLY_PHASE1":9329,"PHASE1":9331,"PHASE2":9333,"PHASE3":9349,"PHASE4":9351,"NA":9353},{"trials":9330,"activeCount":102},[],{"trials":9332,"activeCount":102},[],{"trials":9334,"activeCount":102},[9335,9341,9345],{"nctId":9336,"briefTitle":9337,"status":131,"phases":9338,"primaryCompletion":226,"completion":1475,"start":5650,"enrollment":1417,"conditions":9339,"interventions":9340},"NCT00446459","Effects of Mycophenolate Mofetil (MMF) On Anti-HLA (Human Leukocyte Antigen)Antibody Levels In Patients Awaiting Cadaveric Renal Transplant.",[91],[1479,1480,1481,1482],[9327],{"nctId":1471,"briefTitle":1472,"status":131,"phases":9342,"primaryCompletion":1474,"completion":1475,"start":1476,"enrollment":1477,"conditions":9343,"interventions":9344},[91],[1479,1480,1481,1482],[124,1484],{"nctId":2406,"briefTitle":2407,"status":131,"phases":9346,"primaryCompletion":2409,"completion":2410,"start":2411,"enrollment":23,"conditions":9347,"interventions":9348},[91],[2413,2414,2415,2398,2416,2417,2418,2419,2420],[2401,2422,2402,1079,2423,2424,2425,2426,1908,2427],{"trials":9350,"activeCount":102},[],{"trials":9352,"activeCount":102},[],{"trials":9354,"activeCount":102},[],{"intervention":1015,"totalTrials":702,"cells":9356},{"EARLY_PHASE1":9357,"PHASE1":9359,"PHASE2":9365,"PHASE3":9375,"PHASE4":9377,"NA":9379},{"trials":9358,"activeCount":102},[],{"trials":9360,"activeCount":102},[9361],{"nctId":997,"briefTitle":998,"status":131,"phases":9362,"primaryCompletion":1000,"completion":1000,"start":1001,"enrollment":23,"conditions":9363,"interventions":9364},[90],[1003,115,1004,1005,1006,1007,1008,1009,1010,1011],[994,1013,1014,966,124,1015],{"trials":9366,"activeCount":102},[9367,9371],{"nctId":1035,"briefTitle":1036,"status":131,"phases":9368,"primaryCompletion":1038,"completion":1039,"start":1040,"enrollment":1041,"conditions":9369,"interventions":9370},[91],[1043,1044],[994,1046,993,992,1047,966,124,1015],{"nctId":1148,"briefTitle":1149,"status":1150,"phases":9372,"primaryCompletion":1152,"completion":1153,"start":1154,"enrollment":102,"conditions":9373,"interventions":9374},[91],[1156,1157,1158,1026,1159,1028,1160,1076,1161],[1163,994,1013,992,1047,966,124,1015],{"trials":9376,"activeCount":102},[],{"trials":9378,"activeCount":102},[],{"trials":9380,"activeCount":102},[],{"intervention":363,"totalTrials":702,"cells":9382},{"EARLY_PHASE1":9383,"PHASE1":9385,"PHASE2":9391,"PHASE3":9401,"PHASE4":9403,"NA":9405},{"trials":9384,"activeCount":102},[],{"trials":9386,"activeCount":102},[9387],{"nctId":2890,"briefTitle":2891,"status":131,"phases":9388,"primaryCompletion":2893,"completion":2894,"start":2895,"enrollment":350,"conditions":9389,"interventions":9390},[90],[352,2897,2898,2899,275,355,377,36,2900],[2902,207,363],{"trials":9392,"activeCount":102},[9393,9397],{"nctId":3128,"briefTitle":3129,"status":108,"phases":9394,"primaryCompletion":2106,"completion":2106,"start":3131,"enrollment":26,"conditions":9395,"interventions":9396},[91],[353,2897,356,276,277,278],[447,3134,361,362,363,360],{"nctId":344,"briefTitle":345,"status":131,"phases":9398,"primaryCompletion":347,"completion":348,"start":349,"enrollment":350,"conditions":9399,"interventions":9400},[91],[352,353,354,355,356,357,358,277,278],[280,233,360,169,361,362,363,364,365,316],{"trials":9402,"activeCount":102},[],{"trials":9404,"activeCount":102},[],{"trials":9406,"activeCount":102},[],{"intervention":3367,"totalTrials":702,"cells":9408},{"EARLY_PHASE1":9409,"PHASE1":9411,"PHASE2":9422,"PHASE3":9439,"PHASE4":9441,"NA":9443},{"trials":9410,"activeCount":102},[],{"trials":9412,"activeCount":102},[9413],{"nctId":9414,"briefTitle":9415,"status":131,"phases":9416,"primaryCompletion":9417,"completion":9417,"start":9418,"enrollment":1439,"conditions":9419,"interventions":9420},"NCT02532114","Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer",[90],"2017-11-30","2015-12-31",[1836,1355,1058,1197,1198],[3367,9421],"Niclosamide",{"trials":9423,"activeCount":102},[9424,9435],{"nctId":9425,"briefTitle":9426,"status":108,"phases":9427,"primaryCompletion":1904,"completion":1904,"start":9428,"enrollment":317,"conditions":9429,"interventions":9434},"NCT02489123","Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma",[91],"2015-08-11",[9430,9431,9432,9433,158,2523],"Ann Arbor Stage I Mantle Cell Lymphoma","Ann Arbor Stage II Mantle Cell Lymphoma","Ann Arbor Stage III Mantle Cell Lymphoma","Ann Arbor Stage IV Mantle Cell Lymphoma",[3367],{"nctId":3359,"briefTitle":3360,"status":108,"phases":9436,"primaryCompletion":3362,"completion":3362,"start":3363,"enrollment":702,"conditions":9437,"interventions":9438},[91],[1355,3365,1058,1059,1061,1062,1063],[1066,3367,3368],{"trials":9440,"activeCount":102},[],{"trials":9442,"activeCount":102},[],{"trials":9444,"activeCount":102},[],{"intervention":1341,"totalTrials":702,"cells":9446},{"EARLY_PHASE1":9447,"PHASE1":9449,"PHASE2":9451,"PHASE3":9473,"PHASE4":9475,"NA":9477},{"trials":9448,"activeCount":102},[],{"trials":9450,"activeCount":102},[],{"trials":9452,"activeCount":102},[9453,9457,9461],{"nctId":129,"briefTitle":130,"status":131,"phases":9454,"primaryCompletion":133,"start":134,"enrollment":135,"conditions":9455,"interventions":9456},[91],[137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165],[167,168,169,170],{"nctId":1335,"briefTitle":1336,"status":131,"phases":9458,"primaryCompletion":225,"completion":225,"start":189,"enrollment":1338,"conditions":9459,"interventions":9460},[90,91],[146,150],[1341,123,124,992],{"nctId":9462,"briefTitle":9463,"status":131,"phases":9464,"primaryCompletion":7699,"completion":2894,"start":1621,"enrollment":1417,"conditions":9465,"interventions":9472},"NCT00823797","Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma",[91],[9466,9467,9468,9469,9470,9471],"Adult Anaplastic Astrocytoma","Adult Anaplastic Oligodendroglioma","Adult Giant Cell Glioblastoma","Adult Glioblastoma","Adult Gliosarcoma","Recurrent Adult Brain Neoplasm",[1341],{"trials":9474,"activeCount":102},[],{"trials":9476,"activeCount":102},[],{"trials":9478,"activeCount":102},[],{"intervention":1582,"totalTrials":702,"cells":9480},{"EARLY_PHASE1":9481,"PHASE1":9483,"PHASE2":9493,"PHASE3":9499,"PHASE4":9501,"NA":9503},{"trials":9482,"activeCount":102},[],{"trials":9484,"activeCount":102},[9485,9489],{"nctId":1574,"briefTitle":1575,"status":1150,"phases":9486,"primaryCompletion":1577,"start":1578,"enrollment":102,"conditions":9487,"interventions":9488},[90],[354,275,36],[1581,233,1582],{"nctId":1588,"briefTitle":1589,"status":131,"phases":9490,"primaryCompletion":1591,"start":1592,"enrollment":317,"conditions":9491,"interventions":9492},[90],[354,377,1315,1594,1595,36,1596,1597,1598],[1582,233,1600],{"trials":9494,"activeCount":102},[9495],{"nctId":1616,"briefTitle":1617,"status":131,"phases":9496,"primaryCompletion":1619,"completion":1620,"start":1621,"enrollment":34,"conditions":9497,"interventions":9498},[90,91],[354,275,377,36],[1581,1582,233,1624],{"trials":9500,"activeCount":102},[],{"trials":9502,"activeCount":102},[],{"trials":9504,"activeCount":102},[],{"intervention":1870,"totalTrials":702,"cells":9506},{"EARLY_PHASE1":9507,"PHASE1":9509,"PHASE2":9511,"PHASE3":9525,"PHASE4":9527,"NA":9529},{"trials":9508,"activeCount":102},[],{"trials":9510,"activeCount":102},[],{"trials":9512,"activeCount":102},[9513,9517,9521],{"nctId":1860,"briefTitle":1861,"status":131,"phases":9514,"primaryCompletion":1863,"completion":1864,"start":1865,"enrollment":1866,"conditions":9515,"interventions":9516},[91],[1868,1318,1596],[1409,1794,1870,360],{"nctId":3226,"briefTitle":3227,"status":131,"phases":9518,"primaryCompletion":3023,"completion":3229,"start":3230,"enrollment":1114,"conditions":9519,"interventions":9520},[91],[3232,3233,3234,3235,3236],[1870,1794,361,3238],{"nctId":2956,"briefTitle":2957,"status":131,"phases":9522,"primaryCompletion":2959,"completion":2959,"start":719,"enrollment":37,"conditions":9523,"interventions":9524},[90,91],[2961,2962,2963,2964],[1244,2966,1908],{"trials":9526,"activeCount":102},[],{"trials":9528,"activeCount":102},[],{"trials":9530,"activeCount":102},[],{"intervention":1908,"totalTrials":702,"cells":9532},{"EARLY_PHASE1":9533,"PHASE1":9535,"PHASE2":9537,"PHASE3":9551,"PHASE4":9553,"NA":9555},{"trials":9534,"activeCount":102},[],{"trials":9536,"activeCount":102},[],{"trials":9538,"activeCount":102},[9539,9543,9547],{"nctId":2406,"briefTitle":2407,"status":131,"phases":9540,"primaryCompletion":2409,"completion":2410,"start":2411,"enrollment":23,"conditions":9541,"interventions":9542},[91],[2413,2414,2415,2398,2416,2417,2418,2419,2420],[2401,2422,2402,1079,2423,2424,2425,2426,1908,2427],{"nctId":2956,"briefTitle":2957,"status":131,"phases":9544,"primaryCompletion":2959,"completion":2959,"start":719,"enrollment":37,"conditions":9545,"interventions":9546},[90,91],[2961,2962,2963,2964],[1244,2966,1908],{"nctId":1901,"briefTitle":1902,"status":108,"phases":9548,"primaryCompletion":1904,"completion":1904,"start":1905,"enrollment":26,"conditions":9549,"interventions":9550},[90,91],[1355,1058,1092,1057],[123,1842,1908],{"trials":9552,"activeCount":102},[],{"trials":9554,"activeCount":102},[],{"trials":9556,"activeCount":102},[],{"intervention":1654,"totalTrials":702,"cells":9558},{"EARLY_PHASE1":9559,"PHASE1":9561,"PHASE2":9563,"PHASE3":9587,"PHASE4":9589,"NA":9591},{"trials":9560,"activeCount":102},[],{"trials":9562,"activeCount":102},[],{"trials":9564,"activeCount":102},[9565,9579,9583],{"nctId":9566,"briefTitle":9567,"status":131,"phases":9568,"primaryCompletion":329,"completion":1136,"start":6102,"enrollment":1114,"conditions":9569,"interventions":9578},"NCT00519896","Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer",[91],[9570,9571,9572,9573,9574,9575,9576,9577],"Recurrent Thyroid Cancer","Stage IVA Follicular Thyroid Cancer","Stage IVA Papillary Thyroid Cancer","Stage IVB Follicular Thyroid Cancer","Stage IVB Papillary Thyroid Cancer","Stage IVC Follicular Thyroid Cancer","Stage IVC Papillary Thyroid Cancer","Thyroid Gland Medullary Carcinoma",[1654],{"nctId":1646,"briefTitle":1647,"status":131,"phases":9580,"primaryCompletion":739,"completion":1649,"start":1650,"enrollment":427,"conditions":9581,"interventions":9582},[91],[1652,275,277,278,378,379],[1654,360,280,233,169],{"nctId":3248,"briefTitle":3249,"status":108,"phases":9584,"primaryCompletion":3251,"completion":347,"start":3252,"enrollment":273,"conditions":9585,"interventions":9586},[91],[3254,3255,3256,3257],[1654,361],{"trials":9588,"activeCount":102},[],{"trials":9590,"activeCount":102},[],{"trials":9592,"activeCount":102},[],{"intervention":416,"totalTrials":702,"cells":9594},{"EARLY_PHASE1":9595,"PHASE1":9597,"PHASE2":9599,"PHASE3":9619,"PHASE4":9621,"NA":9623},{"trials":9596,"activeCount":102},[],{"trials":9598,"activeCount":102},[],{"trials":9600,"activeCount":102},[9601,9611,9615],{"nctId":9602,"briefTitle":9603,"status":131,"phases":9604,"primaryCompletion":9605,"completion":9605,"start":9606,"enrollment":5919,"conditions":9607,"interventions":9608},"NCT00223665","Effects of IAS in Men With Localized Biochemical Relapsed Prostate Cancer",[91],"2012-09-06","1997-01-08",[4909],[9609,9610],"Flutamide","Leuprolide Acetate",{"nctId":1133,"briefTitle":1134,"status":131,"phases":9612,"primaryCompletion":1136,"completion":1136,"start":1137,"enrollment":1023,"conditions":9613,"interventions":9614},[91],[1139,1140,1141,1142],[1144,1145,416,1146],{"nctId":407,"briefTitle":408,"status":108,"phases":9616,"primaryCompletion":410,"completion":226,"start":411,"enrollment":236,"conditions":9617,"interventions":9618},[91],[413],[415,316,416],{"trials":9620,"activeCount":102},[],{"trials":9622,"activeCount":102},[],{"trials":9624,"activeCount":102},[],{"intervention":2470,"totalTrials":702,"cells":9626},{"EARLY_PHASE1":9627,"PHASE1":9629,"PHASE2":9631,"PHASE3":9645,"PHASE4":9647,"NA":9649},{"trials":9628,"activeCount":102},[],{"trials":9630,"activeCount":102},[],{"trials":9632,"activeCount":102},[9633,9637,9641],{"nctId":2453,"briefTitle":2454,"status":131,"phases":9634,"primaryCompletion":331,"completion":2456,"start":134,"enrollment":350,"conditions":9635,"interventions":9636},[91],[2458,2459,2460,2461,2462,2463,2464,2465,2466,2467,2468],[169,2470,2471],{"nctId":2481,"briefTitle":2482,"status":131,"phases":9638,"primaryCompletion":1137,"completion":2484,"start":410,"enrollment":350,"conditions":9639,"interventions":9640},[90,91],[2396,2458,2460,2461,2462,2463,2486,2487],[2470,2471,169],{"nctId":2490,"briefTitle":2491,"status":108,"phases":9642,"primaryCompletion":190,"start":191,"enrollment":264,"conditions":9643,"interventions":9644},[91],[2494,2458,2460,2461,2462,2463,2487],[2470,2471,169],{"trials":9646,"activeCount":102},[],{"trials":9648,"activeCount":102},[],{"trials":9650,"activeCount":102},[],{"intervention":2425,"totalTrials":264,"cells":9652},{"EARLY_PHASE1":9653,"PHASE1":9655,"PHASE2":9657,"PHASE3":9667,"PHASE4":9669,"NA":9671},{"trials":9654,"activeCount":102},[],{"trials":9656,"activeCount":102},[],{"trials":9658,"activeCount":102},[9659,9663],{"nctId":3419,"briefTitle":3420,"status":131,"phases":9660,"primaryCompletion":1085,"completion":3422,"start":3423,"enrollment":350,"conditions":9661,"interventions":9662},[91],[3425,2396,2417],[2401,2402,3427,2425],{"nctId":2406,"briefTitle":2407,"status":131,"phases":9664,"primaryCompletion":2409,"completion":2410,"start":2411,"enrollment":23,"conditions":9665,"interventions":9666},[91],[2413,2414,2415,2398,2416,2417,2418,2419,2420],[2401,2422,2402,1079,2423,2424,2425,2426,1908,2427],{"trials":9668,"activeCount":102},[],{"trials":9670,"activeCount":102},[],{"trials":9672,"activeCount":102},[],{"intervention":2051,"totalTrials":264,"cells":9674},{"EARLY_PHASE1":9675,"PHASE1":9677,"PHASE2":9683,"PHASE3":9692,"PHASE4":9694,"NA":9696},{"trials":9676,"activeCount":102},[],{"trials":9678,"activeCount":102},[9679],{"nctId":2040,"briefTitle":2041,"status":131,"phases":9680,"primaryCompletion":1137,"completion":2043,"start":2044,"enrollment":2045,"conditions":9681,"interventions":9682},[90],[354,2047,2048,278,378,379,36,1597,1598],[2050,1624,2051],{"trials":9684,"activeCount":102},[9685],{"nctId":9686,"briefTitle":9687,"status":131,"phases":9688,"primaryCompletion":3251,"start":5621,"enrollment":456,"conditions":9689,"interventions":9690},"NCT00425672","ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment",[90,91],[275,377,278,378,379,36],[9691,2051],"ONTAK",{"trials":9693,"activeCount":102},[],{"trials":9695,"activeCount":102},[],{"trials":9697,"activeCount":102},[],{"intervention":9699,"totalTrials":264,"cells":9700},"Goserelin",{"EARLY_PHASE1":9701,"PHASE1":9703,"PHASE2":9705,"PHASE3":9719,"PHASE4":9721,"NA":9723},{"trials":9702,"activeCount":102},[],{"trials":9704,"activeCount":102},[],{"trials":9706,"activeCount":102},[9707,9715],{"nctId":9708,"briefTitle":9709,"status":131,"phases":9710,"primaryCompletion":6483,"completion":5770,"start":1621,"enrollment":1391,"conditions":9711,"interventions":9712},"NCT00769795","Study of Effectiveness of IMC-A12 Antibody Combined With Hormone Therapy Prior to Surgery to Treat Prostate Cancer",[91],[4909],[9713,9714,9699],"IMC-A12","Bicalutamide",{"nctId":407,"briefTitle":408,"status":108,"phases":9716,"primaryCompletion":410,"completion":226,"start":411,"enrollment":236,"conditions":9717,"interventions":9718},[91],[413],[415,316,416],{"trials":9720,"activeCount":102},[],{"trials":9722,"activeCount":102},[],{"trials":9724,"activeCount":102},[],{"intervention":5645,"totalTrials":264,"cells":9726},{"EARLY_PHASE1":9727,"PHASE1":9729,"PHASE2":9731,"PHASE3":9741,"PHASE4":9743,"NA":9745},{"trials":9728,"activeCount":102},[],{"trials":9730,"activeCount":102},[],{"trials":9732,"activeCount":102},[9733,9737],{"nctId":5638,"briefTitle":5639,"status":131,"phases":9734,"primaryCompletion":189,"completion":442,"start":5641,"enrollment":5642,"conditions":9735,"interventions":9736},[90,91],[5069],[340,5645,5645,5645,5071],{"nctId":5704,"briefTitle":5705,"status":1150,"phases":9738,"primaryCompletion":5707,"completion":577,"start":5708,"enrollment":102,"conditions":9739,"interventions":9740},[91],[5710],[5712,340,5074,5713,5714],{"trials":9742,"activeCount":102},[],{"trials":9744,"activeCount":102},[],{"trials":9746,"activeCount":102},[],{"intervention":2934,"totalTrials":264,"cells":9748},{"EARLY_PHASE1":9749,"PHASE1":9751,"PHASE2":9753,"PHASE3":9763,"PHASE4":9765,"NA":9767},{"trials":9750,"activeCount":102},[],{"trials":9752,"activeCount":102},[],{"trials":9754,"activeCount":102},[9755,9759],{"nctId":2926,"briefTitle":2927,"status":131,"phases":9756,"primaryCompletion":2929,"start":2930,"enrollment":2931,"conditions":9757,"interventions":9758},[91],[195,196,197,198,199,200,201,202,203,204],[2934,207],{"nctId":9294,"briefTitle":9295,"status":131,"phases":9760,"primaryCompletion":9297,"completion":9298,"start":9299,"enrollment":5642,"conditions":9761,"interventions":9762},[91],[352,2897,355,377,36,2900],[1679,9195,2934],{"trials":9764,"activeCount":102},[],{"trials":9766,"activeCount":102},[],{"trials":9768,"activeCount":102},[],{"intervention":9770,"totalTrials":264,"cells":9771},"13-cis retinoic acid",{"EARLY_PHASE1":9772,"PHASE1":9774,"PHASE2":9776,"PHASE3":9797,"PHASE4":9799,"NA":9801},{"trials":9773,"activeCount":102},[],{"trials":9775,"activeCount":102},[],{"trials":9777,"activeCount":102},[9778,9787],{"nctId":9779,"briefTitle":9780,"status":131,"phases":9781,"primaryCompletion":9782,"completion":5342,"start":9783,"enrollment":261,"conditions":9784,"interventions":9786},"NCT03323801","RA-4: 13-cis Retinoic Acid for Treatment of Men With Azoospermia",[91],"2019-05-16","2017-07-25",[9785],"Male Infertility, Azoospermia",[9770],{"nctId":9788,"briefTitle":9789,"status":131,"phases":9790,"primaryCompletion":5977,"completion":5977,"start":6176,"enrollment":673,"conditions":9791,"interventions":9795},"NCT02061384","RA-2 13-cis Retinoic Acid (Isotretinoin)",[91],[9792,9793,9794],"Male Infertility","Klinefelter's Syndrome","Y-chromosome Microdeletions",[9770,9796],"Calcitriol",{"trials":9798,"activeCount":102},[],{"trials":9800,"activeCount":102},[],{"trials":9802,"activeCount":102},[],{"intervention":9195,"totalTrials":264,"cells":9804},{"EARLY_PHASE1":9805,"PHASE1":9807,"PHASE2":9809,"PHASE3":9819,"PHASE4":9821,"NA":9823},{"trials":9806,"activeCount":102},[],{"trials":9808,"activeCount":102},[],{"trials":9810,"activeCount":102},[9811,9815],{"nctId":9190,"briefTitle":9191,"status":131,"phases":9812,"primaryCompletion":1865,"completion":5673,"start":5720,"enrollment":350,"conditions":9813,"interventions":9814},[91],[2036],[9195,3147],{"nctId":9294,"briefTitle":9295,"status":131,"phases":9816,"primaryCompletion":9297,"completion":9298,"start":9299,"enrollment":5642,"conditions":9817,"interventions":9818},[91],[352,2897,355,377,36,2900],[1679,9195,2934],{"trials":9820,"activeCount":102},[],{"trials":9822,"activeCount":102},[],{"trials":9824,"activeCount":102},[],{"intervention":9826,"totalTrials":264,"cells":9827},"RNA analysis",{"EARLY_PHASE1":9828,"PHASE1":9830,"PHASE2":9832,"PHASE3":9854,"PHASE4":9856,"NA":9858},{"trials":9829,"activeCount":102},[],{"trials":9831,"activeCount":102},[],{"trials":9833,"activeCount":102},[9834,9844],{"nctId":9835,"briefTitle":9836,"status":131,"phases":9837,"primaryCompletion":455,"completion":9838,"start":1475,"enrollment":456,"conditions":9839,"interventions":9841},"NCT00821964","Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer",[91],"2012-11-29",[275,377,9840,36],"Skin Metastases",[9842,9843,9826],"imiquimod","Abraxane",{"nctId":9845,"briefTitle":9846,"status":131,"phases":9847,"primaryCompletion":3251,"completion":9848,"start":1476,"enrollment":1439,"conditions":9849,"interventions":9850},"NCT00466752","Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer",[91],"2011-07-01",[1139,1140,1141],[9851,9852,448,9853,9826],"sorafenib tosylate","microarray analysis","western blotting",{"trials":9855,"activeCount":102},[],{"trials":9857,"activeCount":102},[],{"trials":9859,"activeCount":102},[],{"intervention":9861,"totalTrials":264,"cells":9862},"eribulin mesylate",{"EARLY_PHASE1":9863,"PHASE1":9865,"PHASE2":9867,"PHASE3":9891,"PHASE4":9893,"NA":9895},{"trials":9864,"activeCount":102},[],{"trials":9866,"activeCount":102},[],{"trials":9868,"activeCount":102},[9869,9881],{"nctId":9870,"briefTitle":9871,"status":131,"phases":9872,"primaryCompletion":9873,"completion":9873,"start":9874,"enrollment":1391,"conditions":9875,"interventions":9880},"NCT01613768","Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer",[91],"2017-08-23","2012-05-08",[9876,9877,9878,9879],"Recurrent Salivary Gland Cancer","Stage IVA Salivary Gland Cancer","Stage IVB Salivary Gland Cancer","Stage IVC Salivary Gland Cancer",[9861],{"nctId":9882,"briefTitle":9883,"status":131,"phases":9884,"primaryCompletion":9885,"completion":9885,"start":9886,"enrollment":9887,"conditions":9888,"interventions":9889},"NCT01908101","Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer",[91],"2019-05-04","2014-01-08",86,[1710,36],[9890],"Eribulin Mesylate",{"trials":9892,"activeCount":102},[],{"trials":9894,"activeCount":102},[],{"trials":9896,"activeCount":102},[],{"intervention":1503,"totalTrials":264,"cells":9898},{"EARLY_PHASE1":9899,"PHASE1":9901,"PHASE2":9903,"PHASE3":9913,"PHASE4":9915,"NA":9917},{"trials":9900,"activeCount":102},[],{"trials":9902,"activeCount":102},[],{"trials":9904,"activeCount":102},[9905,9909],{"nctId":1494,"briefTitle":1495,"status":108,"phases":9906,"primaryCompletion":1497,"completion":1498,"start":1499,"enrollment":1182,"conditions":9907,"interventions":9908},[91],[116,117,118,1501],[1014,124,1503],{"nctId":2663,"briefTitle":2664,"status":131,"phases":9910,"primaryCompletion":2666,"completion":2666,"start":2667,"enrollment":1707,"conditions":9911,"interventions":9912},[91],[2669,2670,2671,2672,2301,1528,1529,1530],[2674,1503,991],{"trials":9914,"activeCount":102},[],{"trials":9916,"activeCount":102},[],{"trials":9918,"activeCount":102},[],{"intervention":121,"totalTrials":264,"cells":9920},{"EARLY_PHASE1":9921,"PHASE1":9923,"PHASE2":9929,"PHASE3":9935,"PHASE4":9937,"NA":9939},{"trials":9922,"activeCount":102},[],{"trials":9924,"activeCount":102},[9925],{"nctId":106,"briefTitle":107,"status":108,"phases":9926,"primaryCompletion":110,"completion":111,"start":112,"enrollment":113,"conditions":9927,"interventions":9928},[90],[115,116,117,118,119],[121,122,123,97,124,125],{"trials":9930,"activeCount":102},[9931],{"nctId":1505,"briefTitle":1506,"status":108,"phases":9932,"primaryCompletion":1508,"completion":1508,"start":1509,"enrollment":236,"conditions":9933,"interventions":9934},[91],[1511,119,1512,1513],[121,124,1515],{"trials":9936,"activeCount":102},[],{"trials":9938,"activeCount":102},[],{"trials":9940,"activeCount":102},[],{"intervention":3683,"totalTrials":264,"cells":9942},{"EARLY_PHASE1":9943,"PHASE1":9945,"PHASE2":9947,"PHASE3":9957,"PHASE4":9959,"NA":9961},{"trials":9944,"activeCount":102},[],{"trials":9946,"activeCount":102},[],{"trials":9948,"activeCount":102},[9949,9953],{"nctId":5716,"briefTitle":5717,"status":131,"phases":9950,"primaryCompletion":5719,"completion":5719,"start":5720,"enrollment":673,"conditions":9951,"interventions":9952},[90,91],[5614],[3683,3683,5074,5074],{"nctId":3674,"briefTitle":3675,"status":131,"phases":9954,"primaryCompletion":3677,"completion":3678,"start":3679,"enrollment":3680,"conditions":9955,"interventions":9956},[91],[1355,1059],[3322,3683,1358],{"trials":9958,"activeCount":102},[],{"trials":9960,"activeCount":102},[],{"trials":9962,"activeCount":102},[],{"intervention":2330,"totalTrials":264,"cells":9964},{"EARLY_PHASE1":9965,"PHASE1":9967,"PHASE2":9969,"PHASE3":9987,"PHASE4":9989,"NA":9991},{"trials":9966,"activeCount":102},[],{"trials":9968,"activeCount":102},[],{"trials":9970,"activeCount":102},[9971,9983],{"nctId":9972,"briefTitle":9973,"status":108,"phases":9974,"primaryCompletion":3463,"completion":9975,"start":6545,"enrollment":192,"conditions":9976,"interventions":9982},"NCT04220229","Cabozantinib With Radiation Therapy for the Treatment of Sarcomas of the Extremities",[90,91],"2024-10-31",[9977,9978,9979,9980,9981],"Sarcoma of the Extremity","Stage I Soft Tissue Sarcoma of the Trunk and Extremities","Stage IA Soft Tissue Sarcoma of the Trunk and Extremities","Stage IB Soft Tissue Sarcoma of the Trunk and Extremities","Stage II Soft Tissue Sarcoma of the Trunk and Extremities",[2330],{"nctId":2320,"briefTitle":2321,"status":108,"phases":9984,"primaryCompletion":2323,"completion":2324,"start":1895,"enrollment":264,"conditions":9985,"interventions":9986},[91],[2326,2327,2328],[2330,1014],{"trials":9988,"activeCount":102},[],{"trials":9990,"activeCount":102},[],{"trials":9992,"activeCount":102},[],{"intervention":234,"totalTrials":264,"cells":9994},{"EARLY_PHASE1":9995,"PHASE1":9997,"PHASE2":9999,"PHASE3":10009,"PHASE4":10011,"NA":10013},{"trials":9996,"activeCount":102},[],{"trials":9998,"activeCount":102},[],{"trials":10000,"activeCount":102},[10001,10005],{"nctId":1638,"briefTitle":1639,"status":131,"phases":10002,"primaryCompletion":190,"completion":1641,"start":1642,"enrollment":23,"conditions":10003,"interventions":10004},[90,91],[354,275,377,36],[234,233,364],{"nctId":221,"briefTitle":222,"status":108,"phases":10006,"primaryCompletion":224,"completion":225,"start":226,"enrollment":227,"conditions":10007,"interventions":10008},[90,91],[162,229,230,231],[233,234,235,168],{"trials":10010,"activeCount":102},[],{"trials":10012,"activeCount":102},[],{"trials":10014,"activeCount":102},[],{"intervention":2550,"totalTrials":264,"cells":10016},{"EARLY_PHASE1":10017,"PHASE1":10019,"PHASE2":10021,"PHASE3":10038,"PHASE4":10040,"NA":10042},{"trials":10018,"activeCount":102},[],{"trials":10020,"activeCount":102},[],{"trials":10022,"activeCount":102},[10023,10034],{"nctId":10024,"briefTitle":10025,"status":108,"phases":10026,"primaryCompletion":10027,"completion":10028,"start":10029,"enrollment":34,"conditions":10030,"interventions":10033},"NCT01970527","Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma",[91],"2018-11-03","2019-06-21","2014-03",[10031,10032],"Recurrent Melanoma","Stage IV Skin Melanoma",[2550],{"nctId":2536,"briefTitle":2537,"status":131,"phases":10035,"primaryCompletion":2539,"completion":2540,"start":2541,"enrollment":673,"conditions":10036,"interventions":10037},[90,91],[1057,2543,2544,2545,2546,2547,2548],[1262,2550],{"trials":10039,"activeCount":102},[],{"trials":10041,"activeCount":102},[],{"trials":10043,"activeCount":102},[],{"intervention":9851,"totalTrials":264,"cells":10045},{"EARLY_PHASE1":10046,"PHASE1":10048,"PHASE2":10057,"PHASE3":10063,"PHASE4":10065,"NA":10067},{"trials":10047,"activeCount":102},[],{"trials":10049,"activeCount":102},[10050],{"nctId":10051,"briefTitle":10052,"status":131,"phases":10053,"primaryCompletion":347,"start":5665,"enrollment":1547,"conditions":10054,"interventions":10056},"NCT00844168","Sorafenib Tosylate in Treating Patients With Liver Cancer Who Have Undergone a Liver Transplant",[90],[3254,3255,10055,3256,3257],"Localized Resectable Adult Primary Liver Cancer",[9851],{"trials":10058,"activeCount":102},[10059],{"nctId":9845,"briefTitle":9846,"status":131,"phases":10060,"primaryCompletion":3251,"completion":9848,"start":1476,"enrollment":1439,"conditions":10061,"interventions":10062},[91],[1139,1140,1141],[9851,9852,448,9853,9826],{"trials":10064,"activeCount":102},[],{"trials":10066,"activeCount":102},[],{"trials":10068,"activeCount":102},[],{"intervention":5729,"totalTrials":264,"cells":10070},{"EARLY_PHASE1":10071,"PHASE1":10073,"PHASE2":10079,"PHASE3":10085,"PHASE4":10087,"NA":10089},{"trials":10072,"activeCount":102},[],{"trials":10074,"activeCount":102},[10075],{"nctId":7525,"briefTitle":7526,"status":131,"phases":10076,"primaryCompletion":7528,"completion":1578,"start":2895,"enrollment":1477,"conditions":10077,"interventions":10078},[90],[5667],[5729,340],{"trials":10080,"activeCount":102},[10081],{"nctId":5724,"briefTitle":5725,"status":131,"phases":10082,"primaryCompletion":4906,"completion":4906,"start":5685,"enrollment":1182,"conditions":10083,"interventions":10084},[91],[5614,5613],[5729,5730,5074],{"trials":10086,"activeCount":102},[],{"trials":10088,"activeCount":102},[],{"trials":10090,"activeCount":102},[],{"intervention":1046,"totalTrials":236,"cells":10092},{"EARLY_PHASE1":10093,"PHASE1":10095,"PHASE2":10097,"PHASE3":10103,"PHASE4":10105,"NA":10107},{"trials":10094,"activeCount":102},[],{"trials":10096,"activeCount":102},[],{"trials":10098,"activeCount":102},[10099],{"nctId":1035,"briefTitle":1036,"status":131,"phases":10100,"primaryCompletion":1038,"completion":1039,"start":1040,"enrollment":1041,"conditions":10101,"interventions":10102},[91],[1043,1044],[994,1046,993,992,1047,966,124,1015],{"trials":10104,"activeCount":102},[],{"trials":10106,"activeCount":102},[],{"trials":10108,"activeCount":102},[],{"intervention":10110,"totalTrials":236,"cells":10111},"Aranesp",{"EARLY_PHASE1":10112,"PHASE1":10114,"PHASE2":10116,"PHASE3":10126,"PHASE4":10128,"NA":10130},{"trials":10113,"activeCount":102},[],{"trials":10115,"activeCount":102},[],{"trials":10117,"activeCount":102},[10118],{"nctId":10119,"briefTitle":10120,"status":131,"phases":10121,"completion":10122,"start":7012,"enrollment":673,"conditions":10123,"interventions":10125},"NCT00245895","Study of Aranesp to Treat Anemia in Prostate Cancer Patients.",[91],"2005-02",[4909,10124],"Anemia",[10110],{"trials":10127,"activeCount":102},[],{"trials":10129,"activeCount":102},[],{"trials":10131,"activeCount":102},[],{"intervention":10133,"totalTrials":236,"cells":10134},"Gallium nitrate",{"EARLY_PHASE1":10135,"PHASE1":10137,"PHASE2":10139,"PHASE3":10150,"PHASE4":10152,"NA":10154},{"trials":10136,"activeCount":102},[],{"trials":10138,"activeCount":102},[],{"trials":10140,"activeCount":102},[10141],{"nctId":10142,"briefTitle":10143,"status":131,"phases":10144,"primaryCompletion":10145,"completion":10145,"start":5987,"enrollment":10146,"conditions":10147,"interventions":10148},"NCT02354859","A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)",[91],"2018-02-01",119,[8035],[10133,10149],"Normal Saline",{"trials":10151,"activeCount":102},[],{"trials":10153,"activeCount":102},[],{"trials":10155,"activeCount":102},[],{"intervention":3134,"totalTrials":236,"cells":10157},{"EARLY_PHASE1":10158,"PHASE1":10160,"PHASE2":10162,"PHASE3":10168,"PHASE4":10170,"NA":10172},{"trials":10159,"activeCount":102},[],{"trials":10161,"activeCount":102},[],{"trials":10163,"activeCount":102},[10164],{"nctId":3128,"briefTitle":3129,"status":108,"phases":10165,"primaryCompletion":2106,"completion":2106,"start":3131,"enrollment":26,"conditions":10166,"interventions":10167},[91],[353,2897,356,276,277,278],[447,3134,361,362,363,360],{"trials":10169,"activeCount":102},[],{"trials":10171,"activeCount":102},[],{"trials":10173,"activeCount":102},[],{"intervention":10175,"totalTrials":236,"cells":10176},"Dihydrotestosterone",{"EARLY_PHASE1":10177,"PHASE1":10179,"PHASE2":10181,"PHASE3":10189,"PHASE4":10191,"NA":10193},{"trials":10178,"activeCount":102},[],{"trials":10180,"activeCount":102},[],{"trials":10182,"activeCount":102},[10183],{"nctId":10184,"briefTitle":10185,"status":131,"phases":10186,"primaryCompletion":5665,"completion":5665,"start":1650,"enrollment":227,"conditions":10187,"interventions":10188},"NCT00490022","Effect of Dihydrotestosterone (DHT) on Prostate Tissue [Short Title: DHT-3]",[90,91],[5667],[10175],{"trials":10190,"activeCount":102},[],{"trials":10192,"activeCount":102},[],{"trials":10194,"activeCount":102},[],{"intervention":3528,"totalTrials":236,"cells":10196},{"EARLY_PHASE1":10197,"PHASE1":10199,"PHASE2":10201,"PHASE3":10207,"PHASE4":10209,"NA":10211},{"trials":10198,"activeCount":102},[],{"trials":10200,"activeCount":102},[],{"trials":10202,"activeCount":102},[10203],{"nctId":3518,"briefTitle":3519,"status":1150,"phases":10204,"primaryCompletion":3521,"completion":3521,"start":3522,"enrollment":102,"conditions":10205,"interventions":10206},[90,91],[3524,3525,3526],[72,3528],{"trials":10208,"activeCount":102},[],{"trials":10210,"activeCount":102},[],{"trials":10212,"activeCount":102},[],{"intervention":10214,"totalTrials":236,"cells":10215},"Ibrutinib",{"EARLY_PHASE1":10216,"PHASE1":10218,"PHASE2":10220,"PHASE3":10230,"PHASE4":10232,"NA":10234},{"trials":10217,"activeCount":102},[],{"trials":10219,"activeCount":102},[],{"trials":10221,"activeCount":102},[10222],{"nctId":10223,"briefTitle":10224,"status":131,"phases":10225,"primaryCompletion":2348,"completion":2348,"start":6125,"enrollment":673,"conditions":10226,"interventions":10229},"NCT02207062","Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma",[91],[10227,10228],"Recurrent Transformed B-Cell Non-Hodgkin Lymphoma","Refractory Transformed B-Cell Non-Hodgkin Lymphoma",[10214],{"trials":10231,"activeCount":102},[],{"trials":10233,"activeCount":102},[],{"trials":10235,"activeCount":102},[],{"intervention":10237,"totalTrials":236,"cells":10238},"IC14",{"EARLY_PHASE1":10239,"PHASE1":10241,"PHASE2":10243,"PHASE3":10253,"PHASE4":10255,"NA":10257},{"trials":10240,"activeCount":102},[],{"trials":10242,"activeCount":102},[],{"trials":10244,"activeCount":102},[10245],{"nctId":10246,"briefTitle":10247,"status":108,"phases":10248,"completion":1650,"start":5621,"enrollment":2370,"conditions":10249,"interventions":10252},"NCT00233207","IC14 Antibodies to Treat Individuals With Acute Lung Injury",[91],[10250,10251],"Respiratory Distress Syndrome, Adult","Lung Diseases",[10237],{"trials":10254,"activeCount":102},[],{"trials":10256,"activeCount":102},[],{"trials":10258,"activeCount":102},[],{"intervention":2916,"totalTrials":236,"cells":10260},{"EARLY_PHASE1":10261,"PHASE1":10263,"PHASE2":10265,"PHASE3":10271,"PHASE4":10273,"NA":10275},{"trials":10262,"activeCount":102},[],{"trials":10264,"activeCount":102},[],{"trials":10266,"activeCount":102},[10267],{"nctId":2910,"briefTitle":2911,"status":131,"phases":10268,"primaryCompletion":1137,"completion":133,"start":2913,"enrollment":29,"conditions":10269,"interventions":10270},[91],[2036],[207,2916],{"trials":10272,"activeCount":102},[],{"trials":10274,"activeCount":102},[],{"trials":10276,"activeCount":102},[],{"intervention":10278,"totalTrials":236,"cells":10279},"Baricitinib",{"EARLY_PHASE1":10280,"PHASE1":10282,"PHASE2":10284,"PHASE3":10295,"PHASE4":10297,"NA":10299},{"trials":10281,"activeCount":102},[],{"trials":10283,"activeCount":102},[],{"trials":10285,"activeCount":102},[10286],{"nctId":10287,"briefTitle":10288,"status":1150,"phases":10289,"primaryCompletion":10290,"completion":10290,"start":10291,"enrollment":102,"conditions":10292,"interventions":10294},"NCT05361109","Baricitinib for Cutaneous Dermatomyositis",[91],"2023-03-31","2022-06-01",[10293],"Dermatomyositis",[10278],{"trials":10296,"activeCount":102},[],{"trials":10298,"activeCount":102},[],{"trials":10300,"activeCount":102},[],{"intervention":3299,"totalTrials":236,"cells":10302},{"EARLY_PHASE1":10303,"PHASE1":10305,"PHASE2":10307,"PHASE3":10313,"PHASE4":10315,"NA":10317},{"trials":10304,"activeCount":102},[],{"trials":10306,"activeCount":102},[],{"trials":10308,"activeCount":102},[10309],{"nctId":3289,"briefTitle":3290,"status":108,"phases":10310,"primaryCompletion":3292,"completion":3293,"start":3294,"enrollment":192,"conditions":10311,"interventions":10312},[90,91],[3296,3297],[1372,3299],{"trials":10314,"activeCount":102},[],{"trials":10316,"activeCount":102},[],{"trials":10318,"activeCount":102},[],{"intervention":10320,"totalTrials":236,"cells":10321},"irinotecan hydrochloride",{"EARLY_PHASE1":10322,"PHASE1":10324,"PHASE2":10326,"PHASE3":10338,"PHASE4":10340,"NA":10342},{"trials":10323,"activeCount":102},[],{"trials":10325,"activeCount":102},[],{"trials":10327,"activeCount":102},[10328],{"nctId":10329,"briefTitle":10330,"status":131,"phases":10331,"primaryCompletion":10332,"completion":10333,"start":10334,"conditions":10335,"interventions":10337},"NCT00030563","Surgery With or Without Radiofrequency Ablation Followed by Irinotecan in Treating Patients With Colorectal Cancer That is Metastatic to the Liver",[91],"2004-10","2005-10","2001-05",[10336,4928],"Colorectal Cancer",[10320],{"trials":10339,"activeCount":102},[],{"trials":10341,"activeCount":102},[],{"trials":10343,"activeCount":102},[],{"intervention":7682,"totalTrials":236,"cells":10345},{"EARLY_PHASE1":10346,"PHASE1":10348,"PHASE2":10350,"PHASE3":10356,"PHASE4":10358,"NA":10360},{"trials":10347,"activeCount":102},[],{"trials":10349,"activeCount":102},[],{"trials":10351,"activeCount":102},[10352],{"nctId":7674,"briefTitle":7675,"status":131,"phases":10353,"primaryCompletion":7677,"completion":1039,"start":7678,"enrollment":98,"conditions":10354,"interventions":10355},[91],[7680],[7682,677],{"trials":10357,"activeCount":102},[],{"trials":10359,"activeCount":102},[],{"trials":10361,"activeCount":102},[],{"intervention":3427,"totalTrials":236,"cells":10363},{"EARLY_PHASE1":10364,"PHASE1":10366,"PHASE2":10368,"PHASE3":10374,"PHASE4":10376,"NA":10378},{"trials":10365,"activeCount":102},[],{"trials":10367,"activeCount":102},[],{"trials":10369,"activeCount":102},[10370],{"nctId":3419,"briefTitle":3420,"status":131,"phases":10371,"primaryCompletion":1085,"completion":3422,"start":3423,"enrollment":350,"conditions":10372,"interventions":10373},[91],[3425,2396,2417],[2401,2402,3427,2425],{"trials":10375,"activeCount":102},[],{"trials":10377,"activeCount":102},[],{"trials":10379,"activeCount":102},[],{"intervention":1843,"totalTrials":236,"cells":10381},{"EARLY_PHASE1":10382,"PHASE1":10384,"PHASE2":10386,"PHASE3":10392,"PHASE4":10394,"NA":10396},{"trials":10383,"activeCount":102},[],{"trials":10385,"activeCount":102},[],{"trials":10387,"activeCount":102},[10388],{"nctId":1827,"briefTitle":1828,"status":108,"phases":10389,"primaryCompletion":1830,"completion":1830,"start":1831,"enrollment":1182,"conditions":10390,"interventions":10391},[91],[1833,1834,1835,1836,1355,1837,1838,1839,1840,1091],[123,1842,1843,1844],{"trials":10393,"activeCount":102},[],{"trials":10395,"activeCount":102},[],{"trials":10397,"activeCount":102},[],{"intervention":1844,"totalTrials":236,"cells":10399},{"EARLY_PHASE1":10400,"PHASE1":10402,"PHASE2":10404,"PHASE3":10410,"PHASE4":10412,"NA":10414},{"trials":10401,"activeCount":102},[],{"trials":10403,"activeCount":102},[],{"trials":10405,"activeCount":102},[10406],{"nctId":1827,"briefTitle":1828,"status":108,"phases":10407,"primaryCompletion":1830,"completion":1830,"start":1831,"enrollment":1182,"conditions":10408,"interventions":10409},[91],[1833,1834,1835,1836,1355,1837,1838,1839,1840,1091],[123,1842,1843,1844],{"trials":10411,"activeCount":102},[],{"trials":10413,"activeCount":102},[],{"trials":10415,"activeCount":102},[],{"intervention":10417,"totalTrials":236,"cells":10418},"Exisulind",{"EARLY_PHASE1":10419,"PHASE1":10421,"PHASE2":10423,"PHASE3":10434,"PHASE4":10436,"NA":10438},{"trials":10420,"activeCount":102},[],{"trials":10422,"activeCount":102},[],{"trials":10424,"activeCount":102},[10425],{"nctId":10426,"briefTitle":10427,"status":131,"phases":10428,"primaryCompletion":1313,"completion":1313,"start":10429,"enrollment":1129,"conditions":10430,"interventions":10431},"NCT00283803","Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer",[91],"2002-03-12",[4909],[10417,10432,10433],"luteinizing hormone-releasing hormone (LHRH) agonist","Antiandrogen",{"trials":10435,"activeCount":102},[],{"trials":10437,"activeCount":102},[],{"trials":10439,"activeCount":102},[],{"intervention":10432,"totalTrials":236,"cells":10441},{"EARLY_PHASE1":10442,"PHASE1":10444,"PHASE2":10446,"PHASE3":10452,"PHASE4":10454,"NA":10456},{"trials":10443,"activeCount":102},[],{"trials":10445,"activeCount":102},[],{"trials":10447,"activeCount":102},[10448],{"nctId":10426,"briefTitle":10427,"status":131,"phases":10449,"primaryCompletion":1313,"completion":1313,"start":10429,"enrollment":1129,"conditions":10450,"interventions":10451},[91],[4909],[10417,10432,10433],{"trials":10453,"activeCount":102},[],{"trials":10455,"activeCount":102},[],{"trials":10457,"activeCount":102},[],{"intervention":10433,"totalTrials":236,"cells":10459},{"EARLY_PHASE1":10460,"PHASE1":10462,"PHASE2":10464,"PHASE3":10470,"PHASE4":10472,"NA":10474},{"trials":10461,"activeCount":102},[],{"trials":10463,"activeCount":102},[],{"trials":10465,"activeCount":102},[10466],{"nctId":10426,"briefTitle":10427,"status":131,"phases":10467,"primaryCompletion":1313,"completion":1313,"start":10429,"enrollment":1129,"conditions":10468,"interventions":10469},[91],[4909],[10417,10432,10433],{"trials":10471,"activeCount":102},[],{"trials":10473,"activeCount":102},[],{"trials":10475,"activeCount":102},[],{"intervention":3457,"totalTrials":236,"cells":10477},{"EARLY_PHASE1":10478,"PHASE1":10480,"PHASE2":10482,"PHASE3":10488,"PHASE4":10490,"NA":10492},{"trials":10479,"activeCount":102},[],{"trials":10481,"activeCount":102},[],{"trials":10483,"activeCount":102},[10484],{"nctId":3451,"briefTitle":3452,"status":1150,"phases":10485,"primaryCompletion":1168,"completion":1168,"start":3454,"enrollment":102,"conditions":10486,"interventions":10487},[91],[2360,2312,1383],[2317,3457],{"trials":10489,"activeCount":102},[],{"trials":10491,"activeCount":102},[],{"trials":10493,"activeCount":102},[],{"intervention":1246,"totalTrials":236,"cells":10495},{"EARLY_PHASE1":10496,"PHASE1":10498,"PHASE2":10500,"PHASE3":10506,"PHASE4":10508,"NA":10510},{"trials":10497,"activeCount":102},[],{"trials":10499,"activeCount":102},[],{"trials":10501,"activeCount":102},[10502],{"nctId":1232,"briefTitle":1233,"status":131,"phases":10503,"primaryCompletion":1235,"completion":1236,"start":1237,"enrollment":1238,"conditions":10504,"interventions":10505},[91],[1240,1241,1242],[1244,993,1245,125,1014,1246],{"trials":10507,"activeCount":102},[],{"trials":10509,"activeCount":102},[],{"trials":10511,"activeCount":102},[],{"intervention":1373,"totalTrials":236,"cells":10513},{"EARLY_PHASE1":10514,"PHASE1":10516,"PHASE2":10518,"PHASE3":10524,"PHASE4":10526,"NA":10528},{"trials":10515,"activeCount":102},[],{"trials":10517,"activeCount":102},[],{"trials":10519,"activeCount":102},[10520],{"nctId":1360,"briefTitle":1361,"status":108,"phases":10521,"primaryCompletion":1363,"completion":1363,"start":1364,"enrollment":236,"conditions":10522,"interventions":10523},[91],[1366,1367,1368,1369,1370],[1244,1372,992,1373],{"trials":10525,"activeCount":102},[],{"trials":10527,"activeCount":102},[],{"trials":10529,"activeCount":102},[],{"intervention":10531,"totalTrials":236,"cells":10532},"Cervical Sympathetic Block",{"EARLY_PHASE1":10533,"PHASE1":10535,"PHASE2":10537,"PHASE3":10547,"PHASE4":10549,"NA":10551},{"trials":10534,"activeCount":102},[],{"trials":10536,"activeCount":102},[],{"trials":10538,"activeCount":102},[10539],{"nctId":10540,"briefTitle":10541,"status":108,"phases":10542,"primaryCompletion":1620,"completion":1620,"start":10543,"enrollment":6989,"conditions":10544,"interventions":10546},"NCT00930072","Safety Study of Cervical Sympathetic Block for Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage",[91],"2009-04",[10545],"Vasospasm",[10531],{"trials":10548,"activeCount":102},[],{"trials":10550,"activeCount":102},[],{"trials":10552,"activeCount":102},[],{"intervention":9713,"totalTrials":236,"cells":10554},{"EARLY_PHASE1":10555,"PHASE1":10557,"PHASE2":10559,"PHASE3":10565,"PHASE4":10567,"NA":10569},{"trials":10556,"activeCount":102},[],{"trials":10558,"activeCount":102},[],{"trials":10560,"activeCount":102},[10561],{"nctId":9708,"briefTitle":9709,"status":131,"phases":10562,"primaryCompletion":6483,"completion":5770,"start":1621,"enrollment":1391,"conditions":10563,"interventions":10564},[91],[4909],[9713,9714,9699],{"trials":10566,"activeCount":102},[],{"trials":10568,"activeCount":102},[],{"trials":10570,"activeCount":102},[],{"intervention":9714,"totalTrials":236,"cells":10572},{"EARLY_PHASE1":10573,"PHASE1":10575,"PHASE2":10577,"PHASE3":10583,"PHASE4":10585,"NA":10587},{"trials":10574,"activeCount":102},[],{"trials":10576,"activeCount":102},[],{"trials":10578,"activeCount":102},[10579],{"nctId":9708,"briefTitle":9709,"status":131,"phases":10580,"primaryCompletion":6483,"completion":5770,"start":1621,"enrollment":1391,"conditions":10581,"interventions":10582},[91],[4909],[9713,9714,9699],{"trials":10584,"activeCount":102},[],{"trials":10586,"activeCount":102},[],{"trials":10588,"activeCount":102},[],{"intervention":2404,"totalTrials":236,"cells":10590},{"EARLY_PHASE1":10591,"PHASE1":10593,"PHASE2":10595,"PHASE3":10601,"PHASE4":10603,"NA":10605},{"trials":10592,"activeCount":102},[],{"trials":10594,"activeCount":102},[],{"trials":10596,"activeCount":102},[10597],{"nctId":2387,"briefTitle":2388,"status":131,"phases":10598,"primaryCompletion":2390,"completion":2391,"start":2392,"enrollment":2393,"conditions":10599,"interventions":10600},[90,91],[2395,2396,2397,2398,2399],[2401,2402,1079,2403,2404],{"trials":10602,"activeCount":102},[],{"trials":10604,"activeCount":102},[],{"trials":10606,"activeCount":102},[],{"intervention":10608,"totalTrials":236,"cells":10609},"Synrinse",{"EARLY_PHASE1":10610,"PHASE1":10612,"PHASE2":10614,"PHASE3":10626,"PHASE4":10628,"NA":10630},{"trials":10611,"activeCount":102},[],{"trials":10613,"activeCount":102},[],{"trials":10615,"activeCount":102},[10616],{"nctId":10617,"briefTitle":10618,"status":131,"phases":10619,"primaryCompletion":10620,"completion":10620,"start":10621,"enrollment":23,"conditions":10622,"interventions":10625},"NCT03154541","SynRinse Irrigation Pilot (SIP) Trial",[90,91],"2018-05-30","2017-06-06",[10623,10624],"Sinusitis, Chronic","Cystic Fibrosis With Other Manifestations",[10608],{"trials":10627,"activeCount":102},[],{"trials":10629,"activeCount":102},[],{"trials":10631,"activeCount":102},[],{"intervention":5072,"totalTrials":236,"cells":10633},{"EARLY_PHASE1":10634,"PHASE1":10636,"PHASE2":10638,"PHASE3":10644,"PHASE4":10646,"NA":10648},{"trials":10635,"activeCount":102},[],{"trials":10637,"activeCount":102},[],{"trials":10639,"activeCount":102},[10640],{"nctId":5063,"briefTitle":5064,"status":131,"phases":10641,"primaryCompletion":1864,"completion":1864,"start":5066,"enrollment":5067,"conditions":10642,"interventions":10643},[90,91],[5069],[340,5071,5072,5073,5074,399],{"trials":10645,"activeCount":102},[],{"trials":10647,"activeCount":102},[],{"trials":10649,"activeCount":102},[],{"intervention":5073,"totalTrials":236,"cells":10651},{"EARLY_PHASE1":10652,"PHASE1":10654,"PHASE2":10656,"PHASE3":10662,"PHASE4":10664,"NA":10666},{"trials":10653,"activeCount":102},[],{"trials":10655,"activeCount":102},[],{"trials":10657,"activeCount":102},[10658],{"nctId":5063,"briefTitle":5064,"status":131,"phases":10659,"primaryCompletion":1864,"completion":1864,"start":5066,"enrollment":5067,"conditions":10660,"interventions":10661},[90,91],[5069],[340,5071,5072,5073,5074,399],{"trials":10663,"activeCount":102},[],{"trials":10665,"activeCount":102},[],{"trials":10667,"activeCount":102},[],{"intervention":341,"totalTrials":236,"cells":10669},{"EARLY_PHASE1":10670,"PHASE1":10672,"PHASE2":10674,"PHASE3":10680,"PHASE4":10682,"NA":10684},{"trials":10671,"activeCount":102},[],{"trials":10673,"activeCount":102},[],{"trials":10675,"activeCount":102},[10676],{"nctId":326,"briefTitle":327,"status":131,"phases":10677,"primaryCompletion":329,"completion":330,"start":331,"enrollment":332,"conditions":10678,"interventions":10679},[90,91],[334,335,336,337,338],[340,341,342],{"trials":10681,"activeCount":102},[],{"trials":10683,"activeCount":102},[],{"trials":10685,"activeCount":102},[],{"intervention":10687,"totalTrials":236,"cells":10688},"goserelin with dutasteride",{"EARLY_PHASE1":10689,"PHASE1":10691,"PHASE2":10693,"PHASE3":10706,"PHASE4":10708,"NA":10710},{"trials":10690,"activeCount":102},[],{"trials":10692,"activeCount":102},[],{"trials":10694,"activeCount":102},[10695],{"nctId":10696,"briefTitle":10697,"status":131,"phases":10698,"primaryCompletion":347,"completion":10699,"start":4906,"enrollment":1114,"conditions":10700,"interventions":10703},"NCT00298155","Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer",[91],"2014-01",[10701,10702],"Cancer","Prostate Neoplasms",[10687,10704,10705],"goserelin with bicalutamide and dutasteride","goserelin with bicalutamide and dutasteride and ketoconazole",{"trials":10707,"activeCount":102},[],{"trials":10709,"activeCount":102},[],{"trials":10711,"activeCount":102},[],{"intervention":10704,"totalTrials":236,"cells":10713},{"EARLY_PHASE1":10714,"PHASE1":10716,"PHASE2":10718,"PHASE3":10724,"PHASE4":10726,"NA":10728},{"trials":10715,"activeCount":102},[],{"trials":10717,"activeCount":102},[],{"trials":10719,"activeCount":102},[10720],{"nctId":10696,"briefTitle":10697,"status":131,"phases":10721,"primaryCompletion":347,"completion":10699,"start":4906,"enrollment":1114,"conditions":10722,"interventions":10723},[91],[10701,10702],[10687,10704,10705],{"trials":10725,"activeCount":102},[],{"trials":10727,"activeCount":102},[],{"trials":10729,"activeCount":102},[],{"intervention":10705,"totalTrials":236,"cells":10731},{"EARLY_PHASE1":10732,"PHASE1":10734,"PHASE2":10736,"PHASE3":10742,"PHASE4":10744,"NA":10746},{"trials":10733,"activeCount":102},[],{"trials":10735,"activeCount":102},[],{"trials":10737,"activeCount":102},[10738],{"nctId":10696,"briefTitle":10697,"status":131,"phases":10739,"primaryCompletion":347,"completion":10699,"start":4906,"enrollment":1114,"conditions":10740,"interventions":10741},[91],[10701,10702],[10687,10704,10705],{"trials":10743,"activeCount":102},[],{"trials":10745,"activeCount":102},[],{"trials":10747,"activeCount":102},[],{"intervention":1096,"totalTrials":236,"cells":10749},{"EARLY_PHASE1":10750,"PHASE1":10752,"PHASE2":10754,"PHASE3":10760,"PHASE4":10762,"NA":10764},{"trials":10751,"activeCount":102},[],{"trials":10753,"activeCount":102},[],{"trials":10755,"activeCount":102},[10756],{"nctId":1081,"briefTitle":1082,"status":131,"phases":10757,"primaryCompletion":1084,"completion":1085,"start":1086,"enrollment":1087,"conditions":10758,"interventions":10759},[91],[1089,1090,1091,1092],[1066,1094,1095,1096,966],{"trials":10761,"activeCount":102},[],{"trials":10763,"activeCount":102},[],{"trials":10765,"activeCount":102},[],{"intervention":10767,"totalTrials":236,"cells":10768},"Sumatriptan 100 mg",{"EARLY_PHASE1":10769,"PHASE1":10771,"PHASE2":10773,"PHASE3":10783,"PHASE4":10785,"NA":10787},{"trials":10770,"activeCount":102},[],{"trials":10772,"activeCount":102},[],{"trials":10774,"activeCount":102},[10775],{"nctId":10776,"briefTitle":10777,"status":131,"phases":10778,"primaryCompletion":10779,"completion":10779,"start":331,"enrollment":310,"conditions":10780,"interventions":10782},"NCT01854385","Sumatriptan as Treatment for Post-traumatic Headache",[91],"2018-02",[10781],"Post-traumatic Headache",[10767],{"trials":10784,"activeCount":102},[],{"trials":10786,"activeCount":102},[],{"trials":10788,"activeCount":102},[],{"intervention":10790,"totalTrials":236,"cells":10791},"Relugolix 120Mg Tab",{"EARLY_PHASE1":10792,"PHASE1":10794,"PHASE2":10796,"PHASE3":10806,"PHASE4":10808,"NA":10810},{"trials":10793,"activeCount":102},[],{"trials":10795,"activeCount":102},[],{"trials":10797,"activeCount":102},[10798],{"nctId":10799,"briefTitle":10800,"status":5876,"phases":10801,"primaryCompletion":5163,"completion":5163,"start":6150,"enrollment":261,"conditions":10802,"interventions":10804},"NCT06312761","Single-Dose Pharmacokinetics of Oral Testosterone Undecanoate With and Without Concomitant Inhibition of UGT2B17",[90,91],[10803],"Hypogonadism, Male",[10790,10805],"Testosterone Undecanoate 237 MG Oral",{"trials":10807,"activeCount":102},[],{"trials":10809,"activeCount":102},[],{"trials":10811,"activeCount":102},[],{"intervention":10805,"totalTrials":236,"cells":10813},{"EARLY_PHASE1":10814,"PHASE1":10816,"PHASE2":10818,"PHASE3":10824,"PHASE4":10826,"NA":10828},{"trials":10815,"activeCount":102},[],{"trials":10817,"activeCount":102},[],{"trials":10819,"activeCount":102},[10820],{"nctId":10799,"briefTitle":10800,"status":5876,"phases":10821,"primaryCompletion":5163,"completion":5163,"start":6150,"enrollment":261,"conditions":10822,"interventions":10823},[90,91],[10803],[10790,10805],{"trials":10825,"activeCount":102},[],{"trials":10827,"activeCount":102},[],{"trials":10829,"activeCount":102},[],{"intervention":2422,"totalTrials":236,"cells":10831},{"EARLY_PHASE1":10832,"PHASE1":10834,"PHASE2":10836,"PHASE3":10842,"PHASE4":10844,"NA":10846},{"trials":10833,"activeCount":102},[],{"trials":10835,"activeCount":102},[],{"trials":10837,"activeCount":102},[10838],{"nctId":2406,"briefTitle":2407,"status":131,"phases":10839,"primaryCompletion":2409,"completion":2410,"start":2411,"enrollment":23,"conditions":10840,"interventions":10841},[91],[2413,2414,2415,2398,2416,2417,2418,2419,2420],[2401,2422,2402,1079,2423,2424,2425,2426,1908,2427],{"trials":10843,"activeCount":102},[],{"trials":10845,"activeCount":102},[],{"trials":10847,"activeCount":102},[],{"intervention":2423,"totalTrials":236,"cells":10849},{"EARLY_PHASE1":10850,"PHASE1":10852,"PHASE2":10854,"PHASE3":10860,"PHASE4":10862,"NA":10864},{"trials":10851,"activeCount":102},[],{"trials":10853,"activeCount":102},[],{"trials":10855,"activeCount":102},[10856],{"nctId":2406,"briefTitle":2407,"status":131,"phases":10857,"primaryCompletion":2409,"completion":2410,"start":2411,"enrollment":23,"conditions":10858,"interventions":10859},[91],[2413,2414,2415,2398,2416,2417,2418,2419,2420],[2401,2422,2402,1079,2423,2424,2425,2426,1908,2427],{"trials":10861,"activeCount":102},[],{"trials":10863,"activeCount":102},[],{"trials":10865,"activeCount":102},[],{"intervention":2424,"totalTrials":236,"cells":10867},{"EARLY_PHASE1":10868,"PHASE1":10870,"PHASE2":10872,"PHASE3":10878,"PHASE4":10880,"NA":10882},{"trials":10869,"activeCount":102},[],{"trials":10871,"activeCount":102},[],{"trials":10873,"activeCount":102},[10874],{"nctId":2406,"briefTitle":2407,"status":131,"phases":10875,"primaryCompletion":2409,"completion":2410,"start":2411,"enrollment":23,"conditions":10876,"interventions":10877},[91],[2413,2414,2415,2398,2416,2417,2418,2419,2420],[2401,2422,2402,1079,2423,2424,2425,2426,1908,2427],{"trials":10879,"activeCount":102},[],{"trials":10881,"activeCount":102},[],{"trials":10883,"activeCount":102},[],{"intervention":2427,"totalTrials":236,"cells":10885},{"EARLY_PHASE1":10886,"PHASE1":10888,"PHASE2":10890,"PHASE3":10896,"PHASE4":10898,"NA":10900},{"trials":10887,"activeCount":102},[],{"trials":10889,"activeCount":102},[],{"trials":10891,"activeCount":102},[10892],{"nctId":2406,"briefTitle":2407,"status":131,"phases":10893,"primaryCompletion":2409,"completion":2410,"start":2411,"enrollment":23,"conditions":10894,"interventions":10895},[91],[2413,2414,2415,2398,2416,2417,2418,2419,2420],[2401,2422,2402,1079,2423,2424,2425,2426,1908,2427],{"trials":10897,"activeCount":102},[],{"trials":10899,"activeCount":102},[],{"trials":10901,"activeCount":102},[],{"intervention":9842,"totalTrials":236,"cells":10903},{"EARLY_PHASE1":10904,"PHASE1":10906,"PHASE2":10908,"PHASE3":10914,"PHASE4":10916,"NA":10918},{"trials":10905,"activeCount":102},[],{"trials":10907,"activeCount":102},[],{"trials":10909,"activeCount":102},[10910],{"nctId":9835,"briefTitle":9836,"status":131,"phases":10911,"primaryCompletion":455,"completion":9838,"start":1475,"enrollment":456,"conditions":10912,"interventions":10913},[91],[275,377,9840,36],[9842,9843,9826],{"trials":10915,"activeCount":102},[],{"trials":10917,"activeCount":102},[],{"trials":10919,"activeCount":102},[],{"intervention":9843,"totalTrials":236,"cells":10921},{"EARLY_PHASE1":10922,"PHASE1":10924,"PHASE2":10926,"PHASE3":10932,"PHASE4":10934,"NA":10936},{"trials":10923,"activeCount":102},[],{"trials":10925,"activeCount":102},[],{"trials":10927,"activeCount":102},[10928],{"nctId":9835,"briefTitle":9836,"status":131,"phases":10929,"primaryCompletion":455,"completion":9838,"start":1475,"enrollment":456,"conditions":10930,"interventions":10931},[91],[275,377,9840,36],[9842,9843,9826],{"trials":10933,"activeCount":102},[],{"trials":10935,"activeCount":102},[],{"trials":10937,"activeCount":102},[],{"intervention":10939,"totalTrials":236,"cells":10940},"Psychotherapy plus Methylene Blue, USP",{"EARLY_PHASE1":10941,"PHASE1":10943,"PHASE2":10945,"PHASE3":10956,"PHASE4":10958,"NA":10960},{"trials":10942,"activeCount":102},[],{"trials":10944,"activeCount":102},[],{"trials":10946,"activeCount":102},[10947],{"nctId":10948,"briefTitle":10949,"status":131,"phases":10950,"primaryCompletion":10951,"completion":10951,"start":10952,"enrollment":1707,"conditions":10953,"interventions":10955},"NCT01188694","Enhancing Extinction Learning in Post Traumatic Stress Disorder (PTSD)",[91],"2013-04","2009-09",[10954],"Chronic Posttraumatic Stress Disorder",[10939],{"trials":10957,"activeCount":102},[],{"trials":10959,"activeCount":102},[],{"trials":10961,"activeCount":102},[],{"intervention":7559,"totalTrials":236,"cells":10963},{"EARLY_PHASE1":10964,"PHASE1":10966,"PHASE2":10968,"PHASE3":10974,"PHASE4":10976,"NA":10978},{"trials":10965,"activeCount":102},[],{"trials":10967,"activeCount":102},[],{"trials":10969,"activeCount":102},[10970],{"nctId":7554,"briefTitle":7555,"status":131,"phases":10971,"primaryCompletion":370,"completion":370,"start":1475,"enrollment":227,"conditions":10972,"interventions":10973},[91],[5667],[340,7559,7560],{"trials":10975,"activeCount":102},[],{"trials":10977,"activeCount":102},[],{"trials":10979,"activeCount":102},[],{"intervention":7560,"totalTrials":236,"cells":10981},{"EARLY_PHASE1":10982,"PHASE1":10984,"PHASE2":10986,"PHASE3":10992,"PHASE4":10994,"NA":10996},{"trials":10983,"activeCount":102},[],{"trials":10985,"activeCount":102},[],{"trials":10987,"activeCount":102},[10988],{"nctId":7554,"briefTitle":7555,"status":131,"phases":10989,"primaryCompletion":370,"completion":370,"start":1475,"enrollment":227,"conditions":10990,"interventions":10991},[91],[5667],[340,7559,7560],{"trials":10993,"activeCount":102},[],{"trials":10995,"activeCount":102},[],{"trials":10997,"activeCount":102},[],{"intervention":206,"totalTrials":236,"cells":10999},{"EARLY_PHASE1":11000,"PHASE1":11002,"PHASE2":11004,"PHASE3":11010,"PHASE4":11012,"NA":11014},{"trials":11001,"activeCount":102},[],{"trials":11003,"activeCount":102},[],{"trials":11005,"activeCount":102},[11006],{"nctId":186,"briefTitle":187,"status":108,"phases":11007,"primaryCompletion":189,"completion":190,"start":191,"enrollment":192,"conditions":11008,"interventions":11009},[91],[194,195,196,197,198,199,200,201,202,203,204],[206,207,208,168],{"trials":11011,"activeCount":102},[],{"trials":11013,"activeCount":102},[],{"trials":11015,"activeCount":102},[],{"intervention":11017,"totalTrials":236,"cells":11018},"Cimzia",{"EARLY_PHASE1":11019,"PHASE1":11021,"PHASE2":11023,"PHASE3":11032,"PHASE4":11034,"NA":11036},{"trials":11020,"activeCount":102},[],{"trials":11022,"activeCount":102},[],{"trials":11024,"activeCount":102},[11025],{"nctId":11026,"briefTitle":11027,"status":131,"phases":11028,"primaryCompletion":1364,"completion":1364,"start":11029,"enrollment":2817,"conditions":11030,"interventions":11031},"NCT01090154","Study of Cimzia for the Treatment of Ulcerative Colitis",[91],"2010-12-01",[6991],[11017],{"trials":11033,"activeCount":102},[],{"trials":11035,"activeCount":102},[],{"trials":11037,"activeCount":102},[],{"intervention":3238,"totalTrials":236,"cells":11039},{"EARLY_PHASE1":11040,"PHASE1":11042,"PHASE2":11044,"PHASE3":11050,"PHASE4":11052,"NA":11054},{"trials":11041,"activeCount":102},[],{"trials":11043,"activeCount":102},[],{"trials":11045,"activeCount":102},[11046],{"nctId":3226,"briefTitle":3227,"status":131,"phases":11047,"primaryCompletion":3023,"completion":3229,"start":3230,"enrollment":1114,"conditions":11048,"interventions":11049},[91],[3232,3233,3234,3235,3236],[1870,1794,361,3238],{"trials":11051,"activeCount":102},[],{"trials":11053,"activeCount":102},[],{"trials":11055,"activeCount":102},[],{"intervention":1515,"totalTrials":236,"cells":11057},{"EARLY_PHASE1":11058,"PHASE1":11060,"PHASE2":11062,"PHASE3":11068,"PHASE4":11070,"NA":11072},{"trials":11059,"activeCount":102},[],{"trials":11061,"activeCount":102},[],{"trials":11063,"activeCount":102},[11064],{"nctId":1505,"briefTitle":1506,"status":108,"phases":11065,"primaryCompletion":1508,"completion":1508,"start":1509,"enrollment":236,"conditions":11066,"interventions":11067},[91],[1511,119,1512,1513],[121,124,1515],{"trials":11069,"activeCount":102},[],{"trials":11071,"activeCount":102},[],{"trials":11073,"activeCount":102},[],{"intervention":365,"totalTrials":236,"cells":11075},{"EARLY_PHASE1":11076,"PHASE1":11078,"PHASE2":11080,"PHASE3":11086,"PHASE4":11088,"NA":11090},{"trials":11077,"activeCount":102},[],{"trials":11079,"activeCount":102},[],{"trials":11081,"activeCount":102},[11082],{"nctId":344,"briefTitle":345,"status":131,"phases":11083,"primaryCompletion":347,"completion":348,"start":349,"enrollment":350,"conditions":11084,"interventions":11085},[91],[352,353,354,355,356,357,358,277,278],[280,233,360,169,361,362,363,364,365,316],{"trials":11087,"activeCount":102},[],{"trials":11089,"activeCount":102},[],{"trials":11091,"activeCount":102},[],{"intervention":9235,"totalTrials":236,"cells":11093},{"EARLY_PHASE1":11094,"PHASE1":11096,"PHASE2":11098,"PHASE3":11104,"PHASE4":11106,"NA":11108},{"trials":11095,"activeCount":102},[],{"trials":11097,"activeCount":102},[],{"trials":11099,"activeCount":102},[11100],{"nctId":9227,"briefTitle":9228,"status":131,"phases":11101,"primaryCompletion":331,"completion":6125,"start":7195,"enrollment":702,"conditions":11102,"interventions":11103},[91],[9231,9232,377,36,9233],[362,9235],{"trials":11105,"activeCount":102},[],{"trials":11107,"activeCount":102},[],{"trials":11109,"activeCount":102},[],{"intervention":5712,"totalTrials":236,"cells":11111},{"EARLY_PHASE1":11112,"PHASE1":11114,"PHASE2":11116,"PHASE3":11122,"PHASE4":11124,"NA":11126},{"trials":11113,"activeCount":102},[],{"trials":11115,"activeCount":102},[],{"trials":11117,"activeCount":102},[11118],{"nctId":5704,"briefTitle":5705,"status":1150,"phases":11119,"primaryCompletion":5707,"completion":577,"start":5708,"enrollment":102,"conditions":11120,"interventions":11121},[91],[5710],[5712,340,5074,5713,5714],{"trials":11123,"activeCount":102},[],{"trials":11125,"activeCount":102},[],{"trials":11127,"activeCount":102},[],{"intervention":5713,"totalTrials":236,"cells":11129},{"EARLY_PHASE1":11130,"PHASE1":11132,"PHASE2":11134,"PHASE3":11140,"PHASE4":11142,"NA":11144},{"trials":11131,"activeCount":102},[],{"trials":11133,"activeCount":102},[],{"trials":11135,"activeCount":102},[11136],{"nctId":5704,"briefTitle":5705,"status":1150,"phases":11137,"primaryCompletion":5707,"completion":577,"start":5708,"enrollment":102,"conditions":11138,"interventions":11139},[91],[5710],[5712,340,5074,5713,5714],{"trials":11141,"activeCount":102},[],{"trials":11143,"activeCount":102},[],{"trials":11145,"activeCount":102},[],{"intervention":11147,"totalTrials":236,"cells":11148},"Lactin-V",{"EARLY_PHASE1":11149,"PHASE1":11151,"PHASE2":11153,"PHASE3":11164,"PHASE4":11166,"NA":11168},{"trials":11150,"activeCount":102},[],{"trials":11152,"activeCount":102},[],{"trials":11154,"activeCount":102},[11155],{"nctId":11156,"briefTitle":11157,"status":131,"phases":11158,"primaryCompletion":11159,"completion":11159,"start":11160,"enrollment":372,"conditions":11161,"interventions":11163},"NCT00305227","Intravaginal LACTIN-V for Prevention of Recurrent Urinary Tract Infection",[91],"2012-04","2006-03",[11162],"Urinary Tract Infection",[11147],{"trials":11165,"activeCount":102},[],{"trials":11167,"activeCount":102},[],{"trials":11169,"activeCount":102},[],{"intervention":11171,"totalTrials":236,"cells":11172},"Famotidine 20 MG",{"EARLY_PHASE1":11173,"PHASE1":11175,"PHASE2":11177,"PHASE3":11187,"PHASE4":11189,"NA":11191},{"trials":11174,"activeCount":102},[],{"trials":11176,"activeCount":102},[],{"trials":11178,"activeCount":102},[11179],{"nctId":11180,"briefTitle":11181,"status":131,"phases":11182,"primaryCompletion":11183,"completion":11183,"start":11184,"enrollment":1274,"conditions":11185,"interventions":11186},"NCT03554291","Repurposing a Histamine Antagonist to Benefit Patients With Pulmonary Hypertension",[91],"2023-07-11","2019-05-01",[4269,4270],[11171],{"trials":11188,"activeCount":102},[],{"trials":11190,"activeCount":102},[],{"trials":11192,"activeCount":102},[],{"intervention":3468,"totalTrials":236,"cells":11194},{"EARLY_PHASE1":11195,"PHASE1":11197,"PHASE2":11199,"PHASE3":11205,"PHASE4":11207,"NA":11209},{"trials":11196,"activeCount":102},[],{"trials":11198,"activeCount":102},[],{"trials":11200,"activeCount":102},[11201],{"nctId":3459,"briefTitle":3460,"status":108,"phases":11202,"primaryCompletion":3462,"completion":3463,"start":3464,"enrollment":702,"conditions":11203,"interventions":11204},[90,91],[1382,3466],[3468,2317],{"trials":11206,"activeCount":102},[],{"trials":11208,"activeCount":102},[],{"trials":11210,"activeCount":102},[],{"intervention":2268,"totalTrials":236,"cells":11212},{"EARLY_PHASE1":11213,"PHASE1":11215,"PHASE2":11217,"PHASE3":11223,"PHASE4":11225,"NA":11227},{"trials":11214,"activeCount":102},[],{"trials":11216,"activeCount":102},[],{"trials":11218,"activeCount":102},[11219],{"nctId":2261,"briefTitle":2262,"status":108,"phases":11220,"primaryCompletion":1875,"completion":1875,"start":2264,"enrollment":192,"conditions":11221,"interventions":11222},[91],[2266],[1014,2268],{"trials":11224,"activeCount":102},[],{"trials":11226,"activeCount":102},[],{"trials":11228,"activeCount":102},[],{"intervention":11230,"totalTrials":236,"cells":11231},"1 gram Tranexamic Acid",{"EARLY_PHASE1":11232,"PHASE1":11234,"PHASE2":11236,"PHASE3":11249,"PHASE4":11251,"NA":11253},{"trials":11233,"activeCount":102},[],{"trials":11235,"activeCount":102},[],{"trials":11237,"activeCount":102},[11238],{"nctId":11239,"briefTitle":11240,"status":131,"phases":11241,"primaryCompletion":11242,"completion":11242,"start":329,"enrollment":11243,"conditions":11244,"interventions":11246},"NCT01990768","Prehospital Tranexamic Acid Use for Traumatic Brain Injury",[91],"2017-11-07",967,[11245],"Traumatic Brain Injury",[11230,11247,11248],"2 grams TXA","0.9% Sodium Chloride injectable",{"trials":11250,"activeCount":102},[],{"trials":11252,"activeCount":102},[],{"trials":11254,"activeCount":102},[],{"intervention":11247,"totalTrials":236,"cells":11256},{"EARLY_PHASE1":11257,"PHASE1":11259,"PHASE2":11261,"PHASE3":11267,"PHASE4":11269,"NA":11271},{"trials":11258,"activeCount":102},[],{"trials":11260,"activeCount":102},[],{"trials":11262,"activeCount":102},[11263],{"nctId":11239,"briefTitle":11240,"status":131,"phases":11264,"primaryCompletion":11242,"completion":11242,"start":329,"enrollment":11243,"conditions":11265,"interventions":11266},[91],[11245],[11230,11247,11248],{"trials":11268,"activeCount":102},[],{"trials":11270,"activeCount":102},[],{"trials":11272,"activeCount":102},[],{"intervention":11248,"totalTrials":236,"cells":11274},{"EARLY_PHASE1":11275,"PHASE1":11277,"PHASE2":11279,"PHASE3":11285,"PHASE4":11287,"NA":11289},{"trials":11276,"activeCount":102},[],{"trials":11278,"activeCount":102},[],{"trials":11280,"activeCount":102},[11281],{"nctId":11239,"briefTitle":11240,"status":131,"phases":11282,"primaryCompletion":11242,"completion":11242,"start":329,"enrollment":11243,"conditions":11283,"interventions":11284},[91],[11245],[11230,11247,11248],{"trials":11286,"activeCount":102},[],{"trials":11288,"activeCount":102},[],{"trials":11290,"activeCount":102},[],{"intervention":3734,"totalTrials":236,"cells":11292},{"EARLY_PHASE1":11293,"PHASE1":11295,"PHASE2":11297,"PHASE3":11303,"PHASE4":11305,"NA":11307},{"trials":11294,"activeCount":102},[],{"trials":11296,"activeCount":102},[],{"trials":11298,"activeCount":102},[11299],{"nctId":3725,"briefTitle":3726,"status":131,"phases":11300,"primaryCompletion":2001,"completion":3728,"start":3729,"enrollment":227,"conditions":11301,"interventions":11302},[90,91],[3731,1710,36],[3733,1858,3734,1857],{"trials":11304,"activeCount":102},[],{"trials":11306,"activeCount":102},[],{"trials":11308,"activeCount":102},[],{"intervention":11310,"totalTrials":236,"cells":11311},"First Intervention",{"EARLY_PHASE1":11312,"PHASE1":11314,"PHASE2":11316,"PHASE3":11327,"PHASE4":11329,"NA":11331},{"trials":11313,"activeCount":102},[],{"trials":11315,"activeCount":102},[],{"trials":11317,"activeCount":102},[11318],{"nctId":11319,"briefTitle":11320,"status":131,"phases":11321,"primaryCompletion":740,"completion":8413,"start":5673,"enrollment":1207,"conditions":11322,"interventions":11324},"NCT00842751","Oral T7 Oral Testosterone in Man",[91],[5069,11323],"Male Contraceptive",[11310,11325,11326],"Second Intervention","Third Intervention",{"trials":11328,"activeCount":102},[],{"trials":11330,"activeCount":102},[],{"trials":11332,"activeCount":102},[],{"intervention":11325,"totalTrials":236,"cells":11334},{"EARLY_PHASE1":11335,"PHASE1":11337,"PHASE2":11339,"PHASE3":11345,"PHASE4":11347,"NA":11349},{"trials":11336,"activeCount":102},[],{"trials":11338,"activeCount":102},[],{"trials":11340,"activeCount":102},[11341],{"nctId":11319,"briefTitle":11320,"status":131,"phases":11342,"primaryCompletion":740,"completion":8413,"start":5673,"enrollment":1207,"conditions":11343,"interventions":11344},[91],[5069,11323],[11310,11325,11326],{"trials":11346,"activeCount":102},[],{"trials":11348,"activeCount":102},[],{"trials":11350,"activeCount":102},[],{"intervention":11326,"totalTrials":236,"cells":11352},{"EARLY_PHASE1":11353,"PHASE1":11355,"PHASE2":11357,"PHASE3":11363,"PHASE4":11365,"NA":11367},{"trials":11354,"activeCount":102},[],{"trials":11356,"activeCount":102},[],{"trials":11358,"activeCount":102},[11359],{"nctId":11319,"briefTitle":11320,"status":131,"phases":11360,"primaryCompletion":740,"completion":8413,"start":5673,"enrollment":1207,"conditions":11361,"interventions":11362},[91],[5069,11323],[11310,11325,11326],{"trials":11364,"activeCount":102},[],{"trials":11366,"activeCount":102},[],{"trials":11368,"activeCount":102},[],{"intervention":381,"totalTrials":236,"cells":11370},{"EARLY_PHASE1":11371,"PHASE1":11373,"PHASE2":11375,"PHASE3":11381,"PHASE4":11383,"NA":11385},{"trials":11372,"activeCount":102},[],{"trials":11374,"activeCount":102},[],{"trials":11376,"activeCount":102},[11377],{"nctId":367,"briefTitle":368,"status":131,"phases":11378,"primaryCompletion":370,"completion":370,"start":371,"enrollment":372,"conditions":11379,"interventions":11380},[91],[374,375,376,377,276,277,278,378,379],[316,381],{"trials":11382,"activeCount":102},[],{"trials":11384,"activeCount":102},[],{"trials":11386,"activeCount":102},[],{"intervention":11388,"totalTrials":236,"cells":11389},"Clofazimine",{"EARLY_PHASE1":11390,"PHASE1":11392,"PHASE2":11394,"PHASE3":11405,"PHASE4":11407,"NA":11409},{"trials":11391,"activeCount":102},[],{"trials":11393,"activeCount":102},[],{"trials":11395,"activeCount":102},[11396],{"nctId":11397,"briefTitle":11398,"status":108,"phases":11399,"primaryCompletion":2275,"completion":11400,"start":11401,"enrollment":1170,"conditions":11402,"interventions":11404},"NCT03341767","A Phase 2A Evaluation of the Safety, Tolerability, Pharmacokinetics, Efficacy of Clofazimine (CFZ) in Cryptosporidiosis",[91],"2019-07-05","2017-12-14",[11403],"Cryptosporidiosis",[11388],{"trials":11406,"activeCount":102},[],{"trials":11408,"activeCount":102},[],{"trials":11410,"activeCount":102},[],{"intervention":219,"totalTrials":236,"cells":11412},{"EARLY_PHASE1":11413,"PHASE1":11415,"PHASE2":11417,"PHASE3":11423,"PHASE4":11425,"NA":11427},{"trials":11414,"activeCount":102},[],{"trials":11416,"activeCount":102},[],{"trials":11418,"activeCount":102},[11419],{"nctId":210,"briefTitle":211,"status":108,"phases":11420,"primaryCompletion":213,"completion":213,"start":214,"enrollment":98,"conditions":11421,"interventions":11422},[91],[216,217],[182,97,219],{"trials":11424,"activeCount":102},[],{"trials":11426,"activeCount":102},[],{"trials":11428,"activeCount":102},[],{"intervention":11430,"totalTrials":236,"cells":11431},"Flumazenil",{"EARLY_PHASE1":11432,"PHASE1":11434,"PHASE2":11436,"PHASE3":11446,"PHASE4":11448,"NA":11450},{"trials":11433,"activeCount":102},[],{"trials":11435,"activeCount":102},[],{"trials":11437,"activeCount":102},[11438],{"nctId":11439,"briefTitle":11440,"status":131,"phases":11441,"primaryCompletion":410,"completion":410,"start":11442,"enrollment":1477,"conditions":11443,"interventions":11445},"NCT00695630","Flumazenil Reversal of Oral Triazolam",[90,91],"2006-09",[11444],"Dental Anxiety",[11430],{"trials":11447,"activeCount":102},[],{"trials":11449,"activeCount":102},[],{"trials":11451,"activeCount":102},[],{"intervention":1279,"totalTrials":236,"cells":11453},{"EARLY_PHASE1":11454,"PHASE1":11456,"PHASE2":11458,"PHASE3":11464,"PHASE4":11466,"NA":11468},{"trials":11455,"activeCount":102},[],{"trials":11457,"activeCount":102},[],{"trials":11459,"activeCount":102},[11460],{"nctId":1269,"briefTitle":1270,"status":131,"phases":11461,"primaryCompletion":1272,"completion":1272,"start":1273,"enrollment":1274,"conditions":11462,"interventions":11463},[91],[1276],[1278,993,994,1279],{"trials":11465,"activeCount":102},[],{"trials":11467,"activeCount":102},[],{"trials":11469,"activeCount":102},[],{"intervention":11471,"totalTrials":236,"cells":11472},"Cabozantinib",{"EARLY_PHASE1":11473,"PHASE1":11475,"PHASE2":11477,"PHASE3":11490,"PHASE4":11492,"NA":11494},{"trials":11474,"activeCount":102},[],{"trials":11476,"activeCount":102},[],{"trials":11478,"activeCount":102},[11479],{"nctId":11480,"briefTitle":11481,"status":108,"phases":11482,"primaryCompletion":11483,"completion":11484,"start":11485,"enrollment":98,"conditions":11486,"interventions":11489},"NCT01703065","Cabozantinib in Men With Castration-Resistant Prostate Cancer",[91],"2015-02-02","2015-09-18","2013-06-18",[1139,11487,11488,1141,1142],"Castration-resistant Prostate Cancer","Recurrent Prostate Cancer",[11471],{"trials":11491,"activeCount":102},[],{"trials":11493,"activeCount":102},[],{"trials":11495,"activeCount":102},[],{"intervention":7692,"totalTrials":236,"cells":11497},{"EARLY_PHASE1":11498,"PHASE1":11500,"PHASE2":11502,"PHASE3":11508,"PHASE4":11510,"NA":11512},{"trials":11499,"activeCount":102},[],{"trials":11501,"activeCount":102},[],{"trials":11503,"activeCount":102},[11504],{"nctId":7684,"briefTitle":7685,"status":131,"phases":11505,"primaryCompletion":7687,"completion":7687,"start":7688,"enrollment":7689,"conditions":11506,"interventions":11507},[90,91],[4909],[7692,677],{"trials":11509,"activeCount":102},[],{"trials":11511,"activeCount":102},[],{"trials":11513,"activeCount":102},[],{"intervention":2318,"totalTrials":236,"cells":11515},{"EARLY_PHASE1":11516,"PHASE1":11518,"PHASE2":11520,"PHASE3":11526,"PHASE4":11528,"NA":11530},{"trials":11517,"activeCount":102},[],{"trials":11519,"activeCount":102},[],{"trials":11521,"activeCount":102},[11522],{"nctId":2304,"briefTitle":2305,"status":108,"phases":11523,"primaryCompletion":2307,"completion":2308,"start":2309,"enrollment":37,"conditions":11524,"interventions":11525},[91],[2311,2312,2313,2314,2315],[2317,2318,1262,1014],{"trials":11527,"activeCount":102},[],{"trials":11529,"activeCount":102},[],{"trials":11531,"activeCount":102},[],{"intervention":9609,"totalTrials":236,"cells":11533},{"EARLY_PHASE1":11534,"PHASE1":11536,"PHASE2":11538,"PHASE3":11544,"PHASE4":11546,"NA":11548},{"trials":11535,"activeCount":102},[],{"trials":11537,"activeCount":102},[],{"trials":11539,"activeCount":102},[11540],{"nctId":9602,"briefTitle":9603,"status":131,"phases":11541,"primaryCompletion":9605,"completion":9605,"start":9606,"enrollment":5919,"conditions":11542,"interventions":11543},[91],[4909],[9609,9610],{"trials":11545,"activeCount":102},[],{"trials":11547,"activeCount":102},[],{"trials":11549,"activeCount":102},[],{"intervention":11551,"totalTrials":236,"cells":11552},"Paricalcitol",{"EARLY_PHASE1":11553,"PHASE1":11555,"PHASE2":11557,"PHASE3":11566,"PHASE4":11568,"NA":11570},{"trials":11554,"activeCount":102},[],{"trials":11556,"activeCount":102},[],{"trials":11558,"activeCount":102},[11559],{"nctId":11560,"briefTitle":11561,"status":131,"phases":11562,"primaryCompletion":5770,"completion":5770,"start":7168,"enrollment":1087,"conditions":11563,"interventions":11565},"NCT01003275","Metabolic Effects of Paricalcitol",[91],[11564],"Chronic Kidney Disease",[11551],{"trials":11567,"activeCount":102},[],{"trials":11569,"activeCount":102},[],{"trials":11571,"activeCount":102},[],{"intervention":3273,"totalTrials":236,"cells":11573},{"EARLY_PHASE1":11574,"PHASE1":11576,"PHASE2":11578,"PHASE3":11584,"PHASE4":11586,"NA":11588},{"trials":11575,"activeCount":102},[],{"trials":11577,"activeCount":102},[],{"trials":11579,"activeCount":102},[11580],{"nctId":3260,"briefTitle":3261,"status":108,"phases":11581,"primaryCompletion":3263,"completion":3263,"start":3264,"enrollment":2817,"conditions":11582,"interventions":11583},[91],[3266,3267,3268,3269,3270,3271],[1723,3273],{"trials":11585,"activeCount":102},[],{"trials":11587,"activeCount":102},[],{"trials":11589,"activeCount":102},[],{"intervention":2444,"totalTrials":236,"cells":11591},{"EARLY_PHASE1":11592,"PHASE1":11594,"PHASE2":11596,"PHASE3":11602,"PHASE4":11604,"NA":11606},{"trials":11593,"activeCount":102},[],{"trials":11595,"activeCount":102},[],{"trials":11597,"activeCount":102},[11598],{"nctId":2437,"briefTitle":2438,"status":108,"phases":11599,"primaryCompletion":1789,"completion":1789,"start":2440,"enrollment":2089,"conditions":11600,"interventions":11601},[90,91],[413],[1278,2443,2444,1079],{"trials":11603,"activeCount":102},[],{"trials":11605,"activeCount":102},[],{"trials":11607,"activeCount":102},[],{"intervention":11609,"totalTrials":236,"cells":11610},"Docetaxel and Diethylstilbestrol",{"EARLY_PHASE1":11611,"PHASE1":11613,"PHASE2":11615,"PHASE3":11623,"PHASE4":11625,"NA":11627},{"trials":11612,"activeCount":102},[],{"trials":11614,"activeCount":102},[],{"trials":11616,"activeCount":102},[11617],{"nctId":11618,"briefTitle":11619,"status":131,"phases":11620,"completion":1865,"start":5941,"enrollment":23,"conditions":11621,"interventions":11622},"NCT00136526","Docetaxel and Diethylstilbestrol in the Treatment of Androgen Independent Prostate Cancer",[91],[4909],[11609],{"trials":11624,"activeCount":102},[],{"trials":11626,"activeCount":102},[],{"trials":11628,"activeCount":102},[],{"intervention":11630,"totalTrials":236,"cells":11631},"XR-NTX",{"EARLY_PHASE1":11632,"PHASE1":11634,"PHASE2":11636,"PHASE3":11649,"PHASE4":11651,"NA":11653},{"trials":11633,"activeCount":102},[],{"trials":11635,"activeCount":102},[],{"trials":11637,"activeCount":102},[11638],{"nctId":11639,"briefTitle":11640,"status":131,"phases":11641,"primaryCompletion":11642,"completion":11643,"start":11644,"enrollment":11645,"conditions":11646,"interventions":11648},"NCT01932801","Harm Reduction With Pharmacotherapy (HaRP)",[91],"2018-10-11","2019-06-30","2013-08-01",308,[11647],"Alcohol Use Disorder",[11630],{"trials":11650,"activeCount":102},[],{"trials":11652,"activeCount":102},[],{"trials":11654,"activeCount":102},[],{"intervention":3368,"totalTrials":236,"cells":11656},{"EARLY_PHASE1":11657,"PHASE1":11659,"PHASE2":11661,"PHASE3":11667,"PHASE4":11669,"NA":11671},{"trials":11658,"activeCount":102},[],{"trials":11660,"activeCount":102},[],{"trials":11662,"activeCount":102},[11663],{"nctId":3359,"briefTitle":3360,"status":108,"phases":11664,"primaryCompletion":3362,"completion":3362,"start":3363,"enrollment":702,"conditions":11665,"interventions":11666},[91],[1355,3365,1058,1059,1061,1062,1063],[1066,3367,3368],{"trials":11668,"activeCount":102},[],{"trials":11670,"activeCount":102},[],{"trials":11672,"activeCount":102},[],{"intervention":5763,"totalTrials":236,"cells":11674},{"EARLY_PHASE1":11675,"PHASE1":11677,"PHASE2":11679,"PHASE3":11685,"PHASE4":11687,"NA":11689},{"trials":11676,"activeCount":102},[],{"trials":11678,"activeCount":102},[],{"trials":11680,"activeCount":102},[11681],{"nctId":5755,"briefTitle":5756,"status":108,"phases":11682,"primaryCompletion":5758,"completion":5758,"start":5759,"enrollment":113,"conditions":11683,"interventions":11684},[90,91],[5761],[5763,5746],{"trials":11686,"activeCount":102},[],{"trials":11688,"activeCount":102},[],{"trials":11690,"activeCount":102},[],{"intervention":9852,"totalTrials":236,"cells":11692},{"EARLY_PHASE1":11693,"PHASE1":11695,"PHASE2":11697,"PHASE3":11703,"PHASE4":11705,"NA":11707},{"trials":11694,"activeCount":102},[],{"trials":11696,"activeCount":102},[],{"trials":11698,"activeCount":102},[11699],{"nctId":9845,"briefTitle":9846,"status":131,"phases":11700,"primaryCompletion":3251,"completion":9848,"start":1476,"enrollment":1439,"conditions":11701,"interventions":11702},[91],[1139,1140,1141],[9851,9852,448,9853,9826],{"trials":11704,"activeCount":102},[],{"trials":11706,"activeCount":102},[],{"trials":11708,"activeCount":102},[],{"intervention":9853,"totalTrials":236,"cells":11710},{"EARLY_PHASE1":11711,"PHASE1":11713,"PHASE2":11715,"PHASE3":11721,"PHASE4":11723,"NA":11725},{"trials":11712,"activeCount":102},[],{"trials":11714,"activeCount":102},[],{"trials":11716,"activeCount":102},[11717],{"nctId":9845,"briefTitle":9846,"status":131,"phases":11718,"primaryCompletion":3251,"completion":9848,"start":1476,"enrollment":1439,"conditions":11719,"interventions":11720},[91],[1139,1140,1141],[9851,9852,448,9853,9826],{"trials":11722,"activeCount":102},[],{"trials":11724,"activeCount":102},[],{"trials":11726,"activeCount":102},[],{"intervention":2570,"totalTrials":236,"cells":11728},{"EARLY_PHASE1":11729,"PHASE1":11731,"PHASE2":11733,"PHASE3":11739,"PHASE4":11741,"NA":11743},{"trials":11730,"activeCount":102},[],{"trials":11732,"activeCount":102},[],{"trials":11734,"activeCount":102},[11735],{"nctId":2556,"briefTitle":2557,"status":108,"phases":11736,"primaryCompletion":2559,"completion":2560,"start":2561,"enrollment":1439,"conditions":11737,"interventions":11738},[90,91],[2563,2564,2565,2566,2567,2568],[1262,2570],{"trials":11740,"activeCount":102},[],{"trials":11742,"activeCount":102},[],{"trials":11744,"activeCount":102},[],{"intervention":2093,"totalTrials":236,"cells":11746},{"EARLY_PHASE1":11747,"PHASE1":11749,"PHASE2":11751,"PHASE3":11757,"PHASE4":11759,"NA":11761},{"trials":11748,"activeCount":102},[],{"trials":11750,"activeCount":102},[],{"trials":11752,"activeCount":102},[11753],{"nctId":2085,"briefTitle":2086,"status":131,"phases":11754,"primaryCompletion":225,"start":2088,"enrollment":2089,"conditions":11755,"interventions":11756},[91],[354,275,378,379,36],[2092,1624,2093],{"trials":11758,"activeCount":102},[],{"trials":11760,"activeCount":102},[],{"trials":11762,"activeCount":102},[],{"intervention":11764,"totalTrials":236,"cells":11765},"Up to 2 liter infusion of cold 4 degree C normal saline",{"EARLY_PHASE1":11766,"PHASE1":11768,"PHASE2":11770,"PHASE3":11778,"PHASE4":11780,"NA":11782},{"trials":11767,"activeCount":102},[],{"trials":11769,"activeCount":102},[],{"trials":11771,"activeCount":102},[11772],{"nctId":11773,"briefTitle":11774,"status":131,"phases":11775,"completion":11160,"start":5610,"enrollment":1254,"conditions":11776,"interventions":11777},"NCT00329563","Pilot Community Clinical Study of Hypothermia in Cardiac Arrest",[90,91],[7703],[11764],{"trials":11779,"activeCount":102},[],{"trials":11781,"activeCount":102},[],{"trials":11783,"activeCount":102},[],{"intervention":5730,"totalTrials":236,"cells":11785},{"EARLY_PHASE1":11786,"PHASE1":11788,"PHASE2":11790,"PHASE3":11796,"PHASE4":11798,"NA":11800},{"trials":11787,"activeCount":102},[],{"trials":11789,"activeCount":102},[],{"trials":11791,"activeCount":102},[11792],{"nctId":5724,"briefTitle":5725,"status":131,"phases":11793,"primaryCompletion":4906,"completion":4906,"start":5685,"enrollment":1182,"conditions":11794,"interventions":11795},[91],[5614,5613],[5729,5730,5074],{"trials":11797,"activeCount":102},[],{"trials":11799,"activeCount":102},[],{"trials":11801,"activeCount":102},[],{"intervention":11803,"totalTrials":236,"cells":11804},"TH9507 human growth hormone releasing hormone",{"EARLY_PHASE1":11805,"PHASE1":11807,"PHASE2":11809,"PHASE3":11819,"PHASE4":11821,"NA":11823},{"trials":11806,"activeCount":102},[],{"trials":11808,"activeCount":102},[],{"trials":11810,"activeCount":102},[11811],{"nctId":11812,"briefTitle":11813,"status":131,"phases":11814,"primaryCompletion":224,"completion":224,"start":1642,"enrollment":11815,"conditions":11816,"interventions":11818},"NCT00257712","SMART: Somatotrophics, Memory, and Aging Research Trial",[91],151,[11817,5675],"Aging",[11803],{"trials":11820,"activeCount":102},[],{"trials":11822,"activeCount":102},[],{"trials":11824,"activeCount":102},[],{"intervention":235,"totalTrials":236,"cells":11826},{"EARLY_PHASE1":11827,"PHASE1":11829,"PHASE2":11831,"PHASE3":11837,"PHASE4":11839,"NA":11841},{"trials":11828,"activeCount":102},[],{"trials":11830,"activeCount":102},[],{"trials":11832,"activeCount":102},[11833],{"nctId":221,"briefTitle":222,"status":108,"phases":11834,"primaryCompletion":224,"completion":225,"start":226,"enrollment":227,"conditions":11835,"interventions":11836},[90,91],[162,229,230,231],[233,234,235,168],{"trials":11838,"activeCount":102},[],{"trials":11840,"activeCount":102},[],{"trials":11842,"activeCount":102},[],{"intervention":1146,"totalTrials":236,"cells":11844},{"EARLY_PHASE1":11845,"PHASE1":11847,"PHASE2":11849,"PHASE3":11855,"PHASE4":11857,"NA":11859},{"trials":11846,"activeCount":102},[],{"trials":11848,"activeCount":102},[],{"trials":11850,"activeCount":102},[11851],{"nctId":1133,"briefTitle":1134,"status":131,"phases":11852,"primaryCompletion":1136,"completion":1136,"start":1137,"enrollment":1023,"conditions":11853,"interventions":11854},[91],[1139,1140,1141,1142],[1144,1145,416,1146],{"trials":11856,"activeCount":102},[],{"trials":11858,"activeCount":102},[],{"trials":11860,"activeCount":102},[],{"intervention":11862,"totalTrials":236,"cells":11863},"Leuprolide or goserelin",{"EARLY_PHASE1":11864,"PHASE1":11866,"PHASE2":11868,"PHASE3":11877,"PHASE4":11879,"NA":11881},{"trials":11865,"activeCount":102},[],{"trials":11867,"activeCount":102},[],{"trials":11869,"activeCount":102},[11870],{"nctId":11871,"briefTitle":11872,"status":131,"phases":11873,"primaryCompletion":1476,"completion":1476,"start":5685,"enrollment":1238,"conditions":11874,"interventions":11875},"NCT00167648","Neoadjuvant Estradiol or Androgen Deprivation in Clinically Localized Prostate Cancer",[91],[10701,10702],[11862,11876],"Transdermal estradiol",{"trials":11878,"activeCount":102},[],{"trials":11880,"activeCount":102},[],{"trials":11882,"activeCount":102},[],{"intervention":11876,"totalTrials":236,"cells":11884},{"EARLY_PHASE1":11885,"PHASE1":11887,"PHASE2":11889,"PHASE3":11895,"PHASE4":11897,"NA":11899},{"trials":11886,"activeCount":102},[],{"trials":11888,"activeCount":102},[],{"trials":11890,"activeCount":102},[11891],{"nctId":11871,"briefTitle":11872,"status":131,"phases":11892,"primaryCompletion":1476,"completion":1476,"start":5685,"enrollment":1238,"conditions":11893,"interventions":11894},[91],[10701,10702],[11862,11876],{"trials":11896,"activeCount":102},[],{"trials":11898,"activeCount":102},[],{"trials":11900,"activeCount":102},[],{"intervention":11902,"totalTrials":236,"cells":11903},"Fish oil",{"EARLY_PHASE1":11904,"PHASE1":11906,"PHASE2":11908,"PHASE3":11918,"PHASE4":11920,"NA":11922},{"trials":11905,"activeCount":102},[],{"trials":11907,"activeCount":102},[],{"trials":11909,"activeCount":102},[11910],{"nctId":11911,"briefTitle":11912,"status":131,"phases":11913,"primaryCompletion":5665,"completion":7756,"start":4906,"enrollment":741,"conditions":11914,"interventions":11917},"NCT00351533","A Phase II Randomized Trial of Fish Oil in Patients With Acute Lung Injury (ALI)",[91],[10250,11915,11916],"Acute Lung Injury","Acute Respiratory Distress Syndrome",[11902],{"trials":11919,"activeCount":102},[],{"trials":11921,"activeCount":102},[],{"trials":11923,"activeCount":102},[],{"intervention":1163,"totalTrials":236,"cells":11925},{"EARLY_PHASE1":11926,"PHASE1":11928,"PHASE2":11930,"PHASE3":11936,"PHASE4":11938,"NA":11940},{"trials":11927,"activeCount":102},[],{"trials":11929,"activeCount":102},[],{"trials":11931,"activeCount":102},[11932],{"nctId":1148,"briefTitle":1149,"status":1150,"phases":11933,"primaryCompletion":1152,"completion":1153,"start":1154,"enrollment":102,"conditions":11934,"interventions":11935},[91],[1156,1157,1158,1026,1159,1028,1160,1076,1161],[1163,994,1013,992,1047,966,124,1015],{"trials":11937,"activeCount":102},[],{"trials":11939,"activeCount":102},[],{"trials":11941,"activeCount":102},[],{"intervention":11943,"totalTrials":236,"cells":11944},"Sacituzumab Govitecan",{"EARLY_PHASE1":11945,"PHASE1":11947,"PHASE2":11949,"PHASE3":11960,"PHASE4":11962,"NA":11964},{"trials":11946,"activeCount":102},[],{"trials":11948,"activeCount":102},[],{"trials":11950,"activeCount":102},[11951],{"nctId":11952,"briefTitle":11953,"status":108,"phases":11954,"primaryCompletion":11955,"completion":11956,"start":11957,"enrollment":1547,"conditions":11958,"interventions":11959},"NCT05581589","Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer",[91],"2024-10-15","2026-03-06","2023-06-15",[1242,1240,1241],[11943],{"trials":11961,"activeCount":102},[],{"trials":11963,"activeCount":102},[],{"trials":11965,"activeCount":102},[],{"intervention":4911,"totalTrials":236,"cells":11967},{"EARLY_PHASE1":11968,"PHASE1":11970,"PHASE2":11972,"PHASE3":11978,"PHASE4":11980,"NA":11982},{"trials":11969,"activeCount":102},[],{"trials":11971,"activeCount":102},[],{"trials":11973,"activeCount":102},[11974],{"nctId":4903,"briefTitle":4904,"status":131,"phases":11975,"completion":4906,"start":4907,"enrollment":23,"conditions":11976,"interventions":11977},[90,91],[4909],[1794,4911],{"trials":11979,"activeCount":102},[],{"trials":11981,"activeCount":102},[],{"trials":11983,"activeCount":102},[],{"intervention":11985,"totalTrials":236,"cells":11986},"insulin detemir",{"EARLY_PHASE1":11987,"PHASE1":11989,"PHASE2":11991,"PHASE3":11999,"PHASE4":12001,"NA":12003},{"trials":11988,"activeCount":102},[],{"trials":11990,"activeCount":102},[],{"trials":11992,"activeCount":102},[11993],{"nctId":11994,"briefTitle":11995,"status":131,"phases":11996,"primaryCompletion":1194,"completion":1194,"start":1272,"enrollment":389,"conditions":11997,"interventions":11998},"NCT01547169","Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 21 Days",[91],[5676,5675],[11985,11985],{"trials":12000,"activeCount":102},[],{"trials":12002,"activeCount":102},[],{"trials":12004,"activeCount":102},[],{"intervention":12006,"totalTrials":236,"cells":12007},"Nitrofurantoin 100mg twice daily x 5 days",{"EARLY_PHASE1":12008,"PHASE1":12010,"PHASE2":12012,"PHASE3":12023,"PHASE4":12025,"NA":12027},{"trials":12009,"activeCount":102},[],{"trials":12011,"activeCount":102},[],{"trials":12013,"activeCount":102},[12014],{"nctId":12015,"briefTitle":12016,"status":131,"phases":12017,"primaryCompletion":2913,"completion":2913,"start":12018,"enrollment":12019,"conditions":12020,"interventions":12021},"NCT00391651","Short Course Nitrofurantoin for Acute Cystitis",[91],"2002-01",338,[11162],[12006,12022],"TMP\u002FSMX DS twice daily x 3 days",{"trials":12024,"activeCount":102},[],{"trials":12026,"activeCount":102},[],{"trials":12028,"activeCount":102},[],{"intervention":12022,"totalTrials":236,"cells":12030},{"EARLY_PHASE1":12031,"PHASE1":12033,"PHASE2":12035,"PHASE3":12041,"PHASE4":12043,"NA":12045},{"trials":12032,"activeCount":102},[],{"trials":12034,"activeCount":102},[],{"trials":12036,"activeCount":102},[12037],{"nctId":12015,"briefTitle":12016,"status":131,"phases":12038,"primaryCompletion":2913,"completion":2913,"start":12018,"enrollment":12019,"conditions":12039,"interventions":12040},[91],[11162],[12006,12022],{"trials":12042,"activeCount":102},[],{"trials":12044,"activeCount":102},[],{"trials":12046,"activeCount":102},[],{"intervention":2109,"totalTrials":236,"cells":12048},{"EARLY_PHASE1":12049,"PHASE1":12051,"PHASE2":12053,"PHASE3":12059,"PHASE4":12061,"NA":12063},{"trials":12050,"activeCount":102},[],{"trials":12052,"activeCount":102},[],{"trials":12054,"activeCount":102},[12055],{"nctId":2103,"briefTitle":2104,"status":131,"phases":12056,"primaryCompletion":133,"start":2106,"enrollment":350,"conditions":12057,"interventions":12058},[90,91],[354,275,377,277,278,378,379,36],[1581,1624,2109],{"trials":12060,"activeCount":102},[],{"trials":12062,"activeCount":102},[],{"trials":12064,"activeCount":102},[],{"intervention":12066,"totalTrials":236,"cells":12067},"Combined short-course zidovudine\u002Fnevirapine",{"EARLY_PHASE1":12068,"PHASE1":12070,"PHASE2":12072,"PHASE3":12083,"PHASE4":12085,"NA":12087},{"trials":12069,"activeCount":102},[],{"trials":12071,"activeCount":102},[],{"trials":12073,"activeCount":102},[12074],{"nctId":12075,"briefTitle":12076,"status":131,"phases":12077,"primaryCompletion":5685,"completion":5650,"start":12078,"enrollment":12079,"conditions":12080,"interventions":12081},"NCT00167674","ARVs to Prevent Breastmilk HIV:Viral and Immune Responses",[91],"2003-11-03",58,[19],[12066,12082],"HAART",{"trials":12084,"activeCount":102},[],{"trials":12086,"activeCount":102},[],{"trials":12088,"activeCount":102},[],{"intervention":12090,"totalTrials":236,"cells":12091},"H. pylori treatment",{"EARLY_PHASE1":12092,"PHASE1":12094,"PHASE2":12096,"PHASE3":12107,"PHASE4":12109,"NA":12111},{"trials":12093,"activeCount":102},[],{"trials":12095,"activeCount":102},[],{"trials":12097,"activeCount":102},[12098],{"nctId":12099,"briefTitle":12100,"status":131,"phases":12101,"completion":6588,"start":12102,"enrollment":12103,"conditions":12104,"interventions":12106},"NCT00194688","Breath Ammonia Method for H. Pylori Detection: Phase II",[91],"2003-03",278,[12105],"Helicobacter Infections",[12090],{"trials":12108,"activeCount":102},[],{"trials":12110,"activeCount":102},[],{"trials":12112,"activeCount":102},[],{"intervention":9691,"totalTrials":236,"cells":12114},{"EARLY_PHASE1":12115,"PHASE1":12117,"PHASE2":12119,"PHASE3":12125,"PHASE4":12127,"NA":12129},{"trials":12116,"activeCount":102},[],{"trials":12118,"activeCount":102},[],{"trials":12120,"activeCount":102},[12121],{"nctId":9686,"briefTitle":9687,"status":131,"phases":12122,"primaryCompletion":3251,"start":5621,"enrollment":456,"conditions":12123,"interventions":12124},[90,91],[275,377,278,378,379,36],[9691,2051],{"trials":12126,"activeCount":102},[],{"trials":12128,"activeCount":102},[],{"trials":12130,"activeCount":102},[],{"intervention":12132,"totalTrials":236,"cells":12133},"Sirolimus Albumin-bound Nanoparticles",{"EARLY_PHASE1":12134,"PHASE1":12136,"PHASE2":12138,"PHASE3":12151,"PHASE4":12153,"NA":12155},{"trials":12135,"activeCount":102},[],{"trials":12137,"activeCount":102},[],{"trials":12139,"activeCount":102},[12140],{"nctId":12141,"briefTitle":12142,"status":108,"phases":12143,"primaryCompletion":1745,"completion":12144,"start":2275,"enrollment":7013,"conditions":12145,"interventions":12149},"NCT03660930","Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas",[90,91],"2024-07-31",[12146,12147,12148],"Advanced Soft Tissue Sarcoma","Locally Advanced Soft Tissue Sarcoma","Metastatic Soft Tissue Sarcoma",[12132,12150],"Pazopanib hydrochloride",{"trials":12152,"activeCount":102},[],{"trials":12154,"activeCount":102},[],{"trials":12156,"activeCount":102},[],{"intervention":12158,"totalTrials":236,"cells":12159},"Regular Insulin",{"EARLY_PHASE1":12160,"PHASE1":12162,"PHASE2":12164,"PHASE3":12173,"PHASE4":12175,"NA":12177},{"trials":12161,"activeCount":102},[],{"trials":12163,"activeCount":102},[],{"trials":12165,"activeCount":102},[12166],{"nctId":12167,"briefTitle":12168,"status":131,"phases":12169,"primaryCompletion":224,"completion":224,"start":2930,"enrollment":12170,"conditions":12171,"interventions":12172},"NCT00438568","SNIFF 120: Study of Nasal Insulin to Fight Forgetfulness (120 Days)",[91],173,[5675,5676],[12158],{"trials":12174,"activeCount":102},[],{"trials":12176,"activeCount":102},[],{"trials":12178,"activeCount":102},[],{"intervention":12180,"totalTrials":236,"cells":12181},"Oxytocin nasal spray",{"EARLY_PHASE1":12182,"PHASE1":12184,"PHASE2":12186,"PHASE3":12198,"PHASE4":12200,"NA":12202},{"trials":12183,"activeCount":102},[],{"trials":12185,"activeCount":102},[],{"trials":12187,"activeCount":102},[12188],{"nctId":12189,"briefTitle":12190,"status":131,"phases":12191,"primaryCompletion":12192,"completion":12192,"start":12193,"enrollment":12194,"conditions":12195,"interventions":12197},"NCT05968651","Social Safety Learning in the Brain Oxytocin System",[91],"2024-09-30","2023-06-26",121,[12196],"Social Phobia",[12180],{"trials":12199,"activeCount":102},[],{"trials":12201,"activeCount":102},[],{"trials":12203,"activeCount":102},[],{"intervention":12205,"totalTrials":236,"cells":12206},"Tozuleristide",{"EARLY_PHASE1":12207,"PHASE1":12209,"PHASE2":12211,"PHASE3":12227,"PHASE4":12229,"NA":12231},{"trials":12208,"activeCount":102},[],{"trials":12210,"activeCount":102},[],{"trials":12212,"activeCount":102},[12213],{"nctId":12214,"briefTitle":12215,"status":108,"phases":12216,"primaryCompletion":12217,"completion":12218,"start":12219,"enrollment":317,"conditions":12220,"interventions":12226},"NCT05316688","A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery",[90,91],"2025-09-09","2025-09-26","2024-04-17",[12221,12222,12223,12224,12225],"Oral Cavity Squamous Cell Carcinoma","Stage I Lip and Oral Cavity Cancer AJCC v8","Stage II Lip and Oral Cavity Cancer AJCC v8","Stage III Lip and Oral Cavity Cancer AJCC v8","Stage IVA Lip and Oral Cavity Cancer AJCC v8",[12205],{"trials":12228,"activeCount":102},[],{"trials":12230,"activeCount":102},[],{"trials":12232,"activeCount":102},[],{"intervention":12234,"totalTrials":236,"cells":12235},"Gamunex-C",{"EARLY_PHASE1":12236,"PHASE1":12238,"PHASE2":12240,"PHASE3":12252,"PHASE4":12254,"NA":12256},{"trials":12237,"activeCount":102},[],{"trials":12239,"activeCount":102},[],{"trials":12241,"activeCount":102},[12242],{"nctId":12243,"briefTitle":12244,"status":1150,"phases":12245,"primaryCompletion":12246,"completion":12246,"start":12247,"enrollment":102,"conditions":12248,"interventions":12250},"NCT04450654","Monotherapy IVIG Gamunex-C for HMG-CoA Reductase Auto-Antibody Positive Necrotizing Myopathy Treatment (The MIGHT Trial)",[91],"2022-07-25","2022-05",[12249],"Immune-Mediated Necrotizing Myopathy",[12234,12251],"Albumin",{"trials":12253,"activeCount":102},[],{"trials":12255,"activeCount":102},[],{"trials":12257,"activeCount":102},[],{"intervention":12251,"totalTrials":236,"cells":12259},{"EARLY_PHASE1":12260,"PHASE1":12262,"PHASE2":12264,"PHASE3":12270,"PHASE4":12272,"NA":12274},{"trials":12261,"activeCount":102},[],{"trials":12263,"activeCount":102},[],{"trials":12265,"activeCount":102},[12266],{"nctId":12243,"briefTitle":12244,"status":1150,"phases":12267,"primaryCompletion":12246,"completion":12246,"start":12247,"enrollment":102,"conditions":12268,"interventions":12269},[91],[12249],[12234,12251],{"trials":12271,"activeCount":102},[],{"trials":12273,"activeCount":102},[],{"trials":12275,"activeCount":102},[],{"intervention":12277,"totalTrials":236,"cells":12278},"Lanreotide Prefilled Syringe",{"EARLY_PHASE1":12279,"PHASE1":12281,"PHASE2":12283,"PHASE3":12299,"PHASE4":12301,"NA":12303},{"trials":12280,"activeCount":102},[],{"trials":12282,"activeCount":102},[],{"trials":12284,"activeCount":102},[12285],{"nctId":12286,"briefTitle":12287,"status":131,"phases":12288,"primaryCompletion":12289,"completion":12290,"start":12291,"enrollment":12292,"conditions":12293,"interventions":12298},"NCT03174353","A Phase II Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula",[91],"2021-02-01","2021-04-01","2018-02-20",114,[12294,12295,12296,12297],"Pancreatic Leak","Pancreatic Fistula","Pancreaticoduodenal; Fistula","Pancreatectomy; Hyperglycemia",[12277],{"trials":12300,"activeCount":102},[],{"trials":12302,"activeCount":102},[],{"trials":12304,"activeCount":102},[],{"intervention":12306,"totalTrials":236,"cells":12307},"0.9% Sodium Chloride 250 mL bolus",{"EARLY_PHASE1":12308,"PHASE1":12310,"PHASE2":12312,"PHASE3":12325,"PHASE4":12327,"NA":12329},{"trials":12309,"activeCount":102},[],{"trials":12311,"activeCount":102},[],{"trials":12313,"activeCount":102},[12314],{"nctId":12315,"briefTitle":12316,"status":131,"phases":12317,"primaryCompletion":10951,"completion":10951,"start":1864,"enrollment":12318,"conditions":12319,"interventions":12323},"NCT01411852","Field Trial of Hypotensive Versus Standard Resuscitation for Hemorrhagic Shock After Trauma",[91],192,[12320,12321,12322],"Blunt Trauma","Penetrating Wound","Hemorrhagic Shock",[12306,12324],"0.9% Sodium Chloride 2000 mL bolus",{"trials":12326,"activeCount":102},[],{"trials":12328,"activeCount":102},[],{"trials":12330,"activeCount":102},[],{"intervention":12324,"totalTrials":236,"cells":12332},{"EARLY_PHASE1":12333,"PHASE1":12335,"PHASE2":12337,"PHASE3":12343,"PHASE4":12345,"NA":12347},{"trials":12334,"activeCount":102},[],{"trials":12336,"activeCount":102},[],{"trials":12338,"activeCount":102},[12339],{"nctId":12315,"briefTitle":12316,"status":131,"phases":12340,"primaryCompletion":10951,"completion":10951,"start":1864,"enrollment":12318,"conditions":12341,"interventions":12342},[91],[12320,12321,12322],[12306,12324],{"trials":12344,"activeCount":102},[],{"trials":12346,"activeCount":102},[],{"trials":12348,"activeCount":102},[],{"intervention":12350,"totalTrials":236,"cells":12351},"Isoniazid",{"EARLY_PHASE1":12352,"PHASE1":12354,"PHASE2":12356,"PHASE3":12368,"PHASE4":12370,"NA":12372},{"trials":12353,"activeCount":102},[],{"trials":12355,"activeCount":102},[],{"trials":12357,"activeCount":102},[12358],{"nctId":12359,"briefTitle":12360,"status":131,"phases":12361,"primaryCompletion":12362,"completion":12363,"start":8773,"enrollment":12364,"conditions":12365,"interventions":12367},"NCT02613169","Infant TB Infection Prevention Study",[91],"2019-10","2020-12",300,[12366],"Tuberculosis",[12350],{"trials":12369,"activeCount":102},[],{"trials":12371,"activeCount":102},[],{"trials":12373,"activeCount":102},[],{"intervention":12375,"totalTrials":236,"cells":12376},"Amitriptyline",{"EARLY_PHASE1":12377,"PHASE1":12379,"PHASE2":12381,"PHASE3":12390,"PHASE4":12392,"NA":12394},{"trials":12378,"activeCount":102},[],{"trials":12380,"activeCount":102},[],{"trials":12382,"activeCount":102},[12383],{"nctId":12384,"briefTitle":12385,"status":131,"phases":12386,"primaryCompletion":6020,"completion":6020,"start":10951,"enrollment":350,"conditions":12387,"interventions":12389},"NCT01856270","Amitriptyline to Prevent Headache After Traumatic Brain Injury",[91],[8191,12388],"Post-Traumatic Headache",[12375],{"trials":12391,"activeCount":102},[],{"trials":12393,"activeCount":102},[],{"trials":12395,"activeCount":102},[],{"intervention":12397,"totalTrials":236,"cells":12398},"Ortho-Cyclen",{"EARLY_PHASE1":12399,"PHASE1":12401,"PHASE2":12403,"PHASE3":12413,"PHASE4":12415,"NA":12417},{"trials":12400,"activeCount":102},[],{"trials":12402,"activeCount":102},[],{"trials":12404,"activeCount":102},[12405],{"nctId":12406,"briefTitle":12407,"status":5876,"phases":12408,"primaryCompletion":224,"completion":224,"start":411,"enrollment":3680,"conditions":12409,"interventions":12410},"NCT00439972","Oral Versus Patch Hormonal Contraceptive Effects on Metabolism, Clotting, Inflammatory Factors and Vascular Reactivity",[91],[5614],[12397,12411,12412],"Ortho Evra","extended use of Ortho Evra",{"trials":12414,"activeCount":102},[],{"trials":12416,"activeCount":102},[],{"trials":12418,"activeCount":102},[],{"intervention":12411,"totalTrials":236,"cells":12420},{"EARLY_PHASE1":12421,"PHASE1":12423,"PHASE2":12425,"PHASE3":12431,"PHASE4":12433,"NA":12435},{"trials":12422,"activeCount":102},[],{"trials":12424,"activeCount":102},[],{"trials":12426,"activeCount":102},[12427],{"nctId":12406,"briefTitle":12407,"status":5876,"phases":12428,"primaryCompletion":224,"completion":224,"start":411,"enrollment":3680,"conditions":12429,"interventions":12430},[91],[5614],[12397,12411,12412],{"trials":12432,"activeCount":102},[],{"trials":12434,"activeCount":102},[],{"trials":12436,"activeCount":102},[],{"intervention":12412,"totalTrials":236,"cells":12438},{"EARLY_PHASE1":12439,"PHASE1":12441,"PHASE2":12443,"PHASE3":12449,"PHASE4":12451,"NA":12453},{"trials":12440,"activeCount":102},[],{"trials":12442,"activeCount":102},[],{"trials":12444,"activeCount":102},[12445],{"nctId":12406,"briefTitle":12407,"status":5876,"phases":12446,"primaryCompletion":224,"completion":224,"start":411,"enrollment":3680,"conditions":12447,"interventions":12448},[91],[5614],[12397,12411,12412],{"trials":12450,"activeCount":102},[],{"trials":12452,"activeCount":102},[],{"trials":12454,"activeCount":102},[],{"intervention":12456,"totalTrials":236,"cells":12457},"Temozolomide",{"EARLY_PHASE1":12458,"PHASE1":12460,"PHASE2":12462,"PHASE3":12472,"PHASE4":12474,"NA":12476},{"trials":12459,"activeCount":102},[],{"trials":12461,"activeCount":102},[],{"trials":12463,"activeCount":102},[12464],{"nctId":12465,"briefTitle":12466,"status":131,"phases":12467,"completion":1476,"start":12468,"enrollment":1114,"conditions":12469,"interventions":12471},"NCT00194766","Continuous Temozolomide in Patients With Advanced or Metastatic Soft Tissue Sarcoma or Metastatic Breast Cancer",[91],"2000-07",[413,12470],"Soft Tissue Sarcoma",[12456],{"trials":12473,"activeCount":102},[],{"trials":12475,"activeCount":102},[],{"trials":12477,"activeCount":102},[],{"intervention":9796,"totalTrials":236,"cells":12479},{"EARLY_PHASE1":12480,"PHASE1":12482,"PHASE2":12484,"PHASE3":12490,"PHASE4":12492,"NA":12494},{"trials":12481,"activeCount":102},[],{"trials":12483,"activeCount":102},[],{"trials":12485,"activeCount":102},[12486],{"nctId":9788,"briefTitle":9789,"status":131,"phases":12487,"primaryCompletion":5977,"completion":5977,"start":6176,"enrollment":673,"conditions":12488,"interventions":12489},[91],[9792,9793,9794],[9770,9796],{"trials":12491,"activeCount":102},[],{"trials":12493,"activeCount":102},[],{"trials":12495,"activeCount":102},[],{"intervention":12497,"totalTrials":702,"cells":12498},"aldesleukin",{"EARLY_PHASE1":12499,"PHASE1":12501,"PHASE2":12527,"PHASE3":12529,"PHASE4":12531,"NA":12533},{"trials":12500,"activeCount":102},[],{"trials":12502,"activeCount":102},[12503,12512,12523],{"nctId":12504,"briefTitle":12505,"status":131,"phases":12506,"primaryCompletion":12507,"completion":12507,"start":12508,"enrollment":23,"conditions":12509,"interventions":12511},"NCT00002687","Interleukin-2 in Treating Patients With Mycosis Fungoides",[90],"2003-07","1995-02",[12510],"Lymphoma",[12497],{"nctId":12513,"briefTitle":12514,"status":131,"phases":12515,"primaryCompletion":12516,"completion":12516,"start":12517,"enrollment":1023,"conditions":12518,"interventions":12522},"NCT00002746","Interleukin-2 in Treating Patients With Myelodysplastic Syndrome",[90],"2004-04","1996-01",[12519,12520,12521],"Leukemia","Myelodysplastic Syndromes","Myelodysplastic\u002FMyeloproliferative Neoplasms",[12497],{"nctId":2205,"briefTitle":2206,"status":108,"phases":12524,"primaryCompletion":2208,"completion":2208,"start":2209,"enrollment":192,"conditions":12525,"interventions":12526},[90],[2211,2212,2213,2214],[2216,1014],{"trials":12528,"activeCount":102},[],{"trials":12530,"activeCount":102},[],{"trials":12532,"activeCount":102},[],{"trials":12534,"activeCount":102},[],{"intervention":12536,"totalTrials":702,"cells":12537},"D6-25-hydroxyvitamin D3",{"EARLY_PHASE1":12538,"PHASE1":12540,"PHASE2":12568,"PHASE3":12570,"PHASE4":12572,"NA":12574},{"trials":12539,"activeCount":102},[],{"trials":12541,"activeCount":102},[12542,12551,12560],{"nctId":12543,"briefTitle":12544,"status":131,"phases":12545,"primaryCompletion":12546,"completion":12547,"start":1915,"enrollment":261,"conditions":12548,"interventions":12549},"NCT03104855","Clearance of 25-hydroxyvitamin D in Cystic Fibrosis",[90],"2018-10-09","2023-09-06",[8035],[12550],"d6-25-hydroxyvitamin D3",{"nctId":12552,"briefTitle":12553,"status":131,"phases":12554,"primaryCompletion":12555,"completion":12556,"start":12557,"enrollment":7013,"conditions":12558,"interventions":12559},"NCT03576716","Clearance of 25-hydroxyvitamin D3 During Vitamin D3 Supplementation",[90],"2019-07-08","2021-01-01","2018-06-01",[11564],[12536],{"nctId":12561,"briefTitle":12562,"status":131,"phases":12563,"primaryCompletion":12555,"completion":12556,"start":12564,"enrollment":12565,"conditions":12566,"interventions":12567},"NCT02937350","Clearance of 25-hydroxyvitamin D in Chronic Kidney Disease",[90],"2017-03-01",88,[11564],[12536],{"trials":12569,"activeCount":102},[],{"trials":12571,"activeCount":102},[],{"trials":12573,"activeCount":102},[],{"trials":12575,"activeCount":102},[],{"intervention":12577,"totalTrials":264,"cells":12578},"FDA-Approved Anti-Anxiety Medications",{"EARLY_PHASE1":12579,"PHASE1":12581,"PHASE2":12598,"PHASE3":12600,"PHASE4":12602,"NA":12604},{"trials":12580,"activeCount":102},[],{"trials":12582,"activeCount":102},[12583,12590],{"nctId":12584,"briefTitle":12585,"status":108,"phases":12586,"primaryCompletion":5770,"completion":5770,"start":5066,"enrollment":1547,"conditions":12587,"interventions":12589},"NCT01347541","Piloting Acute Care to Primary Care Linkage of Safety Net Patients",[90],[12588],"Posttraumatic Stress Disorder",[12577],{"nctId":12591,"briefTitle":12592,"status":131,"phases":12593,"primaryCompletion":189,"completion":3264,"start":2930,"enrollment":12594,"conditions":12595,"interventions":12597},"NCT00270959","Patient-Centered Collaborative Care for Preventing Post-Traumatic Stress Disorder After Traumatic Injury",[90],207,[12596],"Post-Traumatic Stress Disorder",[12577],{"trials":12599,"activeCount":102},[],{"trials":12601,"activeCount":102},[],{"trials":12603,"activeCount":102},[],{"trials":12605,"activeCount":102},[],{"intervention":1600,"totalTrials":264,"cells":12607},{"EARLY_PHASE1":12608,"PHASE1":12610,"PHASE2":12623,"PHASE3":12625,"PHASE4":12627,"NA":12629},{"trials":12609,"activeCount":102},[],{"trials":12611,"activeCount":102},[12612,12616],{"nctId":1588,"briefTitle":1589,"status":131,"phases":12613,"primaryCompletion":1591,"start":1592,"enrollment":317,"conditions":12614,"interventions":12615},[90],[354,377,1315,1594,1595,36,1596,1597,1598],[1582,233,1600],{"nctId":12617,"briefTitle":12618,"status":131,"phases":12619,"primaryCompletion":740,"start":12620,"enrollment":1207,"conditions":12621,"interventions":12622},"NCT00357448","Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer",[90],"2005-04",[2116,2117,2118,2119,2120,2121,2122,2123,1594,2047,1597],[1600],{"trials":12624,"activeCount":102},[],{"trials":12626,"activeCount":102},[],{"trials":12628,"activeCount":102},[],{"trials":12630,"activeCount":102},[],{"intervention":12632,"totalTrials":236,"cells":12633},"MyoRx Cream",{"EARLY_PHASE1":12634,"PHASE1":12636,"PHASE2":12646,"PHASE3":12648,"PHASE4":12650,"NA":12652},{"trials":12635,"activeCount":102},[],{"trials":12637,"activeCount":102},[12638],{"nctId":12639,"briefTitle":12640,"status":131,"phases":12641,"primaryCompletion":12642,"completion":12642,"start":1474,"enrollment":310,"conditions":12643,"interventions":12645},"NCT00690625","Topical Application of MyoRx (Omega 3 Fatty Acids Containing) Cream",[90],"2008-07",[12644],"Myofacial Pain",[12632],{"trials":12647,"activeCount":102},[],{"trials":12649,"activeCount":102},[],{"trials":12651,"activeCount":102},[],{"trials":12653,"activeCount":102},[],{"intervention":12655,"totalTrials":236,"cells":12656},"aminolevulinic acid",{"EARLY_PHASE1":12657,"PHASE1":12659,"PHASE2":12669,"PHASE3":12671,"PHASE4":12673,"NA":12675},{"trials":12658,"activeCount":102},[],{"trials":12660,"activeCount":102},[12661],{"nctId":12662,"briefTitle":12663,"status":108,"phases":12664,"primaryCompletion":11159,"start":347,"enrollment":192,"conditions":12665,"interventions":12668},"NCT01148966","Aminolevulinic Acid During Surgery in Treating Patients With Malignant Brain Tumors",[90],[9466,9467,9468,9469,9470,12666,12667],"Adult Mixed Glioma","Recurrent Adult Brain Tumor",[12655],{"trials":12670,"activeCount":102},[],{"trials":12672,"activeCount":102},[],{"trials":12674,"activeCount":102},[],{"trials":12676,"activeCount":102},[],{"intervention":12678,"totalTrials":236,"cells":12679},"AMD3100 or plerixafor",{"EARLY_PHASE1":12680,"PHASE1":12682,"PHASE2":12691,"PHASE3":12693,"PHASE4":12695,"NA":12697},{"trials":12681,"activeCount":102},[],{"trials":12683,"activeCount":102},[12684],{"nctId":12685,"briefTitle":12686,"status":131,"phases":12687,"primaryCompletion":1272,"completion":7195,"start":7528,"enrollment":192,"conditions":12688,"interventions":12690},"NCT01058993","AMD 3100 for Treatment of Myelokathexis",[90],[12689],"Neutropenia",[12678],{"trials":12692,"activeCount":102},[],{"trials":12694,"activeCount":102},[],{"trials":12696,"activeCount":102},[],{"trials":12698,"activeCount":102},[],{"intervention":2050,"totalTrials":236,"cells":12700},{"EARLY_PHASE1":12701,"PHASE1":12703,"PHASE2":12709,"PHASE3":12711,"PHASE4":12713,"NA":12715},{"trials":12702,"activeCount":102},[],{"trials":12704,"activeCount":102},[12705],{"nctId":2040,"briefTitle":2041,"status":131,"phases":12706,"primaryCompletion":1137,"completion":2043,"start":2044,"enrollment":2045,"conditions":12707,"interventions":12708},[90],[354,2047,2048,278,378,379,36,1597,1598],[2050,1624,2051],{"trials":12710,"activeCount":102},[],{"trials":12712,"activeCount":102},[],{"trials":12714,"activeCount":102},[],{"trials":12716,"activeCount":102},[],{"intervention":12718,"totalTrials":236,"cells":12719},"nitrite",{"EARLY_PHASE1":12720,"PHASE1":12722,"PHASE2":12731,"PHASE3":12733,"PHASE4":12735,"NA":12737},{"trials":12721,"activeCount":102},[],{"trials":12723,"activeCount":102},[12724],{"nctId":12725,"briefTitle":12726,"status":131,"phases":12727,"primaryCompletion":12728,"completion":12728,"start":3156,"enrollment":1207,"conditions":12729,"interventions":12730},"NCT01178359","Pilot Study of Sodium Nitrite in Resuscitated Cardiac Arrest Patients",[90],"2016-04",[7703],[12718],{"trials":12732,"activeCount":102},[],{"trials":12734,"activeCount":102},[],{"trials":12736,"activeCount":102},[],{"trials":12738,"activeCount":102},[],{"intervention":5625,"totalTrials":236,"cells":12740},{"EARLY_PHASE1":12741,"PHASE1":12743,"PHASE2":12749,"PHASE3":12751,"PHASE4":12753,"NA":12755},{"trials":12742,"activeCount":102},[],{"trials":12744,"activeCount":102},[12745],{"nctId":5617,"briefTitle":5618,"status":131,"phases":12746,"primaryCompletion":5620,"completion":5620,"start":5621,"enrollment":5622,"conditions":12747,"interventions":12748},[90],[5614],[5625,5626],{"trials":12750,"activeCount":102},[],{"trials":12752,"activeCount":102},[],{"trials":12754,"activeCount":102},[],{"trials":12756,"activeCount":102},[],{"intervention":9421,"totalTrials":236,"cells":12758},{"EARLY_PHASE1":12759,"PHASE1":12761,"PHASE2":12767,"PHASE3":12769,"PHASE4":12771,"NA":12773},{"trials":12760,"activeCount":102},[],{"trials":12762,"activeCount":102},[12763],{"nctId":9414,"briefTitle":9415,"status":131,"phases":12764,"primaryCompletion":9417,"completion":9417,"start":9418,"enrollment":1439,"conditions":12765,"interventions":12766},[90],[1836,1355,1058,1197,1198],[3367,9421],{"trials":12768,"activeCount":102},[],{"trials":12770,"activeCount":102},[],{"trials":12772,"activeCount":102},[],{"trials":12774,"activeCount":102},[],{"intervention":12776,"totalTrials":236,"cells":12777},"Rifampicin",{"EARLY_PHASE1":12778,"PHASE1":12780,"PHASE2":12789,"PHASE3":12791,"PHASE4":12793,"NA":12795},{"trials":12779,"activeCount":102},[],{"trials":12781,"activeCount":102},[12782],{"nctId":12783,"briefTitle":12784,"status":131,"phases":12785,"primaryCompletion":347,"completion":189,"start":3157,"enrollment":1391,"conditions":12786,"interventions":12788},"NCT00621309","Sulforaphane as an Antagonist to Human PXR-mediated Drug-drug Interactions",[90],[12787],"Adverse Drug Interactions",[12776],{"trials":12790,"activeCount":102},[],{"trials":12792,"activeCount":102},[],{"trials":12794,"activeCount":102},[],{"trials":12796,"activeCount":102},[],{"intervention":2888,"totalTrials":236,"cells":12798},{"EARLY_PHASE1":12799,"PHASE1":12801,"PHASE2":12807,"PHASE3":12809,"PHASE4":12811,"NA":12813},{"trials":12800,"activeCount":102},[],{"trials":12802,"activeCount":102},[12803],{"nctId":2881,"briefTitle":2882,"status":131,"phases":12804,"primaryCompletion":2884,"completion":2884,"start":2885,"enrollment":113,"conditions":12805,"interventions":12806},[90],[2235],[1244,1842,2888],{"trials":12808,"activeCount":102},[],{"trials":12810,"activeCount":102},[],{"trials":12812,"activeCount":102},[],{"trials":12814,"activeCount":102},[],{"intervention":12816,"totalTrials":236,"cells":12817},"Standard Dose Kappa Agonist",{"EARLY_PHASE1":12818,"PHASE1":12820,"PHASE2":12830,"PHASE3":12832,"PHASE4":12834,"NA":12836},{"trials":12819,"activeCount":102},[],{"trials":12821,"activeCount":102},[12822],{"nctId":12823,"briefTitle":12824,"status":131,"phases":12825,"primaryCompletion":1619,"completion":1619,"start":6393,"enrollment":113,"conditions":12826,"interventions":12828},"NCT02070718","Effects of a Kappa Agonist on Hot Flashes in Menopausal Women",[90],[12827],"Treatment of Menopausal Hot Flashes",[12816,12829],"Half Dose Kappa Agonist",{"trials":12831,"activeCount":102},[],{"trials":12833,"activeCount":102},[],{"trials":12835,"activeCount":102},[],{"trials":12837,"activeCount":102},[],{"intervention":12829,"totalTrials":236,"cells":12839},{"EARLY_PHASE1":12840,"PHASE1":12842,"PHASE2":12848,"PHASE3":12850,"PHASE4":12852,"NA":12854},{"trials":12841,"activeCount":102},[],{"trials":12843,"activeCount":102},[12844],{"nctId":12823,"briefTitle":12824,"status":131,"phases":12845,"primaryCompletion":1619,"completion":1619,"start":6393,"enrollment":113,"conditions":12846,"interventions":12847},[90],[12827],[12816,12829],{"trials":12849,"activeCount":102},[],{"trials":12851,"activeCount":102},[],{"trials":12853,"activeCount":102},[],{"trials":12855,"activeCount":102},[],{"intervention":12857,"totalTrials":236,"cells":12858},"Bupropion",{"EARLY_PHASE1":12859,"PHASE1":12861,"PHASE2":12872,"PHASE3":12874,"PHASE4":12876,"NA":12878},{"trials":12860,"activeCount":102},[],{"trials":12862,"activeCount":102},[12863],{"nctId":12864,"briefTitle":12865,"status":5876,"phases":12866,"primaryCompletion":5066,"completion":5066,"start":6102,"enrollment":673,"conditions":12867,"interventions":12869},"NCT00504413","Role of CYP2B6, CYP3A4, and MDR1 in the Metabolic Clearance of Methadone",[90],[12868],"Substance-Related Disorders",[12870,12857,12871],"midazolam","Methadone",{"trials":12873,"activeCount":102},[],{"trials":12875,"activeCount":102},[],{"trials":12877,"activeCount":102},[],{"trials":12879,"activeCount":102},[],{"intervention":12871,"totalTrials":236,"cells":12881},{"EARLY_PHASE1":12882,"PHASE1":12884,"PHASE2":12890,"PHASE3":12892,"PHASE4":12894,"NA":12896},{"trials":12883,"activeCount":102},[],{"trials":12885,"activeCount":102},[12886],{"nctId":12864,"briefTitle":12865,"status":5876,"phases":12887,"primaryCompletion":5066,"completion":5066,"start":6102,"enrollment":673,"conditions":12888,"interventions":12889},[90],[12868],[12870,12857,12871],{"trials":12891,"activeCount":102},[],{"trials":12893,"activeCount":102},[],{"trials":12895,"activeCount":102},[],{"trials":12897,"activeCount":102},[],{"intervention":3124,"totalTrials":236,"cells":12899},{"EARLY_PHASE1":12900,"PHASE1":12902,"PHASE2":12908,"PHASE3":12910,"PHASE4":12912,"NA":12914},{"trials":12901,"activeCount":102},[],{"trials":12903,"activeCount":102},[12904],{"nctId":3115,"briefTitle":3116,"status":131,"phases":12905,"primaryCompletion":3118,"completion":3119,"start":3120,"enrollment":264,"conditions":12906,"interventions":12907},[90],[3122],[3124,1278],{"trials":12909,"activeCount":102},[],{"trials":12911,"activeCount":102},[],{"trials":12913,"activeCount":102},[],{"trials":12915,"activeCount":102},[],{"intervention":12917,"totalTrials":236,"cells":12918},"Trastuzumab Emtansine",{"EARLY_PHASE1":12919,"PHASE1":12921,"PHASE2":12929,"PHASE3":12931,"PHASE4":12933,"NA":12935},{"trials":12920,"activeCount":102},[],{"trials":12922,"activeCount":102},[12923],{"nctId":12924,"briefTitle":12925,"status":131,"phases":12926,"primaryCompletion":3229,"completion":2894,"start":1577,"enrollment":2370,"conditions":12927,"interventions":12928},"NCT01816035","Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery",[90],[3731,1710,378,379,36],[12917],{"trials":12930,"activeCount":102},[],{"trials":12932,"activeCount":102},[],{"trials":12934,"activeCount":102},[],{"trials":12936,"activeCount":102},[],{"intervention":3207,"totalTrials":236,"cells":12938},{"EARLY_PHASE1":12939,"PHASE1":12941,"PHASE2":12947,"PHASE3":12949,"PHASE4":12951,"NA":12953},{"trials":12940,"activeCount":102},[],{"trials":12942,"activeCount":102},[12943],{"nctId":3193,"briefTitle":3194,"status":131,"phases":12944,"primaryCompletion":3196,"completion":3196,"start":3197,"enrollment":273,"conditions":12945,"interventions":12946},[90],[3199,3200,3201,3202,3203,3204,3205],[3207,1723],{"trials":12948,"activeCount":102},[],{"trials":12950,"activeCount":102},[],{"trials":12952,"activeCount":102},[],{"trials":12954,"activeCount":102},[],{"intervention":12956,"totalTrials":236,"cells":12957},"Vitamin A",{"EARLY_PHASE1":12958,"PHASE1":12960,"PHASE2":12970,"PHASE3":12972,"PHASE4":12974,"NA":12976},{"trials":12959,"activeCount":102},[],{"trials":12961,"activeCount":102},[12962],{"nctId":12963,"briefTitle":12964,"status":131,"phases":12965,"primaryCompletion":12966,"completion":12966,"start":9783,"enrollment":12967,"conditions":12968,"interventions":12969},"NCT03117660","Effects of Retinoids on CYP2D6 Activity During Pregnancy",[90],"2022-10-31",82,[7058],[12956],{"trials":12971,"activeCount":102},[],{"trials":12973,"activeCount":102},[],{"trials":12975,"activeCount":102},[],{"trials":12977,"activeCount":102},[],{"intervention":12979,"totalTrials":236,"cells":12980},"Conivaptan",{"EARLY_PHASE1":12981,"PHASE1":12983,"PHASE2":12992,"PHASE3":12994,"PHASE4":12996,"NA":12998},{"trials":12982,"activeCount":102},[],{"trials":12984,"activeCount":102},[12985],{"nctId":12986,"briefTitle":12987,"status":131,"phases":12988,"primaryCompletion":370,"completion":347,"start":7756,"enrollment":261,"conditions":12989,"interventions":12991},"NCT00930202","Study of the Safety and Efficacy of Conivaptan (Vaprisol®) to Raise Serum Sodium Levels in Patients With Severe Traumatic Brain Injury",[90],[12990],"Severe Traumatic Brain Injury",[12979],{"trials":12993,"activeCount":102},[],{"trials":12995,"activeCount":102},[],{"trials":12997,"activeCount":102},[],{"trials":12999,"activeCount":102},[],{"intervention":13001,"totalTrials":236,"cells":13002},"Polyvinyl Alcohol",{"EARLY_PHASE1":13003,"PHASE1":13005,"PHASE2":13016,"PHASE3":13018,"PHASE4":13020,"NA":13022},{"trials":13004,"activeCount":102},[],{"trials":13006,"activeCount":102},[13007],{"nctId":13008,"briefTitle":13009,"status":1150,"phases":13010,"primaryCompletion":66,"completion":66,"start":2339,"enrollment":102,"conditions":13011,"interventions":13014},"NCT05490381","Preoperative Embolization of Hypervascular Head and Neck Tumors to Improve Surgical Outcomes",[90],[13012,13013],"Malignant Neoplasm in the Head and Neck","Metastatic Malignant Neoplasm in the Head and Neck",[13001,13015],"Ethiodized Oil",{"trials":13017,"activeCount":102},[],{"trials":13019,"activeCount":102},[],{"trials":13021,"activeCount":102},[],{"trials":13023,"activeCount":102},[],{"intervention":13015,"totalTrials":236,"cells":13025},{"EARLY_PHASE1":13026,"PHASE1":13028,"PHASE2":13034,"PHASE3":13036,"PHASE4":13038,"NA":13040},{"trials":13027,"activeCount":102},[],{"trials":13029,"activeCount":102},[13030],{"nctId":13008,"briefTitle":13009,"status":1150,"phases":13031,"primaryCompletion":66,"completion":66,"start":2339,"enrollment":102,"conditions":13032,"interventions":13033},[90],[13012,13013],[13001,13015],{"trials":13035,"activeCount":102},[],{"trials":13037,"activeCount":102},[],{"trials":13039,"activeCount":102},[],{"trials":13041,"activeCount":102},[],{"intervention":13043,"totalTrials":236,"cells":13044},"TLR8 agonist VTX-2337",{"EARLY_PHASE1":13045,"PHASE1":13047,"PHASE2":13091,"PHASE3":13093,"PHASE4":13095,"NA":13097},{"trials":13046,"activeCount":102},[],{"trials":13048,"activeCount":102},[13049],{"nctId":13050,"briefTitle":13051,"status":131,"phases":13052,"primaryCompletion":1577,"start":348,"enrollment":2370,"conditions":13053,"interventions":13089},"NCT01334177","TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck",[90],[13054,13055,9876,13056,13057,13058,13059,13060,13061,13062,13063,13064,13065,195,196,197,198,199,13066,13067,13068,13069,13070,13071,13072,13073,13074,13075,13076,13077,13078,13079,13080,13081,13082,13083,13084,13085,13086,13087,13088],"Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma","Recurrent Metastatic Squamous Neck Cancer With Occult Primary","Recurrent Squamous Cell Carcinoma of the Hypopharynx","Recurrent Squamous Cell Carcinoma of the Larynx","Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity","Recurrent Squamous Cell Carcinoma of the Nasopharynx","Recurrent Squamous Cell Carcinoma of the Oropharynx","Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Recurrent Verrucous Carcinoma of the Larynx","Recurrent Verrucous Carcinoma of the Oral Cavity","Salivary Gland Squamous Cell Carcinoma","Stage III Salivary Gland Cancer","Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage III Verrucous Carcinoma of the Larynx","Stage III Verrucous Carcinoma of the Oral Cavity","Stage IV Salivary Gland Cancer","Stage IVA Squamous Cell Carcinoma of the Larynx","Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVA Squamous Cell Carcinoma of the Oropharynx","Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVA Verrucous Carcinoma of the Larynx","Stage IVA Verrucous Carcinoma of the Oral Cavity","Stage IVB Squamous Cell Carcinoma of the Larynx","Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVB Squamous Cell Carcinoma of the Oropharynx","Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVB Verrucous Carcinoma of the Larynx","Stage IVB Verrucous Carcinoma of the Oral Cavity","Stage IVC Squamous Cell Carcinoma of the Larynx","Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVC Squamous Cell Carcinoma of the Oropharynx","Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVC Verrucous Carcinoma of the Larynx","Stage IVC Verrucous Carcinoma of the Oral Cavity","Tongue Cancer",[13043,13090],"cetuximab",{"trials":13092,"activeCount":102},[],{"trials":13094,"activeCount":102},[],{"trials":13096,"activeCount":102},[],{"trials":13098,"activeCount":102},[],{"intervention":13090,"totalTrials":236,"cells":13100},{"EARLY_PHASE1":13101,"PHASE1":13103,"PHASE2":13109,"PHASE3":13111,"PHASE4":13113,"NA":13115},{"trials":13102,"activeCount":102},[],{"trials":13104,"activeCount":102},[13105],{"nctId":13050,"briefTitle":13051,"status":131,"phases":13106,"primaryCompletion":1577,"start":348,"enrollment":2370,"conditions":13107,"interventions":13108},[90],[13054,13055,9876,13056,13057,13058,13059,13060,13061,13062,13063,13064,13065,195,196,197,198,199,13066,13067,13068,13069,13070,13071,13072,13073,13074,13075,13076,13077,13078,13079,13080,13081,13082,13083,13084,13085,13086,13087,13088],[13043,13090],{"trials":13110,"activeCount":102},[],{"trials":13112,"activeCount":102},[],{"trials":13114,"activeCount":102},[],{"trials":13116,"activeCount":102},[],{"intervention":13118,"totalTrials":236,"cells":13119},"100 mg\u002Fm2 dose",{"EARLY_PHASE1":13120,"PHASE1":13122,"PHASE2":13132,"PHASE3":13134,"PHASE4":13136,"NA":13138},{"trials":13121,"activeCount":102},[],{"trials":13123,"activeCount":102},[13124],{"nctId":13125,"briefTitle":13126,"status":131,"phases":13127,"primaryCompletion":11159,"completion":13128,"start":3251,"enrollment":673,"conditions":13129,"interventions":13130},"NCT01093521","A Pharmacokinetic and Safety Study of IV Gallium Nitrate (Ganite) in Cystic Fibrosis Patients",[90],"2013-08-31",[8035],[13118,13131],"200 mg\u002Fm2 dose",{"trials":13133,"activeCount":102},[],{"trials":13135,"activeCount":102},[],{"trials":13137,"activeCount":102},[],{"trials":13139,"activeCount":102},[],{"intervention":13131,"totalTrials":236,"cells":13141},{"EARLY_PHASE1":13142,"PHASE1":13144,"PHASE2":13150,"PHASE3":13152,"PHASE4":13154,"NA":13156},{"trials":13143,"activeCount":102},[],{"trials":13145,"activeCount":102},[13146],{"nctId":13125,"briefTitle":13126,"status":131,"phases":13147,"primaryCompletion":11159,"completion":13128,"start":3251,"enrollment":673,"conditions":13148,"interventions":13149},[90],[8035],[13118,13131],{"trials":13151,"activeCount":102},[],{"trials":13153,"activeCount":102},[],{"trials":13155,"activeCount":102},[],{"trials":13157,"activeCount":102},[],{"intervention":13159,"totalTrials":236,"cells":13160},"TLC-ART",{"EARLY_PHASE1":13161,"PHASE1":13163,"PHASE2":13175,"PHASE3":13177,"PHASE4":13179,"NA":13181},{"trials":13162,"activeCount":102},[],{"trials":13164,"activeCount":102},[13165],{"nctId":13166,"briefTitle":13167,"status":131,"phases":13168,"primaryCompletion":13169,"completion":13169,"start":13170,"enrollment":113,"conditions":13171,"interventions":13174},"NCT05850728","First in Human Study of TLC-ART 101 (ACTU 2001)",[90],"2024-06-28","2023-04-01",[7404,13172,13173],"Treatment","Antiretroviral Therapy",[13159],{"trials":13176,"activeCount":102},[],{"trials":13178,"activeCount":102},[],{"trials":13180,"activeCount":102},[],{"trials":13182,"activeCount":102},[],{"intervention":7516,"totalTrials":236,"cells":13184},{"EARLY_PHASE1":13185,"PHASE1":13187,"PHASE2":13193,"PHASE3":13195,"PHASE4":13197,"NA":13199},{"trials":13186,"activeCount":102},[],{"trials":13188,"activeCount":102},[13189],{"nctId":7511,"briefTitle":7512,"status":131,"phases":13190,"primaryCompletion":1675,"completion":7307,"start":1621,"enrollment":1299,"conditions":13191,"interventions":13192},[90],[5614,5613],[340,7516,7517],{"trials":13194,"activeCount":102},[],{"trials":13196,"activeCount":102},[],{"trials":13198,"activeCount":102},[],{"trials":13200,"activeCount":102},[],{"intervention":7517,"totalTrials":236,"cells":13202},{"EARLY_PHASE1":13203,"PHASE1":13205,"PHASE2":13211,"PHASE3":13213,"PHASE4":13215,"NA":13217},{"trials":13204,"activeCount":102},[],{"trials":13206,"activeCount":102},[13207],{"nctId":7511,"briefTitle":7512,"status":131,"phases":13208,"primaryCompletion":1675,"completion":7307,"start":1621,"enrollment":1299,"conditions":13209,"interventions":13210},[90],[5614,5613],[340,7516,7517],{"trials":13212,"activeCount":102},[],{"trials":13214,"activeCount":102},[],{"trials":13216,"activeCount":102},[],{"trials":13218,"activeCount":102},[],{"intervention":13220,"totalTrials":236,"cells":13221},"Vevoctadekin",{"EARLY_PHASE1":13222,"PHASE1":13224,"PHASE2":13235,"PHASE3":13237,"PHASE4":13239,"NA":13241},{"trials":13223,"activeCount":102},[],{"trials":13225,"activeCount":102},[13226],{"nctId":13227,"briefTitle":13228,"status":108,"phases":13229,"primaryCompletion":13230,"completion":13230,"start":13231,"enrollment":236,"conditions":13232,"interventions":13233},"NCT06588660","ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma",[90],"2025-02-14","2024-12-18",[180,162],[13220,13234],"Teclistamab",{"trials":13236,"activeCount":102},[],{"trials":13238,"activeCount":102},[],{"trials":13240,"activeCount":102},[],{"trials":13242,"activeCount":102},[],{"intervention":13234,"totalTrials":236,"cells":13244},{"EARLY_PHASE1":13245,"PHASE1":13247,"PHASE2":13253,"PHASE3":13255,"PHASE4":13257,"NA":13259},{"trials":13246,"activeCount":102},[],{"trials":13248,"activeCount":102},[13249],{"nctId":13227,"briefTitle":13228,"status":108,"phases":13250,"primaryCompletion":13230,"completion":13230,"start":13231,"enrollment":236,"conditions":13251,"interventions":13252},[90],[180,162],[13220,13234],{"trials":13254,"activeCount":102},[],{"trials":13256,"activeCount":102},[],{"trials":13258,"activeCount":102},[],{"trials":13260,"activeCount":102},[],{"intervention":13262,"totalTrials":236,"cells":13263},"Sodium Nitrite",{"EARLY_PHASE1":13264,"PHASE1":13266,"PHASE2":13275,"PHASE3":13277,"PHASE4":13279,"NA":13281},{"trials":13265,"activeCount":102},[],{"trials":13267,"activeCount":102},[13268],{"nctId":13269,"briefTitle":13270,"status":131,"phases":13271,"primaryCompletion":8550,"completion":13272,"start":3229,"enrollment":861,"conditions":13273,"interventions":13274},"NCT02987088","Phase 1 Clinical Trial of Sodium Nitrite for Out of Hospital Cardiac Arrest",[90],"2017-05-02",[8241],[13262],{"trials":13276,"activeCount":102},[],{"trials":13278,"activeCount":102},[],{"trials":13280,"activeCount":102},[],{"trials":13282,"activeCount":102},[],{"intervention":13284,"totalTrials":236,"cells":13285},"Reduced Glutathione",{"EARLY_PHASE1":13286,"PHASE1":13288,"PHASE2":13297,"PHASE3":13299,"PHASE4":13301,"NA":13303},{"trials":13287,"activeCount":102},[],{"trials":13289,"activeCount":102},[13290],{"nctId":13291,"briefTitle":13292,"status":131,"phases":13293,"primaryCompletion":453,"completion":453,"start":1620,"enrollment":456,"conditions":13294,"interventions":13296},"NCT02324426","CNS Uptake of Intranasal Glutathione",[90],[13295],"Parkinson's Disease",[13284],{"trials":13298,"activeCount":102},[],{"trials":13300,"activeCount":102},[],{"trials":13302,"activeCount":102},[],{"trials":13304,"activeCount":102},[],{"intervention":1031,"totalTrials":236,"cells":13306},{"EARLY_PHASE1":13307,"PHASE1":13309,"PHASE2":13315,"PHASE3":13317,"PHASE4":13319,"NA":13321},{"trials":13308,"activeCount":102},[],{"trials":13310,"activeCount":102},[13311],{"nctId":1017,"briefTitle":1018,"status":131,"phases":13312,"primaryCompletion":1020,"completion":1021,"start":1022,"enrollment":1023,"conditions":13313,"interventions":13314},[90],[1025,1026,1027,1028],[992,993,1030,966,994,1031],{"trials":13316,"activeCount":102},[],{"trials":13318,"activeCount":102},[],{"trials":13320,"activeCount":102},[],{"trials":13322,"activeCount":102},[],{"intervention":13324,"totalTrials":236,"cells":13325},"Naloxone hydrochloride injection solution, SmartDose wearable auto injector and mobile respiratory sensing system",{"EARLY_PHASE1":13326,"PHASE1":13337,"PHASE2":13339,"PHASE3":13341,"PHASE4":13343,"NA":13345},{"trials":13327,"activeCount":102},[13328],{"nctId":13329,"briefTitle":13330,"status":131,"phases":13331,"primaryCompletion":13332,"completion":13332,"start":13333,"enrollment":673,"conditions":13334,"interventions":13336},"NCT05099614","Naloxone Auto-injection in Healthy Volunteers",[89],"2021-04-05","2021-03-10",[13335],"Overdose Antidote",[13324],{"trials":13338,"activeCount":102},[],{"trials":13340,"activeCount":102},[],{"trials":13342,"activeCount":102},[],{"trials":13344,"activeCount":102},[],{"trials":13346,"activeCount":102},[],{"intervention":13348,"totalTrials":236,"cells":13349},"Rifampin",{"EARLY_PHASE1":13350,"PHASE1":13360,"PHASE2":13362,"PHASE3":13364,"PHASE4":13366,"NA":13368},{"trials":13351,"activeCount":102},[13352],{"nctId":13353,"briefTitle":13354,"status":131,"phases":13355,"primaryCompletion":12363,"completion":12363,"start":1577,"enrollment":300,"conditions":13356,"interventions":13358},"NCT02019875","CYP3A4 Activity and Mineral Homeostasis",[89],[13357],"Vitamin D and Calcium Homeostasis",[13348,13359],"Clarithromycin",{"trials":13361,"activeCount":102},[],{"trials":13363,"activeCount":102},[],{"trials":13365,"activeCount":102},[],{"trials":13367,"activeCount":102},[],{"trials":13369,"activeCount":102},[],{"intervention":13359,"totalTrials":236,"cells":13371},{"EARLY_PHASE1":13372,"PHASE1":13378,"PHASE2":13380,"PHASE3":13382,"PHASE4":13384,"NA":13386},{"trials":13373,"activeCount":102},[13374],{"nctId":13353,"briefTitle":13354,"status":131,"phases":13375,"primaryCompletion":12363,"completion":12363,"start":1577,"enrollment":300,"conditions":13376,"interventions":13377},[89],[13357],[13348,13359],{"trials":13379,"activeCount":102},[],{"trials":13381,"activeCount":102},[],{"trials":13383,"activeCount":102},[],{"trials":13385,"activeCount":102},[],{"trials":13387,"activeCount":102},[],{"intervention":13389,"totalTrials":98,"cells":13390},"valacyclovir",{"EARLY_PHASE1":13391,"PHASE1":13393,"PHASE2":13395,"PHASE3":13405,"PHASE4":13421,"NA":13457},{"trials":13392,"activeCount":102},[],{"trials":13394,"activeCount":102},[],{"trials":13396,"activeCount":102},[13397],{"nctId":13398,"briefTitle":13399,"status":131,"phases":13400,"primaryCompletion":134,"completion":134,"start":1474,"enrollment":13401,"conditions":13402,"interventions":13404},"NCT00530777","HSV-2 Suppression to Reduce Maternal HIV-1 RNA Levels During Pregnancy and Breastfeeding",[91],148,[19,13403],"Herpes Simplex",[13389],{"trials":13406,"activeCount":102},[13407,13415],{"nctId":13408,"briefTitle":13409,"status":131,"phases":13410,"primaryCompletion":4926,"completion":410,"start":13411,"enrollment":673,"conditions":13412,"interventions":13413},"NCT00465205","HSV-2 Suppression to Reduce HIV-1 Levels in HIV-1 Co-infected Persons",[92],"2005-01",[19,13403,8644],[13414],"Valacyclovir",{"nctId":13416,"briefTitle":13417,"status":131,"phases":13418,"completion":5611,"start":6296,"enrollment":673,"conditions":13419,"interventions":13420},"NCT00378976","HSV-2 Suppression to Reduce HIV-1 Levels in HIV-1, HSV-2 Co-infected Men.",[92],[6220,13403,8644],[13389],{"trials":13422,"activeCount":102},[13423,13430,13436,13443,13449],{"nctId":13424,"briefTitle":13425,"status":131,"phases":13426,"primaryCompletion":2895,"completion":1863,"start":226,"enrollment":350,"conditions":13427,"interventions":13429},"NCT01346475","Randomized Trial to Evaluate Suppressive Effect of High-Dose Valacyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2",[93],[13428],"Genital Herpes",[13389,13414],{"nctId":13431,"briefTitle":13432,"status":131,"phases":13433,"primaryCompletion":2930,"completion":2930,"start":12102,"enrollment":389,"conditions":13434,"interventions":13435},"NCT00161434","A Study of Valacyclovir to Suppress HSV and HIV Shedding in Coinfected Persons",[93],[13403,19],[13389],{"nctId":13437,"briefTitle":13438,"status":131,"phases":13439,"primaryCompletion":1272,"completion":1272,"start":410,"enrollment":26,"conditions":13440,"interventions":13441},"NCT00527618","Trial to Study the Effect of Dose of Herpes Simplex Virus-2 (HSV-2) Suppressive Therapy on HSV and HIV",[93],[13428,6220],[13389,13442],"acyclovir",{"nctId":13444,"briefTitle":13445,"status":131,"phases":13446,"primaryCompletion":1475,"completion":1863,"start":11442,"enrollment":227,"conditions":13447,"interventions":13448},"NCT00362297","Randomized Trial to Evaluate Suppressive Effect of High-Dose Acyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2",[93],[13428],[13442,13389],{"nctId":13450,"briefTitle":13451,"status":131,"phases":13452,"primaryCompletion":442,"completion":271,"start":13453,"enrollment":1129,"conditions":13454,"interventions":13456},"NCT01026454","Valacyclovir vs. Acyclovir as HSV-2 Suppressive Therapy: Effect on Plasma HIV-1 Levels Among HIV-1\u002FHSV-2 Co-infected Persons",[93],"2010-02",[13455,6220],"HSV Infection",[13442,13389],{"trials":13458,"activeCount":102},[13459],{"nctId":13460,"briefTitle":13461,"status":1150,"phases":13462,"primaryCompletion":1194,"completion":1194,"start":3156,"enrollment":102,"conditions":13463,"interventions":13464},"NCT01059084","An Open-label Trial of the Effect of Valacyclovir on Plasma HIV-1 Levels Among HIV-1 Seropositive and HSV-1\u002F2 Seronegative Persons",[94],[25,19],[13414],{"intervention":1013,"totalTrials":317,"cells":13466},{"EARLY_PHASE1":13467,"PHASE1":13469,"PHASE2":13475,"PHASE3":13497,"PHASE4":13499,"NA":13501},{"trials":13468,"activeCount":102},[],{"trials":13470,"activeCount":102},[13471],{"nctId":997,"briefTitle":998,"status":131,"phases":13472,"primaryCompletion":1000,"completion":1000,"start":1001,"enrollment":23,"conditions":13473,"interventions":13474},[90],[1003,115,1004,1005,1006,1007,1008,1009,1010,1011],[994,1013,1014,966,124,1015],{"trials":13476,"activeCount":102},[13477,13481,13485,13489,13493],{"nctId":344,"briefTitle":345,"status":131,"phases":13478,"primaryCompletion":347,"completion":348,"start":349,"enrollment":350,"conditions":13479,"interventions":13480},[91],[352,353,354,355,356,357,358,277,278],[280,233,360,169,361,362,363,364,365,316],{"nctId":1646,"briefTitle":1647,"status":131,"phases":13482,"primaryCompletion":739,"completion":1649,"start":1650,"enrollment":427,"conditions":13483,"interventions":13484},[91],[1652,275,277,278,378,379],[1654,360,280,233,169],{"nctId":1148,"briefTitle":1149,"status":1150,"phases":13486,"primaryCompletion":1152,"completion":1153,"start":1154,"enrollment":102,"conditions":13487,"interventions":13488},[91],[1156,1157,1158,1026,1159,1028,1160,1076,1161],[1163,994,1013,992,1047,966,124,1015],{"nctId":1672,"briefTitle":1673,"status":131,"phases":13490,"primaryCompletion":1675,"completion":440,"start":1676,"enrollment":389,"conditions":13491,"interventions":13492},[91],[353,354,357,358,277,278,378,379,36],[280,233,169,1679,364],{"nctId":2336,"briefTitle":2337,"status":131,"phases":13494,"primaryCompletion":2339,"completion":2339,"start":2340,"enrollment":350,"conditions":13495,"interventions":13496},[90,91],[2342],[1261,1013,1014,1263],{"trials":13498,"activeCount":102},[],{"trials":13500,"activeCount":102},[],{"trials":13502,"activeCount":102},[13503,13514],{"nctId":13504,"briefTitle":13505,"status":131,"phases":13506,"primaryCompletion":13507,"completion":13507,"start":11159,"enrollment":34,"conditions":13508,"interventions":13512},"NCT01446809","Pazopanib Hydrochloride Followed by Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma",[94],"2019-01",[13509,13510,13511],"Stage IIA Adult Soft Tissue Sarcoma","Stage III Adult Soft Tissue Sarcoma","Stage IV Adult Soft Tissue Sarcoma",[1013,1422,13513],"Pazopanib Hydrochloride",{"nctId":268,"briefTitle":269,"status":131,"phases":13515,"primaryCompletion":271,"completion":271,"start":272,"enrollment":273,"conditions":13516,"interventions":13517},[94],[275,194,276,277,278],[208,233,168,280,281],{"intervention":13442,"totalTrials":6989,"cells":13519},{"EARLY_PHASE1":13520,"PHASE1":13522,"PHASE2":13524,"PHASE3":13526,"PHASE4":13528,"NA":13554},{"trials":13521,"activeCount":102},[],{"trials":13523,"activeCount":102},[],{"trials":13525,"activeCount":102},[],{"trials":13527,"activeCount":102},[],{"trials":13529,"activeCount":102},[13530,13536,13542,13546,13550],{"nctId":13531,"briefTitle":13532,"status":108,"phases":13533,"primaryCompletion":347,"completion":347,"start":3230,"enrollment":2165,"conditions":13534,"interventions":13535},"NCT00495716","Effect of HSV-2 Suppressive Therapy on Sexual Behavior",[93],[13428],[13442,13442],{"nctId":13537,"briefTitle":13538,"status":131,"phases":13539,"primaryCompletion":2895,"completion":1863,"start":1789,"enrollment":1338,"conditions":13540,"interventions":13541},"NCT00723229","A Randomized Trial to Evaluated the Suppressive Effect of Acyclovir on Rapidly Cleared HSV-2 Reactivation",[93],[13428],[13442],{"nctId":13437,"briefTitle":13438,"status":131,"phases":13543,"primaryCompletion":1272,"completion":1272,"start":410,"enrollment":26,"conditions":13544,"interventions":13545},[93],[13428,6220],[13389,13442],{"nctId":13444,"briefTitle":13445,"status":131,"phases":13547,"primaryCompletion":1475,"completion":1863,"start":11442,"enrollment":227,"conditions":13548,"interventions":13549},[93],[13428],[13442,13389],{"nctId":13450,"briefTitle":13451,"status":131,"phases":13551,"primaryCompletion":442,"completion":271,"start":13453,"enrollment":1129,"conditions":13552,"interventions":13553},[93],[13455,6220],[13442,13389],{"trials":13555,"activeCount":102},[13556,13562],{"nctId":13557,"briefTitle":13558,"status":131,"phases":13559,"primaryCompletion":740,"completion":1864,"start":1650,"enrollment":3680,"conditions":13560,"interventions":13561},"NCT00495573","HSV-2 Shedding Resolution After Acyclovir Treatment",[],[13428],[13442],{"nctId":13563,"briefTitle":13564,"status":131,"phases":13565,"primaryCompletion":8413,"completion":2895,"start":5665,"enrollment":12565,"conditions":13566,"interventions":13567},"NCT00808405","GUD Clinical and Virologic Response to Acyclovir in HIV Negative African Women",[94],[13428],[13442],{"intervention":445,"totalTrials":192,"cells":13569},{"EARLY_PHASE1":13570,"PHASE1":13572,"PHASE2":13574,"PHASE3":13599,"PHASE4":13601,"NA":13603},{"trials":13571,"activeCount":102},[],{"trials":13573,"activeCount":102},[],{"trials":13575,"activeCount":102},[13576,13580,13591,13595],{"nctId":2228,"briefTitle":2229,"status":131,"phases":13577,"primaryCompletion":2231,"completion":2232,"start":2233,"enrollment":350,"conditions":13578,"interventions":13579},[90,91],[2235,2236,2237,2238,2239,2240,2241,2242,2243,2244,2245,2246,2247,2248,2249],[1014,2251],{"nctId":13581,"briefTitle":13582,"status":108,"phases":13583,"primaryCompletion":13584,"completion":133,"start":5673,"enrollment":1207,"conditions":13585,"interventions":13590},"NCT00958074","Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma",[91],"2013-02",[13586,13587,13588,13589],"Cutaneous T-cell Lymphoma Stage I","Cutaneous T-cell Lymphoma Stage II","Cutaneous T-cell Lymphoma Stage III","Cutaneous T-cell Lymphoma Stage IV",[445],{"nctId":3153,"briefTitle":3154,"status":108,"phases":13592,"primaryCompletion":3156,"completion":1863,"start":3157,"enrollment":1439,"conditions":13593,"interventions":13594},[90,91],[1317,1318],[445,360],{"nctId":1388,"briefTitle":1389,"status":131,"phases":13596,"primaryCompletion":347,"start":410,"enrollment":1391,"conditions":13597,"interventions":13598},[90,91],[137,138,139,1393,140,141,143,1394,145,146,147,148,149,150,151,152,154,155,156,157,158,159,160,161,164,1395,1396,1397,1398,1399,1400,1401,1402,1403,1404,1405,165],[445,1407,1408,1409,170,448],{"trials":13600,"activeCount":102},[],{"trials":13602,"activeCount":102},[],{"trials":13604,"activeCount":102},[13605,13609],{"nctId":437,"briefTitle":438,"status":131,"phases":13606,"primaryCompletion":440,"completion":441,"start":442,"enrollment":317,"conditions":13607,"interventions":13608},[94],[275,377,36],[445,446,316,447,448],{"nctId":450,"briefTitle":451,"status":131,"phases":13610,"primaryCompletion":453,"completion":454,"start":455,"enrollment":456,"conditions":13611,"interventions":13612},[94],[275,377,36],[445,446,316,447],{"intervention":13614,"totalTrials":1439,"cells":13615},"PrEP",{"EARLY_PHASE1":13616,"PHASE1":13618,"PHASE2":13620,"PHASE3":13622,"PHASE4":13624,"NA":13643},{"trials":13617,"activeCount":102},[],{"trials":13619,"activeCount":102},[],{"trials":13621,"activeCount":102},[],{"trials":13623,"activeCount":102},[],{"trials":13625,"activeCount":102},[13626,13635],{"nctId":13627,"briefTitle":13628,"status":131,"phases":13629,"primaryCompletion":8030,"completion":13630,"start":13631,"enrollment":13632,"conditions":13633,"interventions":13634},"NCT03052010","The Partners Scale-Up Project",[93],"2021-04-30","2017-02-06",4898,[5420],[13614,6222],{"nctId":13636,"briefTitle":13637,"status":131,"phases":13638,"primaryCompletion":1379,"completion":1379,"start":13639,"enrollment":13640,"conditions":13641,"interventions":13642},"NCT04666792","PrEParing Family Planning Clinics to Streamline Integration of HIV Prevention Services for Young Women in Kenya",[93],"2021-03-01",25457,[19,5614,5784],[13614],{"trials":13644,"activeCount":102},[13645,13654,13665],{"nctId":13646,"briefTitle":13647,"status":131,"phases":13648,"primaryCompletion":13649,"completion":13649,"start":13650,"enrollment":13651,"conditions":13652,"interventions":13653},"NCT03586128","Partners PrEP Program",[],"2021-11-19","2018-06-08",1381,[19],[13614,6222],{"nctId":13655,"briefTitle":13656,"status":131,"phases":13657,"primaryCompletion":13658,"completion":13659,"start":6020,"enrollment":13660,"conditions":13661,"interventions":13664},"NCT03030768","Safer Conception Intervention for HIV-1 Serodiscordant Couples",[],"2018-05","2018-07",74,[13662,13663],"HIV Seropositivity","Pregnancy, High-Risk",[13614],{"nctId":13666,"briefTitle":13667,"status":131,"phases":13668,"primaryCompletion":13669,"completion":13669,"start":13670,"enrollment":13671,"conditions":13672,"interventions":13673},"NCT05746065","A Cohort for Evaluation of Open-label PrEP Use and PreP Preferences Among African Women",[],"2023-08-01","2022-08-01",3087,[19],[13614],{"intervention":2443,"totalTrials":1547,"cells":13675},{"EARLY_PHASE1":13676,"PHASE1":13678,"PHASE2":13680,"PHASE3":13694,"PHASE4":13696,"NA":13698},{"trials":13677,"activeCount":102},[],{"trials":13679,"activeCount":102},[],{"trials":13681,"activeCount":102},[13682,13686,13690],{"nctId":3219,"briefTitle":3220,"status":131,"phases":13683,"primaryCompletion":1272,"completion":1272,"start":3222,"enrollment":310,"conditions":13684,"interventions":13685},[91],[1276],[2443,1723],{"nctId":2437,"briefTitle":2438,"status":108,"phases":13687,"primaryCompletion":1789,"completion":1789,"start":2440,"enrollment":2089,"conditions":13688,"interventions":13689},[90,91],[413],[1278,2443,2444,1079],{"nctId":2446,"briefTitle":2447,"status":131,"phases":13691,"completion":1650,"start":2449,"enrollment":1338,"conditions":13692,"interventions":13693},[91],[1276],[1842,2443,1079],{"trials":13695,"activeCount":102},[],{"trials":13697,"activeCount":102},[],{"trials":13699,"activeCount":102},[13700],{"nctId":2974,"briefTitle":2975,"status":2976,"phases":13701,"conditions":13702,"interventions":13703},[],[2979,2980],[2982,1244,2443],{"intervention":448,"totalTrials":1547,"cells":13705},{"EARLY_PHASE1":13706,"PHASE1":13708,"PHASE2":13710,"PHASE3":13720,"PHASE4":13722,"NA":13724},{"trials":13707,"activeCount":102},[],{"trials":13709,"activeCount":102},[],{"trials":13711,"activeCount":102},[13712,13716],{"nctId":1388,"briefTitle":1389,"status":131,"phases":13713,"primaryCompletion":347,"start":410,"enrollment":1391,"conditions":13714,"interventions":13715},[90,91],[137,138,139,1393,140,141,143,1394,145,146,147,148,149,150,151,152,154,155,156,157,158,159,160,161,164,1395,1396,1397,1398,1399,1400,1401,1402,1403,1404,1405,165],[445,1407,1408,1409,170,448],{"nctId":9845,"briefTitle":9846,"status":131,"phases":13717,"primaryCompletion":3251,"completion":9848,"start":1476,"enrollment":1439,"conditions":13718,"interventions":13719},[91],[1139,1140,1141],[9851,9852,448,9853,9826],{"trials":13721,"activeCount":102},[],{"trials":13723,"activeCount":102},[],{"trials":13725,"activeCount":102},[13726,13730],{"nctId":437,"briefTitle":438,"status":131,"phases":13727,"primaryCompletion":440,"completion":441,"start":442,"enrollment":317,"conditions":13728,"interventions":13729},[94],[275,377,36],[445,446,316,447,448],{"nctId":13731,"briefTitle":13732,"status":131,"phases":13733,"primaryCompletion":13734,"completion":13735,"start":13736,"enrollment":3144,"conditions":13737,"interventions":13741},"NCT02551718","High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia",[94],"2020-06-19","2021-05-13","2015-09-11",[13738,2291,2419,13739,2420,13740],"Recurrent Acute Leukemia of Ambiguous Lineage","Refractory Acute Lymphoblastic Leukemia","Refractory Acute Leukemia of Ambiguous Lineage",[13742,13743,13744],"Gene Expression Analysis","Genetic Variation Analysis","In Vitro Sensitivity-Directed Chemotherapy",{"intervention":2092,"totalTrials":702,"cells":13746},{"EARLY_PHASE1":13747,"PHASE1":13749,"PHASE2":13751,"PHASE3":13761,"PHASE4":13763,"NA":13765},{"trials":13748,"activeCount":102},[],{"trials":13750,"activeCount":102},[],{"trials":13752,"activeCount":102},[13753,13757],{"nctId":3725,"briefTitle":3726,"status":131,"phases":13754,"primaryCompletion":2001,"completion":3728,"start":3729,"enrollment":227,"conditions":13755,"interventions":13756},[90,91],[3731,1710,36],[3733,1858,3734,1857],{"nctId":2085,"briefTitle":2086,"status":131,"phases":13758,"primaryCompletion":225,"start":2088,"enrollment":2089,"conditions":13759,"interventions":13760},[91],[354,275,378,379,36],[2092,1624,2093],{"trials":13762,"activeCount":102},[],{"trials":13764,"activeCount":102},[],{"trials":13766,"activeCount":102},[13767],{"nctId":13768,"briefTitle":13769,"status":131,"phases":13770,"primaryCompletion":1137,"completion":1137,"start":5650,"enrollment":979,"conditions":13771,"interventions":13772},"NCT00363012","Immune Response in Patients Who Have Undergone Vaccine Therapy for Stage III or Stage IV Breast Cancer That Overexpresses HER2",[94],[413],[2092],{"intervention":13774,"totalTrials":702,"cells":13775},"Albendazole",{"EARLY_PHASE1":13776,"PHASE1":13778,"PHASE2":13780,"PHASE3":13782,"PHASE4":13795,"NA":13797},{"trials":13777,"activeCount":102},[],{"trials":13779,"activeCount":102},[],{"trials":13781,"activeCount":102},[],{"trials":13783,"activeCount":102},[13784],{"nctId":13785,"briefTitle":13786,"status":131,"phases":13787,"primaryCompletion":13788,"completion":13788,"start":13789,"enrollment":13790,"conditions":13791,"interventions":13794},"NCT03014167","Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH)",[92],"2024-07-02","2017-10-04",357716,[13792,13793],"Helminthiasis","Filariasis",[13774],{"trials":13796,"activeCount":102},[],{"trials":13798,"activeCount":102},[13799,13806],{"nctId":13800,"briefTitle":13801,"status":131,"phases":13802,"completion":1650,"start":11160,"enrollment":13803,"conditions":13804,"interventions":13805},"NCT00130910","Treatment of Helminth co-Infection: Short-Term Effects on HIV-1 Progression Markers and Immune Activation",[94],234,[19,13792],[13774],{"nctId":13807,"briefTitle":13808,"status":131,"phases":13809,"primaryCompletion":2106,"completion":1313,"start":7569,"enrollment":13810,"conditions":13811,"interventions":13812},"NCT00507221","Empiric Therapy of Helminth Co-infection to Reduce HIV-1 Disease Progression",[94],948,[19,13792],[13774,13813,13814],"Praziquantel","Current standard of care in Kenya",{"intervention":1422,"totalTrials":702,"cells":13816},{"EARLY_PHASE1":13817,"PHASE1":13819,"PHASE2":13821,"PHASE3":13831,"PHASE4":13833,"NA":13835},{"trials":13818,"activeCount":102},[],{"trials":13820,"activeCount":102},[],{"trials":13822,"activeCount":102},[13823,13827],{"nctId":1388,"briefTitle":1389,"status":131,"phases":13824,"primaryCompletion":347,"start":410,"enrollment":1391,"conditions":13825,"interventions":13826},[90,91],[137,138,139,1393,140,141,143,1394,145,146,147,148,149,150,151,152,154,155,156,157,158,159,160,161,164,1395,1396,1397,1398,1399,1400,1401,1402,1403,1404,1405,165],[445,1407,1408,1409,170,448],{"nctId":1411,"briefTitle":1412,"status":131,"phases":13828,"primaryCompletion":1414,"completion":1415,"start":1416,"enrollment":1417,"conditions":13829,"interventions":13830},[90,91],[1419,1420],[72,123,992,1422],{"trials":13832,"activeCount":102},[],{"trials":13834,"activeCount":102},[],{"trials":13836,"activeCount":102},[13837],{"nctId":13504,"briefTitle":13505,"status":131,"phases":13838,"primaryCompletion":13507,"completion":13507,"start":11159,"enrollment":34,"conditions":13839,"interventions":13840},[94],[13509,13510,13511],[1013,1422,13513],{"intervention":13513,"totalTrials":702,"cells":13842},{"EARLY_PHASE1":13843,"PHASE1":13845,"PHASE2":13854,"PHASE3":13860,"PHASE4":13862,"NA":13864},{"trials":13844,"activeCount":102},[],{"trials":13846,"activeCount":102},[13847],{"nctId":13848,"briefTitle":13849,"status":131,"phases":13850,"primaryCompletion":133,"completion":6126,"start":224,"enrollment":192,"conditions":13851,"interventions":13852},"NCT01413113","Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and\u002For Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery",[90],[9570,9571,9572,9573,9574,9575,9576],[13853],"pazopanib hydrochloride",{"trials":13855,"activeCount":102},[13856],{"nctId":12141,"briefTitle":12142,"status":108,"phases":13857,"primaryCompletion":1745,"completion":12144,"start":2275,"enrollment":7013,"conditions":13858,"interventions":13859},[90,91],[12146,12147,12148],[12132,12150],{"trials":13861,"activeCount":102},[],{"trials":13863,"activeCount":102},[],{"trials":13865,"activeCount":102},[13866],{"nctId":13504,"briefTitle":13505,"status":131,"phases":13867,"primaryCompletion":13507,"completion":13507,"start":11159,"enrollment":34,"conditions":13868,"interventions":13869},[94],[13509,13510,13511],[1013,1422,13513],{"intervention":13871,"totalTrials":702,"cells":13872},"Simvastatin",{"EARLY_PHASE1":13873,"PHASE1":13875,"PHASE2":13877,"PHASE3":13879,"PHASE4":13885,"NA":13894},{"trials":13874,"activeCount":102},[],{"trials":13876,"activeCount":102},[],{"trials":13878,"activeCount":102},[],{"trials":13880,"activeCount":102},[13881],{"nctId":5811,"briefTitle":5812,"status":131,"phases":13882,"completion":5814,"start":5815,"conditions":13883,"interventions":13884},[92],[22,5817,28,5818],[5820,5800,5821],{"trials":13886,"activeCount":102},[13887],{"nctId":13888,"briefTitle":13889,"status":131,"phases":13890,"primaryCompletion":6126,"completion":6126,"start":347,"enrollment":13891,"conditions":13892,"interventions":13893},"NCT01142336","Effects of Simvastatin on Biomarkers",[93],49,[5676],[13871],{"trials":13895,"activeCount":102},[13896],{"nctId":13897,"briefTitle":13898,"status":131,"phases":13899,"primaryCompletion":6483,"completion":1863,"start":8281,"enrollment":13900,"conditions":13901,"interventions":13902},"NCT00880178","Plaque Inflammation and Dysfunctional HDL in AIM-HIGH",[],324,[22,28,5817,5384,7625],[13903,13871],"Simvastatin and Extended-Release niacin",{"intervention":6222,"totalTrials":702,"cells":13905},{"EARLY_PHASE1":13906,"PHASE1":13908,"PHASE2":13910,"PHASE3":13912,"PHASE4":13914,"NA":13924},{"trials":13907,"activeCount":102},[],{"trials":13909,"activeCount":102},[],{"trials":13911,"activeCount":102},[],{"trials":13913,"activeCount":102},[],{"trials":13915,"activeCount":102},[13916,13920],{"nctId":6215,"briefTitle":6216,"status":131,"phases":13917,"primaryCompletion":5305,"completion":5305,"start":455,"enrollment":6218,"conditions":13918,"interventions":13919},[93],[6220],[6202,6222],{"nctId":13627,"briefTitle":13628,"status":131,"phases":13921,"primaryCompletion":8030,"completion":13630,"start":13631,"enrollment":13632,"conditions":13922,"interventions":13923},[93],[5420],[13614,6222],{"trials":13925,"activeCount":102},[13926],{"nctId":13646,"briefTitle":13647,"status":131,"phases":13927,"primaryCompletion":13649,"completion":13649,"start":13650,"enrollment":13651,"conditions":13928,"interventions":13929},[],[19],[13614,6222],{"intervention":13931,"totalTrials":702,"cells":13932},"prazosin",{"EARLY_PHASE1":13933,"PHASE1":13935,"PHASE2":13937,"PHASE3":13939,"PHASE4":13941,"NA":13950},{"trials":13934,"activeCount":102},[],{"trials":13936,"activeCount":102},[],{"trials":13938,"activeCount":102},[],{"trials":13940,"activeCount":102},[],{"trials":13942,"activeCount":102},[13943],{"nctId":13944,"briefTitle":13945,"status":131,"phases":13946,"primaryCompletion":1865,"completion":1865,"start":5621,"enrollment":34,"conditions":13947,"interventions":13949},"NCT00167687","Prazosin Alcohol Dependence IVR Study",[93],[13948],"Alcoholism",[13931],{"trials":13951,"activeCount":102},[13952,13960],{"nctId":13953,"briefTitle":13954,"status":131,"phases":13955,"primaryCompletion":10952,"completion":10952,"start":2033,"enrollment":1023,"conditions":13956,"interventions":13959},"NCT00161473","Alzheimer's in Long-Term Care--Treatment for Agitation",[94],[13957,13958],"Alzheimer Disease","Psychomotor Agitation",[13931],{"nctId":13961,"briefTitle":13962,"status":131,"phases":13963,"primaryCompletion":6839,"completion":6839,"start":6126,"enrollment":13964,"conditions":13965,"interventions":13971},"NCT02655354","A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity",[94],635,[12588,16,13966,13967,12868,5675,13968,376,13969,8191,13970],"Alcohol-Related Disorders","Suicidal Ideation","Quality of Life","Wounds and Injury","Chronic Disease",[13972,13973,13974,13975,13976,13977,13978,13979,13980,13981,13982],"Fluoxetine","Fluvoxamine","Paroxetine","Sertraline","Citalopram","Venlafaxine","Duloxetine","Mirtazapine","Diphenhydramine","Trazodone","Prazosin",{"intervention":7479,"totalTrials":702,"cells":13984},{"EARLY_PHASE1":13985,"PHASE1":13987,"PHASE2":13989,"PHASE3":13991,"PHASE4":13993,"NA":14010},{"trials":13986,"activeCount":102},[],{"trials":13988,"activeCount":102},[],{"trials":13990,"activeCount":102},[],{"trials":13992,"activeCount":102},[],{"trials":13994,"activeCount":102},[13995,14006],{"nctId":13996,"briefTitle":13997,"status":131,"phases":13998,"primaryCompletion":13999,"completion":14000,"start":13272,"enrollment":6886,"conditions":14001,"interventions":14003},"NCT03523988","Pre-emptive Analgesics in Orthodontic Treatment",[93],"2017-06-23","2017-08-01",[14002,675],"NSAID",[14004,14005],"Acetaminophen","Ibuprofen",{"nctId":7469,"briefTitle":7470,"status":131,"phases":14007,"primaryCompletion":7472,"completion":7472,"start":7473,"enrollment":1087,"conditions":14008,"interventions":14009},[93],[7475],[7477,7478,7479,7456],{"trials":14011,"activeCount":102},[14012],{"nctId":14013,"briefTitle":14014,"status":131,"phases":14015,"primaryCompletion":14016,"completion":5163,"start":14017,"enrollment":1477,"conditions":14018,"interventions":14019},"NCT05116293","Effect of Testosterone Treatment on Drug Metabolism and Transport",[],"2024-02-15","2021-05-01",[7475],[7477,7478,7479],{"intervention":6682,"totalTrials":702,"cells":14021},{"EARLY_PHASE1":14022,"PHASE1":14024,"PHASE2":14030,"PHASE3":14032,"PHASE4":14034,"NA":14040},{"trials":14023,"activeCount":102},[],{"trials":14025,"activeCount":102},[14026],{"nctId":12864,"briefTitle":12865,"status":5876,"phases":14027,"primaryCompletion":5066,"completion":5066,"start":6102,"enrollment":673,"conditions":14028,"interventions":14029},[90],[12868],[12870,12857,12871],{"trials":14031,"activeCount":102},[],{"trials":14033,"activeCount":102},[],{"trials":14035,"activeCount":102},[14036],{"nctId":6671,"briefTitle":6672,"status":131,"phases":14037,"primaryCompletion":6674,"completion":6675,"start":6676,"enrollment":6677,"conditions":14038,"interventions":14039},[93],[6679,6680,6658,6681,6682],[6658,6681,6682],{"trials":14041,"activeCount":102},[14042],{"nctId":14043,"briefTitle":14044,"status":131,"phases":14045,"primaryCompletion":190,"completion":190,"start":2895,"enrollment":192,"conditions":14046,"interventions":14047},"NCT01173640","Resveratrol and Midazolam Metabolism",[94],[5667],[6682],{"intervention":14049,"totalTrials":702,"cells":14050},"Truvada",{"EARLY_PHASE1":14051,"PHASE1":14053,"PHASE2":14055,"PHASE3":14057,"PHASE4":14059,"NA":14061},{"trials":14052,"activeCount":102},[],{"trials":14054,"activeCount":102},[],{"trials":14056,"activeCount":102},[],{"trials":14058,"activeCount":102},[],{"trials":14060,"activeCount":102},[],{"trials":14062,"activeCount":102},[14063,14069,14077],{"nctId":14064,"briefTitle":14065,"status":131,"phases":14066,"primaryCompletion":330,"completion":330,"start":7699,"enrollment":98,"conditions":14067,"interventions":14068},"NCT02621242","Effects of the Anti-HIV Pill Truvada on Gene Transcription in the Gastrointestinal Tract of HIV-uninfected Individuals",[],[25],[14049],{"nctId":14070,"briefTitle":14071,"status":131,"phases":14072,"primaryCompletion":14073,"completion":14073,"start":7283,"enrollment":23,"conditions":14074,"interventions":14076},"NCT03012607","Tenofovir Adherence to Rapidly Guide and Evaluate PrEP and HIV Therapy",[94],"2018-03",[14075],"Hiv",[14049],{"nctId":14078,"briefTitle":14079,"status":131,"phases":14080,"primaryCompletion":14081,"completion":14082,"start":2561,"enrollment":14083,"conditions":14084,"interventions":14085},"NCT03490058","The Prevention Options for Women Evaluation Research (POWER) Cohort",[],"2020-12-04","2021-07-23",2255,[5419],[14049],{"intervention":10149,"totalTrials":264,"cells":14087},{"EARLY_PHASE1":14088,"PHASE1":14090,"PHASE2":14092,"PHASE3":14098,"PHASE4":14100,"NA":14102},{"trials":14089,"activeCount":102},[],{"trials":14091,"activeCount":102},[],{"trials":14093,"activeCount":102},[14094],{"nctId":10142,"briefTitle":10143,"status":131,"phases":14095,"primaryCompletion":10145,"completion":10145,"start":5987,"enrollment":10146,"conditions":14096,"interventions":14097},[91],[8035],[10133,10149],{"trials":14099,"activeCount":102},[],{"trials":14101,"activeCount":102},[],{"trials":14103,"activeCount":102},[14104],{"nctId":14105,"briefTitle":14106,"status":131,"phases":14107,"primaryCompletion":370,"completion":370,"start":7569,"enrollment":310,"conditions":14108,"interventions":14110},"NCT00494832","Influence of Dexmedetomidine on the Evoked Potentials During Spine Surgery",[94],[14109],"Spine Surgery",[14111,10149],"Dexmedetomidine",{"intervention":14113,"totalTrials":264,"cells":14114},"Hyland's earache drops",{"EARLY_PHASE1":14115,"PHASE1":14117,"PHASE2":14119,"PHASE3":14121,"PHASE4":14123,"NA":14125},{"trials":14116,"activeCount":102},[],{"trials":14118,"activeCount":102},[],{"trials":14120,"activeCount":102},[],{"trials":14122,"activeCount":102},[],{"trials":14124,"activeCount":102},[],{"trials":14126,"activeCount":102},[14127,14134],{"nctId":14128,"briefTitle":14129,"status":131,"phases":14130,"primaryCompletion":191,"completion":10543,"start":7569,"enrollment":10146,"conditions":14131,"interventions":14133},"NCT00622518","Ear Drops for Children With Otitis Media",[94],[14132],"Acute Otitis Media",[14113],{"nctId":14135,"briefTitle":14136,"status":131,"phases":14137,"primaryCompletion":10951,"completion":860,"start":7168,"enrollment":6928,"conditions":14138,"interventions":14140},"NCT01003210","Homeopathic Ear Drops for Otitis Media Study",[94],[14139],"Otitis Media",[14113],{"intervention":1065,"totalTrials":264,"cells":14142},{"EARLY_PHASE1":14143,"PHASE1":14145,"PHASE2":14147,"PHASE3":14153,"PHASE4":14155,"NA":14157},{"trials":14144,"activeCount":102},[],{"trials":14146,"activeCount":102},[],{"trials":14148,"activeCount":102},[14149],{"nctId":1049,"briefTitle":1050,"status":108,"phases":14150,"primaryCompletion":1052,"completion":1053,"start":1054,"enrollment":261,"conditions":14151,"interventions":14152},[91],[1056,1057,1058,1059,1060,1061,1062,1063],[1065,1066,966],{"trials":14154,"activeCount":102},[],{"trials":14156,"activeCount":102},[],{"trials":14158,"activeCount":102},[14159],{"nctId":4923,"briefTitle":4924,"status":131,"phases":14160,"primaryCompletion":370,"start":4926,"enrollment":1207,"conditions":14161,"interventions":14162},[],[4928,4909],[4930,1794],{"intervention":14005,"totalTrials":264,"cells":14164},{"EARLY_PHASE1":14165,"PHASE1":14167,"PHASE2":14169,"PHASE3":14171,"PHASE4":14173,"NA":14179},{"trials":14166,"activeCount":102},[],{"trials":14168,"activeCount":102},[],{"trials":14170,"activeCount":102},[],{"trials":14172,"activeCount":102},[],{"trials":14174,"activeCount":102},[14175],{"nctId":13996,"briefTitle":13997,"status":131,"phases":14176,"primaryCompletion":13999,"completion":14000,"start":13272,"enrollment":6886,"conditions":14177,"interventions":14178},[93],[14002,675],[14004,14005],{"trials":14180,"activeCount":102},[14181],{"nctId":14182,"briefTitle":14183,"status":131,"phases":14184,"primaryCompletion":2106,"completion":2106,"start":5673,"enrollment":261,"conditions":14185,"interventions":14187},"NCT00890604","Outcomes Associated With Application of a Normothermia Protocol in Patients With Severe Neurological Insult and Fever",[94],[14186,12990],"Subarachnoid Hemorrhage",[14005,14188],"Acetominophen",{"intervention":14190,"totalTrials":264,"cells":14191},"Rosiglitazone",{"EARLY_PHASE1":14192,"PHASE1":14194,"PHASE2":14196,"PHASE3":14204,"PHASE4":14206,"NA":14208},{"trials":14193,"activeCount":102},[],{"trials":14195,"activeCount":102},[],{"trials":14197,"activeCount":102},[14198],{"nctId":14199,"briefTitle":14200,"status":5876,"phases":14201,"primaryCompletion":224,"completion":224,"start":2930,"enrollment":861,"conditions":14202,"interventions":14203},"NCT00242593","Rosiglitazone Effects on Cognition for Adults in Later Life",[91],[5675],[14190],{"trials":14205,"activeCount":102},[],{"trials":14207,"activeCount":102},[],{"trials":14209,"activeCount":102},[14210],{"nctId":14211,"briefTitle":14212,"status":131,"phases":14213,"primaryCompletion":3252,"completion":1475,"start":14214,"enrollment":6297,"conditions":14215,"interventions":14216},"NCT00194896","Preferred Treatment of Type 1.5 Diabetes",[94],"2000-02",[335],[14217,14218],"rosiglitazone","glyburide",{"intervention":1095,"totalTrials":264,"cells":14220},{"EARLY_PHASE1":14221,"PHASE1":14223,"PHASE2":14225,"PHASE3":14231,"PHASE4":14233,"NA":14235},{"trials":14222,"activeCount":102},[],{"trials":14224,"activeCount":102},[],{"trials":14226,"activeCount":102},[14227],{"nctId":1081,"briefTitle":1082,"status":131,"phases":14228,"primaryCompletion":1084,"completion":1085,"start":1086,"enrollment":1087,"conditions":14229,"interventions":14230},[91],[1089,1090,1091,1092],[1066,1094,1095,1096,966],{"trials":14232,"activeCount":102},[],{"trials":14234,"activeCount":102},[],{"trials":14236,"activeCount":102},[14237],{"nctId":14238,"briefTitle":14239,"status":131,"phases":14240,"primaryCompletion":14241,"completion":14241,"start":8573,"enrollment":1299,"conditions":14242,"interventions":14245},"NCT01731912","Degarelix Acetate Before and During Radiation Therapy in Treating Patients With Prostate Cancer",[94],"2016-09",[1059,14243,14244,1141,1142],"Stage IIA Prostate Cancer","Stage IIB Prostate Cancer",[1095],{"intervention":2982,"totalTrials":264,"cells":14247},{"EARLY_PHASE1":14248,"PHASE1":14250,"PHASE2":14256,"PHASE3":14258,"PHASE4":14260,"NA":14262},{"trials":14249,"activeCount":102},[],{"trials":14251,"activeCount":102},[14252],{"nctId":2890,"briefTitle":2891,"status":131,"phases":14253,"primaryCompletion":2893,"completion":2894,"start":2895,"enrollment":350,"conditions":14254,"interventions":14255},[90],[352,2897,2898,2899,275,355,377,36,2900],[2902,207,363],{"trials":14257,"activeCount":102},[],{"trials":14259,"activeCount":102},[],{"trials":14261,"activeCount":102},[],{"trials":14263,"activeCount":102},[14264],{"nctId":2974,"briefTitle":2975,"status":2976,"phases":14265,"conditions":14266,"interventions":14267},[],[2979,2980],[2982,1244,2443],{"intervention":208,"totalTrials":264,"cells":14269},{"EARLY_PHASE1":14270,"PHASE1":14272,"PHASE2":14274,"PHASE3":14280,"PHASE4":14282,"NA":14284},{"trials":14271,"activeCount":102},[],{"trials":14273,"activeCount":102},[],{"trials":14275,"activeCount":102},[14276],{"nctId":186,"briefTitle":187,"status":108,"phases":14277,"primaryCompletion":189,"completion":190,"start":191,"enrollment":192,"conditions":14278,"interventions":14279},[91],[194,195,196,197,198,199,200,201,202,203,204],[206,207,208,168],{"trials":14281,"activeCount":102},[],{"trials":14283,"activeCount":102},[],{"trials":14285,"activeCount":102},[14286],{"nctId":268,"briefTitle":269,"status":131,"phases":14287,"primaryCompletion":271,"completion":271,"start":272,"enrollment":273,"conditions":14288,"interventions":14289},[94],[275,194,276,277,278],[208,233,168,280,281],{"intervention":14291,"totalTrials":264,"cells":14292},"Aspirin",{"EARLY_PHASE1":14293,"PHASE1":14295,"PHASE2":14297,"PHASE3":14299,"PHASE4":14301,"NA":14313},{"trials":14294,"activeCount":102},[],{"trials":14296,"activeCount":102},[],{"trials":14298,"activeCount":102},[],{"trials":14300,"activeCount":102},[],{"trials":14302,"activeCount":102},[14303],{"nctId":14304,"briefTitle":14305,"status":108,"phases":14306,"primaryCompletion":14307,"completion":14307,"start":14308,"enrollment":14309,"conditions":14310,"interventions":14312},"NCT04456608","Genetic and Dietary Predictors of Anti-platelet Response",[93],"2023-07-31","2016-08-01",126,[14311],"Platelet Function",[14291],{"trials":14314,"activeCount":102},[14315],{"nctId":14316,"briefTitle":14317,"status":131,"phases":14318,"primaryCompletion":7699,"completion":7699,"start":4926,"enrollment":389,"conditions":14319,"interventions":14320},"NCT00234299","Effects of ASA on Prostate Tissue",[94],[4909],[14291],{"intervention":13981,"totalTrials":264,"cells":14322},{"EARLY_PHASE1":14323,"PHASE1":14325,"PHASE2":14327,"PHASE3":14329,"PHASE4":14340,"NA":14342},{"trials":14324,"activeCount":102},[],{"trials":14326,"activeCount":102},[],{"trials":14328,"activeCount":102},[],{"trials":14330,"activeCount":102},[14331],{"nctId":14332,"briefTitle":14333,"status":131,"phases":14334,"primaryCompletion":14335,"completion":1745,"start":14336,"enrollment":14309,"conditions":14337,"interventions":14339},"NCT03534284","Short and Long-Term Effectiveness of Existing Insomnia Therapies for Patients Undergoing Hemodialysis",[92],"2022-10-17","2018-09-19",[14338,8620],"Insomnia",[13981],{"trials":14341,"activeCount":102},[],{"trials":14343,"activeCount":102},[14344],{"nctId":13961,"briefTitle":13962,"status":131,"phases":14345,"primaryCompletion":6839,"completion":6839,"start":6126,"enrollment":13964,"conditions":14346,"interventions":14347},[94],[12588,16,13966,13967,12868,5675,13968,376,13969,8191,13970],[13972,13973,13974,13975,13976,13977,13978,13979,13980,13981,13982],{"intervention":14349,"totalTrials":264,"cells":14350},"Hyland's Cold 'n Cough 4 kids",{"EARLY_PHASE1":14351,"PHASE1":14353,"PHASE2":14355,"PHASE3":14357,"PHASE4":14359,"NA":14361},{"trials":14352,"activeCount":102},[],{"trials":14354,"activeCount":102},[],{"trials":14356,"activeCount":102},[],{"trials":14358,"activeCount":102},[],{"trials":14360,"activeCount":102},[],{"trials":14362,"activeCount":102},[14363,14371],{"nctId":14364,"briefTitle":14365,"status":131,"phases":14366,"primaryCompletion":5021,"completion":860,"start":271,"enrollment":14367,"conditions":14368,"interventions":14370},"NCT01257503","Homeopathic Cold Remedy for Children Study",[94],263,[14369],"Upper Respiratory Tract Infections",[14349],{"nctId":14372,"briefTitle":14373,"status":131,"phases":14374,"primaryCompletion":7168,"completion":7168,"start":5641,"enrollment":350,"conditions":14375,"interventions":14377},"NCT00858494","Homeopathic Cold Medicine for Children",[94],[14376],"Upper Respiratory Tract Infection",[14378],"Hyland's Cold 'n Cough 4 Kids",{"intervention":7406,"totalTrials":264,"cells":14380},{"EARLY_PHASE1":14381,"PHASE1":14383,"PHASE2":14385,"PHASE3":14387,"PHASE4":14389,"NA":14395},{"trials":14382,"activeCount":102},[],{"trials":14384,"activeCount":102},[],{"trials":14386,"activeCount":102},[],{"trials":14388,"activeCount":102},[],{"trials":14390,"activeCount":102},[14391],{"nctId":7400,"briefTitle":7401,"status":108,"phases":14392,"primaryCompletion":1641,"completion":719,"start":191,"enrollment":261,"conditions":14393,"interventions":14394},[93],[7404],[7387,7406],{"trials":14396,"activeCount":102},[14397],{"nctId":14398,"briefTitle":14399,"status":131,"phases":14400,"primaryCompletion":1194,"start":1313,"enrollment":261,"conditions":14401,"interventions":14402},"NCT01327482","Levels of Raltegravir in the Female Genital Tissue",[94],[25],[7406],{"intervention":12082,"totalTrials":264,"cells":14404},{"EARLY_PHASE1":14405,"PHASE1":14407,"PHASE2":14409,"PHASE3":14415,"PHASE4":14417,"NA":14419},{"trials":14406,"activeCount":102},[],{"trials":14408,"activeCount":102},[],{"trials":14410,"activeCount":102},[14411],{"nctId":12075,"briefTitle":12076,"status":131,"phases":14412,"primaryCompletion":5685,"completion":5650,"start":12078,"enrollment":12079,"conditions":14413,"interventions":14414},[91],[19],[12066,12082],{"trials":14416,"activeCount":102},[],{"trials":14418,"activeCount":102},[],{"trials":14420,"activeCount":102},[14421],{"nctId":14422,"briefTitle":14423,"status":108,"phases":14424,"primaryCompletion":1619,"completion":1620,"start":8414,"enrollment":5622,"conditions":14425,"interventions":14426},"NCT00428116","Optimizing Pediatric HIV-1 Treatment, Nairobi, Kenya",[94],[19],[12082],{"intervention":7477,"totalTrials":264,"cells":14428},{"EARLY_PHASE1":14429,"PHASE1":14431,"PHASE2":14433,"PHASE3":14435,"PHASE4":14437,"NA":14443},{"trials":14430,"activeCount":102},[],{"trials":14432,"activeCount":102},[],{"trials":14434,"activeCount":102},[],{"trials":14436,"activeCount":102},[],{"trials":14438,"activeCount":102},[14439],{"nctId":7469,"briefTitle":7470,"status":131,"phases":14440,"primaryCompletion":7472,"completion":7472,"start":7473,"enrollment":1087,"conditions":14441,"interventions":14442},[93],[7475],[7477,7478,7479,7456],{"trials":14444,"activeCount":102},[14445],{"nctId":14013,"briefTitle":14014,"status":131,"phases":14446,"primaryCompletion":14016,"completion":5163,"start":14017,"enrollment":1477,"conditions":14447,"interventions":14448},[],[7475],[7477,7478,7479],{"intervention":7478,"totalTrials":264,"cells":14450},{"EARLY_PHASE1":14451,"PHASE1":14453,"PHASE2":14455,"PHASE3":14457,"PHASE4":14459,"NA":14465},{"trials":14452,"activeCount":102},[],{"trials":14454,"activeCount":102},[],{"trials":14456,"activeCount":102},[],{"trials":14458,"activeCount":102},[],{"trials":14460,"activeCount":102},[14461],{"nctId":7469,"briefTitle":7470,"status":131,"phases":14462,"primaryCompletion":7472,"completion":7472,"start":7473,"enrollment":1087,"conditions":14463,"interventions":14464},[93],[7475],[7477,7478,7479,7456],{"trials":14466,"activeCount":102},[14467],{"nctId":14013,"briefTitle":14014,"status":131,"phases":14468,"primaryCompletion":14016,"completion":5163,"start":14017,"enrollment":1477,"conditions":14469,"interventions":14470},[],[7475],[7477,7478,7479],{"intervention":13972,"totalTrials":264,"cells":14472},{"EARLY_PHASE1":14473,"PHASE1":14475,"PHASE2":14477,"PHASE3":14487,"PHASE4":14489,"NA":14491},{"trials":14474,"activeCount":102},[],{"trials":14476,"activeCount":102},[],{"trials":14478,"activeCount":102},[14479],{"nctId":14480,"briefTitle":14481,"status":131,"phases":14482,"primaryCompletion":14483,"completion":14483,"start":5378,"enrollment":317,"conditions":14484,"interventions":14486},"NCT03826875","Poststroke Depression in Hemorrhagic Stroke",[91],"2025-05-07",[14485,16],"Stroke Hemorrhagic",[13972],{"trials":14488,"activeCount":102},[],{"trials":14490,"activeCount":102},[],{"trials":14492,"activeCount":102},[14493],{"nctId":13961,"briefTitle":13962,"status":131,"phases":14494,"primaryCompletion":6839,"completion":6839,"start":6126,"enrollment":13964,"conditions":14495,"interventions":14496},[94],[12588,16,13966,13967,12868,5675,13968,376,13969,8191,13970],[13972,13973,13974,13975,13976,13977,13978,13979,13980,13981,13982],{"intervention":13977,"totalTrials":264,"cells":14498},{"EARLY_PHASE1":14499,"PHASE1":14501,"PHASE2":14503,"PHASE3":14505,"PHASE4":14507,"NA":14516},{"trials":14500,"activeCount":102},[],{"trials":14502,"activeCount":102},[],{"trials":14504,"activeCount":102},[],{"trials":14506,"activeCount":102},[],{"trials":14508,"activeCount":102},[14509],{"nctId":14510,"briefTitle":14511,"status":131,"phases":14512,"primaryCompletion":411,"completion":411,"start":1790,"enrollment":1182,"conditions":14513,"interventions":14515},"NCT00611676","A Single-Blind Placebo Run-In Study of Venlafaxine for Activity-Limiting Osteoarthritis Pain",[93],[14514,376],"Osteoarthritis",[13977],{"trials":14517,"activeCount":102},[14518],{"nctId":13961,"briefTitle":13962,"status":131,"phases":14519,"primaryCompletion":6839,"completion":6839,"start":6126,"enrollment":13964,"conditions":14520,"interventions":14521},[94],[12588,16,13966,13967,12868,5675,13968,376,13969,8191,13970],[13972,13973,13974,13975,13976,13977,13978,13979,13980,13981,13982],{"intervention":14523,"totalTrials":264,"cells":14524},"duloxetine",{"EARLY_PHASE1":14525,"PHASE1":14527,"PHASE2":14529,"PHASE3":14531,"PHASE4":14533,"NA":14541},{"trials":14526,"activeCount":102},[],{"trials":14528,"activeCount":102},[],{"trials":14530,"activeCount":102},[],{"trials":14532,"activeCount":102},[],{"trials":14534,"activeCount":102},[14535],{"nctId":14536,"briefTitle":14537,"status":131,"phases":14538,"primaryCompletion":411,"completion":411,"start":1790,"enrollment":29,"conditions":14539,"interventions":14540},"NCT00609557","A Single-Blind Placebo Run-in Study of Duloxetine for Activity-Limiting Osteoarthritis Pain",[93],[14514,376],[14523],{"trials":14542,"activeCount":102},[14543],{"nctId":13961,"briefTitle":13962,"status":131,"phases":14544,"primaryCompletion":6839,"completion":6839,"start":6126,"enrollment":13964,"conditions":14545,"interventions":14546},[94],[12588,16,13966,13967,12868,5675,13968,376,13969,8191,13970],[13972,13973,13974,13975,13976,13977,13978,13979,13980,13981,13982],{"intervention":14548,"totalTrials":236,"cells":14549},"Echinacea purpurea",{"EARLY_PHASE1":14550,"PHASE1":14552,"PHASE2":14554,"PHASE3":14556,"PHASE4":14558,"NA":14560},{"trials":14551,"activeCount":102},[],{"trials":14553,"activeCount":102},[],{"trials":14555,"activeCount":102},[],{"trials":14557,"activeCount":102},[],{"trials":14559,"activeCount":102},[],{"trials":14561,"activeCount":102},[14562],{"nctId":14563,"briefTitle":14564,"status":131,"phases":14565,"primaryCompletion":7756,"completion":7756,"start":5641,"enrollment":673,"conditions":14566,"interventions":14567},"NCT00860795","Immunologic Effects of Echinacea",[94],[14369],[14548],{"intervention":14569,"totalTrials":236,"cells":14570},"Fluorothymidine F-18",{"EARLY_PHASE1":14571,"PHASE1":14573,"PHASE2":14575,"PHASE3":14577,"PHASE4":14579,"NA":14581},{"trials":14572,"activeCount":102},[],{"trials":14574,"activeCount":102},[],{"trials":14576,"activeCount":102},[],{"trials":14578,"activeCount":102},[],{"trials":14580,"activeCount":102},[],{"trials":14582,"activeCount":102},[14583],{"nctId":14584,"briefTitle":14585,"status":131,"phases":14586,"primaryCompletion":14587,"completion":14587,"start":1863,"enrollment":26,"conditions":14588,"interventions":14590},"NCT01928186","FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer",[94],"2015-07-20",[3058,2068,14589,357,358,2071,2072,278,378,379],"Male Breast Carcinoma",[14569,14591],"Run-in (short pre-surgery course) of endocrine-targeted therapy",{"intervention":14591,"totalTrials":236,"cells":14593},{"EARLY_PHASE1":14594,"PHASE1":14596,"PHASE2":14598,"PHASE3":14600,"PHASE4":14602,"NA":14604},{"trials":14595,"activeCount":102},[],{"trials":14597,"activeCount":102},[],{"trials":14599,"activeCount":102},[],{"trials":14601,"activeCount":102},[],{"trials":14603,"activeCount":102},[],{"trials":14605,"activeCount":102},[14606],{"nctId":14584,"briefTitle":14585,"status":131,"phases":14607,"primaryCompletion":14587,"completion":14587,"start":1863,"enrollment":26,"conditions":14608,"interventions":14609},[94],[3058,2068,14589,357,358,2071,2072,278,378,379],[14569,14591],{"intervention":14111,"totalTrials":236,"cells":14611},{"EARLY_PHASE1":14612,"PHASE1":14614,"PHASE2":14616,"PHASE3":14618,"PHASE4":14620,"NA":14622},{"trials":14613,"activeCount":102},[],{"trials":14615,"activeCount":102},[],{"trials":14617,"activeCount":102},[],{"trials":14619,"activeCount":102},[],{"trials":14621,"activeCount":102},[],{"trials":14623,"activeCount":102},[14624],{"nctId":14105,"briefTitle":14106,"status":131,"phases":14625,"primaryCompletion":370,"completion":370,"start":7569,"enrollment":310,"conditions":14626,"interventions":14627},[94],[14109],[14111,10149],{"intervention":14629,"totalTrials":236,"cells":14630},"Omega-3 fatty acids",{"EARLY_PHASE1":14631,"PHASE1":14633,"PHASE2":14635,"PHASE3":14637,"PHASE4":14639,"NA":14641},{"trials":14632,"activeCount":102},[],{"trials":14634,"activeCount":102},[],{"trials":14636,"activeCount":102},[],{"trials":14638,"activeCount":102},[],{"trials":14640,"activeCount":102},[],{"trials":14642,"activeCount":102},[14643],{"nctId":14644,"briefTitle":14645,"status":131,"phases":14646,"primaryCompletion":14647,"completion":14647,"start":2895,"enrollment":14648,"conditions":14649,"interventions":14651},"NCT01684722","Vitamin D and Omega-3 Trial to Prevent and Treat Diabetic Kidney Disease",[94],"2019-11-08",1312,[14650],"Diabetes",[14629],{"intervention":14653,"totalTrials":236,"cells":14654},"Echinacea purpurea 100 mg\u002Fml in liquid formulation",{"EARLY_PHASE1":14655,"PHASE1":14657,"PHASE2":14659,"PHASE3":14661,"PHASE4":14663,"NA":14665},{"trials":14656,"activeCount":102},[],{"trials":14658,"activeCount":102},[],{"trials":14660,"activeCount":102},[],{"trials":14662,"activeCount":102},[],{"trials":14664,"activeCount":102},[],{"trials":14666,"activeCount":102},[14667],{"nctId":14668,"briefTitle":14669,"status":1150,"phases":14670,"primaryCompletion":1675,"completion":7756,"start":226,"enrollment":102,"conditions":14671,"interventions":14673},"NCT00773435","Effects of Echinacea in Children",[94],[14672],"Upper Respiratory Infections",[14653],{"intervention":14675,"totalTrials":236,"cells":14676},"Dexlansoprazole",{"EARLY_PHASE1":14677,"PHASE1":14679,"PHASE2":14681,"PHASE3":14683,"PHASE4":14685,"NA":14687},{"trials":14678,"activeCount":102},[],{"trials":14680,"activeCount":102},[],{"trials":14682,"activeCount":102},[],{"trials":14684,"activeCount":102},[],{"trials":14686,"activeCount":102},[],{"trials":14688,"activeCount":102},[14689],{"nctId":14690,"briefTitle":14691,"status":1150,"phases":14692,"primaryCompletion":11159,"completion":11159,"start":1591,"enrollment":102,"conditions":14693,"interventions":14695},"NCT01328392","Evaluating Treatment Response in Laryngo-Pharyngeal Reflux",[94],[14694],"Laryngo-pharyngeal Reflux",[14675],{"intervention":14697,"totalTrials":236,"cells":14698},"Exendin-(9-39) Acetate",{"EARLY_PHASE1":14699,"PHASE1":14701,"PHASE2":14703,"PHASE3":14705,"PHASE4":14707,"NA":14709},{"trials":14700,"activeCount":102},[],{"trials":14702,"activeCount":102},[],{"trials":14704,"activeCount":102},[],{"trials":14706,"activeCount":102},[],{"trials":14708,"activeCount":102},[],{"trials":14710,"activeCount":102},[14711],{"nctId":14712,"briefTitle":14713,"status":1150,"phases":14714,"primaryCompletion":14715,"completion":14715,"start":2895,"enrollment":102,"conditions":14716,"interventions":14718},"NCT01152333","The Role of GLP-1 in Satiety Perception in Humans",[94],"2016-07",[14717,336],"Appetite Regulation",[14697,14719],"Saline 0.9%",{"intervention":14719,"totalTrials":236,"cells":14721},{"EARLY_PHASE1":14722,"PHASE1":14724,"PHASE2":14726,"PHASE3":14728,"PHASE4":14730,"NA":14732},{"trials":14723,"activeCount":102},[],{"trials":14725,"activeCount":102},[],{"trials":14727,"activeCount":102},[],{"trials":14729,"activeCount":102},[],{"trials":14731,"activeCount":102},[],{"trials":14733,"activeCount":102},[14734],{"nctId":14712,"briefTitle":14713,"status":1150,"phases":14735,"primaryCompletion":14715,"completion":14715,"start":2895,"enrollment":102,"conditions":14736,"interventions":14737},[94],[14717,336],[14697,14719],{"intervention":14739,"totalTrials":236,"cells":14740},"7% Hypertonic Saline",{"EARLY_PHASE1":14741,"PHASE1":14743,"PHASE2":14745,"PHASE3":14747,"PHASE4":14749,"NA":14751},{"trials":14742,"activeCount":102},[],{"trials":14744,"activeCount":102},[],{"trials":14746,"activeCount":102},[],{"trials":14748,"activeCount":102},[],{"trials":14750,"activeCount":102},[],{"trials":14752,"activeCount":102},[14753],{"nctId":14754,"briefTitle":14755,"status":131,"phases":14756,"primaryCompletion":14757,"completion":14757,"start":14758,"enrollment":14759,"conditions":14760,"interventions":14761},"NCT02378467","Saline Hypertonic in Preschoolers",[94],"2018-08-31","2015-03-01",150,[8035],[14739,14762],"0.9% Isotonic Saline",{"intervention":14762,"totalTrials":236,"cells":14764},{"EARLY_PHASE1":14765,"PHASE1":14767,"PHASE2":14769,"PHASE3":14771,"PHASE4":14773,"NA":14775},{"trials":14766,"activeCount":102},[],{"trials":14768,"activeCount":102},[],{"trials":14770,"activeCount":102},[],{"trials":14772,"activeCount":102},[],{"trials":14774,"activeCount":102},[],{"trials":14776,"activeCount":102},[14777],{"nctId":14754,"briefTitle":14755,"status":131,"phases":14778,"primaryCompletion":14757,"completion":14757,"start":14758,"enrollment":14759,"conditions":14779,"interventions":14780},[94],[8035],[14739,14762],{"intervention":14782,"totalTrials":236,"cells":14783},"hypertonic saline",{"EARLY_PHASE1":14784,"PHASE1":14786,"PHASE2":14788,"PHASE3":14790,"PHASE4":14792,"NA":14794},{"trials":14785,"activeCount":102},[],{"trials":14787,"activeCount":102},[],{"trials":14789,"activeCount":102},[],{"trials":14791,"activeCount":102},[],{"trials":14793,"activeCount":102},[],{"trials":14795,"activeCount":102},[14796],{"nctId":14797,"briefTitle":14798,"status":108,"phases":14799,"primaryCompletion":8413,"completion":8413,"start":14800,"enrollment":10146,"conditions":14801,"interventions":14802},"NCT00750997","Hypertonic Modulation of Inflammation Following Injury",[],"2007-11",[12322,11245],[14782],{"intervention":14804,"totalTrials":236,"cells":14805},"2nd line ART",{"EARLY_PHASE1":14806,"PHASE1":14808,"PHASE2":14810,"PHASE3":14812,"PHASE4":14814,"NA":14816},{"trials":14807,"activeCount":102},[],{"trials":14809,"activeCount":102},[],{"trials":14811,"activeCount":102},[],{"trials":14813,"activeCount":102},[],{"trials":14815,"activeCount":102},[],{"trials":14817,"activeCount":102},[14818],{"nctId":14819,"briefTitle":14820,"status":108,"phases":14821,"primaryCompletion":14822,"completion":14822,"start":14823,"enrollment":14824,"conditions":14825,"interventions":14826},"NCT03394196","RESIST-2: 2nd-line ART for HIV-2 Infection",[94],"2020-05-31","2018-07-04",152,[7286],[14804,14804,14804],{"intervention":14828,"totalTrials":236,"cells":14829},"Iohexol",{"EARLY_PHASE1":14830,"PHASE1":14832,"PHASE2":14834,"PHASE3":14836,"PHASE4":14838,"NA":14840},{"trials":14831,"activeCount":102},[],{"trials":14833,"activeCount":102},[],{"trials":14835,"activeCount":102},[],{"trials":14837,"activeCount":102},[],{"trials":14839,"activeCount":102},[],{"trials":14841,"activeCount":102},[14842],{"nctId":14843,"briefTitle":14844,"status":131,"phases":14845,"primaryCompletion":7700,"completion":7700,"start":3252,"enrollment":1041,"conditions":14846,"interventions":14849},"NCT01545531","Two-Point Measurement of Glomerular Filtration Rate by Iohexol Plasma Disappearance",[],[14847,14848],"Renal Disease","Renal Insufficiency",[14828],{"intervention":14851,"totalTrials":236,"cells":14852},"Terazosin",{"EARLY_PHASE1":14853,"PHASE1":14855,"PHASE2":14857,"PHASE3":14859,"PHASE4":14861,"NA":14863},{"trials":14854,"activeCount":102},[],{"trials":14856,"activeCount":102},[],{"trials":14858,"activeCount":102},[],{"trials":14860,"activeCount":102},[],{"trials":14862,"activeCount":102},[],{"trials":14864,"activeCount":102},[14865],{"nctId":14866,"briefTitle":14867,"status":5876,"phases":14868,"primaryCompletion":7699,"completion":7699,"start":5664,"enrollment":1023,"conditions":14869,"interventions":14871},"NCT01508637","Diesel Exhaust and Vascular Function",[94],[14870],"Cardiovascular Effects",[14851],{"intervention":14873,"totalTrials":236,"cells":14874},"levonorgestrel 0.75mg taken twice 12 hours apart (Plan B) and condoms",{"EARLY_PHASE1":14875,"PHASE1":14877,"PHASE2":14879,"PHASE3":14881,"PHASE4":14883,"NA":14885},{"trials":14876,"activeCount":102},[],{"trials":14878,"activeCount":102},[],{"trials":14880,"activeCount":102},[],{"trials":14882,"activeCount":102},[],{"trials":14884,"activeCount":102},[],{"trials":14886,"activeCount":102},[14887],{"nctId":14888,"briefTitle":14889,"status":131,"phases":14890,"completion":6588,"start":2056,"enrollment":14891,"conditions":14892,"interventions":14894},"NCT00520455","Randomized Trial of Advanced Provision Emergency Contraception Among Women With Gonorrhea or Chlamydia",[94],177,[14893],"Pregnancy",[14873],{"intervention":14896,"totalTrials":236,"cells":14897},"Technetium Tc-99m Sulfur Colloid",{"EARLY_PHASE1":14898,"PHASE1":14900,"PHASE2":14902,"PHASE3":14904,"PHASE4":14906,"NA":14908},{"trials":14899,"activeCount":102},[],{"trials":14901,"activeCount":102},[],{"trials":14903,"activeCount":102},[],{"trials":14905,"activeCount":102},[],{"trials":14907,"activeCount":102},[],{"trials":14909,"activeCount":102},[14910],{"nctId":14911,"briefTitle":14912,"status":108,"phases":14913,"primaryCompletion":12144,"completion":14914,"start":14915,"enrollment":273,"conditions":14916,"interventions":14923},"NCT02881554","Sulfur Colloid SPECT\u002FCT in Measuring Liver Function in Patients With Primary or Metastatic Liver Cancer Undergoing Radiation Therapy or Surgery",[94],"2025-02-09","2016-12-21",[14917,14918,14919,14920,14921,14922],"Hepatocellular Carcinoma","Intrahepatic Cholangiocarcinoma","Stage IV Liver Cancer","Stage IVA Liver Cancer","Stage IVB Liver Cancer","Vascular Thrombosis",[14896],{"intervention":14925,"totalTrials":236,"cells":14926},"6-month PrEP + blood-based HIV self-test",{"EARLY_PHASE1":14927,"PHASE1":14929,"PHASE2":14931,"PHASE3":14933,"PHASE4":14935,"NA":14937},{"trials":14928,"activeCount":102},[],{"trials":14930,"activeCount":102},[],{"trials":14932,"activeCount":102},[],{"trials":14934,"activeCount":102},[],{"trials":14936,"activeCount":102},[],{"trials":14938,"activeCount":102},[14939],{"nctId":14940,"briefTitle":14941,"status":131,"phases":14942,"primaryCompletion":1085,"completion":14943,"start":14944,"enrollment":14945,"conditions":14946,"interventions":14947},"NCT03593629","Kenya HIV Self-Testing in PrEP Delivery",[94],"2021-05-25","2018-05-28",790,[5420],[14925,14948],"6-month PrEP + oral fluid HIV self-test",{"intervention":14948,"totalTrials":236,"cells":14950},{"EARLY_PHASE1":14951,"PHASE1":14953,"PHASE2":14955,"PHASE3":14957,"PHASE4":14959,"NA":14961},{"trials":14952,"activeCount":102},[],{"trials":14954,"activeCount":102},[],{"trials":14956,"activeCount":102},[],{"trials":14958,"activeCount":102},[],{"trials":14960,"activeCount":102},[],{"trials":14962,"activeCount":102},[14963],{"nctId":14940,"briefTitle":14941,"status":131,"phases":14964,"primaryCompletion":1085,"completion":14943,"start":14944,"enrollment":14945,"conditions":14965,"interventions":14966},[94],[5420],[14925,14948],{"intervention":14968,"totalTrials":236,"cells":14969},"Aromatherapy packet",{"EARLY_PHASE1":14970,"PHASE1":14972,"PHASE2":14974,"PHASE3":14976,"PHASE4":14978,"NA":14980},{"trials":14971,"activeCount":102},[],{"trials":14973,"activeCount":102},[],{"trials":14975,"activeCount":102},[],{"trials":14977,"activeCount":102},[],{"trials":14979,"activeCount":102},[],{"trials":14981,"activeCount":102},[14982],{"nctId":14983,"briefTitle":14984,"status":1150,"phases":14985,"primaryCompletion":81,"completion":81,"start":14986,"enrollment":102,"conditions":14987,"interventions":14988},"NCT05910892","Aromatherapy and Pain",[94],"2025-01",[31],[14968],{"intervention":14990,"totalTrials":236,"cells":14991},"Psychotropic Drugs",{"EARLY_PHASE1":14992,"PHASE1":14994,"PHASE2":14996,"PHASE3":14998,"PHASE4":15000,"NA":15002},{"trials":14993,"activeCount":102},[],{"trials":14995,"activeCount":102},[],{"trials":14997,"activeCount":102},[],{"trials":14999,"activeCount":102},[],{"trials":15001,"activeCount":102},[],{"trials":15003,"activeCount":102},[15004],{"nctId":15005,"briefTitle":15006,"status":131,"phases":15007,"primaryCompletion":8773,"completion":8773,"start":2893,"enrollment":310,"conditions":15008,"interventions":15009},"NCT02335125","A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity Pilot",[94],[12588,16,13966,13967,12868,5675,13968],[14990],{"intervention":15011,"totalTrials":236,"cells":15012},"Linagliptin",{"EARLY_PHASE1":15013,"PHASE1":15015,"PHASE2":15017,"PHASE3":15019,"PHASE4":15021,"NA":15023},{"trials":15014,"activeCount":102},[],{"trials":15016,"activeCount":102},[],{"trials":15018,"activeCount":102},[],{"trials":15020,"activeCount":102},[],{"trials":15022,"activeCount":102},[],{"trials":15024,"activeCount":102},[15025],{"nctId":15026,"briefTitle":15027,"status":131,"phases":15028,"primaryCompletion":15029,"completion":15030,"start":15031,"enrollment":702,"conditions":15032,"interventions":15034},"NCT02608177","Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management",[94],"2017-08","2018-08","2015-11",[15033,5921],"Chronic Kidney Diseases",[15011,15035],"Glipizide",{"intervention":15035,"totalTrials":236,"cells":15037},{"EARLY_PHASE1":15038,"PHASE1":15040,"PHASE2":15042,"PHASE3":15044,"PHASE4":15046,"NA":15048},{"trials":15039,"activeCount":102},[],{"trials":15041,"activeCount":102},[],{"trials":15043,"activeCount":102},[],{"trials":15045,"activeCount":102},[],{"trials":15047,"activeCount":102},[],{"trials":15049,"activeCount":102},[15050],{"nctId":15026,"briefTitle":15027,"status":131,"phases":15051,"primaryCompletion":15029,"completion":15030,"start":15031,"enrollment":702,"conditions":15052,"interventions":15053},[94],[15033,5921],[15011,15035],{"intervention":15055,"totalTrials":236,"cells":15056},"Cefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin",{"EARLY_PHASE1":15057,"PHASE1":15059,"PHASE2":15061,"PHASE3":15063,"PHASE4":15065,"NA":15067},{"trials":15058,"activeCount":102},[],{"trials":15060,"activeCount":102},[],{"trials":15062,"activeCount":102},[],{"trials":15064,"activeCount":102},[],{"trials":15066,"activeCount":102},[],{"trials":15068,"activeCount":102},[15069],{"nctId":15070,"briefTitle":15071,"status":131,"phases":15072,"primaryCompletion":15073,"completion":3728,"start":5978,"enrollment":15074,"conditions":15075,"interventions":15077},"NCT02800785","The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial",[94],"2020-03-05",1552,[15076],"Appendicitis",[15055],{"intervention":15079,"totalTrials":236,"cells":15080},"1:1 volume measured solution of: 1% lidocaine without epinephrine and 0.5% bupivacaine without epinephrine",{"EARLY_PHASE1":15081,"PHASE1":15083,"PHASE2":15085,"PHASE3":15087,"PHASE4":15089,"NA":15091},{"trials":15082,"activeCount":102},[],{"trials":15084,"activeCount":102},[],{"trials":15086,"activeCount":102},[],{"trials":15088,"activeCount":102},[],{"trials":15090,"activeCount":102},[],{"trials":15092,"activeCount":102},[15093],{"nctId":15094,"briefTitle":15095,"status":131,"phases":15096,"primaryCompletion":15097,"completion":15097,"start":15098,"enrollment":456,"conditions":15099,"interventions":15102},"NCT03195413","Early Ultrasound-guided Nerve Block for Painful Hand Injuries in the Emergency Department",[94],"2018-07-10","2017-07-01",[15100,15101],"Hand Injuries","Hand Injuries and Disorders",[15079],{"intervention":15104,"totalTrials":236,"cells":15105},"NTBC",{"EARLY_PHASE1":15106,"PHASE1":15108,"PHASE2":15110,"PHASE3":15112,"PHASE4":15114,"NA":15116},{"trials":15107,"activeCount":102},[],{"trials":15109,"activeCount":102},[],{"trials":15111,"activeCount":102},[],{"trials":15113,"activeCount":102},[],{"trials":15115,"activeCount":102},[],{"trials":15117,"activeCount":102},[15118],{"nctId":15119,"briefTitle":15120,"status":131,"phases":15121,"completion":11442,"start":15122,"enrollment":673,"conditions":15123,"interventions":15125},"NCT00004443","Study of NTBC for Tyrosinemia I",[94],"1998-10",[15124],"Tyrosinemia I",[15104],{"intervention":15127,"totalTrials":236,"cells":15128},"Low-dose pain medication (Ketalar) and saline placebo",{"EARLY_PHASE1":15129,"PHASE1":15131,"PHASE2":15133,"PHASE3":15135,"PHASE4":15137,"NA":15139},{"trials":15130,"activeCount":102},[],{"trials":15132,"activeCount":102},[],{"trials":15134,"activeCount":102},[],{"trials":15136,"activeCount":102},[],{"trials":15138,"activeCount":102},[],{"trials":15140,"activeCount":102},[15141],{"nctId":15142,"briefTitle":15143,"status":5876,"phases":15144,"primaryCompletion":1577,"completion":1577,"start":10951,"enrollment":389,"conditions":15145,"interventions":15147},"NCT01840774","Modifying Virtual Reality Analgesia With Low-Dose Pain Medication",[94],[15146],"Virtual Reality Therapy",[15127],{"intervention":15149,"totalTrials":236,"cells":15150},"Simvastatin, simvastatin plus extended-release niacin",{"EARLY_PHASE1":15151,"PHASE1":15153,"PHASE2":15155,"PHASE3":15157,"PHASE4":15159,"NA":15161},{"trials":15152,"activeCount":102},[],{"trials":15154,"activeCount":102},[],{"trials":15156,"activeCount":102},[],{"trials":15158,"activeCount":102},[],{"trials":15160,"activeCount":102},[],{"trials":15162,"activeCount":102},[15163],{"nctId":15164,"briefTitle":15165,"status":131,"phases":15166,"primaryCompletion":10951,"completion":2893,"start":3157,"enrollment":15167,"conditions":15168,"interventions":15169},"NCT01178320","Carotid Plaque Characteristics by MRI in AIM-HIGH (Carotid MRI Substudy)",[],230,[5382,5383,5384],[15149],{"intervention":15171,"totalTrials":236,"cells":15172},"20 mcg ethinyl estradiol and 100 mcg levonorgestrel",{"EARLY_PHASE1":15173,"PHASE1":15175,"PHASE2":15177,"PHASE3":15179,"PHASE4":15181,"NA":15183},{"trials":15174,"activeCount":102},[],{"trials":15176,"activeCount":102},[],{"trials":15178,"activeCount":102},[],{"trials":15180,"activeCount":102},[],{"trials":15182,"activeCount":102},[],{"trials":15184,"activeCount":102},[15185],{"nctId":15186,"briefTitle":15187,"status":131,"phases":15188,"primaryCompletion":347,"completion":347,"start":10333,"enrollment":15189,"conditions":15190,"interventions":15192},"NCT00237042","Managing Temporomandibular Disorder (TMD) Symptoms",[94],252,[15191],"Temporomandibular Joint Disorders",[15171],{"intervention":13903,"totalTrials":236,"cells":15194},{"EARLY_PHASE1":15195,"PHASE1":15197,"PHASE2":15199,"PHASE3":15201,"PHASE4":15203,"NA":15205},{"trials":15196,"activeCount":102},[],{"trials":15198,"activeCount":102},[],{"trials":15200,"activeCount":102},[],{"trials":15202,"activeCount":102},[],{"trials":15204,"activeCount":102},[],{"trials":15206,"activeCount":102},[15207],{"nctId":13897,"briefTitle":13898,"status":131,"phases":15208,"primaryCompletion":6483,"completion":1863,"start":8281,"enrollment":13900,"conditions":15209,"interventions":15210},[],[22,28,5817,5384,7625],[13903,13871],{"intervention":745,"totalTrials":236,"cells":15212},{"EARLY_PHASE1":15213,"PHASE1":15215,"PHASE2":15217,"PHASE3":15219,"PHASE4":15221,"NA":15223},{"trials":15214,"activeCount":102},[],{"trials":15216,"activeCount":102},[],{"trials":15218,"activeCount":102},[],{"trials":15220,"activeCount":102},[],{"trials":15222,"activeCount":102},[],{"trials":15224,"activeCount":102},[15225],{"nctId":736,"briefTitle":737,"status":131,"phases":15226,"primaryCompletion":134,"completion":739,"start":740,"enrollment":741,"conditions":15227,"interventions":15228},[94],[743],[745,746,701,747],{"intervention":746,"totalTrials":236,"cells":15230},{"EARLY_PHASE1":15231,"PHASE1":15233,"PHASE2":15235,"PHASE3":15237,"PHASE4":15239,"NA":15241},{"trials":15232,"activeCount":102},[],{"trials":15234,"activeCount":102},[],{"trials":15236,"activeCount":102},[],{"trials":15238,"activeCount":102},[],{"trials":15240,"activeCount":102},[],{"trials":15242,"activeCount":102},[15243],{"nctId":736,"briefTitle":737,"status":131,"phases":15244,"primaryCompletion":134,"completion":739,"start":740,"enrollment":741,"conditions":15245,"interventions":15246},[94],[743],[745,746,701,747],{"intervention":747,"totalTrials":236,"cells":15248},{"EARLY_PHASE1":15249,"PHASE1":15251,"PHASE2":15253,"PHASE3":15255,"PHASE4":15257,"NA":15259},{"trials":15250,"activeCount":102},[],{"trials":15252,"activeCount":102},[],{"trials":15254,"activeCount":102},[],{"trials":15256,"activeCount":102},[],{"trials":15258,"activeCount":102},[],{"trials":15260,"activeCount":102},[15261],{"nctId":736,"briefTitle":737,"status":131,"phases":15262,"primaryCompletion":134,"completion":739,"start":740,"enrollment":741,"conditions":15263,"interventions":15264},[94],[743],[745,746,701,747],{"intervention":15266,"totalTrials":236,"cells":15267},"investigational radiotracer [18F]MK6240",{"EARLY_PHASE1":15268,"PHASE1":15270,"PHASE2":15272,"PHASE3":15274,"PHASE4":15276,"NA":15278},{"trials":15269,"activeCount":102},[],{"trials":15271,"activeCount":102},[],{"trials":15273,"activeCount":102},[],{"trials":15275,"activeCount":102},[],{"trials":15277,"activeCount":102},[],{"trials":15279,"activeCount":102},[15280],{"nctId":15281,"briefTitle":15282,"status":5876,"phases":15283,"primaryCompletion":15284,"completion":15284,"start":15285,"enrollment":12364,"conditions":15286,"interventions":15287},"NCT04437290","University of Washington Alzheimer's Disease Research Center (UW ADRC) Imaging & Biomarker Core",[],"2025-04-30","2022-11",[13957],[15266],{"intervention":15289,"totalTrials":236,"cells":15290},"Fluoxetine, Lovastatin, Omeprazole, caffeine, midazolam, dextromethorphan",{"EARLY_PHASE1":15291,"PHASE1":15293,"PHASE2":15295,"PHASE3":15297,"PHASE4":15299,"NA":15301},{"trials":15292,"activeCount":102},[],{"trials":15294,"activeCount":102},[],{"trials":15296,"activeCount":102},[],{"trials":15298,"activeCount":102},[],{"trials":15300,"activeCount":102},[],{"trials":15302,"activeCount":102},[15303],{"nctId":15304,"briefTitle":15305,"status":131,"phases":15306,"primaryCompletion":1578,"completion":1578,"start":1863,"enrollment":261,"conditions":15307,"interventions":15310},"NCT01361217","The Effects of Multiple Dose Fluoxetine and Metabolites on CYP1A2, CYP2C19, CYP2D6 and CYP3A4 Activity",[94],[15308,15309],"Drug-Drug Interaction","Healthy Volunteers",[15289],{"intervention":15312,"totalTrials":236,"cells":15313},"Hypertonic Saline-Dextran Solution",{"EARLY_PHASE1":15314,"PHASE1":15316,"PHASE2":15318,"PHASE3":15320,"PHASE4":15322,"NA":15324},{"trials":15315,"activeCount":102},[],{"trials":15317,"activeCount":102},[],{"trials":15319,"activeCount":102},[],{"trials":15321,"activeCount":102},[],{"trials":15323,"activeCount":102},[],{"trials":15325,"activeCount":102},[15326],{"nctId":15327,"briefTitle":15328,"status":131,"phases":15329,"completion":15330,"start":7012,"enrollment":15331,"conditions":15332,"interventions":15335},"NCT00113685","Hypertonic Saline With Dextran for Treating Hypovolemic Shock and Severe Brain Injury",[94],"2007-03",209,[10250,15333,15334,7759],"Head Injuries, Closed","Shock",[15312,15336],"Lactated Ringer's Solution",{"intervention":15336,"totalTrials":236,"cells":15338},{"EARLY_PHASE1":15339,"PHASE1":15341,"PHASE2":15343,"PHASE3":15345,"PHASE4":15347,"NA":15349},{"trials":15340,"activeCount":102},[],{"trials":15342,"activeCount":102},[],{"trials":15344,"activeCount":102},[],{"trials":15346,"activeCount":102},[],{"trials":15348,"activeCount":102},[],{"trials":15350,"activeCount":102},[15351],{"nctId":15327,"briefTitle":15328,"status":131,"phases":15352,"completion":15330,"start":7012,"enrollment":15331,"conditions":15353,"interventions":15354},[94],[10250,15333,15334,7759],[15312,15336],{"intervention":13743,"totalTrials":236,"cells":15356},{"EARLY_PHASE1":15357,"PHASE1":15359,"PHASE2":15361,"PHASE3":15363,"PHASE4":15365,"NA":15367},{"trials":15358,"activeCount":102},[],{"trials":15360,"activeCount":102},[],{"trials":15362,"activeCount":102},[],{"trials":15364,"activeCount":102},[],{"trials":15366,"activeCount":102},[],{"trials":15368,"activeCount":102},[15369],{"nctId":13731,"briefTitle":13732,"status":131,"phases":15370,"primaryCompletion":13734,"completion":13735,"start":13736,"enrollment":3144,"conditions":15371,"interventions":15372},[94],[13738,2291,2419,13739,2420,13740],[13742,13743,13744],{"intervention":13744,"totalTrials":236,"cells":15374},{"EARLY_PHASE1":15375,"PHASE1":15377,"PHASE2":15379,"PHASE3":15381,"PHASE4":15383,"NA":15385},{"trials":15376,"activeCount":102},[],{"trials":15378,"activeCount":102},[],{"trials":15380,"activeCount":102},[],{"trials":15382,"activeCount":102},[],{"trials":15384,"activeCount":102},[],{"trials":15386,"activeCount":102},[15387],{"nctId":13731,"briefTitle":13732,"status":131,"phases":15388,"primaryCompletion":13734,"completion":13735,"start":13736,"enrollment":3144,"conditions":15389,"interventions":15390},[94],[13738,2291,2419,13739,2420,13740],[13742,13743,13744],{"intervention":14218,"totalTrials":236,"cells":15392},{"EARLY_PHASE1":15393,"PHASE1":15395,"PHASE2":15397,"PHASE3":15399,"PHASE4":15401,"NA":15403},{"trials":15394,"activeCount":102},[],{"trials":15396,"activeCount":102},[],{"trials":15398,"activeCount":102},[],{"trials":15400,"activeCount":102},[],{"trials":15402,"activeCount":102},[],{"trials":15404,"activeCount":102},[15405],{"nctId":14211,"briefTitle":14212,"status":131,"phases":15406,"primaryCompletion":3252,"completion":1475,"start":14214,"enrollment":6297,"conditions":15407,"interventions":15408},[94],[335],[14217,14218],{"intervention":14188,"totalTrials":236,"cells":15410},{"EARLY_PHASE1":15411,"PHASE1":15413,"PHASE2":15415,"PHASE3":15417,"PHASE4":15419,"NA":15421},{"trials":15412,"activeCount":102},[],{"trials":15414,"activeCount":102},[],{"trials":15416,"activeCount":102},[],{"trials":15418,"activeCount":102},[],{"trials":15420,"activeCount":102},[],{"trials":15422,"activeCount":102},[15423],{"nctId":14182,"briefTitle":14183,"status":131,"phases":15424,"primaryCompletion":2106,"completion":2106,"start":5673,"enrollment":261,"conditions":15425,"interventions":15426},[94],[14186,12990],[14005,14188],{"intervention":15428,"totalTrials":236,"cells":15429},"naloxone",{"EARLY_PHASE1":15430,"PHASE1":15432,"PHASE2":15434,"PHASE3":15436,"PHASE4":15438,"NA":15440},{"trials":15431,"activeCount":102},[],{"trials":15433,"activeCount":102},[],{"trials":15435,"activeCount":102},[],{"trials":15437,"activeCount":102},[],{"trials":15439,"activeCount":102},[],{"trials":15441,"activeCount":102},[15442],{"nctId":15443,"briefTitle":15444,"status":5876,"phases":15445,"primaryCompletion":1577,"completion":1577,"start":134,"enrollment":350,"conditions":15446,"interventions":15447},"NCT01105871","Subjective Analgesic Effects of Naloxone and Virtual Reality",[94],[376],[15428],{"intervention":15449,"totalTrials":236,"cells":15450},"TMP\u002FSMX",{"EARLY_PHASE1":15451,"PHASE1":15453,"PHASE2":15455,"PHASE3":15457,"PHASE4":15459,"NA":15461},{"trials":15452,"activeCount":102},[],{"trials":15454,"activeCount":102},[],{"trials":15456,"activeCount":102},[],{"trials":15458,"activeCount":102},[],{"trials":15460,"activeCount":102},[],{"trials":15462,"activeCount":102},[15463],{"nctId":15464,"briefTitle":15465,"status":131,"phases":15466,"primaryCompletion":15467,"completion":15467,"start":15468,"enrollment":12364,"conditions":15469,"interventions":15470},"NCT00976963","Single Dose Monurol for Treatment of Acute Cystitis",[94],"2016-12-27","2009-09-17",[11162],[15449,15471],"Fosfomycin",{"intervention":15471,"totalTrials":236,"cells":15473},{"EARLY_PHASE1":15474,"PHASE1":15476,"PHASE2":15478,"PHASE3":15480,"PHASE4":15482,"NA":15484},{"trials":15475,"activeCount":102},[],{"trials":15477,"activeCount":102},[],{"trials":15479,"activeCount":102},[],{"trials":15481,"activeCount":102},[],{"trials":15483,"activeCount":102},[],{"trials":15485,"activeCount":102},[15486],{"nctId":15464,"briefTitle":15465,"status":131,"phases":15487,"primaryCompletion":15467,"completion":15467,"start":15468,"enrollment":12364,"conditions":15488,"interventions":15489},[94],[11162],[15449,15471],{"intervention":13813,"totalTrials":236,"cells":15491},{"EARLY_PHASE1":15492,"PHASE1":15494,"PHASE2":15496,"PHASE3":15498,"PHASE4":15500,"NA":15502},{"trials":15493,"activeCount":102},[],{"trials":15495,"activeCount":102},[],{"trials":15497,"activeCount":102},[],{"trials":15499,"activeCount":102},[],{"trials":15501,"activeCount":102},[],{"trials":15503,"activeCount":102},[15504],{"nctId":13807,"briefTitle":13808,"status":131,"phases":15505,"primaryCompletion":2106,"completion":1313,"start":7569,"enrollment":13810,"conditions":15506,"interventions":15507},[94],[19,13792],[13774,13813,13814],{"intervention":13814,"totalTrials":236,"cells":15509},{"EARLY_PHASE1":15510,"PHASE1":15512,"PHASE2":15514,"PHASE3":15516,"PHASE4":15518,"NA":15520},{"trials":15511,"activeCount":102},[],{"trials":15513,"activeCount":102},[],{"trials":15515,"activeCount":102},[],{"trials":15517,"activeCount":102},[],{"trials":15519,"activeCount":102},[],{"trials":15521,"activeCount":102},[15522],{"nctId":13807,"briefTitle":13808,"status":131,"phases":15523,"primaryCompletion":2106,"completion":1313,"start":7569,"enrollment":13810,"conditions":15524,"interventions":15525},[94],[19,13792],[13774,13813,13814],{"intervention":3040,"totalTrials":236,"cells":15527},{"EARLY_PHASE1":15528,"PHASE1":15530,"PHASE2":15532,"PHASE3":15534,"PHASE4":15536,"NA":15538},{"trials":15529,"activeCount":102},[],{"trials":15531,"activeCount":102},[],{"trials":15533,"activeCount":102},[],{"trials":15535,"activeCount":102},[],{"trials":15537,"activeCount":102},[],{"trials":15539,"activeCount":102},[15540],{"nctId":3020,"briefTitle":3021,"status":131,"phases":15541,"primaryCompletion":3023,"completion":3024,"start":3025,"enrollment":1299,"conditions":15542,"interventions":15543},[94],[3027,3028,3029,3030,3031,3032,2458,2459,2460,2462,2463,3033,3034,3035,2464,3036,3037,2487,2466],[3039,3040],{"intervention":15545,"totalTrials":236,"cells":15546},"Mozobil",{"EARLY_PHASE1":15547,"PHASE1":15549,"PHASE2":15551,"PHASE3":15553,"PHASE4":15555,"NA":15557},{"trials":15548,"activeCount":102},[],{"trials":15550,"activeCount":102},[],{"trials":15552,"activeCount":102},[],{"trials":15554,"activeCount":102},[],{"trials":15556,"activeCount":102},[],{"trials":15558,"activeCount":102},[15559],{"nctId":15560,"briefTitle":15561,"status":131,"phases":15562,"primaryCompletion":1194,"completion":1620,"start":7528,"enrollment":673,"conditions":15563,"interventions":15565},"NCT01206075","Evaluating the Safety and Effectiveness of Mozobil Mobilization in Adults With Beta-Thalassemia Major",[94],[15564],"Beta-Thalassemia",[15545,15545,15545],{"intervention":15567,"totalTrials":236,"cells":15568},"Cefpodoxime",{"EARLY_PHASE1":15569,"PHASE1":15571,"PHASE2":15573,"PHASE3":15575,"PHASE4":15577,"NA":15579},{"trials":15570,"activeCount":102},[],{"trials":15572,"activeCount":102},[],{"trials":15574,"activeCount":102},[],{"trials":15576,"activeCount":102},[],{"trials":15578,"activeCount":102},[],{"trials":15580,"activeCount":102},[15581],{"nctId":15582,"briefTitle":15583,"status":131,"phases":15584,"primaryCompletion":191,"completion":191,"start":6588,"enrollment":12364,"conditions":15585,"interventions":15586},"NCT00194532","Cefpodoxime vs Ciprofloxacin for Acute Cystitis",[94],[11162],[15567,15587],"Ciprofloxacin",{"intervention":15587,"totalTrials":236,"cells":15589},{"EARLY_PHASE1":15590,"PHASE1":15592,"PHASE2":15594,"PHASE3":15596,"PHASE4":15598,"NA":15600},{"trials":15591,"activeCount":102},[],{"trials":15593,"activeCount":102},[],{"trials":15595,"activeCount":102},[],{"trials":15597,"activeCount":102},[],{"trials":15599,"activeCount":102},[],{"trials":15601,"activeCount":102},[15602],{"nctId":15582,"briefTitle":15583,"status":131,"phases":15603,"primaryCompletion":191,"completion":191,"start":6588,"enrollment":12364,"conditions":15604,"interventions":15605},[94],[11162],[15567,15587],{"intervention":15607,"totalTrials":236,"cells":15608},"Echinacea purpurea product",{"EARLY_PHASE1":15609,"PHASE1":15611,"PHASE2":15613,"PHASE3":15615,"PHASE4":15617,"NA":15619},{"trials":15610,"activeCount":102},[],{"trials":15612,"activeCount":102},[],{"trials":15614,"activeCount":102},[],{"trials":15616,"activeCount":102},[],{"trials":15618,"activeCount":102},[],{"trials":15620,"activeCount":102},[15621],{"nctId":15622,"briefTitle":15623,"status":131,"phases":15624,"primaryCompletion":1272,"completion":1272,"start":370,"enrollment":15625,"conditions":15626,"interventions":15627},"NCT01129128","Three Arm Trial of Immune Effects of Echinacea",[94],67,[14369],[15607,15607],{"intervention":15629,"totalTrials":236,"cells":15630},"N-acetylcysteine, ascorbate",{"EARLY_PHASE1":15631,"PHASE1":15633,"PHASE2":15635,"PHASE3":15637,"PHASE4":15639,"NA":15641},{"trials":15632,"activeCount":102},[],{"trials":15634,"activeCount":102},[],{"trials":15636,"activeCount":102},[],{"trials":15638,"activeCount":102},[],{"trials":15640,"activeCount":102},[],{"trials":15642,"activeCount":102},[15643],{"nctId":15644,"briefTitle":15645,"status":131,"phases":15646,"primaryCompletion":134,"completion":134,"start":12642,"enrollment":1023,"conditions":15647,"interventions":15648},"NCT00434005","Effect of Diesel Exhaust Particulate Exposures on Endothelial Function in Humans",[94],[5667],[15629],{"intervention":15650,"totalTrials":236,"cells":15651},"GHRH",{"EARLY_PHASE1":15652,"PHASE1":15654,"PHASE2":15656,"PHASE3":15658,"PHASE4":15660,"NA":15662},{"trials":15653,"activeCount":102},[],{"trials":15655,"activeCount":102},[],{"trials":15657,"activeCount":102},[],{"trials":15659,"activeCount":102},[],{"trials":15661,"activeCount":102},[],{"trials":15663,"activeCount":102},[15664],{"nctId":15665,"briefTitle":15666,"status":131,"phases":15667,"primaryCompletion":6102,"completion":6102,"start":15668,"conditions":15669,"interventions":15671},"NCT00000380","Growth Hormone Releasing Hormone (GHRH) Treatment for Age-Related Sleep Disturbances",[94],"1996-06",[15670],"Sleep Disorders",[15650],{"intervention":15673,"totalTrials":236,"cells":15674},"Exparel 266 MG Per 20 ML",{"EARLY_PHASE1":15675,"PHASE1":15677,"PHASE2":15679,"PHASE3":15681,"PHASE4":15683,"NA":15685},{"trials":15676,"activeCount":102},[],{"trials":15678,"activeCount":102},[],{"trials":15680,"activeCount":102},[],{"trials":15682,"activeCount":102},[],{"trials":15684,"activeCount":102},[],{"trials":15686,"activeCount":102},[15687],{"nctId":15688,"briefTitle":15689,"status":5876,"phases":15690,"primaryCompletion":15691,"completion":15691,"start":15692,"enrollment":14759,"conditions":15693,"interventions":15697},"NCT03927326","Postoperative Analgesia in Laparoscopic Abdominal Surgery After Exparel Via TAP or Local Infiltration",[94],"2020-07","2019-08",[15694,15695,15696,6930,6054],"Pain, Postoperative","Anesthesia, Local","Anesthesia; Functional",[15673],{"intervention":15699,"totalTrials":236,"cells":15700},"Hydroxyurea",{"EARLY_PHASE1":15701,"PHASE1":15703,"PHASE2":15705,"PHASE3":15707,"PHASE4":15709,"NA":15711},{"trials":15702,"activeCount":102},[],{"trials":15704,"activeCount":102},[],{"trials":15706,"activeCount":102},[],{"trials":15708,"activeCount":102},[],{"trials":15710,"activeCount":102},[],{"trials":15712,"activeCount":102},[15713],{"nctId":15714,"briefTitle":15715,"status":131,"phases":15716,"primaryCompletion":134,"completion":134,"start":4906,"enrollment":1815,"conditions":15717,"interventions":15718},"NCT00336362","Evaluating the Safety of G-CSF Mobilization in Individuals With Beta Thalassemia Major",[94],[15564],[15699],{"intervention":15720,"totalTrials":236,"cells":15721},"Technetium Tc-99m DTPA",{"EARLY_PHASE1":15722,"PHASE1":15724,"PHASE2":15726,"PHASE3":15728,"PHASE4":15730,"NA":15732},{"trials":15723,"activeCount":102},[],{"trials":15725,"activeCount":102},[],{"trials":15727,"activeCount":102},[],{"trials":15729,"activeCount":102},[],{"trials":15731,"activeCount":102},[],{"trials":15733,"activeCount":102},[15734],{"nctId":15735,"briefTitle":15736,"status":131,"phases":15737,"primaryCompletion":15738,"completion":15738,"start":15739,"enrollment":113,"conditions":15740,"interventions":15743},"NCT01982123","SPECT\u002FCT in Measuring Lung Function in Patients With Cancer Undergoing Radiation Therapy",[94],"2017-09-13","2014-01-17",[15741,15742],"Lung Carcinoma","Malignant Neoplasm",[15720],{"intervention":281,"totalTrials":236,"cells":15745},{"EARLY_PHASE1":15746,"PHASE1":15748,"PHASE2":15750,"PHASE3":15752,"PHASE4":15754,"NA":15756},{"trials":15747,"activeCount":102},[],{"trials":15749,"activeCount":102},[],{"trials":15751,"activeCount":102},[],{"trials":15753,"activeCount":102},[],{"trials":15755,"activeCount":102},[],{"trials":15757,"activeCount":102},[15758],{"nctId":268,"briefTitle":269,"status":131,"phases":15759,"primaryCompletion":271,"completion":271,"start":272,"enrollment":273,"conditions":15760,"interventions":15761},[94],[275,194,276,277,278],[208,233,168,280,281],{"intervention":15763,"totalTrials":236,"cells":15764},"Phase I, Buccal Swab Collection for DNA Isolation",{"EARLY_PHASE1":15765,"PHASE1":15767,"PHASE2":15769,"PHASE3":15771,"PHASE4":15773,"NA":15775},{"trials":15766,"activeCount":102},[],{"trials":15768,"activeCount":102},[],{"trials":15770,"activeCount":102},[],{"trials":15772,"activeCount":102},[],{"trials":15774,"activeCount":102},[],{"trials":15776,"activeCount":102},[15777],{"nctId":15778,"briefTitle":15779,"status":108,"phases":15780,"primaryCompletion":14307,"completion":14307,"start":15781,"enrollment":7334,"conditions":15782,"interventions":15784},"NCT04450212","Vitamin K Supplementation Study in Healthy Volunteers (Aim 2B)",[94],"2017-08-25",[15783],"Vitamin K Status",[15763],{"intervention":13973,"totalTrials":236,"cells":15786},{"EARLY_PHASE1":15787,"PHASE1":15789,"PHASE2":15791,"PHASE3":15793,"PHASE4":15795,"NA":15797},{"trials":15788,"activeCount":102},[],{"trials":15790,"activeCount":102},[],{"trials":15792,"activeCount":102},[],{"trials":15794,"activeCount":102},[],{"trials":15796,"activeCount":102},[],{"trials":15798,"activeCount":102},[15799],{"nctId":13961,"briefTitle":13962,"status":131,"phases":15800,"primaryCompletion":6839,"completion":6839,"start":6126,"enrollment":13964,"conditions":15801,"interventions":15802},[94],[12588,16,13966,13967,12868,5675,13968,376,13969,8191,13970],[13972,13973,13974,13975,13976,13977,13978,13979,13980,13981,13982],{"intervention":13974,"totalTrials":236,"cells":15804},{"EARLY_PHASE1":15805,"PHASE1":15807,"PHASE2":15809,"PHASE3":15811,"PHASE4":15813,"NA":15815},{"trials":15806,"activeCount":102},[],{"trials":15808,"activeCount":102},[],{"trials":15810,"activeCount":102},[],{"trials":15812,"activeCount":102},[],{"trials":15814,"activeCount":102},[],{"trials":15816,"activeCount":102},[15817],{"nctId":13961,"briefTitle":13962,"status":131,"phases":15818,"primaryCompletion":6839,"completion":6839,"start":6126,"enrollment":13964,"conditions":15819,"interventions":15820},[94],[12588,16,13966,13967,12868,5675,13968,376,13969,8191,13970],[13972,13973,13974,13975,13976,13977,13978,13979,13980,13981,13982],{"intervention":13975,"totalTrials":236,"cells":15822},{"EARLY_PHASE1":15823,"PHASE1":15825,"PHASE2":15827,"PHASE3":15829,"PHASE4":15831,"NA":15833},{"trials":15824,"activeCount":102},[],{"trials":15826,"activeCount":102},[],{"trials":15828,"activeCount":102},[],{"trials":15830,"activeCount":102},[],{"trials":15832,"activeCount":102},[],{"trials":15834,"activeCount":102},[15835],{"nctId":13961,"briefTitle":13962,"status":131,"phases":15836,"primaryCompletion":6839,"completion":6839,"start":6126,"enrollment":13964,"conditions":15837,"interventions":15838},[94],[12588,16,13966,13967,12868,5675,13968,376,13969,8191,13970],[13972,13973,13974,13975,13976,13977,13978,13979,13980,13981,13982],{"intervention":13976,"totalTrials":236,"cells":15840},{"EARLY_PHASE1":15841,"PHASE1":15843,"PHASE2":15845,"PHASE3":15847,"PHASE4":15849,"NA":15851},{"trials":15842,"activeCount":102},[],{"trials":15844,"activeCount":102},[],{"trials":15846,"activeCount":102},[],{"trials":15848,"activeCount":102},[],{"trials":15850,"activeCount":102},[],{"trials":15852,"activeCount":102},[15853],{"nctId":13961,"briefTitle":13962,"status":131,"phases":15854,"primaryCompletion":6839,"completion":6839,"start":6126,"enrollment":13964,"conditions":15855,"interventions":15856},[94],[12588,16,13966,13967,12868,5675,13968,376,13969,8191,13970],[13972,13973,13974,13975,13976,13977,13978,13979,13980,13981,13982],{"intervention":13979,"totalTrials":236,"cells":15858},{"EARLY_PHASE1":15859,"PHASE1":15861,"PHASE2":15863,"PHASE3":15865,"PHASE4":15867,"NA":15869},{"trials":15860,"activeCount":102},[],{"trials":15862,"activeCount":102},[],{"trials":15864,"activeCount":102},[],{"trials":15866,"activeCount":102},[],{"trials":15868,"activeCount":102},[],{"trials":15870,"activeCount":102},[15871],{"nctId":13961,"briefTitle":13962,"status":131,"phases":15872,"primaryCompletion":6839,"completion":6839,"start":6126,"enrollment":13964,"conditions":15873,"interventions":15874},[94],[12588,16,13966,13967,12868,5675,13968,376,13969,8191,13970],[13972,13973,13974,13975,13976,13977,13978,13979,13980,13981,13982],{"intervention":13980,"totalTrials":236,"cells":15876},{"EARLY_PHASE1":15877,"PHASE1":15879,"PHASE2":15881,"PHASE3":15883,"PHASE4":15885,"NA":15887},{"trials":15878,"activeCount":102},[],{"trials":15880,"activeCount":102},[],{"trials":15882,"activeCount":102},[],{"trials":15884,"activeCount":102},[],{"trials":15886,"activeCount":102},[],{"trials":15888,"activeCount":102},[15889],{"nctId":13961,"briefTitle":13962,"status":131,"phases":15890,"primaryCompletion":6839,"completion":6839,"start":6126,"enrollment":13964,"conditions":15891,"interventions":15892},[94],[12588,16,13966,13967,12868,5675,13968,376,13969,8191,13970],[13972,13973,13974,13975,13976,13977,13978,13979,13980,13981,13982]]